 
 
 
 interface Pharmacokinetics {
    Absorption: string;
    Distribution: string;
    Metabolism: string;
    Excretion: string;
  }
  
  interface ChemicalStructure {
    MolecularFormula: string;
    MolecularWeight: string;
  }
  
  interface UseInSpecialPopulations {
    Pregnancy: string;
    PediatricUse: string;
    GeriatricUse: string;
    HepaticImpairment: string;
    RenalImpairment: string;
  }
  
 
  
  export interface DrugSchema {
    
    GenericName: string;
    BrandNames: string[];
    DrugClass: string;
    MechanismOfAction: string;
    Pharmacodynamics: string;
    OnsetOfAction: string;
    DurationOfAction: string;
    PeakPlasmaConcentration: string;
    Indications: string[];
    RoutesOfAdministration: string;
    DosageForms: string[];
    StrengthsOfDosageForms: string[];
    Pharmacokinetics: Pharmacokinetics;
    SideEffects: string[];
    DrugInteractions: string[];
    Contraindications: string;
    ChemicalStructure: ChemicalStructure;
    UseInSpecialPopulations: UseInSpecialPopulations;
    StorageAndHandling: string;
    
  }
  
 
 export const drugs: DrugSchema[] = 

[{"GenericName":"Metformin","BrandNames":["Glucophage","Glumetza","Fortamet","Riomet"],"DrugClass":"Biguanide","MechanismOfAction":"Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.","Pharmacodynamics":"Metformin lowers both basal and postprandial plasma glucose levels, and its actions do not depend on stimulating insulin secretion, so it rarely causes hypoglycemia when used as monotherapy.","OnsetOfAction":"Begins working within days, but maximum glycemic control may take up to 2 weeks of regular dosing","DurationOfAction":"About 6-12 hours","PeakPlasmaConcentration":"Approximately 2.5 hours after ingestion for the immediate-release formulation","Indications":["Type 2 diabetes mellitus","Polycystic ovary syndrome (PCOS)","Prevention of type 2 diabetes (off-label)"],"RoutesOfAdministration":"Oral","DosageForms":["Immediate-release tablet","Extended-release tablet","Oral solution"],"StrengthsOfDosageForms":["500 mg","750 mg","850 mg","1000 mg"],"Pharmacokinetics":{"Absorption":"Absorbed primarily in the small intestine, bioavailability is approximately 50% to 60%.","Distribution":"Widely distributed in the body, minimal protein binding (<5%)","Metabolism":"Not metabolized; excreted unchanged in urine","Excretion":"Primarily renal excretion; approximately 90% of the absorbed drug is eliminated via the kidneys within the first 24 hours."},"SideEffects":["Gastrointestinal disturbances (nausea, vomiting, diarrhea)","Lactic acidosis (rare but serious)","Vitamin B12 deficiency","Metallic taste"],"DrugInteractions":["Cimetidine can increase metformin levels by competing for renal tubular secretion","Alcohol increases the risk of lactic acidosis","Iodinated contrast media can increase the risk of lactic acidosis with metformin"],"Contraindications":"Severe renal impairment (eGFR below 30 mL/min/1.73 m^2), known hypersensitivity to metformin, acute or chronic metabolic acidosis, including diabetic ketoacidosis.","ChemicalStructure":{"MolecularFormula":"C4H11N5","MolecularWeight":"129.16 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Generally considered safe, but always consult a physician.","PediatricUse":"Approved for use in children aged 10 years and older for type 2 diabetes.","GeriatricUse":"Used with caution in elderly; assess renal function regularly.","HepaticImpairment":"Use with caution due to risk of lactic acidosis.","RenalImpairment":"Dose adjustment required for mild to moderate impairment; contraindicated in severe impairment."},"StorageAndHandling":"Store at room temperature (20-25°C or 68-77°F); protect from moisture and keep bottle tightly closed."},{"GenericName":"Amlodipine","BrandNames":["Norvasc"],"DrugClass":"Calcium Channel Blocker","MechanismOfAction":"Amlodipine blocks calcium ion influx into vascular smooth muscle and cardiac muscle, which causes vasodilation and a subsequent decrease in blood pressure.","Pharmacodynamics":"Amlodipine causes relaxation of vascular smooth muscle, leading to reduced peripheral vascular resistance, decreased blood pressure, and increased blood supply to the heart.","OnsetOfAction":"6-12 hours","DurationOfAction":"24 hours","PeakPlasmaConcentration":"6-12 hours after oral administration","Indications":["Hypertension","Stable angina","Prinzmetal's angina"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["2.5 mg","5 mg","10 mg"],"Pharmacokinetics":{"Absorption":"Amlodipine is well absorbed orally with a bioavailability of 64-90%.","Distribution":"Amlodipine is extensively distributed in body tissues; volume of distribution is approximately 21 L/kg. It is approximately 93% bound to plasma proteins.","Metabolism":"Amlodipine is extensively metabolized in the liver to inactive metabolites.","Excretion":"60% excreted in urine (10% as unchanged drug) and 20-25% in feces."},"SideEffects":["Edema","Fatigue","Nausea","Abdominal pain","Somnolence","Flushing","Palpitations"],"DrugInteractions":["CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","Simvastatin","Dantrolene","Grapefruit juice may increase serum concentrations"],"Contraindications":"Known hypersensitivity to amlodipine or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C20H25ClN2O5","MolecularWeight":"408.88 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C: Risk cannot be ruled out. Use only if potential benefits justify the potential risks to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have been established for certain indications.","GeriatricUse":"Use with caution; dosage should be adjusted based on renal and hepatic function.","HepaticImpairment":"Dose adjustment may be required as amlodipine is extensively metabolized in the liver.","RenalImpairment":"Generally well-tolerated in renal impairment; no dose adjustment is generally required."},"StorageAndHandling":"Store at room temperature, between 20°C and 25°C (68°F and 77°F). Protect from moisture and light."},{"GenericName":"Metoprolol","BrandNames":["Lopressor","Toprol XL"],"DrugClass":"Beta-blocker","MechanismOfAction":"Metoprolol selectively inhibits beta-1 adrenergic receptors, primarily in cardiac tissue, which leads to decreased heart rate and cardiac output.","Pharmacodynamics":"Metoprolol decreases cardiac output by lowering heart rate and contractility, reduces myocardial oxygen demand, and increases diastolic filling time. This contributes to its effectiveness in treating hypertension and angina.","OnsetOfAction":"1 to 2 hours","DurationOfAction":"3 to 6 hours for immediate-release; 24 hours for extended-release","PeakPlasmaConcentration":"1.5 to 2 hours for immediate-release; 6 to 12 hours for extended-release","Indications":["Hypertension","Angina pectoris","Heart failure","Myocardial infarction"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablet","Injection","Extended-release tablet"],"StrengthsOfDosageForms":["25 mg","50 mg","100 mg","200 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed with an oral bioavailability of about 50% due to first-pass metabolism.","Distribution":"Widely distributed, crosses the blood-brain barrier and the placenta.","Metabolism":"Primarily metabolized in the liver by CYP2D6.","Excretion":"Excreted in urine, with less than 10% excreted as unchanged drug."},"SideEffects":["Bradycardia","Hypotension","Dizziness","Fatigue","Depression","Shortness of breath"],"DrugInteractions":["CYP2D6 inhibitors (e.g., fluoxetine)","Calcium channel blockers","Digoxin","Clonidine"],"Contraindications":"Severe bradycardia, second or third-degree heart block, cardiogenic shock, overt cardiac failure.","ChemicalStructure":{"MolecularFormula":"C15H25NO3","MolecularWeight":"267.37 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C; should only be used if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No overall differences in effectiveness or safety observed, but increased sensitivity in some older individuals cannot be ruled out.","HepaticImpairment":"Use with caution as metabolism may be impaired.","RenalImpairment":"No dose adjustment needed, but caution is advised."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); protect from moisture and light."},{"GenericName":"Albuterol","BrandNames":["ProAir","Ventolin","Proventil"],"DrugClass":"Beta-2 adrenergic receptor agonist","MechanismOfAction":"Albuterol works by stimulating beta-2 adrenergic receptors in the lungs which leads to relaxation of bronchial smooth muscle, resulting in bronchodilation.","Pharmacodynamics":"Albuterol facilitates an increase in airflow by relaxation of smooth muscle in the airway, aiding individuals in respiratory distress. It has a rapid onset and acts primarily as a bronchodilator.","OnsetOfAction":"Within 5 to 15 minutes","DurationOfAction":"4 to 6 hours","PeakPlasmaConcentration":"Approximately 2 to 4 hours after administration","Indications":["Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease","Prevention of exercise-induced bronchospasm"],"RoutesOfAdministration":"Inhalation (via aerosol or powder)","DosageForms":["Metered-dose inhaler","Dry powder inhaler","Nebulizer solution"],"StrengthsOfDosageForms":["90 mcg per actuation (inhalers)","2.5 mg/3 ml (nebulizer solution)"],"Pharmacokinetics":{"Absorption":"Rapid absorption via inhalation with systemic bioavailability of 10-20%","Distribution":"Widely distributed throughout the body; minimally protein bound (~10%)","Metabolism":"Liver (via sulfation); undergoes extensive first-pass metabolism when swallowed after inhalation","Excretion":"Primarily renal; ~80-100% in the urine as unchanged drug and metabolites"},"SideEffects":["Tremor","Nervousness","Headache","Palpitations","Tachycardia","Muscle cramps","Nausea"],"DrugInteractions":["Beta-blockers (may inhibit effect)","Diuretics (may increase hypokalemia)","MAO inhibitors (may enhance adverse effects)"],"Contraindications":"None specific; caution in patients with a history of hypersensitivity to albuterol or any of its ingredients.","ChemicalStructure":{"MolecularFormula":"C13H21NO3","MolecularWeight":"239.31 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C. Should be used only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness have been established in children two years of age and older.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients.","HepaticImpairment":"Use with caution; may need dosage adjustments or monitoring.","RenalImpairment":"Use with caution; excretion is renal. Dosage adjustment might be necessary."},"StorageAndHandling":"Store at room temperature, 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Avoid exposure to extreme heat or cold."},{"GenericName":"Omeprazole","BrandNames":["Prilosec","Losec"],"DrugClass":"Proton Pump Inhibitor (PPI)","MechanismOfAction":"Omeprazole inhibits the proton pump (H+/K+ ATPase) in the gastric parietal cells, leading to a reduction in gastric acid secretion.","Pharmacodynamics":"Omeprazole suppresses gastric acid secretion in response to any stimulus due to its action on the final step of acid production.","OnsetOfAction":"1 hour","DurationOfAction":"Up to 72 hours","PeakPlasmaConcentration":"0.5 to 3.5 hours after administration","Indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Erosive esophagitis","Helicobacter pylori eradication (in combination)"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Capsule","Tablet","Suspension","Injection"],"StrengthsOfDosageForms":["10 mg","20 mg","40 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed, with bioavailability improved with repeated dosing","Distribution":"Volume of distribution approximately 0.3 L/kg","Metabolism":"Primarily hepatic via CYP2C19 and CYP3A4","Excretion":"Mainly renal, with approximately 80% excreted in urine"},"SideEffects":["Headache","Nausea","Diarrhea","Abdominal pain","Dizziness"],"DrugInteractions":["Clopidogrel","Warfarin","Cilostazol","Methotrexate","Diazepam"],"Contraindications":"Known hypersensitivity to omeprazole, substituted benzimidazoles, or any component of the formulation","ChemicalStructure":{"MolecularFormula":"C17H19N3O3S","MolecularWeight":"345.42 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C - Risk cannot be ruled out. Caution is advised.","PediatricUse":"Safety and efficacy have been established in pediatric patients for certain conditions.","GeriatricUse":"No significant differences in response compared to younger adults, but sensitivity in some older individuals cannot be ruled out.","HepaticImpairment":"Dose adjustment may be necessary. Use with caution.","RenalImpairment":"No dose adjustment is necessary."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F), protect from moisture and light."},{"GenericName":"Losartan","BrandNames":["Cozaar","Hyzaar (when combined with hydrochlorothiazide)"],"DrugClass":"Angiotensin II receptor blocker (ARB)","MechanismOfAction":"Losartan selectively blocks the binding of angiotensin II to the AT1 receptor, which inhibits vasoconstriction and the secretion of aldosterone.","Pharmacodynamics":"Losartan decreases blood pressure by blocking the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation and reduced blood pressure.","OnsetOfAction":"Approximately 1 hour","DurationOfAction":"Lasts for approximately 24 hours, with peak effects occurring in 3 to 6 weeks of continuous use.","PeakPlasmaConcentration":"Achieved in approximately 1 to 2 hours following an oral dose.","Indications":["Hypertension","Diabetic nephropathy","Hypertension with left ventricular hypertrophy"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["25 mg","50 mg","100 mg"],"Pharmacokinetics":{"Absorption":"Absorbed from the GI tract with a bioavailability of about 33%.","Distribution":"Volume of distribution around 34 liters, and it is highly bound to plasma proteins (>99%).","Metabolism":"Undergoes first-pass metabolism by cytochrome P450 enzymes to form an active metabolite, EXP3174.","Excretion":"Approximately 35% is excreted in urine and 60% in feces."},"SideEffects":["Dizziness","Nasal congestion","Back pain","Upper respiratory infection","Hyperkalemia"],"DrugInteractions":["Concomitant use with ACE inhibitors may increase the risk of hyperkalemia.","Additive effects with other antihypertensive agents.","NSAIDs may reduce the antihypertensive effect.","Use with potassium-sparing diuretics or potassium supplements may increase the risk of hyperkalemia."],"Contraindications":"Hypersensitivity to losartan or any component of the formulation. It should not be used during pregnancy.","ChemicalStructure":{"MolecularFormula":"C22H23ClN6O","MolecularWeight":"422.91 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated, especially in the second and third trimesters.","PediatricUse":"Safety and effectiveness have been established in pediatric patients with hypertension aged 6 and older.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients.","HepaticImpairment":"Given that losartan is metabolized in the liver, caution should be used, and lower doses may be necessary.","RenalImpairment":"Caution is advised as the drug is excreted in the urine. Serum electrolytes and renal function should be monitored."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F). Protect from light and moisture."},{"GenericName":"Gabapentin","BrandNames":["Neurontin","Gabarone","Gralise"],"DrugClass":"Anticonvulsant","MechanismOfAction":"Gabapentin is structurally related to the neurotransmitter GABA (gamma-aminobutyric acid) but does not bind to GABA receptors or influence the synthesis, uptake, or degradation of GABA. Its mechanism of action is not fully understood but is thought to involve the binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, leading to decreased excitatory neurotransmitter release.","Pharmacodynamics":"Gabapentin is effective in reducing the frequency of seizures in some patients and has analgesic properties, which may decrease pain in certain neuropathic conditions.","OnsetOfAction":"Gabapentin generally takes several hours to reach its onset of action with therapeutic effects observed in several days to weeks.","DurationOfAction":"The duration of action is approximately 5 to 7 hours per dose, depending on the dose and formulation used.","PeakPlasmaConcentration":"Peak plasma concentrations are typically reached within 2 to 3 hours after administration.","Indications":["Partial seizures","Postherpetic neuralgia","Neuropathic pain"],"RoutesOfAdministration":"Oral","DosageForms":["Capsule","Tablet","Oral solution"],"StrengthsOfDosageForms":["Capsules: 100 mg, 300 mg, 400 mg","Tablets: 600 mg, 800 mg","Oral solution: 250 mg/5 mL"],"Pharmacokinetics":{"Absorption":"Absorbed in the proximal small bowel via an L-amino acid transport system; absorption decreases with increasing dose, leading to nonlinear pharmacokinetics.","Distribution":"Not bound to plasma proteins; volume of distribution is approximately 58 liters.","Metabolism":"Gabapentin undergoes negligible metabolism; it is not appreciably metabolized in humans.","Excretion":"Excreted primarily by the kidneys as unchanged drug; elimination half-life is 5 to 7 hours."},"SideEffects":["Dizziness","Somnolence","Peripheral edema","Ataxia","Fatigue"],"DrugInteractions":["Antacids (can decrease gabapentin bioavailability if taken simultaneously)","CNS depressants (can increase the sedative effect)"],"Contraindications":"Hypersensitivity to gabapentin or any component of its formulation.","ChemicalStructure":{"MolecularFormula":"C9H17NO2","MolecularWeight":"171.24 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus. Classified as pregnancy category C.","PediatricUse":"Safety and efficacy for treating partial seizures have been established in patients 3 years and older, but not for other indications.","GeriatricUse":"Dosage adjustments may be necessary based on renal function as elimination is primarily renal.","HepaticImpairment":"No specific dosing adjustments are recommended, but caution is advised as hepatic disease could alter drug metabolism.","RenalImpairment":"Dose adjustments are necessary as gabapentin is excreted unchanged by the kidneys."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F), away from light and moisture."},{"GenericName":"Hydrochlorothiazide","BrandNames":["Microzide","Esidrix","Hydrodiuril"],"DrugClass":"Thiazide diuretic","MechanismOfAction":"Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules, causing increased excretion of sodium and water as well as potassium and hydrogen ions.","Pharmacodynamics":"Hydrochlorothiazide reduces blood pressure by reducing plasma volume, cardiac output, and possibly by some direct vasodilatory action. It also promotes dieresis, thus leading to a reduction in extracellular fluid volume.","OnsetOfAction":"2 hours","DurationOfAction":"6-12 hours","PeakPlasmaConcentration":"1.5-5 hours after dosing","Indications":["Hypertension","Edema associated with congestive heart failure, hepatic cirrhosis, or corticosteroid therapy"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Capsule"],"StrengthsOfDosageForms":["12.5 mg","25 mg","50 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract.","Distribution":"Widely distributed in the body but does not readily cross the blood-brain barrier.","Metabolism":"Minimally metabolized in the liver.","Excretion":"Primarily excreted unchanged in the urine."},"SideEffects":["Electrolyte imbalance","Dizziness","Headache","Nausea","Vomiting","Muscle cramps","Photosensitivity"],"DrugInteractions":["Lithium (increased risk of lithium toxicity)","NSAIDs (reduced diuretic and antihypertensive effects)","Digoxin (increased risk of digoxin toxicity due to hypokalemia)"],"Contraindications":"Anuria, hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs.","ChemicalStructure":{"MolecularFormula":"C7H8ClN3O4S2","MolecularWeight":"297.74 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Should be used during pregnancy only if clearly needed. May cause fetal harm when administered in the second or third trimester.","PediatricUse":"Safety and efficacy in children have not been established.","GeriatricUse":"May be more prone to side effects such as electrolyte imbalance.","HepaticImpairment":"Use with caution; electrolyte disturbances may precipitate hepatic coma in susceptible patients.","RenalImpairment":"Use with caution; effectiveness may be reduced."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture."},{"GenericName":"Acetaminophen/Hydrocodone","BrandNames":["Vicodin","Norco","Lorcet","Lortab"],"DrugClass":"Opioid Analgesic Combination","MechanismOfAction":"Hydrocodone binds to the mu-opioid receptor in the central nervous system to alter the perception and response to pain. Acetaminophen is a non-opioid analgesic and antipyretic that works by inhibiting the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation.","Pharmacodynamics":"Hydrocodone exhibits analgesic effects through opioid receptor activation, leading to pain relief. Acetaminophen enhances the analgesic effect by inhibiting prostaglandin synthesis. Together, the combination provides greater pain relief than either agent alone.","OnsetOfAction":"15 to 30 minutes","DurationOfAction":"4 to 6 hours","PeakPlasmaConcentration":"Approximately 1.3 hours for hydrocodone","Indications":["Relief of moderate to severe pain"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Oral solution"],"StrengthsOfDosageForms":["5 mg/325 mg","7.5 mg/325 mg","10 mg/325 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Volume of distribution is 4 L/kg for hydrocodone.","Metabolism":"Hydrocodone is metabolized in the liver by CYP3A4 and CYP2D6 to active and inactive metabolites. Acetaminophen is primarily metabolized in the liver.","Excretion":"Excreted primarily in the urine as metabolites."},"SideEffects":["Nausea","Vomiting","Constipation","Drowsiness","Dizziness","Respiratory depression","Hepatotoxicity (at high doses)"],"DrugInteractions":["Alcohol","CNS depressants","MAO inhibitors","CYP3A4 inhibitors and inducers","CYP2D6 inhibitors"],"Contraindications":"Significant respiratory depression, acute or severe bronchial asthma, gastrointestinal obstruction, hypersensitivity to hydrocodone or acetaminophen","ChemicalStructure":{"MolecularFormula":"C18H21NO3 (hydrocodone)","MolecularWeight":"299.364 g/mol (hydrocodone); 151.16 g/mol (acetaminophen)"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; potential risk to fetus (Category C).","PediatricUse":"Safety and efficacy not established in children under 2 years.","GeriatricUse":"Increased sensitivity; use with caution.","HepaticImpairment":"Use with caution; adjust dose as necessary.","RenalImpairment":"Use with caution; adjust dose as necessary."},"StorageAndHandling":"Store at room temperature, away from light and moisture."},{"GenericName":"Sertraline","BrandNames":["Zoloft","Lustral"],"DrugClass":"Selective Serotonin Reuptake Inhibitor (SSRI)","MechanismOfAction":"Sertraline works by selectively inhibiting the central nervous system's neuronal uptake of serotonin (5HT). It has only very weak effects on norepinephrine and dopamine neuronal uptake.","Pharmacodynamics":"Sertraline enhances the action of serotonin by inhibiting its reuptake into the presynaptic neuron, thereby increasing serotonin levels in the synaptic cleft and its serotonergic activity.","OnsetOfAction":"May take 1 to 2 weeks to start showing effects; full response may take 4 to 6 weeks.","DurationOfAction":"Half-life is approximately 26 hours, providing prolonged action, so it is usually administered once daily.","PeakPlasmaConcentration":"Achieved within 4.5 to 8.4 hours after oral administration.","Indications":["Major Depressive Disorder","Obsessive-Compulsive Disorder","Panic Disorder","Post-Traumatic Stress Disorder","Social Anxiety Disorder","Premenstrual Dysphoric Disorder"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Oral concentrate"],"StrengthsOfDosageForms":["Tablets: 25 mg, 50 mg, 100 mg","Oral concentrate: 20 mg/mL"],"Pharmacokinetics":{"Absorption":"Slow; approximately 44% bioavailability, with food increasing plasma concentration by approximately 25%","Distribution":"Sertraline is widely distributed throughout the body and is highly protein-bound (98%)","Metabolism":"Extensively hepatic; sertraline undergoes N-demethylation to form an active metabolite, desmethylsertraline","Excretion":"Excreted primarily in feces (40-45%) and urine (12-14%)"},"SideEffects":["Nausea","Diarrhea","Insomnia","Dry mouth","Sexual dysfunction","Dizziness","Fatigue","Sweating"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Pimozide","Warfarin","Other serotonergic drugs","NSAIDs"],"Contraindications":"Concurrent use with MAOIs, pimozide, or in patients with hypersensitivity to sertraline or any of its components","ChemicalStructure":{"MolecularFormula":"C17H17Cl2N","MolecularWeight":"306.23 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus","PediatricUse":"Approved for pediatric use in obsessive-compulsive disorder (OCD) starting from ages 6 to 17 years","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients, but greater sensitivity in some older individuals is possible","HepaticImpairment":"Use with caution; dosage adjustments may be necessary","RenalImpairment":"No dosage adjustment required in renal impairment"},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and light."},{"GenericName":"Montelukast","BrandNames":["Singulair","Montelo-10"],"DrugClass":"Leukotriene receptor antagonist","MechanismOfAction":"Montelukast works by selectively binding to cysteinyl leukotriene receptors (CysLT1) in the lungs and overactive immune cells, thus inhibiting the action of leukotrienes that cause airways inflammation and constriction.","Pharmacodynamics":"The drug reduces leukotriene-mediated bronchoconstriction, inflammation, and mucus secretion, which helps improve breathing by reducing asthma symptoms and preventing asthma attacks.","OnsetOfAction":"Within 3 to 4 hours","DurationOfAction":"At least 24 hours","PeakPlasmaConcentration":"2 to 4 hours after oral administration","Indications":["Asthma prophylaxis and chronic treatment","Seasonal and perennial allergic rhinitis","Prevention of exercise-induced bronchoconstriction"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Chewable tablets","Granules"],"StrengthsOfDosageForms":["10 mg tablets","5 mg chewable tablets","4 mg chewable tablets","4 mg granules"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following oral administration with a bioavailability of 64% (chewable tablet) to 73% (tablet).","Distribution":"Volume of distribution is approximately 8 to 11 liters, and it is more than 99% bound to plasma proteins.","Metabolism":"Extensively metabolized in the liver via CYP3A4, CYP2C8, and CYP2C9 enzymes.","Excretion":"Primarily excreted in the bile and very little is found in urine."},"SideEffects":["Headache","Abdominal pain","Cough","Dizziness","Fatigue"],"DrugInteractions":["CYP450 inducers such as rifampin and phenobarbital may decrease its efficacy","Concurrent use with other hepatically metabolized drugs should be monitored carefully"],"Contraindications":"Hypersensitivity to montelukast or any of its ingredients.","ChemicalStructure":{"MolecularFormula":"C35H36ClNO3S","MolecularWeight":"586.18 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Class B; animal studies have not demonstrated a risk to the fetus, and no adequate studies in pregnant women.","PediatricUse":"Approved for use in children 6 months and older with appropriate dosing adjustments.","GeriatricUse":"No specific dose adjustment required; however, increased sensitivity in some older adults cannot be ruled out.","HepaticImpairment":"No dose adjustment necessary in mild to moderate hepatic impairment.","RenalImpairment":"No dose adjustment required."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and light. Keep container tightly closed to protect from air. Keep out of reach of children."},{"GenericName":"Fluticasone","BrandNames":["Flonase","Flovent","Arnuity Ellipta"],"DrugClass":"Corticosteroid","MechanismOfAction":"Fluticasone acts as a potent glucocorticoid receptor agonist. It binds to glucocorticoid receptors and modulates gene expression for anti-inflammatory proteins, reducing inflammation and immune responses.","Pharmacodynamics":"Fluticasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. It reduces symptoms of allergic reactions and certain chronic asthma symptoms by local action in the lungs or nasal passages.","OnsetOfAction":"12 hours for inhaled formulation in asthma; 3 to 10 hours for allergic rhinitis with nasal spray.","DurationOfAction":"24 hours","PeakPlasmaConcentration":"Usually occurs within 0.5 to 1 hour after administration for inhaled formulations.","Indications":["Asthma","Allergic rhinitis","Nasal polyps"],"RoutesOfAdministration":"Inhalation, Intranasal","DosageForms":["Inhaler","Nasal spray"],"StrengthsOfDosageForms":["50 mcg per actuation (nasal spray)","100 mcg per actuation (inhaler)","250 mcg per actuation (inhaler)"],"Pharmacokinetics":{"Absorption":"Less than 2% is absorbed into the bloodstream when used in the nasal cavity.","Distribution":"The volume of distribution is 318 L. It is widely distributed in body tissues.","Metabolism":"Undergoes extensive first-pass metabolism in the liver by CYP3A4 to an inactive carboxylic acid metabolite.","Excretion":"Excreted mostly in feces (up to 90%); urine excretion is minimal (less than 5%)."},"SideEffects":["Nasal irritation","Nosebleeds","Headache","Sore throat","Hoarseness"],"DrugInteractions":["Ritonavir","Ketoconazole","Itraconazole"],"Contraindications":"Hypersensitivity to fluticasone or any of the excipients in the formulation.","ChemicalStructure":{"MolecularFormula":"C22H27F3O4S","MolecularWeight":"444.51 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution. Category C; not enough adequate studies in pregnant women.","PediatricUse":"Can be used; dose adjustments may be necessary depending on age.","GeriatricUse":"No specific adjustments needed, but monitor for increased side effects.","HepaticImpairment":"Caution is advised due to potential for prolonged corticosteroid effects.","RenalImpairment":"No dosage adjustment necessary due to minimal renal excretion."},"StorageAndHandling":"Store in a dry place at room temperature, away from direct sunlight and moisture. Keep out of reach of children."},{"GenericName":"Amoxicillin","BrandNames":["Amoxil","Trimox","Moxatag"],"DrugClass":"Penicillin Antibiotic","MechanismOfAction":"Amoxicillin works by inhibiting the synthesis of bacterial cell walls by binding to penicillin-binding proteins, which prevents the formation of a vital component of the cell wall, leading to cell lysis and death.","Pharmacodynamics":"Amoxicillin is a bactericidal antibiotic that is effective against a broad spectrum of gram-positive and some gram-negative bacteria. It is similar in action to penicillin but more effective against certain strains of bacteria.","OnsetOfAction":"The onset of action for amoxicillin is typically within 1-2 hours after oral administration.","DurationOfAction":"The duration of action varies but is generally around 6-8 hours, necessitating multiple doses throughout the day.","PeakPlasmaConcentration":"Achieved in 1-2 hours after oral administration.","Indications":["Upper respiratory tract infections","Urinary tract infections","Skin infections","Helicobacter pylori eradication","Strep throat","Otitis media"],"RoutesOfAdministration":"Oral","DosageForms":["Capsule","Tablet","Chewable tablet","Suspension"],"StrengthsOfDosageForms":["250 mg","500 mg","875 mg","125 mg/5 mL","200 mg/5 mL","250 mg/5 mL","400 mg/5 mL"],"Pharmacokinetics":{"Absorption":"Approximately 74-92% absorbed from the gastrointestinal tract.","Distribution":"Widely distributed throughout the body; does not penetrate the blood-brain barrier unless meninges are inflamed.","Metabolism":"Only partially metabolized in the liver.","Excretion":"Excreted primarily in urine, with around 60-70% excreted unchanged."},"SideEffects":["Nausea","Vomiting","Diarrhea","Rash","Allergic reactions","Hepatitis","Interstitial nephritis"],"DrugInteractions":["Methotrexate","Warfarin","Probenecid","Allopurinol"],"Contraindications":"Hypersensitivity to amoxicillin or other penicillins.","ChemicalStructure":{"MolecularFormula":"C16H19N3O5S","MolecularWeight":"365.4 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B: No proven risk in humans, but should only be used if clearly needed.","PediatricUse":"Safe and effective in pediatric patients, with dosages adjusted according to weight.","GeriatricUse":"No specific precautions; standard dosing applies.","HepaticImpairment":"Caution is advised as dosage adjustment may be necessary.","RenalImpairment":"Dosage adjustments are recommended based on the degree of renal impairment."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Dry suspension should be refrigerated and used within 14 days after reconstitution."},{"GenericName":"Pantoprazole","BrandNames":["Protonix","Pantoloc"],"DrugClass":"Proton Pump Inhibitor (PPI)","MechanismOfAction":"Pantoprazole suppresses gastric acid production by specifically inhibiting the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. It is a substituted benzimidazole that increases gastric pH by blocking acid secretion at its source, the proton pump, thereby providing relief from acid-related conditions.","Pharmacodynamics":"Pantoprazole decreases gastric acid secretion by inhibiting the parietal cell H+/K+ ATP pump. Its suppression of gastric acid secretion is dose-dependent and leads to a significant, lasting decrease in acid, which persists over a 24-hour period.","OnsetOfAction":"2.5 hours after oral administration.","DurationOfAction":"Nearly 24 hours.","PeakPlasmaConcentration":"Approximately 2.5 hours after administration.","Indications":["Gastroesophageal reflux disease (GERD)","Erosive esophagitis","Zollinger-Ellison syndrome","Other conditions associated with excessive acid production"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablets","Injection (lyophilized powder)","Granules for oral suspension"],"StrengthsOfDosageForms":["Tablet: 20 mg, 40 mg","Injection: 40 mg vial","Granules: 40 mg"],"Pharmacokinetics":{"Absorption":"Pantoprazole is well absorbed with a bioavailability of approximately 77% after oral administration. Food slightly delays and decreases the extent of absorption.","Distribution":"Widely distributed with a volume of distribution of 0.15 L/kg. Binding to plasma proteins is about 98%.","Metabolism":"Extensively metabolized in the liver via CYP2C19 and to a lesser extent CYP3A4.","Excretion":"Mainly excreted in the urine (about 71%) with the remainder excreted in feces."},"SideEffects":["Headache","Diarrhea","Nausea","Abdominal pain","Flatulence"],"DrugInteractions":["Warfarin (may increase INR)","Clopidogrel (may reduce antiplatelet effect)","Methotrexate (may increase methotrexate toxicity)","HIV protease inhibitors (such as atazanavir)"],"Contraindications":"Hypersensitivity to pantoprazole, other benzimidazole prodrugs, or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C16H14F2N3NaO4S","MolecularWeight":"405.36 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B. Use only if clearly needed and the potential benefits justify the potential risk to the fetus.","PediatricUse":"Safety and effectiveness have been established in pediatric patients (ages 1-16) for short-term treatment of erosive esophagitis.","GeriatricUse":"No dosage adjustment is recommended based on age alone. Consider monitoring for decreased renal function.","HepaticImpairment":"No dosage adjustment is needed in patients with mild hepatic impairment. Severe hepatic impairment may require adjustment.","RenalImpairment":"No dosage adjustment is necessary."},"StorageAndHandling":"Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). Protect from moisture. Store in the original package."},{"GenericName":"Escitalopram","BrandNames":["Lexapro","Cipralex"],"DrugClass":"Selective Serotonin Reuptake Inhibitor (SSRI)","MechanismOfAction":"Escitalopram works by increasing the serotonin levels in the brain, which helps improve mood and reduces symptoms of depression and anxiety. It selectively inhibits the reuptake of serotonin into the presynaptic neuron, enhancing serotonin signaling.","Pharmacodynamics":"Escitalopram increases serotonergic activity in the central nervous system through selective inhibition of serotonin reuptake with minimal effects on norepinephrine and dopamine reuptake.","OnsetOfAction":"1 to 4 weeks","DurationOfAction":"Approximately 1 month after discontinuation, though it varies depending on the individual therapy duration.","PeakPlasmaConcentration":"4 to 5 hours post-dose","Indications":["Major depressive disorder (MDD)","Generalized anxiety disorder (GAD)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Oral solution"],"StrengthsOfDosageForms":["5 mg tablets","10 mg tablets","20 mg tablets","1 mg/ml oral solution"],"Pharmacokinetics":{"Absorption":"Well absorbed orally with a bioavailability of about 80%.","Distribution":"Apparent volume of distribution is about 12-26 L/kg.","Metabolism":"Primarily metabolized in the liver via CYP2C19, CYP2D6, and CYP3A4 to demethylated and didemethylated metabolites.","Excretion":"About 13% is excreted in the urine as unchanged drug, with the majority excreted as metabolites."},"SideEffects":["Nausea","Insomnia","Fatigue","Decreased libido","Anorgasmia","Diarrhea","Dry mouth"],"DrugInteractions":["MAO inhibitors","NSAIDs","Anticoagulants","Alcohol","Triptans","Other SSRIs or SNRIs"],"Contraindications":"Contraindicated in patients with known hypersensitivity to escitalopram or citalopram, and in patients taking MAO inhibitors or within 14 days of discontinuation of an MAO inhibitor.","ChemicalStructure":{"MolecularFormula":"C20H21FN2O","MolecularWeight":"324.4 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if potential benefit justifies the potential risk to the fetus. Classified as Category C.","PediatricUse":"May be used in adolescents aged 12 and older for major depressive disorder, but effects on growth should be monitored.","GeriatricUse":"Use may require adjustment of dosage, often starting at lower dosages due to increased susceptibility to adverse effects.","HepaticImpairment":"Dose adjustment may be necessary; recommended dose is 10 mg/day.","RenalImpairment":"Dose adjustment not typically required, but caution is advised in severe impairment."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F), protected from moisture and light."},{"GenericName":"Alprazolam","BrandNames":["Xanax","Niravam","Xanor"],"DrugClass":"Benzodiazepine","MechanismOfAction":"Alprazolam binds to GABA-A receptors in the brain and enhances the effects of gamma-aminobutyric acid (GABA), leading to the inhibition of neuronal activity and producing sedative, anxiolytic, and muscle relaxant effects.","Pharmacodynamics":"Alprazolam has central nervous system depressant properties, which result in anxiolytic, anticonvulsant, hypnotic, and muscle relaxant effects. It reduces anxiety, causes sedation, and is generally calming.","OnsetOfAction":"Onset of action is typically within 1 to 2 hours after oral administration.","DurationOfAction":"The duration of action is approximately 6 to 12 hours.","PeakPlasmaConcentration":"Peak plasma concentrations occur within 1 to 2 hours after oral administration.","Indications":["Anxiety disorders","Panic disorder","Generalized anxiety disorder (GAD)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets (immediate and extended release)","Orally disintegrating tablets","Liquid solution"],"StrengthsOfDosageForms":["0.25 mg","0.5 mg","1 mg","2 mg","3 mg (extended release tablets)"],"Pharmacokinetics":{"Absorption":"Well absorbed with bioavailability of 80-100% after oral administration.","Distribution":"Widely distributed in body tissues; highly bound to plasma proteins (about 80%).","Metabolism":"Primarily hepatic via cytochrome P450 3A4 (CYP3A4).","Excretion":"Excreted primarily in urine, with a half-life of 11.2 hours on average."},"SideEffects":["Drowsiness","Dizziness","Fatigue","Memory impairment","Depression","Headache","Dry mouth"],"DrugInteractions":["Alcohol","Other benzodiazepines","CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","Opioids"],"Contraindications":"Hypersensitivity to alprazolam or other benzodiazepines, acute narrow-angle glaucoma.","ChemicalStructure":{"MolecularFormula":"C17H13ClN4","MolecularWeight":"308.765 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D; there is evidence of human fetal risk based on adverse reaction data, but potential benefits may warrant use of the drug in pregnant women despite potential risks.","PediatricUse":"Safety and effectiveness have not been established in pediatric population.","GeriatricUse":"Caution is advised due to the increased sensitivity of the elderly population to benzodiazepines.","HepaticImpairment":"Use with caution and dose adjustment may be needed due to altered drug metabolism.","RenalImpairment":"No dose adjustment is usually necessary, but caution is advised."},"StorageAndHandling":"Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Protect from light and moisture."},{"GenericName":"Furosemide","BrandNames":["Lasix","Furosed","Frumex"],"DrugClass":"Loop diuretic","MechanismOfAction":"Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, resulting in decreased reabsorption of sodium and chloride, leading to increased excretion of water, sodium, chloride, magnesium, and calcium.","Pharmacodynamics":"Furosemide leads to increased excretion of sodium and water, reduces blood volume, increases urine production, and decreases blood pressure.","OnsetOfAction":"Oral: 1 hour, IV: 5 minutes","DurationOfAction":"4 to 6 hours","PeakPlasmaConcentration":"1 to 2 hours (oral), 30 minutes (IV)","Indications":["Edema associated with congestive heart failure","Cirrhosis of the liver","Renal disease including nephrotic syndrome","Hypertension"],"RoutesOfAdministration":"Oral, Intravenous (IV), Intramuscular (IM)","DosageForms":["Tablet","Oral solution","Injection"],"StrengthsOfDosageForms":["20 mg","40 mg","80 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following oral administration with bioavailability of 47-64%","Distribution":"Widely distributed in body tissues, 91-99% protein-bound","Metabolism":"Minimal hepatic metabolism","Excretion":"Excreted primarily in the urine (50% as unchanged drug)"},"SideEffects":["Hypokalemia","Dehydration","Hyponatremia","Hypocalcemia","Hypotension","Dizziness","Headache"],"DrugInteractions":["NSAIDs may reduce diuretic efficacy","Aminoglycosides may increase ototoxicity","ACE inhibitors may increase risk of hypotension"],"Contraindications":"Anuria, hypersensitivity to furosemide or sulfonamides","ChemicalStructure":{"MolecularFormula":"C12H11ClN2O5S","MolecularWeight":"330.74 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed and the benefit outweighs the risk (Category C)","PediatricUse":"Safety and efficacy have been established in pediatric patients","GeriatricUse":"May be more sensitive to the hypotensive and electrolyte effects","HepaticImpairment":"Use with caution, starting with low doses","RenalImpairment":"Requires close monitoring, may need adjusted dosing"},"StorageAndHandling":"Store at room temperature, protect from light."},{"GenericName":"Sulfamethoxazole/Trimethoprim","BrandNames":["Bactrim","Septra","Cotrim"],"DrugClass":"Antibacterial (sulfonamide and diaminopyrimidine combination)","MechanismOfAction":"Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA), while Trimethoprim inhibits the enzyme dihydrofolate reductase, blocking the production of tetrahydrofolic acid.","Pharmacodynamics":"The combination of sulfamethoxazole and trimethoprim results in synergy, achieving bactericidal activity, which is more effective than either agent alone, due to sequential blockade of folate synthesis.","OnsetOfAction":"Variable onset based on infection type, generally within a few hours to a few days.","DurationOfAction":"6-12 hours for oral administration, depending on kidney function and dosing regimen.","PeakPlasmaConcentration":"1-4 hours post oral dose for trimethoprim and sulfamethoxazole respectively.","Indications":["Urinary Tract Infections","Acute Otitis Media","Bronchitis","Travelers' Diarrhea","Pneumocystis jirovecii pneumonia","Shigellosis"],"RoutesOfAdministration":"Oral and intravenous (IV).","DosageForms":["Tablet","Suspension","IV solution"],"StrengthsOfDosageForms":["Tablet: 400 mg/80 mg (sulfamethoxazole/trimethoprim), 800 mg/160 mg (sulfamethoxazole/trimethoprim)","Suspension: 200 mg/40 mg per 5 mL (sulfamethoxazole/trimethoprim)","IV solution: 80 mg/16 mg per mL (sulfamethoxazole/trimethoprim)"],"Pharmacokinetics":{"Absorption":"Well absorbed orally, with approximately 90-100% bioavailability for both drugs.","Distribution":"Widely distributed in body tissues and fluids, crosses the placenta and blood-brain barrier; volume of distribution for trimethoprim is about 1.6 L/kg.","Metabolism":"Primarily hepatic via the liver; trimethoprim undergoes extensive metabolism.","Excretion":"Renal excretion, with 50-60% of sulfonamide and 40-50% of trimethoprim being eliminated unchanged in urine."},"SideEffects":["Nausea","Vomiting","Anorexia","Rash","Urticaria","Photosensitivity","Hyperkalemia","Thrombocytopenia","Neutropenia"],"DrugInteractions":["Warfarin","Methotrexate","Phenytoin","Cyclosporine","Oral hypoglycemics","ACE inhibitors"],"Contraindications":"Hypersensitivity to trimethoprim, sulfamethoxazole, or sulfonamides; patients with a history of drug-induced immune thrombocytopenia with the use of trimethoprim and/or sulfonamides; marked hepatic damage or severe renal insufficiency when renal function status cannot be monitored.","ChemicalStructure":{"MolecularFormula":"Sulfamethoxazole: C10H11N3O3S; Trimethoprim: C14H18N4O3","MolecularWeight":"Sulfamethoxazole: 253.28 g/mol; Trimethoprim: 290.32 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D; should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Not recommended for use in infants younger than 2 months.","GeriatricUse":"Caution is advised due to the increased risk of severe side effects, particularly in patients with decreased renal function.","HepaticImpairment":"Use with caution in patients with hepatic impairment.","RenalImpairment":"Dosage adjustments may be necessary; monitor renal function due to the risk of further renal damage."},"StorageAndHandling":"Store at 15°C to 30°C (59°F to 86°F). Protect from light and moisture for oral and IV forms."},{"GenericName":"Clopidogrel","BrandNames":["Plavix"],"DrugClass":"Antiplatelet agent","MechanismOfAction":"Clopidogrel inhibits platelet aggregation by selectively and irreversibly blocking the adenosine diphosphate (ADP) receptor on platelet cell membranes, which prevents activation of the glycoprotein IIb/IIIa complex necessary for platelet aggregation.","Pharmacodynamics":"Clopidogrel reduces the formation of thrombi by inhibiting platelet aggregation. Its effect is related to the binding of its active metabolite to the platelet P2Y12 ADP receptor.","OnsetOfAction":"Approximately 2 hours","DurationOfAction":"7–10 days (duration of platelet life cycle)","PeakPlasmaConcentration":"4 hours after oral administration","Indications":["Acute coronary syndrome (ACS)","Myocardial infarction (MI)","Stroke","Peripheral arterial disease"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["75 mg","300 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed after oral administration","Distribution":"Clopidogrel and its active metabolite bind reversibly to albumin (98% and 94%, respectively)","Metabolism":"Hepatic metabolism, primarily by CYP2C19 and other CYP enzymes","Excretion":"Renally and through feces (about 50% of the orally administered dose)"},"SideEffects":["Bleeding","Bruising","Gastrointestinal discomfort","Rash","Diarrhea","Thrombocytopenic purpura"],"DrugInteractions":["Proton pump inhibitors like omeprazole (can reduce clopidogrel’s effectiveness)","Warfarin (increased risk of bleeding)","Nonsteroidal anti-inflammatory drugs (NSAIDs) (increased risk of GI bleeding)"],"Contraindications":"Active pathological bleeding (e.g. peptic ulcer, intracranial hemorrhage)","ChemicalStructure":{"MolecularFormula":"C16H16ClNO2S","MolecularWeight":"321.82 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B - No evidence of risk in humans, but studies are limited.","PediatricUse":"Safety and efficacy not established in pediatric patients.","GeriatricUse":"Generally safe, but the risk of bleeding might be higher.","HepaticImpairment":"Use with caution in severe hepatic impairment due to increased bleeding risk.","RenalImpairment":"Use with caution in severe renal impairment due to increased bleeding risk."},"StorageAndHandling":"Store at room temperature between 20°C and 25°C (68°F and 77°F) in a tightly closed container."},{"GenericName":"Prednisone","BrandNames":["Deltasone","Rayos","Winpred"],"DrugClass":"Glucocorticoid","MechanismOfAction":"Prednisone is a synthetic glucocorticoid medication. It works by suppressing the immune system and reducing inflammation through inhibition of leukocyte infiltration at the site of inflammation, interference in the function of inflammatory mediators, suppression of humoral immune responses, and reduction in edema or scar tissue.","Pharmacodynamics":"Prednisone modulates the immune response by down-regulating the expression of genes coding for various cytokines and enzymes involved in the inflammatory process. It affects the body's metabolism of carbohydrates, proteins, and fats, and modifies the body's immune response to diverse stimuli.","OnsetOfAction":"Several hours to day of onset depending on the condition being treated.","DurationOfAction":"The duration of its anti-inflammatory effects lasts approximately 18-36 hours.","PeakPlasmaConcentration":"1 to 2 hours after oral administration.","Indications":["Allergic reactions","Inflammatory diseases","Autoimmune diseases","Asthma","Rheumatoid arthritis","Lupus","Chronic obstructive pulmonary disease (COPD)","Adrenal insufficiency"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Solution"],"StrengthsOfDosageForms":["1 mg tablet","2.5 mg tablet","5 mg tablet","10 mg tablet","20 mg tablet","50 mg tablet","5 mg/5 mL oral solution"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract.","Distribution":"Widely distributed throughout the body, including the breast milk.","Metabolism":"Extensively metabolized in the liver to its active form, prednisolone.","Excretion":"Primarily excreted by the kidneys as inactive metabolites."},"SideEffects":["Increased appetite","Weight gain","Insomnia","Mood swings","Increased risk of infections","Hypertension","Hyperglycemia","Osteoporosis with long-term use"],"DrugInteractions":["NSAIDs can increase gastrointestinal bleeding risk","Live vaccines may not be effective","Can interact with other immunosuppressive therapies","Antifungals may increase the effect of prednisone"],"Contraindications":"Systemic fungal infections and known hypersensitivity to prednisone or any components of its formulation.","ChemicalStructure":{"MolecularFormula":"C21H26O5","MolecularWeight":"358.43 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C: Risk cannot be ruled out. Should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Should be used with caution; growth and development monitoring is necessary.","GeriatricUse":"No specific information, but dosing may need to be adjusted due to age-related health factors.","HepaticImpairment":"Use with caution; dosage adjustments may be necessary.","RenalImpairment":"Use with caution, although specific adjustment guidelines might not be clear."},"StorageAndHandling":"Store at controlled room temperature 20-25°C (68-77°F). Protect from light and moisture."},{"GenericName":"Ibuprofen","BrandNames":["Advil","Motrin","Nurofen"],"DrugClass":"Nonsteroidal anti-inflammatory drug (NSAID)","MechanismOfAction":"Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, leading to a decrease in the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever.","Pharmacodynamics":"Ibuprofen has anti-inflammatory, analgesic, and antipyretic properties. It works by reducing the levels of prostaglandins involved in inflammation and pain processes.","OnsetOfAction":"30 to 60 minutes","DurationOfAction":"Approximately 4 to 6 hours","PeakPlasmaConcentration":"1 to 2 hours after oral administration","Indications":["Pain relief","Inflammation reduction","Fever reduction","Treatment of headaches","Dysmenorrhea","Musculoskeletal pain","Arthritis"],"RoutesOfAdministration":"Oral, intravenous, topical","DosageForms":["Tablets","Capsules","Suspensions","Gels","Creams","Injectables"],"StrengthsOfDosageForms":["200 mg tablets","400 mg tablets","600 mg tablets","800 mg tablets","100 mg/5 mL suspension"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract","Distribution":"Widely distributed throughout the body; binds extensively (90-99%) to plasma proteins","Metabolism":"Hepatically metabolized mainly via the cytochrome P450 enzymes","Excretion":"Primarily excreted via the urine"},"SideEffects":["Nausea","Dizziness","Dyspepsia","Abdominal pain","Rash","Headache","Heartburn","Renal impairment"],"DrugInteractions":["Aspirin","Other NSAIDs","Anticoagulants (e.g., warfarin)","Diuretics","Antihypertensives","Lithium","Methotrexate"],"Contraindications":"Hypersensitivity to ibuprofen or other NSAIDs, history of asthma or allergies precipitated by NSAIDs, active gastrointestinal bleeding or ulcers.","ChemicalStructure":{"MolecularFormula":"C13H18O2","MolecularWeight":"206.29 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Caution is recommended, especially in the third trimester due to risks of premature closure of the ductus arteriosus","PediatricUse":"Approved for use in children over 6 months of age for fever and pain","GeriatricUse":"Increased risk of adverse effects, including gastrointestinal bleeding and renal impairment","HepaticImpairment":"Caution is required; may need dose adjustments","RenalImpairment":"Caution and dose adjustments are necessary due to increased risk of renal toxicity"},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F). Keep away from moisture and heat."},{"GenericName":"Citalopram","BrandNames":["Celexa","Cipramil"],"DrugClass":"Selective Serotonin Reuptake Inhibitor (SSRI)","MechanismOfAction":"Citalopram works by selectively inhibiting the reuptake of serotonin in the brain, which increases the level of serotonin and thereby enhances mood and emotional stability.","Pharmacodynamics":"Citalopram increases serotonin levels in the synaptic cleft by inhibiting its reuptake into the presynaptic neuron. This alteration in synaptic transmission is believed to contribute to its antidepressant and anxiolytic effects.","OnsetOfAction":"Typically 1 to 4 weeks for antidepressant effects.","DurationOfAction":"About 24 to 36 hours.","PeakPlasmaConcentration":"Achieved in about 4 hours after oral administration.","Indications":["Major Depressive Disorder (MDD)","Generalized Anxiety Disorder (GAD) (off-label)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Solution"],"StrengthsOfDosageForms":["10 mg tablets","20 mg tablets","40 mg tablets","Oral solution: 10 mg/5 mL"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract with an absolute bioavailability of about 80%.","Distribution":"Widely distributed throughout the body with a volume of distribution of about 12 L/kg. It is approximately 80% bound to plasma proteins.","Metabolism":"Primarily metabolized in the liver by cytochrome P450 enzymes (CYP2C19, CYP3A4, and CYP2D6) to inactive metabolites.","Excretion":"Mainly excreted in the urine (85%), with 20% of a dose excreted as unchanged drug."},"SideEffects":["Nausea","Dry mouth","Somnolence","Sweating increased","Tremor","Diarrhea","Insomnia","Ejaculation disorder","Fatigue"],"DrugInteractions":["Increased risk of QT prolongation when used with other drugs that prolong QT interval.","Increased risk of serotonin syndrome when co-administered with other serotonergic drugs (e.g., MAO inhibitors, triptans).","Possible interaction with CYP2C19, CYP3A4, and CYP2D6 inhibitors (e.g., omeprazole, fluvoxamine)."],"Contraindications":"Contraindicated in patients with known hypersensitivity to citalopram or any of its ingredients; co-administration with monoamine oxidase inhibitors (MAOIs); patients with congenital long QT syndrome.","ChemicalStructure":{"MolecularFormula":"C20H21FN2O","MolecularWeight":"324.39 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C (risk cannot be ruled out). Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy not established in children under 18 years of age.","GeriatricUse":"Caution is advised due to the potential for age-related declines in renal and hepatic function and possible susceptibility to QT prolongation.","HepaticImpairment":"Dose should be reduced because of increased plasma concentrations and prolonged half-life.","RenalImpairment":"Use with caution in severe renal impairment as plasma concentrations may be increased."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture."},{"GenericName":"Tramadol","BrandNames":["Ultram","ConZip","Rybix ODT","Ryzolt"],"DrugClass":"Opioid analgesic","MechanismOfAction":"Tramadol works by binding to the mu-opioid receptors in the brain, altering the perception and response to pain. It also inhibits the reuptake of norepinephrine and serotonin, which may contribute to its pain-relieving effects.","Pharmacodynamics":"Tramadol provides pain relief and sedation through its action on opioid receptors and its influence on monoaminergic neurotransmission (norepinephrine and serotonin pathways).","OnsetOfAction":"Tramadol typically begins to relieve pain within one hour after oral administration.","DurationOfAction":"The analgesic effect usually lasts about 6 hours following a single dose.","PeakPlasmaConcentration":"Peak plasma concentrations occur within 2 to 3 hours after an oral dose.","Indications":["Moderate to moderately severe pain","Chronic pain needing continuous, long-term treatment"],"RoutesOfAdministration":"Oral, intravenous, intramuscular, subcutaneous","DosageForms":["Tablet","Capsule","Oral suspension","Injection"],"StrengthsOfDosageForms":["50 mg","100 mg","150 mg","200 mg","300 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed orally with bioavailability of 75% after a single dose.","Distribution":"Widely distributed in the tissues, volume of distribution is approximately 3 liters per kilogram.","Metabolism":"Extensively metabolized in the liver to several metabolites via CYP2D6 and CYP3A4.","Excretion":"Primarily excreted through the kidneys (approximately 30% as unchanged drug and 60% as metabolites)."},"SideEffects":["Nausea","Dizziness","Constipation","Headache","Drowsiness","Seizures","Addiction potential"],"DrugInteractions":["MAO inhibitors","SSRIs","SNRIs","Carbamazepine","Warfarin"],"Contraindications":"Tramadol is contraindicated in patients with hypersensitivity to tramadol, in individuals with significant respiratory depression, acute or severe bronchial asthma in unmonitored settings or in the absence of resuscitative equipment, and with concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI use.","ChemicalStructure":{"MolecularFormula":"C16H25NO2","MolecularWeight":"263.38 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Tramadol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as it is a category C medication.","PediatricUse":"The safety and efficacy in patients under 17 years of age have not been established.","GeriatricUse":"In elderly patients, dose selection should be cautious, usually starting at the low end of the dosing range.","HepaticImpairment":"Use with caution and dosage adjustment may be needed due to altered metabolism in hepatic impairment.","RenalImpairment":"Dosage adjustment is necessary in patients with renal impairment, especially in severe cases."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) in a tight, light-resistant container. Protect from moisture."},{"GenericName":"Rosuvastatin","BrandNames":["Crestor","Rosulip","Zytor"],"DrugClass":"HMG-CoA Reductase Inhibitor (Statin)","MechanismOfAction":"Rosuvastatin works by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. This results in increased uptake and breakdown of LDL cholesterol.","Pharmacodynamics":"Rosuvastatin lowers total cholesterol, LDL cholesterol, and triglyceride levels, while modestly influencing HDL cholesterol levels.","OnsetOfAction":"Within 1 week","DurationOfAction":"About 24 hours","PeakPlasmaConcentration":"3-5 hours after administration","Indications":["Hyperlipidemia","Mixed Dyslipidemia","Hypertriglyceridemia","Primary Dysbetalipoproteinemia","Slowing the progression of atherosclerosis","Primary prevention of cardiovascular disease"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["5 mg","10 mg","20 mg","40 mg"],"Pharmacokinetics":{"Absorption":"Approximately 20% absorbed in the gastrointestinal tract.","Distribution":"Vd is approximately 134 L; extensively bound to plasma proteins (~88%).","Metabolism":"Limited metabolism via the CYP2C9 and CYP2C19 isoenzymes to a minor extent.","Excretion":"Primarily via feces (~90%) and to a lesser extent via urine (~10%)."},"SideEffects":["Myopathy","Rhinitis","Headache","Asthenia","Nausea","Abdominal pain"],"DrugInteractions":["Ciclosporin","Warfarin","Gemfibrozil","Protease Inhibitors","Antacids containing aluminum and magnesium hydroxide"],"Contraindications":"Active liver disease, including unexplained persistent elevations of hepatic transaminase levels; women who are pregnant or may become pregnant; nursing mothers.","ChemicalStructure":{"MolecularFormula":"C22H28FN3O6S","MolecularWeight":"481.55 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated during pregnancy due to teratogenic effects.","PediatricUse":"Approved for use in children 8 years and older for certain conditions.","GeriatricUse":"No significant difference in safety and efficacy between elderly and younger patients, though increased sensitivity of some older individuals cannot be ruled out.","HepaticImpairment":"Not recommended in patients with active liver disease or unexplained, persistent elevations in hepatic transaminase levels.","RenalImpairment":"Dose adjustment may be necessary; caution is advised in severe renal impairment."},"StorageAndHandling":"Store at controlled room temperature between 20°C to 25°C (68°F to 77°F) in a dry place."},{"GenericName":"Trazodone","BrandNames":["Desyrel","Oleptro"],"DrugClass":"Antidepressant, Serotonin Antagonist and Reuptake Inhibitor (SARI)","MechanismOfAction":"Trazodone inhibits serotonin reuptake in the brain, increasing serotonin activity, and also antagonizes certain serotonin receptors leading to antidepressant and anxiolytic effects.","Pharmacodynamics":"Trazodone modulates the activity of serotonin transporters and receptors, leading to alleviation of depression symptoms and promotion of calmness and sleep. It exhibits affinity for multiple receptors, including histamine and alpha-adrenergic receptors, contributing to side effects like sedation and orthostatic hypotension.","OnsetOfAction":"Symptoms may begin to improve within 1 to 3 weeks; full benefits often observed in 6 to 8 weeks.","DurationOfAction":"The plasma half-life is approximately 7 to 13 hours, but clinical duration may vary depending on individual response.","PeakPlasmaConcentration":"Approximately 1 to 2 hours post-dose for immediate-release formulations.","Indications":["Major depressive disorder","Insomnia (off-label)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet (immediate-release)","Tablet (extended-release)"],"StrengthsOfDosageForms":["50 mg","100 mg","150 mg","300 mg (ER tablet)"],"Pharmacokinetics":{"Absorption":"Well absorbed, with oral bioavailability reduced slightly by food but delaying peak levels.","Distribution":"Widely distributed across tissues; approximately 89-95% bound to plasma proteins.","Metabolism":"Extensively metabolized in the liver primarily via CYP3A4 to active metabolites such as m-CPP.","Excretion":"Mainly excreted in urine as metabolites; small amounts excreted in feces."},"SideEffects":["Drowsiness","Dizziness","Dry mouth","Constipation","Blurred vision","Hypotension"],"DrugInteractions":["MAO inhibitors","CYP3A4 inhibitors or inducers","CNS depressants","SSRIs","Warfarin"],"Contraindications":"Hypersensitivity to trazodone or any component of the formulation; concomitant use with MAO inhibitors or within 14 days of MAO inhibitor therapy.","ChemicalStructure":{"MolecularFormula":"C19H22ClN5O","MolecularWeight":"408.864 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus (pregnancy category C).","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"May require dose adjustments due to increased sensitivity to side effects.","HepaticImpairment":"Caution advised; lower doses or adjustments may be necessary.","RenalImpairment":"Caution advised; lower doses or adjustments may be necessary."},"StorageAndHandling":"Store at room temperature, between 20°C and 25°C (68°F and 77°F). Protect from moisture and light."},{"GenericName":"Duloxetine","BrandNames":["Cymbalta","Irenka","Drizalma Sprinkle"],"DrugClass":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","MechanismOfAction":"Duloxetine inhibits the reuptake of serotonin and norepinephrine, which increases the levels of these neurotransmitters in the synaptic cleft, enhancing their neurotransmission and mood-modulating effects.","Pharmacodynamics":"Duloxetine increases the presence of serotonin and norepinephrine in the CNS which can help to improve mood, reduce anxiety, and alleviate pain.","OnsetOfAction":"Therapeutic effects may begin within one to two weeks, but full response may not be seen until eight weeks or longer.","DurationOfAction":"The elimination half-life is approximately 12 hours, so effects last about 1 to 2 days after last dose.","PeakPlasmaConcentration":"Approximately 6 hours after dosing.","Indications":["Major depressive disorder (MDD)","Generalized anxiety disorder (GAD)","Diabetic peripheral neuropathic pain","Fibromyalgia","Chronic musculoskeletal pain"],"RoutesOfAdministration":"Oral","DosageForms":["Capsules"],"StrengthsOfDosageForms":["20 mg","30 mg","60 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed orally, with an oral bioavailability of about 50% due to first-pass metabolism.","Distribution":"Duloxetine is highly bound to plasma proteins (>90%), primarily to albumin and alpha-1-acid glycoprotein.","Metabolism":"Extensively metabolized in the liver via CYP1A2 and CYP2D6.","Excretion":"Excreted in the urine, primarily as metabolites."},"SideEffects":["Nausea","Dry mouth","Fatigue","Insomnia","Dizziness","Constipation","Sweating"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","CYP1A2 and CYP2D6 inhibitors","Anticoagulants","NSAIDs","Selective serotonin reuptake inhibitors (SSRIs)","Tricyclic antidepressants"],"Contraindications":"Contraindicated in patients with uncontrolled narrow-angle glaucoma, concomitant use with MAOIs, and known hypersensitivity to Duloxetine.","ChemicalStructure":{"MolecularFormula":"C18H19NOS","MolecularWeight":"297.42 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Pregnancy Category C; should only be used if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy not established in children; caution is advised.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger adult patients, but greater sensitivity in some older adults cannot be ruled out.","HepaticImpairment":"Use with caution; duloxetine may require dosage adjustment or may be contraindicated in severe hepatic impairment.","RenalImpairment":"Dosage adjustment may be necessary in patients with renal impairment. Avoid use if creatinine clearance (CrCl) < 30 mL/min."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light and moisture."},{"GenericName":"Warfarin","BrandNames":["Coumadin","Jantoven"],"DrugClass":"Anticoagulant (Vitamin K antagonist)","MechanismOfAction":"Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, specifically factors II, VII, IX, and X, as well as proteins C and S, leading to an anticoagulant effect.","Pharmacodynamics":"Warfarin decreases the body's ability to form blood clots by blocking the formation of functional clotting factors.","OnsetOfAction":"24 to 72 hours","DurationOfAction":"2 to 5 days","PeakPlasmaConcentration":"1.5 to 4 hours after administration","Indications":["Prevention and treatment of venous thrombosis and its extension","Prevention and treatment of pulmonary embolism","Prevention of thromboembolic complications associated with atrial fibrillation and cardiac valve replacement","Reducing the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolism after myocardial infarction"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["1 mg","2 mg","2.5 mg","3 mg","4 mg","5 mg","6 mg","7.5 mg","10 mg"],"Pharmacokinetics":{"Absorption":"Rapid and complete after oral administration","Distribution":"Approximately 99% bound to plasma proteins, primarily albumin","Metabolism":"Primarily hepatic, involving CYP2C9, CYP2C19, and CYP3A4 enzymes","Excretion":"Primarily renal, with a half-life of about 20 to 60 hours (average 40 hours)"},"SideEffects":["Bleeding","Necrosis","Purple toe syndrome","Alopecia","Rash","Nausea","Vomiting"],"DrugInteractions":["Aspirin and other NSAIDs (increase bleeding risk)","Amiodarone","Cimetidine","Cranberry juice","Foods high in vitamin K (antagonistic effect)"],"Contraindications":"Pregnancy (except in women with mechanical heart valves, who are at high risk of thromboembolism), hemorrhagic tendencies, recent or contemplated surgery of the central nervous system or eye, and bleeding tendencies associated with active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tracts and non-compliance.","ChemicalStructure":{"MolecularFormula":"C19H16O4","MolecularWeight":"308.33 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated due to risk of teratogenic effects; alternative anticoagulation is recommended.","PediatricUse":"Use with caution; dosage adjustments necessary based on patient's condition.","GeriatricUse":"Older adults may be more sensitive to the anticoagulant effects of warfarin; monitoring is essential.","HepaticImpairment":"Hepatic impairment can affect metabolism; dosing may require careful adjustment.","RenalImpairment":"Dose should be adjusted carefully; monitoring of INR is crucial."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F); keep in original container and protect from light."},{"GenericName":"Carvedilol","BrandNames":["Coreg","Coreg CR"],"DrugClass":"Non-selective beta-blocker with alpha-1 blocking activity","MechanismOfAction":"Carvedilol functions as a non-selective beta-adrenergic antagonist and alpha-1 adrenergic blocker. It reduces cardiac output, causing vasodilation and decreased peripheral vascular resistance, which lowers blood pressure.","Pharmacodynamics":"Carvedilol reduces the heart rate, decreases myocardial contractility, and reduces myocardial oxygen demand. It also acts as a vasodilator due to its alpha-1 adrenergic blockade.","OnsetOfAction":"The onset of action for the blood pressure-lowering effect is within 1 hour after oral administration.","DurationOfAction":"Carvedilol has a duration of action of approximately 24 hours, allowing for once-daily dosing in certain formulations.","PeakPlasmaConcentration":"The peak plasma concentration is reached approximately 1 to 2 hours after oral administration for immediate-release forms.","Indications":["Hypertension","Heart failure","Left ventricular dysfunction following myocardial infarction"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Extended-release capsule"],"StrengthsOfDosageForms":["Tablet: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg","Extended-release capsule: 10 mg, 20 mg, 40 mg, 80 mg"],"Pharmacokinetics":{"Absorption":"Approximately 25% to 35% when taken orally.","Distribution":"Widely distributed in body tissues, and 95% to 99% bound to plasma proteins.","Metabolism":"Primarily metabolized by cytochrome P450 enzymes, particularly CYP2D6 and CYP2C9.","Excretion":"Excreted primarily in the bile and urine. The half-life ranges from 7 to 10 hours."},"SideEffects":["Dizziness","Fatigue","Hypotension","Diarrhea","Bradycardia"],"DrugInteractions":["Rifampin (may decrease plasma concentrations of carvedilol)","Cimetidine (may increase plasma concentrations of carvedilol)","Calcium channel blockers (may exacerbate bradycardia)"],"Contraindications":"Contraindicated in patients with bronchial asthma, second- or third-degree AV block, severe bradycardia, or decompensated cardiac failure requiring intravenous inotropic therapy.","ChemicalStructure":{"MolecularFormula":"C24H26N2O4","MolecularWeight":"406.47 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C; use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"May be used, but caution advised due to increased sensitivity to medications in the elderly.","HepaticImpairment":"Use with caution; patients may require lower doses due to increased systemic exposure.","RenalImpairment":"No dosage adjustment is necessary in patients with renal impairment."},"StorageAndHandling":"Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Protect from moisture."},{"GenericName":"Fluoxetine","BrandNames":["Prozac","Sarafem"],"DrugClass":"Selective serotonin reuptake inhibitor (SSRI)","MechanismOfAction":"Fluoxetine predominantly inhibits the reuptake of serotonin in the synaptic cleft, increasing its availability and enhancing mood stabilization.","Pharmacodynamics":"Fluoxetine's increase in serotonin levels contributes to mood improvement and alleviation of depressive symptoms.","OnsetOfAction":"2 to 4 weeks","DurationOfAction":"About 1 to 2 weeks, due to its long half-life","PeakPlasmaConcentration":"6 to 8 hours after administration","Indications":["Major depressive disorder","Obsessive-compulsive disorder","Bulimia nervosa","Panic disorder","Premenstrual dysphoric disorder"],"RoutesOfAdministration":"Oral","DosageForms":["Capsule","Tablet (including delayed-release)","Oral solution"],"StrengthsOfDosageForms":["Capsules: 10 mg, 20 mg, 40 mg","Tablets: 10 mg, 20 mg","Oral Solution: 20 mg/5 mL"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract with an oral bioavailability of approximately 80%","Distribution":"Widely distributed in the body, highly protein-bound (approximately 94.5%)","Metabolism":"Primarily metabolized in the liver to norfluoxetine","Excretion":"Primarily excreted in urine as metabolites"},"SideEffects":["Nausea","Dizziness","Drowsiness","Fatigue","Anxiety","Insomnia","Loss of appetite"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Pimozide","Thioridazine","Tryptophan supplements","Anticoagulants (e.g., warfarin)"],"Contraindications":"Concurrent use with MAO inhibitors or within 14 days of discontinuing MAOI treatment.","ChemicalStructure":{"MolecularFormula":"C17H18F3NO","MolecularWeight":"309.33 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (Pregnancy Category C).","PediatricUse":"Approved for use in children and adolescents for certain conditions but with caution regarding side effects.","GeriatricUse":"Cautiously used in elderly populations due to potential for reduced clearance.","HepaticImpairment":"Dose adjustment may be required as fluoxetine is primarily metabolized by the liver.","RenalImpairment":"Generally does not require adjustment but use with caution in severe impairment."},"StorageAndHandling":"Store at 20° to 25°C (68° to 77°F). Protect from light and moisture."},{"GenericName":"Insulin Glargine","BrandNames":["Lantus","Basaglar","Toujeo"],"DrugClass":"Long-acting insulin analogue","MechanismOfAction":"Insulin glargine binds to the insulin receptor which helps in glucose uptake from the bloodstream into tissues. It has a prolonged duration of action due to microprecipitates that release insulin slowly.","Pharmacodynamics":"Insulin glargine mimics natural human insulin in facilitating glucose uptake in muscle and fat and inhibiting hepatic glucose output and lipolysis in adipocytes.","OnsetOfAction":"3-4 hours","DurationOfAction":"Up to 24 hours","PeakPlasmaConcentration":"No pronounced peak","Indications":["Diabetes mellitus type 1","Diabetes mellitus type 2"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Injectable solution"],"StrengthsOfDosageForms":["100 units/mL","300 units/mL (Toujeo)"],"Pharmacokinetics":{"Absorption":"Following subcutaneous administration, insulin glargine forms microprecipitates and is gradually absorbed into the bloodstream.","Distribution":"Distributed similarly to regular insulin, widespread distribution in the extracellular fluid.","Metabolism":"Metabolized in the liver and kidneys into active M1 and M2 metabolites.","Excretion":"Excreted in urine with a minor component excreted in the feces."},"SideEffects":["Hypoglycemia","Injection site reactions","Weight gain","Allergic reactions"],"DrugInteractions":["Oral antihyperglycemics","MAO inhibitors","Beta-blockers","ACE inhibitors"],"Contraindications":"Hypersensitivity to insulin glargine or any of the excipients","ChemicalStructure":{"MolecularFormula":"C267H404N72O78S6","MolecularWeight":"6063 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Classified as Category B. No adequate and well-controlled studies in pregnant women. Should only be used if potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy have been established in pediatric patients 6 years and older with type 1 diabetes.","GeriatricUse":"Dosing should be cautiously selected, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.","HepaticImpairment":"Dose adjustment may be necessary; close monitoring of blood glucose levels is advised.","RenalImpairment":"Dose adjustment may be necessary; close monitoring of blood glucose levels is advised."},"StorageAndHandling":"Unopened vials should be stored in a refrigerator. Once opened, vials can be stored at room temperature away from direct heat and light."},{"GenericName":"Bupropion","BrandNames":["Wellbutrin","Zyban","Aplenzin","Forfivo XL"],"DrugClass":"Norepinephrine-dopamine reuptake inhibitor (NDRI)","MechanismOfAction":"Bupropion primarily works by inhibiting the reuptake of norepinephrine and dopamine, which enhances their availability in the synaptic cleft, potentially improving mood and aiding in smoking cessation.","Pharmacodynamics":"Bupropion increases the concentration of norepinephrine and dopamine in the synaptic cleft, leading to an antidepressant effect and reduced cravings and withdrawal symptoms for nicotine.","OnsetOfAction":"The onset of antidepressant effects usually occurs within 1 to 3 weeks after starting the medication.","DurationOfAction":"The duration of action for sustained-release formulations is approximately 12 hours, while the extended-release formulations act for 24 hours.","PeakPlasmaConcentration":"The peak plasma concentration is typically reached within 3 hours for immediate-release formulations and 5-6 hours for extended-release formulations.","Indications":["Major depressive disorder","Seasonal affective disorder","Smoking cessation"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Extended-release tablet"],"StrengthsOfDosageForms":["75 mg","100 mg","150 mg (SR/XL)","200 mg (SR)","300 mg (XL)","450 mg (XL)"],"Pharmacokinetics":{"Absorption":"Bupropion is well absorbed from the gastrointestinal tract, but it undergoes extensive first-pass metabolism.","Distribution":"Bupropion is roughly 84% bound to human plasma proteins.","Metabolism":"It is extensively metabolized in the liver, mainly by cytochrome P450 isoenzyme CYP2B6, to active metabolites.","Excretion":"Excreted primarily in urine (87%) and to a lesser extent in feces (10%)."},"SideEffects":["Insomnia","Dry mouth","Headache","Nausea","Weight loss","Increased sweating","Palpitations","Dizziness"],"DrugInteractions":["MAO inhibitors","Antipsychotics","Beta-blockers","Warfarin","Digoxin"],"Contraindications":"Contraindicated in patients with a seizure disorder, current or prior diagnosis of bulimia or anorexia nervosa, and those undergoing abrupt discontinuation of alcohol or sedatives, including benzodiazepines.","ChemicalStructure":{"MolecularFormula":"C13H18ClNO","MolecularWeight":"239.74 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C; should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in the pediatric population have not been established.","GeriatricUse":"Caution is advised in elderly patients due to the possibility of renal function decline.","HepaticImpairment":"Use with caution and consider dosage adjustment in patients with hepatic impairment.","RenalImpairment":"Use with caution and consider dosage adjustment in patients with renal impairment."},"StorageAndHandling":"Store at room temperature in a tightly closed container away from moisture and heat."},{"GenericName":"Tamsulosin","BrandNames":["Flomax"],"DrugClass":"Alpha-1 adrenergic receptor antagonist","MechanismOfAction":"Tamsulosin selectively blocks alpha-1 adrenergic receptors in the smooth muscle of the prostate, bladder neck, and urethra. This results in relaxation of the smooth muscle and improvement in urine flow in patients with benign prostatic hyperplasia (BPH).","Pharmacodynamics":"Tamsulosin causes relaxation of smooth muscle in the bladder neck, prostate, and urethra, leading to an improvement in urine flow and reduction in symptoms of BPH.","OnsetOfAction":"Within a few hours, with peak effect around 5 hours after dosing","DurationOfAction":"24 hours","PeakPlasmaConcentration":"4-5 hours after administration","Indications":["Benign prostatic hyperplasia"],"RoutesOfAdministration":"Oral","DosageForms":["Capsule"],"StrengthsOfDosageForms":["0.4 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract with approximately 90% bioavailability","Distribution":"Widely distributed in the body","Metabolism":"Extensively metabolized in the liver by CYP450 enzymes, mainly CYP3A4 and CYP2D6","Excretion":"Excreted primarily in the urine, predominantly as metabolites"},"SideEffects":["Dizziness","Headache","Postural hypotension","Rhinitis","Abnormal ejaculation"],"DrugInteractions":["Strong CYP3A4 inhibitors (e.g., ketoconazole)","PDE5 inhibitors (e.g., sildenafil)","Warfarin"],"Contraindications":"Known hypersensitivity to tamsulosin or any component of the formulation","ChemicalStructure":{"MolecularFormula":"C20H28N2O5S","MolecularWeight":"408.51 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Not indicated for use in women","PediatricUse":"Safety and effectiveness in pediatric patients have not been established","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients","HepaticImpairment":"Caution is advised; no specific dose adjustment is provided","RenalImpairment":"Caution is advised; no specific dose adjustment is provided for mild to moderate impairment"},"StorageAndHandling":"Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Protect from light and moisture."},{"GenericName":"Venlafaxine","BrandNames":["Effexor","Effexor XR"],"DrugClass":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","MechanismOfAction":"Venlafaxine works by inhibiting the reuptake of serotonin and norepinephrine, increasing their levels in the brain, which helps improve mood and relieve depression and anxiety symptoms.","Pharmacodynamics":"Venlafaxine affects neurotransmitter activity in the CNS, leading to antidepressant effects. It has limited affinity for muscarinic, histaminergic, or alpha-1 adrenergic receptors, reducing side effect profiles typical of other antidepressants.","OnsetOfAction":"2 to 4 weeks","DurationOfAction":"Usually 24 hours for immediate-release formulations; 24 to 48 hours for extended-release formulations","PeakPlasmaConcentration":"2.4 hours for immediate-release; 5.5 hours for extended-release","Indications":["Major depressive disorder (MDD)","Generalized anxiety disorder (GAD)","Social anxiety disorder","Panic disorder"],"RoutesOfAdministration":"Oral","DosageForms":["Extended-release capsules","Tablets"],"StrengthsOfDosageForms":["37.5 mg","75 mg","150 mg","225 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Volume of distribution is approximately 4.4 L/kg.","Metabolism":"Primarily metabolized in the liver; major active metabolite: desvenlafaxine.","Excretion":"Excreted primarily in the urine as metabolites."},"SideEffects":["Nausea","Headache","Dizziness","Dry mouth","Insomnia","Sweating","Increased blood pressure","Weight loss or gain"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Other CNS active agents including antidepressants","CYP2D6 inhibitors and inducers"],"Contraindications":"Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI.","ChemicalStructure":{"MolecularFormula":"C17H27NO2","MolecularWeight":"277.4 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C. Should be used only if benefits justify the potential risk to the fetus.","PediatricUse":"Safety and effectiveness not established in pediatric patients.","GeriatricUse":"Use with caution, considering the generally decreased organ function with aging.","HepaticImpairment":"Dose adjustment may be necessary due to increased plasma concentrations.","RenalImpairment":"Dose adjustment may be necessary due to decreased clearance."},"StorageAndHandling":"Store at room temperature, away from moisture and heat. Keep out of reach of children."},{"GenericName":"Zolpidem","BrandNames":["Ambien","Stilnox","Edluar","Intermezzo","Zolpimist"],"DrugClass":"Non-benzodiazepine hypnotic","MechanismOfAction":"Zolpidem works by binding to the GABA-A receptor at the same location as benzodiazepines, but it primarily binds to subtypes associated with sleep-promoting activity. This enhances the effects of GABA, an inhibitory neurotransmitter, leading to sedative and sleep-inducing effects.","Pharmacodynamics":"Zolpidem has sedative properties and is used in the short-term management of insomnia. It induces sleep and prolongs sleep duration but with fewer myorelaxant, anxiolytic, or anticonvulsant properties compared to benzodiazepines.","OnsetOfAction":"Approximately 15 to 30 minutes after oral administration.","DurationOfAction":"Generally 6 to 8 hours.","PeakPlasmaConcentration":"Occurs approximately 1.5 hours after oral administration.","Indications":["Insomnia characterized by difficulties with sleep initiation"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Sublingual tablet","Oral spray"],"StrengthsOfDosageForms":["5 mg tablet","10 mg tablet","1.75 mg sublingual tablet","3.5 mg sublingual tablet","5 mg/metered spray","10 mg/metered spray"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed with a bioavailability of approximately 70% due to first-pass metabolism.","Distribution":"Widely distributed in the body, with a volume of distribution of approximately 0.54 L/kg. It is around 92% bound to plasma proteins.","Metabolism":"Primarily metabolized by the liver, mainly via CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6, into inactive metabolites.","Excretion":"Excreted primarily by the kidneys, with approximately 60-70% of the dose recovered in urine as metabolites. The elimination half-life ranges from 2 to 3 hours."},"SideEffects":["Drowsiness","Dizziness","Diarrhea","Fatigue","Headache","Allergic reactions","Complex sleep behaviors (e.g., sleep-driving)"],"DrugInteractions":["CNS depressants (e.g., alcohol, benzodiazepines)","Cytochrome P450 enzyme inhibitors (e.g., ketoconazole)","Inducers (e.g., rifampin)"],"Contraindications":"Hypersensitivity to zolpidem or any component of the formulation. History of complex sleep behaviors, such as sleepwalking, with zolpidem.","ChemicalStructure":{"MolecularFormula":"C19H21N3O","MolecularWeight":"307.39 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Caution advised; insufficient data on use in pregnancy, use only if benefits justify risks.","PediatricUse":"Safety and efficacy not established in children.","GeriatricUse":"Use with caution; consider lower starting doses due to increased sensitivity and risk of adverse effects.","HepaticImpairment":"Dosage adjustments may be necessary; use caution due to slower metabolism.","RenalImpairment":"No specific dosing adjustments recommended, but monitor for excessive sedation and adverse effects."},"StorageAndHandling":"Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Protect from moisture and light."},{"GenericName":"Pravastatin","BrandNames":["Pravachol"],"DrugClass":"HMG-CoA reductase inhibitor (statin)","MechanismOfAction":"Pravastatin works by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. This reduces the levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the blood while increasing high-density lipoprotein (HDL) cholesterol.","Pharmacodynamics":"Pravastatin is effective in reducing total cholesterol, LDL-C, apolipoprotein B, and triglycerides, and in increasing HDL-C levels. The lipid-modifying effects of pravastatin reduce the risk of atherosclerotic cardiovascular disease.","OnsetOfAction":"Approximately 4 days for a significant cholesterol-lowering effect.","DurationOfAction":"Up to 24 hours, but the clinical effect continues with daily dosing.","PeakPlasmaConcentration":"1 to 1.5 hours after oral administration.","Indications":["Hypercholesterolemia","Prevention of cardiovascular disease","Prevention of myocardial infarction","Prevention of stroke"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["10 mg","20 mg","40 mg","80 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following oral administration; absolute bioavailability is roughly 17%.","Distribution":"Extensive tissue distribution; 43-60% protein binding.","Metabolism":"Minimal metabolism in humans. Metabolism primarily occurs in the liver, with minor metabolism by other tissues.","Excretion":"Primarily excreted in the feces (70%), with about 20% excreted in the urine."},"SideEffects":["Muscle pain","Nausea","Headache","Dizziness","Fatigue"],"DrugInteractions":["Cyclosporine","Erythromycin","Fibrates","Niacin"],"Contraindications":"Active liver disease or unexplained persistent elevations in hepatic transaminase levels.","ChemicalStructure":{"MolecularFormula":"C23H36O7","MolecularWeight":"424.53 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Pravastatin is contraindicated in pregnancy due to the potential for harm to the fetus.","PediatricUse":"Approved for use in children aged 8 years and older for specific indications.","GeriatricUse":"No dosage adjustment is required based solely on age.","HepaticImpairment":"Caution is advised; contraindicated in active liver disease.","RenalImpairment":"Dose adjustment may be necessary for patients with severe renal impairment."},"StorageAndHandling":"Store at room temperature, away from moisture, heat, and light."},{"GenericName":"Cephalexin","BrandNames":["Keflex","Daxbia","Biocef"],"DrugClass":"First-generation cephalosporin antibiotic","MechanismOfAction":"Cephalexin exerts bactericidal activity by inhibiting bacterial cell wall synthesis. It does so by binding to penicillin-binding proteins (PBPs) inside the bacterial cell wall, which prevents the final transpeptidation step of peptidoglycan synthesis, impairing cell wall integrity and leading to cell lysis.","Pharmacodynamics":"Cephalexin has activity against a wide range of gram-positive bacteria and some gram-negative bacteria. It is often used to treat infections caused by susceptible strains of staphylococci and streptococci.","OnsetOfAction":"rapid, usually within 1 hour of administration","DurationOfAction":"6 to 12 hours","PeakPlasmaConcentration":"1.5 - 2 hours after administration","Indications":["Treatment of respiratory tract infections","Otitis media","Skin and skin structure infections","Bone infections","Genitourinary tract infections"],"RoutesOfAdministration":"Oral","DosageForms":["Capsules","Tablets","Oral suspension"],"StrengthsOfDosageForms":["Capsules: 250 mg, 500 mg, 750 mg","Tablets: varied strengths like 250 mg or 500 mg","Oral suspension: 125 mg/5 mL, 250 mg/5 mL"],"Pharmacokinetics":{"Absorption":"Well absorbed from the GI tract.","Distribution":"Widely distributed in the body, including in bones and synovial fluid. It does not penetrate the blood-brain barrier effectively.","Metabolism":"Minimal metabolism as cephalexin is mostly unchanged in the body.","Excretion":"Primarily excreted in the urine."},"SideEffects":["Diarrhea","Nausea","Vomiting","Dizziness","Rash","Hypersensitivity reactions","Pseudomembranous colitis"],"DrugInteractions":["Probenecid","Metformin","Oral anticoagulants","BCG vaccine (live)"],"Contraindications":"Patients with known allergy to cephalexin or any of the other cephalosporins should not use this medication.","ChemicalStructure":{"MolecularFormula":"C16H17N3O4S","MolecularWeight":"347.39 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Cephalexin is categorized as Pregnancy Category B. It is generally considered safe, but should only be used during pregnancy if clearly needed.","PediatricUse":"Cephalexin is safe for use in children. Dosage adjustments are made based on the child's weight and severity of the infection.","GeriatricUse":"Generally safe, though renal function should be monitored.","HepaticImpairment":"No specific dosing adjustments are generally required for hepatic impairment.","RenalImpairment":"Dosage adjustment may be necessary based on the degree of renal impairment."},"StorageAndHandling":"Store capsules and tablets at room temperature between 20°C to 25°C (68°F to 77°F). Oral suspension should be stored in the refrigerator and discarded after 14 days."},{"GenericName":"Cyclobenzaprine","BrandNames":["Flexeril","Amrix","Fexmid"],"DrugClass":"Muscle relaxant","MechanismOfAction":"Cyclobenzaprine acts primarily at the brainstem within the central nervous system to reduce tonic somatic motor activity, influencing both gamma and alpha motor systems.","Pharmacodynamics":"Cyclobenzaprine is a centrally-acting skeletal muscle relaxant. It exhibits anticholinergic effects, which contribute to its side effects and interactions.","OnsetOfAction":"Within 1 hour","DurationOfAction":"12 to 24 hours","PeakPlasmaConcentration":"4 to 8 hours","Indications":["Relief of muscle spasm associated with acute, painful musculoskeletal conditions"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Extended-release capsule"],"StrengthsOfDosageForms":["5 mg","10 mg","15 mg (extended-release)","30 mg (extended-release)"],"Pharmacokinetics":{"Absorption":"Cyclobenzaprine is well absorbed from the gastrointestinal tract.","Distribution":"Widely distributed throughout the body tissues and is highly bound to plasma proteins.","Metabolism":"Primarily metabolized in the liver via cytochrome P450 enzymatic pathways.","Excretion":"Excreted primarily in the urine as glucuronides and sulfates."},"SideEffects":["Drowsiness","Dry mouth","Fatigue","Headache","Dizziness"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Tricyclic antidepressants","CNS depressants"],"Contraindications":"Hypersensitivity to cyclobenzaprine, acute recovery phase of myocardial infarction, arrhythmias, heart block, conduction disturbances, congestive heart failure, hyperthyroidism, concomitant use of MAO inhibitors.","ChemicalStructure":{"MolecularFormula":"C20H21N","MolecularWeight":"275.39 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B - No well-controlled studies in pregnant women; use only if clearly needed.","PediatricUse":"Safety and effectiveness in pediatric patients under 15 years of age have not been established.","GeriatricUse":"Use with caution due to the increased frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.","HepaticImpairment":"Use with caution; monitor liver function closely.","RenalImpairment":"Use with caution, especially in severe impairment."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) in a tight container."},{"GenericName":"Meloxicam","BrandNames":["Mobic","Vivlodex","Metacam"],"DrugClass":"Nonsteroidal anti-inflammatory drug (NSAID)","MechanismOfAction":"Meloxicam works by inhibiting the cyclooxygenase (COX) enzymes COX-1 and COX-2, which are involved in the synthesis of prostaglandins. By reducing prostaglandin levels, it decreases inflammation and pain.","Pharmacodynamics":"Meloxicam exhibits anti-inflammatory, analgesic, and antipyretic effects. It preferentially inhibits COX-2 over COX-1, which is thought to contribute to its lesser gastrointestinal toxicity compared to some other NSAIDs.","OnsetOfAction":"Approximately 30-60 minutes.","DurationOfAction":"Approximately 15 to 24 hours.","PeakPlasmaConcentration":"Peak plasma concentrations are achieved within 4 to 5 hours after administration.","Indications":["Osteoarthritis","Rheumatoid arthritis","Juvenile idiopathic arthritis"],"RoutesOfAdministration":"Oral, parenteral (intramuscular)","DosageForms":["Tablet","Capsule","Oral suspension","Injectable solution"],"StrengthsOfDosageForms":["7.5 mg tablet","15 mg tablet","5 mg capsule","10 mg/mL solution (for injection)"],"Pharmacokinetics":{"Absorption":"Meloxicam is well absorbed following oral administration with an absolute bioavailability of approximately 89%.","Distribution":"Meloxicam is approximately 99.4% protein-bound, primarily to albumin.","Metabolism":"It is extensively metabolized in the liver, primarily by cytochrome P450 2C9.","Excretion":"Meloxicam is excreted predominantly in the form of metabolites via urine and feces."},"SideEffects":["Gastrointestinal upset","Headache","Dizziness","Hypertension","Edema"],"DrugInteractions":["Anticoagulants (e.g., warfarin)","Other NSAIDs","ACE inhibitors","Diuretics","Lithium"],"Contraindications":"Contraindicated in patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, and in the setting of coronary artery bypass graft (CABG) surgery.","ChemicalStructure":{"MolecularFormula":"C14H13N3O4S2","MolecularWeight":"351.4 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; NSAIDs should be avoided in the third trimester due to risk of premature closure of the ductus arteriosus.","PediatricUse":"Approved for use in children 2 years of age and older for juvenile idiopathic arthritis.","GeriatricUse":"Use with caution; consider the increased risk of gastrointestinal bleeding and renal impairment.","HepaticImpairment":"Use with caution; monitor liver function as necessary.","RenalImpairment":"Use with caution; dose adjustment may be necessary."},"StorageAndHandling":"Store at room temperature away from light and moisture. Keep the medication in its original packaging."},{"GenericName":"Ciprofloxacin","BrandNames":["Cipro","Cipro XR","Proquin XR"],"DrugClass":"Fluoroquinolone antibiotic","MechanismOfAction":"Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication, transcription, repair, and recombination, leading to bacterial cell death.","Pharmacodynamics":"Ciprofloxacin is bactericidal and exhibits concentration-dependent killing with a post-antibiotic effect. It is effective against a broad range of Gram-negative and some Gram-positive bacteria.","OnsetOfAction":"1-2 hours","DurationOfAction":"Variable, often requires twice-daily dosing to maintain therapeutic levels.","PeakPlasmaConcentration":"Approximately 1-2 hours after oral administration.","Indications":["Urinary tract infections","Respiratory tract infections","Skin and soft tissue infections","Bone and joint infections","Gastrointestinal infections","Typhoid fever","Prophylaxis of anthrax"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablet","Extended-release tablet","Oral suspension","Injection"],"StrengthsOfDosageForms":["250 mg, 500 mg, 750 mg tablets","500 mg, 1000 mg extended-release tablets","100 mg/mL oral suspension","200 mg/100 mL, 400 mg/200 mL injection"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract, with an oral bioavailability of approximately 70% to 80%.","Distribution":"Widely distributed into body tissues and fluids; approximately 20-40% protein bound.","Metabolism":"Hepatic; ciprofloxacin is partially metabolized to at least four metabolites.","Excretion":"Primarily renal, with 30-50% excreted unchanged in the urine."},"SideEffects":["Nausea","Diarrhea","Dizziness","Headache","Photosensitivity","Tendonitis and tendon rupture","Peripheral neuropathy"],"DrugInteractions":["Theophylline","Warfarin","Antacids containing magnesium or aluminum","Sucralfate","Iron supplements"],"Contraindications":"Hypersensitivity to ciprofloxacin or other quinolone antibiotics.","ChemicalStructure":{"MolecularFormula":"C17H18FN3O3","MolecularWeight":"331.34 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C: Risk cannot be ruled out. Animal studies have shown some risk, and there are no well-controlled studies in pregnant women.","PediatricUse":"Use with caution; not typically first-line due to concerns about joint/tendon adverse effects.","GeriatricUse":"No specific adjustments, but caution due to increased risk of tendonitis/tendon rupture.","HepaticImpairment":"Caution advised; monitor liver function tests periodically.","RenalImpairment":"Dosage adjustment recommended based on renal function."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture."},{"GenericName":"Metronidazole","BrandNames":["Flagyl","Flagyl ER","MetroCream","MetroGel","MetroLotion","Noritate"],"DrugClass":"Antibiotic, Antiprotozoal","MechanismOfAction":"Metronidazole is a nitroimidazole class antibiotic that works by entering bacterial and protozoal cells and interfering with their DNA, causing cell death.","Pharmacodynamics":"Metronidazole exhibits bactericidal activity against anaerobic bacteria and protozoa. It is effective in the treatment of a variety of infections, particularly those caused by anaerobic organisms.","OnsetOfAction":"Varies depending on the type of infection, but typically it begins to work within a few days for most infections.","DurationOfAction":"The duration of action extends for several hours, covering the dosing interval of 6 to 8 hours for immediate-release forms.","PeakPlasmaConcentration":"1 to 2 hours after oral administration.","Indications":["Bacterial vaginosis","Trichomoniasis","Anaerobic bacterial infections","Giardiasis","Amoebiasis","Helicobacter pylori eradication (as part of combination therapy)"],"RoutesOfAdministration":"Oral, intravenous, topical","DosageForms":["Tablet","Capsule","Injection","Topical gel","Topical cream","Topical lotion"],"StrengthsOfDosageForms":["Tablet: 250 mg, 500 mg","Capsule: 375 mg","Injection: 500 mg/100 mL","Topical gel/cream/lotion: 0.75%, 1%"],"Pharmacokinetics":{"Absorption":"Approximately 80% when administered orally.","Distribution":"Widely distributed into the most body tissues and fluids, including the central nervous system, bile, saliva, and breast milk. Plasma protein binding is less than 20%.","Metabolism":"Primarily metabolized in the liver via oxidation.","Excretion":"Excreted mainly in urine (60 to 80%); fecal excretion accounts for 6 to 15%."},"SideEffects":["Nausea","Diarrhea","Metallic taste","Headache","Dizziness","Vomiting","Abdominal pain"],"DrugInteractions":["Warfarin: can increase the anticoagulant effects.","Alcohol: causes a disulfiram-like reaction.","Lithium: may increase lithium levels, causing toxicity."],"Contraindications":"Hypersensitivity to metronidazole or other nitroimidazole derivatives.","ChemicalStructure":{"MolecularFormula":"C6H9N3O3","MolecularWeight":"171.15 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Metronidazole crosses the placenta, but is generally considered safe for use during pregnancy for certain indications as deemed necessary by a physician, particularly in the second and third trimesters.","PediatricUse":"Safety and effectiveness in pediatric populations for certain infections have been established.","GeriatricUse":"Generally safe for use in elderly patients, but caution is advised, especially with liver function impairment.","HepaticImpairment":"Dose adjustments may be needed as the drug is metabolized by the liver.","RenalImpairment":"Dose adjustment is generally not necessary, but caution is advised in cases of severe impairment."},"StorageAndHandling":"Store at room temperature away from light and moisture. Do not freeze the oral suspension. Keep out of reach of children."},{"GenericName":"Lorazepam","BrandNames":["Ativan","Temesta"],"DrugClass":"Benzodiazepine","MechanismOfAction":"Lorazepam enhances the action of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system, by binding to the benzodiazepine site on the GABA-A receptor complex leading to increased GABAergic neurotransmission and resultant anxiolytic, anticonvulsant, and sedative effects.","Pharmacodynamics":"Lorazepam is a benzodiazepine with anxiolytic, sedative, and anticonvulsant properties. It reduces the neuronal depolarization resulting from increased chloride ion influx. The drug's effects include sedation, reduction of anxiety, and muscle relaxation.","OnsetOfAction":"15-30 minutes (oral administration)","DurationOfAction":"6-8 hours","PeakPlasmaConcentration":"2 hours (oral administration)","Indications":["Anxiety disorders","Insomnia due to anxiety or transient situational stress","Preoperative sedation","Status epilepticus"],"RoutesOfAdministration":"Oral, Intramuscular, Intravenous","DosageForms":["Tablets","Oral concentrate","Injection"],"StrengthsOfDosageForms":["0.5 mg","1 mg","2 mg (tablets)","2 mg/mL (injection)"],"Pharmacokinetics":{"Absorption":"Well absorbed with oral administration. Bioavailability of the oral tablet is about 90%.","Distribution":"Extensively distributed in the body and it is about 85% bound to plasma proteins.","Metabolism":"Primarily hepatic through glucuronidation.","Excretion":"Excreted mainly in urine as glucuronide conjugates."},"SideEffects":["Sedation","Dizziness","Weakness","Unsteadiness","Cognitive impairment"],"DrugInteractions":["Alcohol","CNS depressants","Opioids","Valproate","Probenecid"],"Contraindications":"Severe respiratory insufficiency, hypersensitivity to benzodiazepines, acute narrow-angle glaucoma, sleep apnea syndrome.","ChemicalStructure":{"MolecularFormula":"C15H10Cl2N2O2","MolecularWeight":"321.16 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D - Not recommended due to potential risks; can cause fetal damage.","PediatricUse":"Not recommended in children under 12 years.","GeriatricUse":"Use with caution in elderly; lower doses may be needed due to increased sensitivity and potential for impaired renal and hepatic function.","HepaticImpairment":"May require dose adjustment due to slower metabolism.","RenalImpairment":"Use with caution; no specific dosing recommendations but monitor closely."},"StorageAndHandling":"Store at room temperature, protect from light and moisture. Keep out of reach of children."},{"GenericName":"Azithromycin","BrandNames":["Zithromax","Zmax"],"DrugClass":"Macrolide antibiotic","MechanismOfAction":"Azithromycin works by binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting translocation and blocking protein synthesis.","Pharmacodynamics":"Azithromycin is active against a variety of bacteria, including those responsible for respiratory infections, skin infections, and sexually transmitted diseases. It has a long half-life and is slowly released from tissues, allowing for once-daily dosing and shorter treatment durations.","OnsetOfAction":"1-3 hours for peak concentrations","DurationOfAction":"Half-life ranges from 11 to 68 hours, depending on the dosing regimen and the tissue where it is located.","PeakPlasmaConcentration":"0.4 to 0.5 hours (oral dose).","Indications":["Community-acquired pneumonia","Pharyngitis and tonsillitis","Skin and soft tissue infections","Sexually transmitted infections such as chlamydia","Prevention of Mycobacterium avium complex (MAC)"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablet","Oral suspension","Injection"],"StrengthsOfDosageForms":["250 mg (tablet)","500 mg (tablet)","100 mg/5 ml (oral suspension)","200 mg/5 ml (oral suspension)","500 mg (injection)"],"Pharmacokinetics":{"Absorption":"Absorbed well orally; food reduces absorption rate.","Distribution":"Wide distribution to tissues; higher concentrations in tissues such as the lungs and tonsils.","Metabolism":"Hepatic; azithromycin is predominantly excreted unchanged in bile.","Excretion":"Primarily via bile; 6% in urine as unchanged drug."},"SideEffects":["Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)","Dizziness","Headache","Skin rash","QT interval prolongation"],"DrugInteractions":["Warfarin","Antacids containing magnesium or aluminum","Nelfinavir","Digoxin"],"Contraindications":"Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotics.","ChemicalStructure":{"MolecularFormula":"C38H72N2O12","MolecularWeight":"748.984 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B. No controlled studies in pregnant women, but no adverse effects observed in animal studies.","PediatricUse":"Safety and effectiveness have been established for use in pediatric patients 6 months and older for certain infections.","GeriatricUse":"No significant differences in safety or efficacy observed in elderly, but be cautious of Q-T prolongation.","HepaticImpairment":"Use with caution; monitor liver function.","RenalImpairment":"No dosage adjustment necessary for mild to moderate impairment."},"StorageAndHandling":"Store at room temperature, protect from light and moisture. Suspension should not be refrigerated, and unused portion should be discarded after 10 days."},{"GenericName":"Allopurinol","BrandNames":["Zyloprim","Aloprim"],"DrugClass":"Xanthine oxidase inhibitor","MechanismOfAction":"Allopurinol inhibits xanthine oxidase, an enzyme responsible for converting hypoxanthine and xanthine into uric acid.","Pharmacodynamics":"Allopurinol reduces the production of uric acid, thereby lowering serum and urinary uric acid levels and minimizing the risk of urate deposition and the development of gout and kidney stones.","OnsetOfAction":"Approximately 1-2 days","DurationOfAction":"About 1-2 weeks for steady-state uric acid levels to be reached","PeakPlasmaConcentration":"1.5-4.5 hours after oral administration","Indications":["Chronic gout","Hyperuricemia associated with malignancy","Calcium oxalate calculi with hyperuricosuria"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablet","Powder for injection"],"StrengthsOfDosageForms":["100 mg tablets","300 mg tablets","500 mg powder for injection"],"Pharmacokinetics":{"Absorption":"Approximately 80-90% is absorbed after oral administration.","Distribution":"Well distributed throughout the body, does not cross the blood-brain barrier.","Metabolism":"Metabolized to oxypurinol, which is pharmacologically active.","Excretion":"Excreted primarily via the kidney as oxypurinol; some is excreted unchanged."},"SideEffects":["Rash","Gastrointestinal upset","Drowsiness","Hypersensitivity reactions","Hepatotoxicity"],"DrugInteractions":["Azathioprine","Mercaptopurine","Theophylline","Warfarin"],"Contraindications":"Hypersensitivity to allopurinol or any component of the formulation","ChemicalStructure":{"MolecularFormula":"C5H4N4O","MolecularWeight":"136.11 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C; should be used only if clearly needed and the benefits outweigh the risks.","PediatricUse":"Safety and efficacy not established in children under 6 years. Used with caution in children for leukemia and cancer-related hyperuricemia.","GeriatricUse":"Dose selection should generally be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.","HepaticImpairment":"Use with caution; monitor liver function tests.","RenalImpairment":"Dose adjustment is required. More frequent monitoring of uric acid levels and renal function is recommended."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) in a tight, light-resistant container."},{"GenericName":"Paroxetine","BrandNames":["Paxil","Seroxat","Pexeva","Brisdelle"],"DrugClass":"Selective Serotonin Reuptake Inhibitor (SSRI)","MechanismOfAction":"Paroxetine acts by specifically inhibiting the reuptake of serotonin (5-HT) in the brain, enhancing serotonergic activity. It weakly inhibits the norepinephrine uptake and has very little to no effect on the dopamine uptake.","Pharmacodynamics":"As an SSRI, paroxetine enhances serotonergic transmission which is thought to contribute to its antidepressant, anxiolytic, and other therapeutic effects.","OnsetOfAction":"Typically 1-4 weeks for therapeutic effects to be noticeable.","DurationOfAction":"24 hours; this is consistent with its dosing schedule of once daily.","PeakPlasmaConcentration":"About 2-8 hours after oral administration.","Indications":["Major Depressive Disorder","Obsessive-Compulsive Disorder","Panic Disorder","Social Anxiety Disorder","Generalized Anxiety Disorder","Post-Traumatic Stress Disorder (PTSD)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Suspension","Controlled-release tablets"],"StrengthsOfDosageForms":["10 mg","20 mg","30 mg","40 mg","Controlled-release: 12.5 mg, 25 mg, 37.5 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed following oral administration, with peak plasma concentrations occurring within approximately 2-8 hours.","Distribution":"Paroxetine is extensively distributed in the body and is about 95% bound to plasma proteins.","Metabolism":"Extensively metabolized in the liver via CYP2D6 pathway.","Excretion":"Excreted in the urine mostly as metabolites, with less than 2% excreted unchanged."},"SideEffects":["Nausea","Drowsiness","Dizziness","Insomnia","Sweating","Dry mouth","Loss of appetite","Weight changes"],"DrugInteractions":["Monoamine oxidase inhibitors","Thioridazine","Pimozide","Tryptophan","Warfarin","Non-steroidal anti-inflammatory drugs (NSAIDs)"],"Contraindications":"Concomitant use with monoamine oxidase inhibitors (MAOIs), thioridazine, or pimozide is contraindicated. It is also contraindicated in patients with hypersensitivity to paroxetine or other components of the formulation.","ChemicalStructure":{"MolecularFormula":"C19H20FNO3","MolecularWeight":"329.37 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; risks and benefits should be weighed carefully. Brisdelle is contraindicated in pregnancy.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients for most indications.","GeriatricUse":"Caution is advised due to the increased risk of hyponatremia and other side effects.","HepaticImpairment":"Dose adjustment may be necessary. Use with caution.","RenalImpairment":"Caution is advised, and dose adjustment may be necessary."},"StorageAndHandling":"Store at controlled room temperature 20-25°C (68-77°F). Protect from light and moisture."},{"GenericName":"Diclofenac","BrandNames":["Voltaren","Cataflam","Zipsor","Zorvolex","Flector"],"DrugClass":"Nonsteroidal anti-inflammatory drug (NSAID)","MechanismOfAction":"Diclofenac works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, which leads to a decrease in prostaglandin synthesis. This results in reduced inflammation, pain, and fever.","Pharmacodynamics":"Diclofenac decreases inflammation and pain by blocking COX enzymes, which are involved in the production of prostaglandins, mediators of inflammation.","OnsetOfAction":"Depending on the dosage form, onset of action can be within 30 minutes to 1 hour for oral forms.","DurationOfAction":"4 to 6 hours","PeakPlasmaConcentration":"Typically 1 to 4 hours after oral administration, varying by formulation.","Indications":["Rheumatoid arthritis","Osteoarthritis","Ankylosing spondylitis","Dysmenorrhea","Mild to moderate pain","Migraine","Actinic keratosis (when using topical formulations)"],"RoutesOfAdministration":"Oral, topical, rectal, intravenous, intramuscular","DosageForms":["Tablets (immediate and extended-release)","Gel","Cream","Patch","Suppository","Injection"],"StrengthsOfDosageForms":["25 mg tablets","50 mg tablets","75 mg tablets","100 mg extended-release tablets","1% topical gel","3% topical gel","Diclofenac epolamine 1.3% topical patch"],"Pharmacokinetics":{"Absorption":"Well absorbed orally, with bioavailability affected by first-pass metabolism.","Distribution":"Widely distributed throughout the body and is highly protein bound (>99%).","Metabolism":"Extensively metabolized in the liver, predominantly via CYP2C9.","Excretion":"Excreted primarily in the urine as metabolites."},"SideEffects":["Gastrointestinal upset (nausea, vomiting, diarrhea)","Headache","Dizziness","Increased liver enzymes","Edema","Hypertension","Potential for cardiovascular events","Gastrointestinal bleeding or ulcers"],"DrugInteractions":["Warfarin and other anticoagulants","Aspirin and other NSAIDs","ACE inhibitors","Diuretics","Cyclosporine","Lithium","Methotrexate"],"Contraindications":"Known hypersensitivity to diclofenac; patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; use in the setting of coronary artery bypass graft (CABG) surgery.","ChemicalStructure":{"MolecularFormula":"C14H11Cl2NO2","MolecularWeight":"296.15 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution, especially during the third trimester due to risk of premature closure of the fetal ductus arteriosus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established for all forms.","GeriatricUse":"Use with caution due to increased risk of adverse effects, particularly gastrointestinal bleeding.","HepaticImpairment":"Use with caution; dose adjustment may be necessary.","RenalImpairment":"Use with caution; dose adjustment may be necessary."},"StorageAndHandling":"Store at room temperature, between 20°C to 25°C (68°F to 77°F), and protect from moisture and heat."},{"GenericName":"Ranitidine","BrandNames":["Zantac","Ranitidine Hydrochloride","Rantac","Acid Reducer"],"DrugClass":"H2 receptor antagonist","MechanismOfAction":"Ranitidine blocks histamine H2 receptors on the parietal cells of the stomach, leading to a reduction in stomach acid production.","Pharmacodynamics":"By inhibiting H2 receptors in the stomach lining, ranitidine decreases the amount of acid produced in the stomach, providing relief from acid-related indigestion and heartburn.","OnsetOfAction":"30 to 60 minutes after oral administration.","DurationOfAction":"Up to 12 hours with a single dose.","PeakPlasmaConcentration":"Typically reached within 2 to 3 hours post-oral administration.","Indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Erosive esophagitis","Pathological hypersecretory conditions"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablets","Syrup","Injection"],"StrengthsOfDosageForms":["Tablets: 75 mg, 150 mg, 300 mg","Syrup: 15 mg/mL","Injection: 25 mg/mL"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Widely distributed throughout the body with a volume of distribution of about 1.4 L/kg.","Metabolism":"Partially metabolized by the liver to N-oxide, desmethylranitidine, and ranitidine S-oxide.","Excretion":"Excreted primarily through the kidneys, with approximately 30% of the oral dose excreted unchanged in the urine."},"SideEffects":["Headache","Diarrhea","Constipation","Nausea","Vomiting","Abdominal discomfort"],"DrugInteractions":["Warfarin","Ketoconazole","Propranolol","Midazolam","Glipizide"],"Contraindications":"Hypersensitivity to ranitidine or other components of the formulation.","ChemicalStructure":{"MolecularFormula":"C13H22N4O3S","MolecularWeight":"314.41 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Has been used without apparent harmful effects; classified as Pregnancy Category B.","PediatricUse":"Approved for use in children for certain indications at appropriate dosages.","GeriatricUse":"Generally safe, but caution with dose adjustments might be needed.","HepaticImpairment":"Use with caution; dose adjustment may be necessary.","RenalImpairment":"Dose adjustment required in individuals with impaired renal function."},"StorageAndHandling":"Store at controlled room temperature, 20-25°C (68-77°F). Protect from light and moisture."},{"GenericName":"Naproxen","BrandNames":["Aleve","Naprosyn","Anaprox","Naprelan"],"DrugClass":"Nonsteroidal Anti-inflammatory Drug (NSAID)","MechanismOfAction":"Naproxen works by inhibiting the cyclooxygenase (COX-1 and COX-2) enzymes, leading to a decrease in the synthesis of prostaglandins, which are mediators of inflammation and pain.","Pharmacodynamics":"Naproxen reduces inflammation, pain, and fever by inhibiting the production of prostaglandins.","OnsetOfAction":"Within 1 hour","DurationOfAction":"8 to 12 hours","PeakPlasmaConcentration":"2 to 4 hours after administration","Indications":["Relief of pain from various conditions such as headache, muscle aches, tendonitis, dental pain, and menstrual cramps","Reduction of inflammation associated with various forms of arthritis, including rheumatoid arthritis, osteoarthritis, juvenile arthritis, and ankylosing spondylitis"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Capsule","Suspension"],"StrengthsOfDosageForms":["250 mg","375 mg","500 mg","550 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract","Distribution":"Extensively bound to plasma proteins, mainly albumin","Metabolism":"Partially metabolized by the liver","Excretion":"Excreted in the urine as unchanged drug and metabolites"},"SideEffects":["Gastrointestinal upset","Heartburn","Nausea","Dizziness","Headache","Drowsiness","Stomach ache","Increased risk of gastrointestinal bleeding","Renal impairment"],"DrugInteractions":["Aspirin may increase the risk of bleeding.","Anticoagulants like warfarin may increase the risk of bleeding.","Diuretics may decrease the effectiveness due to NSAID-induced fluid retention.","Lithium levels may be increased, leading to toxicity.","Methotrexate toxicity may be increased."],"Contraindications":"Known hypersensitivity to naproxen or other NSAIDs, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.","ChemicalStructure":{"MolecularFormula":"C14H14O3","MolecularWeight":"230.26 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Should be avoided, especially during the third trimester.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established for certain formulations.","GeriatricUse":"Elderly patients are more likely to have renal impairment and serious side effects.","HepaticImpairment":"Use with caution and adjust dose accordingly.","RenalImpairment":"Use with caution and adjust dose accordingly, especially in severe impairment."},"StorageAndHandling":"Store at room temperature away from light and moisture."},{"GenericName":"Atenolol","BrandNames":["Tenormin"],"DrugClass":"Beta-blocker (beta-1 selective adrenergic receptor blocker)","MechanismOfAction":"Atenolol works by selectively blocking beta-1 adrenergic receptors in the heart, reducing heart rate, cardiac output, and blood pressure, ultimately decreasing myocardial oxygen demand.","Pharmacodynamics":"Atenolol produces effects such as lowering of high blood pressure (antihypertensive), reduction of heart rate (antianginal), and it may have protective effects on the heart after myocardial infarction by lowering heart rate and reducing cardiac workload.","OnsetOfAction":"Within 1 hour","DurationOfAction":"24 hours","PeakPlasmaConcentration":"2 to 4 hours after oral dosing","Indications":["Hypertension","Angina pectoris","Acute myocardial infarction (to improve survival)","Cardiac dysrhythmias"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["25 mg","50 mg","100 mg"],"Pharmacokinetics":{"Absorption":"Approximately 50% absorbed from the gastrointestinal tract.","Distribution":"Widely distributed; crosses the blood-brain barrier to a limited extent.","Metabolism":"Minimal hepatic metabolism; atenolol is metabolized to a very minor extent, with more than 90% found unchanged in the urine.","Excretion":"Primarily renal; approximately 50% of the dose is eliminated unchanged in the urine."},"SideEffects":["Bradycardia","Hypotension","Fatigue","Dizziness","Depression","Cold extremities","Bronchospasm in susceptible individuals"],"DrugInteractions":["Calcium channel blockers (e.g., verapamil, diltiazem)","Other antihypertensives","Non-steroidal anti-inflammatory drugs (NSAIDs)","Insulin and oral antidiabetic drugs","Epinephrine"],"Contraindications":"Atenolol is contraindicated in patients with sinus bradycardia, greater than first-degree heart block, overt cardiac failure, and cardiogenic shock.","ChemicalStructure":{"MolecularFormula":"C14H22N2O3","MolecularWeight":"266.34 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D: There is positive evidence of human fetal risk, but the potential benefits may warrant use in pregnant women despite potential risks.","PediatricUse":"Safety and efficacy have not been established in children.","GeriatricUse":"Dose selection should be cautious, typically starting at the low end of the dosing range.","HepaticImpairment":"Not suggested for patients with severe hepatic impairment due to primary renal excretion pathways.","RenalImpairment":"Dose adjustments may be necessary; carefully monitor renal function."},"StorageAndHandling":"Store at controlled room temperature, between 15°C to 30°C (59°F to 86°F). Protect from light."},{"GenericName":"Glipizide","BrandNames":["Glucotrol","Glucotrol XL"],"DrugClass":"Sulfonylurea","MechanismOfAction":"Glipizide stimulates the release of insulin from beta cells in pancreatic islets. This is achieved by inhibiting adenosine triphosphate (ATP)-dependent potassium channels, leading to depolarization of the beta cell membrane and influx of calcium, which results in insulin secretion.","Pharmacodynamics":"Glipizide lowers blood glucose levels by increasing insulin secretion. Its efficacy is dependent on functioning pancreatic beta cells.","OnsetOfAction":"About 30 minutes to 1 hour after oral administration.","DurationOfAction":"Approximately 12 to 24 hours.","PeakPlasmaConcentration":"1 to 3 hours post-oral dose for immediate-release.","Indications":["Type 2 diabetes mellitus"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Extended-release tablets"],"StrengthsOfDosageForms":["2.5 mg","5 mg","10 mg (immediate-release)","5 mg","10 mg (extended-release)"],"Pharmacokinetics":{"Absorption":"Rapid and nearly complete for immediate-release.","Distribution":"Widely distributed in body tissues; protein binding is about 98% to 99%.","Metabolism":"Extensively metabolized in the liver, primarily via CYP2C9.","Excretion":"Mainly via urine as metabolites (approximately 80%); about 10% is excreted unchanged."},"SideEffects":["Hypoglycemia","Nausea","Diarrhea","Dizziness","Tremor","Headache"],"DrugInteractions":["Avoid alcohol as it may potentiate the hypoglycemic effect.","Beta-blockers may mask some of the signs of hypoglycemia.","Certain antifungal medications like itraconazole can increase glipizide levels."],"Contraindications":"Known hypersensitivity to glipizide, diabetes in ketoacidosis, with or without coma. This condition should be treated with insulin.","ChemicalStructure":{"MolecularFormula":"C21H27N5O4S","MolecularWeight":"445.54 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy in pediatric patients have not been established.","GeriatricUse":"Use caution; start therapy at the lower end of the dosing range.","HepaticImpairment":"Use with caution in patients with hepatic impairment.","RenalImpairment":"Use with caution in patients with renal impairment, as there is increased risk of hypoglycemia."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F); protect from light and moisture."},{"GenericName":"Fenofibrate","BrandNames":["Tricor","Lipofen","Antara","Fenoglide","Triglide"],"DrugClass":"Fibric acid derivatives (Fibrates)","MechanismOfAction":"Fenofibrate acts by activating peroxisome proliferator-activated receptor alpha (PPARα). This facilitates lipid metabolism and decreases low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) while increasing high-density lipoprotein (HDL).","Pharmacodynamics":"Fenofibrate lowers triglycerides and, to a lesser extent, low-density lipoprotein cholesterol (LDL-C) levels by promoting the elimination of triglyceride-rich lipoproteins from plasma. It increases the size and decreases the density of LDL particles and enhances the activity of lipoprotein lipase, subsequently increasing the catabolism of triglycerides.","OnsetOfAction":"The lipid-lowering effect is typically seen within one month of starting treatment.","DurationOfAction":"The duration of action is maintained with continuous daily dosing.","PeakPlasmaConcentration":"Peak plasma concentration is reached in approximately 4 to 5 hours post-dose.","Indications":["Primary hypercholesterolemia or mixed dyslipidemia","Hypertriglyceridemia"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Capsule"],"StrengthsOfDosageForms":["Tablet: 48 mg, 145 mg","Capsule: 50 mg, 150 mg"],"Pharmacokinetics":{"Absorption":"Fenofibrate is well absorbed when administered with food.","Distribution":"Distributed widely throughout the body.","Metabolism":"Fenofibrate is metabolized in the liver to its active form, fenofibric acid.","Excretion":"Primarily excreted in urine as fenofibric acid and its conjugates."},"SideEffects":["Abdominal pain","Back pain","Headache","Increased liver enzymes","Increased creatinine"],"DrugInteractions":["Warfarin (increased bleeding risk)","Statins (increased risk of myopathy)","Cyclosporine","Bile acid sequestrants (reduced absorption)"],"Contraindications":"Severe renal impairment, active liver disease, gallbladder disease, nursing mothers, known hypersensitivity to fenofibrate.","ChemicalStructure":{"MolecularFormula":"C20H21ClO4","MolecularWeight":"360.83 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness not established in pediatric patients.","GeriatricUse":"No specific dosage adjustment is required for the elderly, but caution is advised.","HepaticImpairment":"Contraindicated in patients with active liver disease.","RenalImpairment":"Dose adjustment may be required in patients with mild to moderate renal impairment."},"StorageAndHandling":"Store at room temperature, 20°C to 25°C (68°F to 77°F), in a tightly closed container."},{"GenericName":"Clonidine","BrandNames":["Catapres","Kapvay"],"DrugClass":"Alpha-2 adrenergic agonist","MechanismOfAction":"Clonidine stimulates alpha-2 adrenergic receptors in the brain, which results in a reduction of the sympathetic outflow from the central nervous system. This leads to decreased peripheral resistance, renal vascular resistance, heart rate, and blood pressure.","Pharmacodynamics":"Clonidine reduces sympathetic nervous system signals, which generally results in a decrease in blood pressure and heart rate. It can also have effects on pain perception and attention processes.","OnsetOfAction":"30 to 60 minutes for antihypertensive effect","DurationOfAction":"Approximately 6 to 10 hours","PeakPlasmaConcentration":"1 to 3 hours after oral administration","Indications":["Hypertension","Attention Deficit Hyperactivity Disorder (ADHD)","Pain management (as part of epidural therapy)"],"RoutesOfAdministration":"Oral, epidural, transdermal","DosageForms":["Tablets","Transdermal patch","Epidural injection"],"StrengthsOfDosageForms":["Tablet: 0.1 mg, 0.2 mg, 0.3 mg","Transdermal patch: 0.1 mg/day, 0.2 mg/day, 0.3 mg/day"],"Pharmacokinetics":{"Absorption":"Well absorbed orally with a bioavailability of around 70-80%.","Distribution":"Small volume of distribution; protein binding is about 20% to 40%.","Metabolism":"Metabolized primarily in the liver.","Excretion":"Excreted mostly through the urine as unchanged drug and metabolites."},"SideEffects":["Dry mouth","Drowsiness","Dizziness","Constipation","Fatigue","Headache"],"DrugInteractions":["Beta blockers (may increase risk of bradycardia)","Tricyclic antidepressants (may reduce antihypertensive effect)","Alcohol (may enhance sedative effects)","Other antihypertensive medications (potential additive effects)"],"Contraindications":"Hypersensitivity to clonidine, severe bradyarrhythmia","ChemicalStructure":{"MolecularFormula":"C9H9Cl2N3","MolecularWeight":"230.1 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed; potential risk to fetus.","PediatricUse":"Safety and effectiveness For ADHD: approved for use in children.","GeriatricUse":"Caution is advised; possible increased sensitivity.","HepaticImpairment":"Use with caution; dosage adjustment may be necessary.","RenalImpairment":"Use with caution; monitor renal function."},"StorageAndHandling":"Store at controlled room temperature, 20° to 25°C (68° to 77°F). Keep away from moisture and light."},{"GenericName":"Spironolactone","BrandNames":["Aldactone","CaroSpir"],"DrugClass":"Potassium-sparing diuretic; Aldosterone antagonist","MechanismOfAction":"Spironolactone is a competitive antagonist of the mineralocorticoid receptor, which inhibits aldosterone's effects in the distal nephron. This results in increased sodium excretion and potassium retention.","Pharmacodynamics":"Spironolactone blocks the effects of aldosterone, leading to diuresis and natriuresis with subsequent decrease in blood pressure and reduced risk of heart failure progression.","OnsetOfAction":"2-4 hours","DurationOfAction":"24-72 hours","PeakPlasmaConcentration":"2.6 to 4.3 hours post-dose","Indications":["Hypertension","Heart failure","Edema associated with heart failure, hepatic cirrhosis, or nephrotic syndrome","Primary hyperaldosteronism","Hypokalemia management"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Suspension"],"StrengthsOfDosageForms":["Tablets: 25 mg, 50 mg, 100 mg","Suspension: 25 mg/5 mL"],"Pharmacokinetics":{"Absorption":"Absorbed from the gastrointestinal tract; bioavailability increases with food intake.","Distribution":"Widely distributed in tissues, with high protein binding (~90%).","Metabolism":"Extensively metabolized primarily by the liver into several active metabolites, including canrenone and 7-α-thiomethylspirolactone.","Excretion":"Excreted mainly in urine (50%) as metabolites, with a smaller amount excreted in feces."},"SideEffects":["Hyperkalemia","Hyponatremia","Nausea","Vomiting","Diarrhea","Dizziness","Gynecomastia","Menstrual irregularities","Impotence"],"DrugInteractions":["ACE inhibitors","Angiotensin II receptor blockers","NSAIDs","Potassium supplements","Digoxin"],"Contraindications":"Anuria, acute renal insufficiency, significant impairment of renal function, hyperkalemia, Addison's disease, or sensitivity to spironolactone.","ChemicalStructure":{"MolecularFormula":"C24H32O4S","MolecularWeight":"416.58 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed; potential risk of feminization of male infants.","PediatricUse":"Safety and effectiveness have been established for hypertension in children.","GeriatricUse":"Use with caution due to the potential increased risk of hyperkalemia.","HepaticImpairment":"Use with caution; may require dose adjustment.","RenalImpairment":"Contraindicated in renal impairment due to risk of hyperkalemia and other electrolyte imbalances."},"StorageAndHandling":"Store at room temperature, away from light and moisture."},{"GenericName":"Doxycycline","BrandNames":["Vibramycin","Doryx","Oracea","Acticlate","Adoxa"],"DrugClass":"Tetracycline Antibiotic","MechanismOfAction":"Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the RNA-ribosome complex, thereby inhibiting bacterial growth.","Pharmacodynamics":"Doxycycline exhibits bacteriostatic activity against a wide range of Gram-positive and Gram-negative bacteria. It is effective against certain spirochetes, rickettsiae, chlamydiae, and mycoplasmas, primarily by inhibiting protein synthesis.","OnsetOfAction":"Varies with the type of infection treated; typically within hours to a few days.","DurationOfAction":"24 hours","PeakPlasmaConcentration":"2 to 4 hours after administration","Indications":["Treatment of various bacterial infections, including respiratory tract infections and Lyme disease","Acne and rosacea management","Prophylaxis for malaria"],"RoutesOfAdministration":"Oral and Intravenous","DosageForms":["Tablet","Capsule","Suspension","Injection"],"StrengthsOfDosageForms":["50 mg","100 mg"],"Pharmacokinetics":{"Absorption":"70-90% after oral administration","Distribution":"Widely distributed in body tissues and fluids","Metabolism":"Limited hepatic metabolism","Excretion":"Excreted primarily via feces and urine"},"SideEffects":["Nausea","Diarrhea","Photosensitivity","Esophagitis","Discoloration of teeth in children"],"DrugInteractions":["Warfarin","Antacids containing calcium, magnesium, or aluminum","Iron supplements","Oral contraceptives","Isotretinoin"],"Contraindications":"Hypersensitivity to doxycycline, tetracyclines, or any component of the formulation. Use during the second and third trimesters of pregnancy, and in children younger than 8 years, is usually contraindicated due to risks of permanent tooth discoloration.","ChemicalStructure":{"MolecularFormula":"C22H24N2O8","MolecularWeight":"444.44 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D. Risk of fetal harm exists, contraindicated during pregnancy for non-critical issues.","PediatricUse":"Avoid use in children under 8 years due to tooth discoloration risks.","GeriatricUse":"No specific adjustment is generally needed, but caution in renal or hepatic impairment.","HepaticImpairment":"Use cautiously; doxycycline is mostly non-hepatically metabolized but consult specific recommendations.","RenalImpairment":"No significant adjustment needed, but exercise caution in severe impairment."},"StorageAndHandling":"Store at room temperature, away from light and moisture. Do not store in the bathroom."},{"GenericName":"Amoxicillin/Clavulanate","BrandNames":["Augmentin"],"DrugClass":"Penicillin-based antibiotic","MechanismOfAction":"Amoxicillin works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Clavulanate is a beta-lactamase inhibitor that protects amoxicillin from degradation by beta-lactamase enzymes produced by certain bacteria.","Pharmacodynamics":"The combination of amoxicillin and clavulanate extends the antibiotic spectrum of amoxicillin to include bacteria that produce beta-lactamase enzymes, which could otherwise degrade the antibiotic.","OnsetOfAction":"1-2 hours after oral administration","DurationOfAction":"Typically lasts 8-12 hours depending on the formulation used.","PeakPlasmaConcentration":"Reached within 1-2 hours after oral dose","Indications":["Ear infections","Sinus infections","Urinary tract infections","Skin infections","Lower respiratory tract infections (e.g., pneumonia)","Bite wounds"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Chewable tablet","Oral suspension"],"StrengthsOfDosageForms":["250 mg/125 mg","500 mg/125 mg","875 mg/125 mg","125 mg/31.25 mg per 5 ml suspension","200 mg/28.5 mg per 5 ml suspension","400 mg/57 mg per 5 ml suspension"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract.","Distribution":"Widely distributed in body tissues and fluids.","Metabolism":"Amoxicillin is metabolized to a minor extent in the body.","Excretion":"Primarily excreted in the urine."},"SideEffects":["Nausea","Vomiting","Diarrhea","Rash","Hypersensitivity reactions"],"DrugInteractions":["Methotrexate","Probenecid","Warfarin","Oral contraceptives"],"Contraindications":"Patients with a history of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin, clavulanate, or other beta-lactams.","ChemicalStructure":{"MolecularFormula":"C16H19N3O5S (Amoxicillin component) and C8H9NO5 (Clavulanate component)","MolecularWeight":"365.4 g/mol (Amoxicillin component) and 199.16 g/mol (Clavulanate component)"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed and benefits outweigh the risks (Category B).","PediatricUse":"Safe and often used in pediatric populations, dosage varies by weight and age.","GeriatricUse":"No dosage adjustment necessary unless renal function is impaired.","HepaticImpairment":"Use with caution, monitor liver function tests with prolonged use.","RenalImpairment":"Dosage adjustment may be necessary depending on the degree of impairment."},"StorageAndHandling":"Store at room temperature, away from excess heat and moisture. The oral suspension should be refrigerated after reconstitution and discarded after 10 days."},{"GenericName":"Sitagliptin","BrandNames":["Januvia"],"DrugClass":"Dipeptidyl peptidase-4 (DPP-4) inhibitor","MechanismOfAction":"Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is involved in the inactivation of incretin hormones, which play a role in regulating glucose homeostasis. By inhibiting DPP-4, sitagliptin increases the levels of active incretin hormones, leading to an increase in insulin release and a decrease in glucagon levels in the circulation in a glucose-dependent manner.","Pharmacodynamics":"The reduction of blood glucose level after administration of sitagliptin is primarily achieved by enhancing the effect of incretin hormones due to the inhibition of DPP-4, thus promoting the release of insulin and suppression of glucagon.","OnsetOfAction":"1-4 hours","DurationOfAction":"Approximately 24 hours","PeakPlasmaConcentration":"1 to 4 hours after dosing","Indications":["Type 2 diabetes mellitus"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["25 mg","50 mg","100 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed with an absolute bioavailability of approximately 87%.","Distribution":"The mean volume of distribution at steady state is approximately 198 liters.","Metabolism":"Sitagliptin is not extensively metabolized. Approximately 79% of sitagliptin is excreted unchanged in the urine.","Excretion":"Primarily renally excreted, with approximately 87% eliminated via the kidneys."},"SideEffects":["Nasopharyngitis","Headache","Upper respiratory tract infection","Hypoglycemia (when used with insulin or sulfonylureas)"],"DrugInteractions":["May increase the risk of hypoglycemia when used with insulin or sulfonylureas","May interact with strong CYP3A4 inducers (e.g., rifampin) which might decrease the efficacy of sitagliptin"],"Contraindications":"History of serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.","ChemicalStructure":{"MolecularFormula":"C16H15F6N5O","MolecularWeight":"407.31 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate studies in pregnant women; use only if clearly needed and the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients under 18 years of age have not been established.","GeriatricUse":"No overall differences in safety or effectiveness were observed between subjects aged 65 and over and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.","HepaticImpairment":"No dose adjustment is necessary for patients with mild to moderate hepatic impairment; caution is advised for severe hepatic impairment due to lack of studies.","RenalImpairment":"Dosage adjustment is necessary based on renal function; not recommended in patients with severe renal impairment or end-stage renal disease."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and keep the bottle tightly closed."},{"GenericName":"Ondansetron","BrandNames":["Zofran","Zuplenz"],"DrugClass":"Serotonin 5-HT3 receptor antagonist","MechanismOfAction":"Ondansetron works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting.","Pharmacodynamics":"Ondansetron helps alleviate nausea and vomiting by selectively inhibiting the 5-HT3 receptors located both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema.","OnsetOfAction":"The onset of action for ondansetron is approximately 30 minutes.","DurationOfAction":"The duration of action is about 4 to 8 hours.","PeakPlasmaConcentration":"Peak plasma concentrations are typically reached within 1.5 to 2 hours after oral administration.","Indications":["Prevention of nausea and vomiting associated with cancer chemotherapy","Prevention of postoperative nausea and vomiting","Prevention of nausea and vomiting associated with radiotherapy"],"RoutesOfAdministration":"Oral, intravenous, intramuscular","DosageForms":["Tablets","Oral disintegrating tablets","Oral solution","Intravenous injection"],"StrengthsOfDosageForms":["4 mg","8 mg","24 mg (oral)"],"Pharmacokinetics":{"Absorption":"Ondansetron is well absorbed from the gastrointestinal tract following oral administration, but undergoes first-pass metabolism.","Distribution":"The volume of distribution is 2.5 L/kg.","Metabolism":"Ondansetron is extensively metabolized in the liver via hydroxylation and subsequent glucuronide or sulfate conjugation.","Excretion":"Excretion is primarily through the liver, with approximately 5% of a dose excreted as the parent compound in the urine."},"SideEffects":["Headache","Constipation","Diarrhea","Fatigue","Malaise"],"DrugInteractions":["Apomorphine (increased risk of severe hypotension and loss of consciousness)","Drugs that affect the heart rhythm, such as antiarrhythmics","Other serotonergic drugs (risk of serotonin syndrome)"],"Contraindications":"Hypersensitivity to ondansetron or any component of the formulation; concomitant use with apomorphine is contraindicated due to risk of profound hypotension and loss of consciousness.","ChemicalStructure":{"MolecularFormula":"C18H19N3O","MolecularWeight":"293.37 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; although animal studies have not shown harm, human studies are lacking. Consult with a healthcare provider.","PediatricUse":"Safety and effectiveness established for certain age groups; use under guidance.","GeriatricUse":"No overall differences in safety or effectiveness observed between the elderly and younger patients, but greater sensitivity in some older individuals cannot be ruled out.","HepaticImpairment":"Dosage adjustment is advised in patients with severe hepatic impairment.","RenalImpairment":"No dosage adjustment is necessary in patients with renal impairment."},"StorageAndHandling":"Store at room temperature, away from moisture and light. Keep out of reach of children."},{"GenericName":"Lisdexamfetamine","BrandNames":["Vyvanse"],"DrugClass":"Central Nervous System Stimulant","MechanismOfAction":"Lisdexamfetamine is a prodrug of dextroamphetamine. Lisdexamfetamine itself is inactive until it is converted to dextroamphetamine, which releases norepinephrine and dopamine into the extraneuronal space. This increases neurotransmitter levels in the brain, resulting in its therapeutic effects.","Pharmacodynamics":"Lisdexamfetamine increases the release of the monoamines dopamine and norepinephrine from their storage sites in presynaptic neurons. The pharmacodynamic effects include increased attention span, decreased distractibility, increased wakefulness, and physical activity.","OnsetOfAction":"Approximately 1-2 hours after oral administration.","DurationOfAction":"The effects of lisdexamfetamine can last about 10-12 hours after a single dose.","PeakPlasmaConcentration":"Occurs approximately 4.4 hours after administration.","Indications":["Attention-Deficit/Hyperactivity Disorder (ADHD)","Moderate to Severe Binge Eating Disorder"],"RoutesOfAdministration":"Oral","DosageForms":["Capsules","Chewable Tablets"],"StrengthsOfDosageForms":["Capsules: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg","Chewable Tablets: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg"],"Pharmacokinetics":{"Absorption":"Lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and is converted to dextroamphetamine. Peak plasma concentrations are achieved in about 3.5 hours for dextroamphetamine.","Distribution":"The drug is well-distributed throughout the body, with a volume of distribution around 3.4 L/kg.","Metabolism":"Lisdexamfetamine is converted to the active form, dextroamphetamine, in the blood through enzymatic hydrolysis.","Excretion":"The drug's metabolites, primarily as dextroamphetamine, are excreted via urine. The half-life of dextroamphetamine ranges from 8-12 hours."},"SideEffects":["Decreased appetite","Insomnia","Dry mouth","Increased heart rate","Anxiety","Nausea","Dizziness"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Tricyclic antidepressants","Selective serotonin reuptake inhibitors (SSRIs)","Antihypertensive medications","Proton pump inhibitors"],"Contraindications":"Contraindicated in patients with a known hypersensitivity or idiosyncrasy to the sympathomimetic amines or those with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, known drug abuse-related issues, or during or within 14 days following the administration of monoamine oxidase inhibitors.","ChemicalStructure":{"MolecularFormula":"C15H25N3O","MolecularWeight":"263.38 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Lisdexamfetamine is a Category C medication. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy have been established in pediatric patients ages 6 to 17 years.","GeriatricUse":"Clinical studies have not been conducted in geriatric patients; use in this age group should be cautious, considering decreased physical reserve.","HepaticImpairment":"There is limited specific information available, but the drug should be used with caution as alterations in pharmacokinetics may be expected.","RenalImpairment":"Dose adjustments may be necessary as lisdexamfetamine and its metabolite dextroamphetamine are primarily excreted by the kidneys."},"StorageAndHandling":"Store capsules and chewable tablets at 20° to 25°C (68° to 77°F). Protect from moisture. Store in a tight, light-resistant container."},{"GenericName":"Propranolol","BrandNames":["Inderal","InnoPran XL","Hemangeol"],"DrugClass":"Beta-blocker (non-selective)","MechanismOfAction":"Propranolol is a non-selective beta-adrenergic receptor blocker. It blocks both beta-1 and beta-2 adrenergic receptors, leading to a decrease in heart rate, myocardial contractility, and blood pressure. Additionally, it reduces the effects of peripheral sympathetic nerve impulses.","Pharmacodynamics":"Propranolol reduces cardiac output and blood pressure, leading to decreased myocardial oxygen demand. It also reduces peripheral vasoconstriction and has membrane-stabilizing activity.","OnsetOfAction":"1 to 3 hours (oral); Immediate (IV)","DurationOfAction":"Up to 12 hours (oral); 6 to 8 hours (IV)","PeakPlasmaConcentration":"1 to 4 hours (oral)","Indications":["Hypertension","Angina pectoris","Myocardial infarction","Migraine prophylaxis","Essential tremor","Arrhythmias","Hypertrophic subaortic stenosis","Pheochromocytoma","Anxiety"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablet","Capsule (extended-release)","Oral solution","Injection"],"StrengthsOfDosageForms":["10 mg","20 mg","40 mg","60 mg","80 mg","120 mg","160 mg"],"Pharmacokinetics":{"Absorption":"60-80% absorbed from the gastrointestinal tract.","Distribution":"Widely distributed, crosses the blood-brain barrier. Volume of distribution is 3-5 L/kg.","Metabolism":"Extensively metabolized in the liver via CYP450 2D6.","Excretion":"Primarily renal as metabolites; less than 1% excreted unchanged in urine."},"SideEffects":["Bradycardia","Hypotension","Fatigue","Dizziness","Nausea","Diarrhea","Bronchospasm","Sleep disturbances","Depression","Impotence"],"DrugInteractions":["Calcium channel blockers (e.g., verapamil, diltiazem)","Nonsteroidal anti-inflammatory drugs (NSAIDs)","Antihypertensives","Antiarrhythmics","Anesthetics","Antidiabetic medications"],"Contraindications":"Severe bradycardia, sick sinus syndrome, second or third-degree heart block (unless a functioning pacemaker is present), cardiogenic shock, bronchial asthma, and hypersensitivity to propranolol or any component of the product.","ChemicalStructure":{"MolecularFormula":"C16H21NO2","MolecularWeight":"259.34 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus (Category C).","PediatricUse":"Safety and effectiveness have been established for certain conditions like migraine and cardiac indications.","GeriatricUse":"Dose selection should be cautious, usually starting at the low end of the dosing range.","HepaticImpairment":"Dosage adjustment may be needed due to reduced metabolism.","RenalImpairment":"Use with caution; clearance may be decreased."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) in a dry place. Protect from light and moisture."},{"GenericName":"Oxycodone","BrandNames":["OxyContin","Roxicodone","Oxaydo","Xtampza ER"],"DrugClass":"Opioid analgesic","MechanismOfAction":"Oxycodone acts on the central nervous system by binding to the mu-opioid receptor, causing inhibition of ascending pain pathways, which alters the perception of and response to pain.","Pharmacodynamics":"Oxycodone provides pain relief by altering the central nervous system's response to pain. It may also cause central nervous system depression, resulting in sedation.","OnsetOfAction":"10 to 30 minutes","DurationOfAction":"3 to 6 hours for immediate-release formulations; up to 12 hours for extended-release formulations","PeakPlasmaConcentration":"1 to 2 hours after oral administration for immediate-release","Indications":["Management of moderate to severe pain","Chronic pain requiring long-term opioid treatment"],"RoutesOfAdministration":"Oral","DosageForms":["Immediate-release tablets","Extended-release tablets","Capsules","Oral solution"],"StrengthsOfDosageForms":["Immediate-release tablets: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg","Extended-release tablets: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract","Distribution":"Widely distributed in the body; protein binding approximately 45%","Metabolism":"Primarily hepatic via CYP3A4 and CYP2D6 to active and inactive metabolites","Excretion":"Urine, mostly as metabolites; 8-14% of the dose excreted unchanged"},"SideEffects":["Nausea","Constipation","Drowsiness","Dizziness","Vomiting","Itching","Respiratory depression (severe cases)"],"DrugInteractions":["Concurrent use with other CNS depressants can enhance sedation and respiratory depression","Inhibitors or inducers of CYP3A4 may affect oxycodone plasma levels","CYP2D6 inhibitors may affect the formation of active metabolites"],"Contraindications":"Significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, hypersensitivity to oxycodone or any component of the product","ChemicalStructure":{"MolecularFormula":"C18H21NO4","MolecularWeight":"315.36 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus; prolonged use may result in neonatal opioid withdrawal syndrome.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"May require dose adjustment, as older adults may have increased sensitivity to oxycodone.","HepaticImpairment":"Use with caution; dose adjustment may be necessary.","RenalImpairment":"Use with caution; dose adjustment may be necessary."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) and keep away from light and moisture."},{"GenericName":"Lovastatin","BrandNames":["Mevacor","Altoprev"],"DrugClass":"Statin (HMG-CoA reductase inhibitor)","MechanismOfAction":"Lovastatin works by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis in the liver, which leads to decreased production of cholesterol and upregulation of LDL receptors, thereby increasing clearance of LDL cholesterol from the blood.","Pharmacodynamics":"Lovastatin lowers cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol, by inhibiting cholesterol synthesis and enhancing clearance of LDL from the bloodstream. This helps prevent cardiovascular diseases, especially in high-risk patients.","OnsetOfAction":"Within 3 days","DurationOfAction":"Approximately 24 to 48 hours","PeakPlasmaConcentration":"1 to 2 hours after administration","Indications":["Hypercholesterolemia","Prevention of coronary heart disease in patients at high risk","Heterozygous familial hypercholesterolemia in adolescents"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Extended-release tablet"],"StrengthsOfDosageForms":["10 mg","20 mg","40 mg","60 mg (extended-release)"],"Pharmacokinetics":{"Absorption":"Approximately 30% absorbed after oral administration","Distribution":"Widely distributed, protein binding of 95%","Metabolism":"Extensively metabolized by the liver, primarily via CYP3A4","Excretion":"Excreted mainly in the feces (83%), with about 10% excreted in the urine"},"SideEffects":["Muscle pain or weakness","Headache","Dizziness","Abdominal pain","Nausea","Elevated liver enzymes"],"DrugInteractions":["Grapefruit juice can increase lovastatin concentration","Interacts with other CYP3A4 inhibitors like ketoconazole and erythromycin","Increased risk of muscle damage with fibrates or niacin"],"Contraindications":"Active liver disease, unexplained persistent elevations of liver transaminases, pregnancy, and breastfeeding.","ChemicalStructure":{"MolecularFormula":"C24H36O5","MolecularWeight":"404.55 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category X - contraindicated","PediatricUse":"Approved for use in adolescents with heterozygous familial hypercholesterolemia","GeriatricUse":"Caution in elderly patients; monitor for increased sensitivity","HepaticImpairment":"Contraindicated in active liver disease; use with caution in those with a history of liver impairment","RenalImpairment":"Use with caution in patients with severe renal impairment"},"StorageAndHandling":"Store at room temperature, between 20°C to 25°C (68°F to 77°F), in a tightly sealed container away from moisture and light."},{"GenericName":"Risperidone","BrandNames":["Risperdal","Risperdal Consta","Risperdal M-Tabs"],"DrugClass":"Atypical antipsychotic","MechanismOfAction":"Risperidone works by antagonizing dopamine D2 receptors and serotonin 5-HT2A receptors in the brain, which helps balance neurotransmitters and alleviates symptoms of schizophrenia and bipolar disorder.","Pharmacodynamics":"Risperidone helps improve positive and negative symptoms of schizophrenia and may affect mood by altering neuronal dopamine and serotonin receptor binding. It has a lower incidence of extrapyramidal side effects compared to typical antipsychotics.","OnsetOfAction":"1 to 2 weeks for significant effects, although some improvement can be seen earlier.","DurationOfAction":"About 24 hours for the oral forms, whereas the long-acting injectable forms last several weeks.","PeakPlasmaConcentration":"1-2 hours after oral administration.","Indications":["Schizophrenia","Bipolar disorder","Irritability associated with autism"],"RoutesOfAdministration":"Oral, intramuscular injection","DosageForms":["Tablets","Orally disintegrating tablets","Oral solution","Extended-release injection"],"StrengthsOfDosageForms":["Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg","Orally disintegrating tablets: 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg","Oral solution: 1 mg/mL","Injection: 12.5 mg, 25 mg, 37.5 mg, 50 mg (long-acting)"],"Pharmacokinetics":{"Absorption":"Risperidone is well absorbed from the gastrointestinal tract with an oral bioavailability of approximately 70%.","Distribution":"Risperidone is widely distributed throughout the body, with a volume of distribution of about 1-2 L/kg.","Metabolism":"Risperidone is extensively metabolized in the liver via CYP2D6 to its active metabolite, 9-hydroxyrisperidone.","Excretion":"Risperidone and its metabolites are excreted primarily in urine (70%) and, to a lesser extent, in feces (15%)."},"SideEffects":["Weight gain","Drowsiness","Dizziness","Constipation","Nausea","Fatigue","Anxiety","Agitation","Extrapyramidal symptoms"],"DrugInteractions":["Carbamazepine","Fluoxetine","Paroxetine","Clozapine","Levodopa"],"Contraindications":"Hypersensitivity to risperidone or any of the components of the formulation.","ChemicalStructure":{"MolecularFormula":"C23H27FN4O2","MolecularWeight":"410.49 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C - Risk cannot be ruled out; use only if benefits justify the potential risks.","PediatricUse":"Approved for use in children with specific indications such as autism-related irritability and schizophrenia, but dosing must be carefully managed.","GeriatricUse":"Caution in elderly, especially those with dementia-related psychosis due to an increased risk of mortality.","HepaticImpairment":"Dose adjustment may be necessary as risperidone is metabolized in the liver.","RenalImpairment":"Caution and dose adjustments are recommended in patients with significant renal impairment."},"StorageAndHandling":"Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), away from light and moisture. Keep the injectable form refrigerated if required."},{"GenericName":"Insulin Aspart","BrandNames":["NovoLog","NovoRapid","Fiasp"],"DrugClass":"Rapid-acting insulin","MechanismOfAction":"Insulin aspart is a rapid-acting human insulin analog. It binds to insulin receptors on muscle and fat cells, facilitating cellular uptake of glucose and inhibiting hepatic glucose output.","Pharmacodynamics":"Insulin aspart lowers blood glucose levels by facilitating cellular glucose uptake in peripheral tissues and inhibiting glucose production in the liver.","OnsetOfAction":"10 to 20 minutes","DurationOfAction":"3 to 5 hours","PeakPlasmaConcentration":"Approximately 40 to 50 minutes","Indications":["Diabetes mellitus type 1","Diabetes mellitus type 2"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Injection for subcutaneous use"],"StrengthsOfDosageForms":["100 units/mL (U-100)"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed after subcutaneous injection.","Distribution":"Widely distributed. Volume of distribution is comparable to human insulin.","Metabolism":"Metabolized by proteolytic cleavage of the peptide chain.","Excretion":"Excreted primarily by the kidneys."},"SideEffects":["Hypoglycemia","Injection site reactions","Lipodystrophy","Skin rash"],"DrugInteractions":["Beta-blockers","Salicylates","Alcohol","Thiazolidinediones"],"Contraindications":"Hypersensitivity to insulin aspart or any component of the product","ChemicalStructure":{"MolecularFormula":"C256H381N65O79S6","MolecularWeight":"5825.8 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B. Insulin aspart is considered safe during pregnancy, but dose adjustments may be necessary.","PediatricUse":"Safety and effectiveness have been established in pediatric patients.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients.","HepaticImpairment":"May require dose adjustments; monitor blood glucose closely.","RenalImpairment":"May require dose adjustments; monitor blood glucose closely."},"StorageAndHandling":"Store in a refrigerator (2-8°C). Do not freeze. Once opened, vials can be stored at a room temperature below 30°C for up to 28 days."},{"GenericName":"Aripiprazole","BrandNames":["Abilify","Aristada"],"DrugClass":"Atypical antipsychotic","MechanismOfAction":"Aripiprazole acts as a partial agonist at the D2 and 5-HT1A receptors and as an antagonist at the 5-HT2A receptor. This action helps in optimizing dopaminergic and serotonergic neurotransmission in the brain, leading to its effectiveness in treating symptoms of schizophrenia and bipolar disorder.","Pharmacodynamics":"Aripiprazole has a unique mechanism of action compared to other atypical antipsychotics due to its partial agonist activity at D2 receptors, contributing to therapeutic effects and a lower risk of side effects like extrapyramidal symptoms.","OnsetOfAction":"The onset of action may vary; improvement in symptoms can be noticed within 1-2 weeks, but full medication effects may take several weeks.","DurationOfAction":"The effect can last for about 24 hours with oral formulations; long-acting injections like Aristada can last up to 8 weeks.","PeakPlasmaConcentration":"For oral formulations, peak plasma concentration is reached in 3-5 hours.","Indications":["Schizophrenia","Bipolar I disorder","Irritability associated with autistic disorder","Adjunctive treatment of major depressive disorder","Tourette syndrome"],"RoutesOfAdministration":"Oral, Intramuscular (IM)","DosageForms":["Tablets","Orally Disintegrating Tablets (ODT)","Oral Solution","Intramuscular Injection"],"StrengthsOfDosageForms":["2 mg","5 mg","10 mg","15 mg","20 mg","30 mg","300 mg (intramuscular)","400 mg (intramuscular)","660 mg (intramuscular)"],"Pharmacokinetics":{"Absorption":"Aripiprazole is well absorbed, with an absolute oral bioavailability of 87%.","Distribution":"The volume of distribution is approximately 4.9 L/kg; about 99% is protein-bound, mainly to albumin.","Metabolism":"Aripiprazole is extensively metabolized by the liver, primarily through the CYP2D6 and CYP3A4 pathways.","Excretion":"Elimination occurs through feces (55%) and urine (27%), with a half-life of about 75 hours."},"SideEffects":["Akathisia","Weight gain","Insomnia","Nausea","Somnolence","Constipation","Headache","Anxiety","Dizziness"],"DrugInteractions":["Ketoconazole (CYP3A4 inhibitor) can increase aripiprazole levels.","Fluoxetine (CYP2D6 inhibitor) can increase aripiprazole levels.","Carbamazepine (CYP3A4 inducer) can decrease aripiprazole levels."],"Contraindications":"Known hypersensitivity to aripiprazole or any of its excipients.","ChemicalStructure":{"MolecularFormula":"C23H27Cl2N3O2","MolecularWeight":"448.38 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C; use only if benefits justify potential risk to fetus.","PediatricUse":"Approved for use in children for certain indications; consult specifics for age restrictions.","GeriatricUse":"May have increased sensitivity; monitor for side effects and adjust dose accordingly.","HepaticImpairment":"Dose adjustment may not be necessary, but monitor patients closely.","RenalImpairment":"Dose adjustment is not generally required."},"StorageAndHandling":"Store at room temperature; protect from moisture and light. Keep out of reach of children."},{"GenericName":"Topiramate","BrandNames":["Topamax","Trokendi XR","Qudexy XR"],"DrugClass":"Anticonvulsant","MechanismOfAction":"Topiramate is a sulfamate-substituted monosaccharide with a mechanism not completely understood. It is thought to involve blocking voltage-dependent sodium channels, enhancing the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, antagonizing the AMPA/kainate subtype of the glutamate receptor, and inhibiting carbonic anhydrase enzymes, particularly isozymes II and IV.","Pharmacodynamics":"Topiramate stabilizes neuronal membranes and suppresses seizure activity. Its use leads to reduced frequency and severity of seizures.","OnsetOfAction":"Variable, can start to show effects within several days, but it may take several weeks to reach full efficacy.","DurationOfAction":"Approximately 24 hours when taken in extended-release forms.","PeakPlasmaConcentration":"1-4 hours for immediate-release; 24 hours for extended-release forms.","Indications":["Epilepsy","Migraine prophylaxis","Lennox-Gastaut syndrome","Seizures (partial onset or primary generalized tonic-clonic)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Capsules (sprinkle)","Extended-release capsules"],"StrengthsOfDosageForms":["25 mg","50 mg","100 mg","200 mg","15 mg sprinkle","25 mg sprinkle"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed; oral bioavailability is about 80%.","Distribution":"Vd is approximately 0.8 L/kg. Low protein binding (15-41%).","Metabolism":"Minimal (<20% undergo hepatic metabolism) and variable depending on concomitant medications.","Excretion":"Excreted primarily unchanged in the urine (about 70%)."},"SideEffects":["Paresthesia","Anorexia","Weight loss","Memory difficulties","Dizziness","Fatigue","Nausea","Diarrhea","Nervousness"],"DrugInteractions":["Reduced plasma concentrations when used with carbamazepine and phenytoin.","Increased risk of metabolic acidosis when used with carbonic anhydrase inhibitors.","May interfere with oral contraceptives."],"Contraindications":"Hypersensitivity to topiramate or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C12H21NO8S","MolecularWeight":"339.36 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D - potential risk of fetal harm; consult healthcare provider.","PediatricUse":"Approved for use in children for specific indications like seizures.","GeriatricUse":"No specific differences noted, but increased sensitivity in some older individuals is possible.","HepaticImpairment":"Use with caution; may require dosage adjustments.","RenalImpairment":"Dose adjustment recommended based on creatinine clearance."},"StorageAndHandling":"Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Protect from moisture."},{"GenericName":"Quetiapine","BrandNames":["Seroquel","Seroquel XR"],"DrugClass":"Atypical antipsychotic","MechanismOfAction":"Quetiapine is believed to act by antagonizing the 5-HT2A serotonin receptor and dopamine D2 receptor, leading to antipsychotic effects. It also has affinity for other receptors, including histaminergic H1, adrenergic alpha1 and alpha2 receptors.","Pharmacodynamics":"Quetiapine reduces symptoms of schizophrenia and bipolar disorder through its action on serotonin and dopamine receptors. It has calming effects and mood stabilization properties.","OnsetOfAction":"1.5 to 6 hours after oral administration","DurationOfAction":"For the immediate-release formulation, the duration is 6 to 12 hours, while the extended-release formulation lasts longer.","PeakPlasmaConcentration":"Approximately 1 to 2 hours for immediate-release; 5 to 6 hours for extended-release","Indications":["Schizophrenia","Bipolar disorder","Major depressive disorder (as adjunct therapy)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Extended-release tablet"],"StrengthsOfDosageForms":["25 mg","50 mg","100 mg","150 mg","200 mg","300 mg","400 mg"],"Pharmacokinetics":{"Absorption":"Rapid absorption with oral administration. Bioavailability is approximately 9% due to first-pass metabolism.","Distribution":"Widely distributed in the body with a volume of distribution of approximately 10 L/kg.","Metabolism":"Extensively metabolized in the liver primarily via CYP3A4 enzyme.","Excretion":"Excreted in urine (73%) and feces (20%), with less than 1% excreted unchanged."},"SideEffects":["Drowsiness","Dizziness","Dry mouth","Constipation","Weight gain","Increased appetite","Orthostatic hypotension","Extrapyramidal symptoms","Increased levels of cholesterol and triglycerides"],"DrugInteractions":["CYP3A4 inhibitors and inducers (e.g., ketoconazole, erythromycin, rifampin) may alter quetiapine levels","Other CNS depressants may enhance sedative effects","Antihypertensive agents may enhance hypotensive effects"],"Contraindications":"Known hypersensitivity to quetiapine or any components of the product.","ChemicalStructure":{"MolecularFormula":"C21H25N3O2S","MolecularWeight":"383.51 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C; use only if potential benefits justify the potential risk to the fetus.","PediatricUse":"Safety and effectiveness not established for certain conditions; consult a healthcare provider.","GeriatricUse":"May be more susceptible to orthostatic hypotension and sedation; use with caution.","HepaticImpairment":"Consider dose adjustment as quetiapine is extensively metabolized by the liver.","RenalImpairment":"Dose adjustment may not be necessary but use cautiously."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); protect from light and moisture."},{"GenericName":"Varenicline","BrandNames":["Chantix","Champix"],"DrugClass":"Nicotine receptor partial agonists","MechanismOfAction":"Varenicline works by binding to nicotinic acetylcholine receptors in the brain. As a partial agonist, it binds to the receptor and provides partial stimulation, which helps reduce cravings and withdrawal symptoms associated with smoking cessation. It also blocks nicotine from binding to these receptors if the person smokes, reducing the pleasurable effects of smoking.","Pharmacodynamics":"Varenicline partially stimulates dopamine release, alleviating craving and withdrawal symptoms associated with smoking cessation.","OnsetOfAction":"Within one week of treatment initiation.","DurationOfAction":"Approximately 24 hours.","PeakPlasmaConcentration":"3-4 hours after administration.","Indications":["Smoking cessation","Reduction of withdrawal symptoms associated with quitting smoking"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["0.5 mg","1 mg"],"Pharmacokinetics":{"Absorption":"Varenicline is well absorbed after oral administration, with an absolute oral bioavailability of approximately 90%.","Distribution":"Volume of distribution is approximately 415 liters.","Metabolism":"Minimal metabolism; less than 10% is metabolized through the liver.","Excretion":"Primarily eliminated through renal excretion; approximately 92% is excreted in the urine unchanged."},"SideEffects":["Nausea","Insomnia","Headache","Abnormal dreams","Flatulence","Constipation","Vomiting"],"DrugInteractions":["Concurrent use with nicotine replacement therapy may increase the incidence of adverse effects.","Use with alcohol may enhance the effects of alcohol."],"Contraindications":"Hypersensitivity to varenicline or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C13H13N3","MolecularWeight":"211.27 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate data on the developmental risk associated with the use of varenicline in pregnant women.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No dosage adjustment is necessary for elderly patients unless renal function is impaired.","HepaticImpairment":"No dosage adjustment is necessary.","RenalImpairment":"Dosage adjustment is recommended for patients with severe renal impairment (creatinine clearance < 30 mL/min)."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F). Protect from moisture and light."},{"GenericName":"Methotrexate","BrandNames":["Rheumatrex","Trexall","Otrexup","Rasuvo","Xatmep"],"DrugClass":"Antimetabolite","MechanismOfAction":"Methotrexate inhibits dihydrofolate reductase, an enzyme involved in the synthesis of tetrahydrofolate. This inhibition leads to decreased formation of thymidylate, inhibiting DNA synthesis and cell replication, primarily affecting rapidly dividing cells.","Pharmacodynamics":"Methotrexate has cytotoxic effects on rapidly dividing cells and is used to reduce inflammation through its immunosuppressive activities. The action is dose-dependent, with therapeutic concentrations leading to different cellular responses.","OnsetOfAction":"The onset of action varies with condition treated; for rheumatoid arthritis, improvement may be seen within 3-6 weeks, while psoriasis may improve in 3-6 weeks.","DurationOfAction":"The duration of action is variable, often requiring weekly dosing for chronic conditions.","PeakPlasmaConcentration":"Peak plasma concentrations are reached approximately 1-2 hours after oral administration.","Indications":["Rheumatoid arthritis","Psoriasis","Acute lymphoblastic leukemia","Non-Hodgkin's lymphoma","Choriocarcinoma","Breast cancer"],"RoutesOfAdministration":"Oral, subcutaneous, intramuscular, intravenous, intrathecal","DosageForms":["Tablets","Injection (solution or suspension)"],"StrengthsOfDosageForms":["2.5 mg tablet","7.5 mg/mL (subcutaneous injection)","25 mg/mL (intramuscular, intravenous injection)"],"Pharmacokinetics":{"Absorption":"Variable and dose-dependent oral bioavailability, approximately 70% at lower doses, less at higher doses.","Distribution":"Widely distributed, but penetrates poor into third spaces; protein binding is about 50%.","Metabolism":"Primarily hepatic, with some metabolism occurring in the intestines and other tissues.","Excretion":"Renally excreted, primarily unchanged; requires dose adjustment in renal impairment."},"SideEffects":["Mucositis","Nausea","Hepatotoxicity","Myelosuppression","Pulmonary toxicity","Alopecia"],"DrugInteractions":["NSAIDs can increase methotrexate levels and toxicity.","Penicillins may reduce renal clearance of methotrexate, increasing toxicity.","Trimethoprim can enhance antifolate effects, increasing risk of bone marrow suppression."],"Contraindications":"Pregnancy, breastfeeding, alcoholism, severe liver disease, immunodeficiency syndromes, pre-existing blood dyscrasias.","ChemicalStructure":{"MolecularFormula":"C20H22N8O5","MolecularWeight":"454.44 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category X; contraindicated due to teratogenic effects.","PediatricUse":"Used with caution, primarily in oncology settings.","GeriatricUse":"May require lower doses due to decreased renal function.","HepaticImpairment":"Use with caution; contraindicated in severe hepatic impairment.","RenalImpairment":"Dose adjustments required; increased risk of toxicity."},"StorageAndHandling":"Store at controlled room temperature, protect from light and moisture."},{"GenericName":"Levofloxacin","BrandNames":["Levaquin","Quixin","Iquix"],"DrugClass":"Antibiotic, Fluoroquinolone","MechanismOfAction":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes involved in DNA replication, transcription, repair, and recombination, leading to bacterial cell death.","Pharmacodynamics":"Levofloxacin has a broad-spectrum antibacterial activity against a variety of gram-positive and gram-negative microorganisms. Its bactericidal action unfolds quickly after intake due to its ability to interfere with crucial bacterial enzymes.","OnsetOfAction":"Typically, therapeutic effects begin within 1-2 hours after administration.","DurationOfAction":"The effects last approximately 24 hours, facilitating once-daily dosing for infections.","PeakPlasmaConcentration":"Peak plasma concentrations are reached 1-2 hours post-oral dose.","Indications":["Acute bacterial sinusitis","Community-acquired pneumonia","Chronic bronchitis with acute bacterial exacerbation","Skin and skin structure infections","Complicated urinary tract infections","Acute pyelonephritis","Prophylaxis of inhalational anthrax"],"RoutesOfAdministration":"Oral and Intravenous (IV)","DosageForms":["Tablets","Oral solution","Injectable solution","Ophthalmic solution"],"StrengthsOfDosageForms":["Tablets: 250 mg, 500 mg, 750 mg","Oral solution: 25 mg/mL","Injectable solution: 5 mg/mL","Ophthalmic solution: 0.5%"],"Pharmacokinetics":{"Absorption":"Levofloxacin exhibits near complete absorption after oral administration, with bioavailability close to 99%.","Distribution":"The drug is widely distributed throughout the body including bones, lungs, and tissues. It also crosses the placenta and can be found in breast milk.","Metabolism":"Levofloxacin is minimally metabolized in the liver, with around 5% of the dose being metabolized to inactive metabolites.","Excretion":"Excreted primarily through urine as unchanged drug (approximately 87% in 48 hours)."},"SideEffects":["Nausea","Diarrhea","Headache","Dizziness","Insomnia","Tendinitis and tendon rupture"],"DrugInteractions":["Concurrent use with anti-inflammatory drugs may increase the risk of CNS stimulation and convulsive seizures.","Levofloxacin absorption is reduced with concomitant use of antacids or mineral supplements.","Increased anticoagulation effect with warfarin.","Increased risk of QT interval prolongation when used with antiarrhythmics, certain antipsychotics, and tricyclic antidepressants."],"Contraindications":"Levofloxacin is contraindicated in patients with a history of hypersensitivity to levofloxacin or other quinolone antibiotics.","ChemicalStructure":{"MolecularFormula":"C18H20FN3O4","MolecularWeight":"361.37 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients below the age of 18 years have not been established, except for treatment of inhalational anthrax.","GeriatricUse":"Elderly patients are more susceptible to adverse effects, including tendon rupture, and often require dosage adjustments due to age-related renal function decline.","HepaticImpairment":"No dosage adjustment is necessary as the drug is minimally metabolized by the liver.","RenalImpairment":"Dosage adjustment is necessary in patients with impaired renal function to prevent accumulation of the drug."},"StorageAndHandling":"Store at 20-25°C (68-77°F), with the oral and injectable forms protected from light and kept in well-closed containers."},{"GenericName":"Morphine","BrandNames":["MS Contin","Roxanol","Kadian","Oramorph SR"],"DrugClass":"Opioid analgesic","MechanismOfAction":"Morphine primarily acts on the central nervous system and smooth muscle. It binds to and activates the mu-opioid receptors in the brain and spinal cord, which inhibits ascending pain pathways, alters the perception of and response to pain, and produces generalized CNS depression.","Pharmacodynamics":"Morphine produces its analgesic effects by acting as an agonist at the mu-opioid receptor, providing significant pain relief. It also impacts emotional reaction to pain and can induce a sense of euphoria, which contributes to its addictive potential.","OnsetOfAction":"IV: 5-10 minutes, IM: 10-30 minutes, Oral: 30-60 minutes","DurationOfAction":"IV: 3-5 hours, IM: 3-5 hours, Oral: 4-6 hours","PeakPlasmaConcentration":"IV: 20 minutes, IM: 30-60 minutes, Oral: 60-120 minutes","Indications":["Acute and chronic pain","Pain due to myocardial infarction","Severe pain which is unresponsive to non-narcotic analgesics"],"RoutesOfAdministration":"Intravenous, Intramuscular, Subcutaneous, Oral, Rectal","DosageForms":["Tablets","Capsules","Liquid","Injection","Suppositories"],"StrengthsOfDosageForms":["Tablets: 15 mg, 30 mg","Capsules: 10 mg, 20 mg, 30 mg, 60 mg","Oral solution: 10 mg/5 mL, 20 mg/5 mL","Injection: 5 mg/mL, 10 mg/mL","Suppositories: 5 mg, 10 mg, 20 mg, 30 mg"],"Pharmacokinetics":{"Absorption":"Absorbed from the gastrointestinal tract relatively slowly when given orally; substantially absorbed subcutaneously and intramuscularly.","Distribution":"Widely distributed throughout the body, binding to plasma proteins.","Metabolism":"Metabolized primarily by the liver via conjugation with glucuronic acid.","Excretion":"Predominantly excreted in the urine as morphine-glucuronide conjugate and in bile."},"SideEffects":["Respiratory depression","Constipation","Euphoria","Nausea and vomiting","Drowsiness","Dizziness","Physical dependence","Itching","Miosis"],"DrugInteractions":["Central nervous system depressants, including alcohol and benzodiazepines","Inhibitors and inducers of cytochrome P450","Other opioids","Monoamine oxidase inhibitors (MAOIs)"],"Contraindications":"Contraindicated in patients with hypersensitivity to morphine, acute or severe bronchial asthma, paralytic ileus, respiratory depression, and conditions where gastrointestinal motility is problematically decreased.","ChemicalStructure":{"MolecularFormula":"C17H19NO3","MolecularWeight":"285.34 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution in pregnancy; it can cross the placenta and may cause neonatal opioid withdrawal syndrome.","PediatricUse":"Safety and effectiveness have not been established for use in children under 18.","GeriatricUse":"Use with caution, considering the increased sensitivity and higher risk of respiratory depression and renal impairment.","HepaticImpairment":"Dosing adjustments may be necessary; closely monitor for side effects.","RenalImpairment":"Carefully monitor for side effects and dose adjustment may be necessary."},"StorageAndHandling":"Store at controlled room temperature, protect from light and moisture. Keep out of reach of children."},{"GenericName":"Valacyclovir","BrandNames":["Valtrex"],"DrugClass":"Antiviral","MechanismOfAction":"Valacyclovir is converted in the body to acyclovir. Acyclovir then inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and incorporating into viral DNA, preventing viral replication.","Pharmacodynamics":"Valacyclovir exhibits antiviral activity primarily by conversion to acyclovir, which interferes with viral DNA synthesis and replication. It is most effective against herpes simplex viruses and varicella-zoster virus.","OnsetOfAction":"Valacyclovir begins to work soon after oral administration, with measurable inhibition of viral replication within 1-2 hours.","DurationOfAction":"The effect typically lasts for about 3 to 5 hours after dosing, but therapeutic effects may extend beyond depending on the antiviral needs.","PeakPlasmaConcentration":"The peak plasma concentration of acyclovir, following valacyclovir administration, is reached in approximately 1 to 2 hours.","Indications":["Herpes zoster (shingles)","Genital herpes (initial and recurrent episodes)","Cold sores (herpes labialis)","Chickenpox in immunocompetent children"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["500 mg","1000 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the GI tract and extensively converted to acyclovir; has bioavailability of about 54% compared to acyclovir itself.","Distribution":"Widely distributed after conversion to acyclovir, with a volume of distribution similar to hydrophilic drugs.","Metabolism":"Metabolized quickly to acyclovir by first-pass intestinal and hepatic metabolism.","Excretion":"Eliminated primarily through the kidneys, with about 80% of the excreted dose as unchanged acyclovir."},"SideEffects":["Nausea","Headache","Dizziness","Vomiting","Abdominal pain","Rash"],"DrugInteractions":["Probenecid","Cimetidine","Other nephrotoxic drugs"],"Contraindications":"Hypersensitivity to valacyclovir, acyclovir, or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C13H20N6O4","MolecularWeight":"324.33 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution. Category B (no well-controlled studies in pregnant women, use only if needed).","PediatricUse":"Safety and efficacy established for children 12 years and older for cold sores and for chickenpox in immunocompetent children 2 to 18 years of age.","GeriatricUse":"Dose adjustment may be necessary in elderly due to decreased renal function.","HepaticImpairment":"Dose adjustment is generally not necessary, but monitor closely.","RenalImpairment":"Dose adjustment is required; severe renal impairment necessitates significant dosing changes."},"StorageAndHandling":"Store at controlled room temperature, between 20-25°C (68-77°F). Protect from moisture."},{"GenericName":"Metoclopramide","BrandNames":["Reglan","Metozolv ODT"],"DrugClass":"Prokinetic agent","MechanismOfAction":"Metoclopramide works by blocking dopamine receptors in the chemoreceptor trigger zone of the central nervous system, among other areas, and enhances the response of the upper gastrointestinal tract to acetylcholine, leading to increased gastrointestinal motility without increasing gastric secretions.","Pharmacodynamics":"It increases lower esophageal sphincter tone and accelerates gastric emptying, while possessing an antiemetic effect by antagonism of dopamine receptors in the medulla.","OnsetOfAction":"30 to 60 minutes after oral administration","DurationOfAction":"1 to 2 hours for gastrointestinal effects, up to 6 hours for antiemetic effects","PeakPlasmaConcentration":"1 to 2 hours after oral administration","Indications":["Diabetic gastroparesis","Postoperative nausea and vomiting","Chemotherapy-induced nausea and vomiting","Facilitation of small bowel intubation","Gastroesophageal reflux disease (GERD)"],"RoutesOfAdministration":"Oral, Intravenous, Intramuscular","DosageForms":["Tablet","Oral disintegrating tablet","Solution for injection","Oral solution"],"StrengthsOfDosageForms":["5 mg tablet","10 mg tablet","5 mg/mL oral solution","5 mg/mL solution for injection","10 mg orally disintegrating tablet"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed after oral administration","Distribution":"Widely distributed with a volume of distribution of approximately 2.2-3.4 L/kg","Metabolism":"Hepatic metabolism via glucuronidation and sulfation","Excretion":"Approximately 85% excreted in the urine, with around 5-10% as unchanged drug"},"SideEffects":["Drowsiness","Fatigue","Extrapyramidal symptoms","Restlessness","Diarrhea","Nausea"],"DrugInteractions":["Antipsychotics","Monoamine oxidase inhibitors","Digoxin","Cyclosporine","Levodopa","Alcohol"],"Contraindications":"Metoclopramide is contraindicated in patients with a history of tardive dyskinesia, seizure disorders, mechanical bowel obstruction, pheochromocytoma, and known hypersensitivity to the drug.","ChemicalStructure":{"MolecularFormula":"C14H22ClN3O2","MolecularWeight":"299.802 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B; should be used during pregnancy only if clearly needed.","PediatricUse":"Not recommended for patients under 1 year. Risk of extrapyramidal symptoms in pediatric patients.","GeriatricUse":"Elderly patients may be more sensitive to adverse effects, especially extrapyramidal symptoms and tardive dyskinesia.","HepaticImpairment":"Use with caution. Dose adjustment may be necessary.","RenalImpairment":"Dose reduction recommended based on creatinine clearance."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F), in a dry place away from light and moisture."},{"GenericName":"Famotidine","BrandNames":["Pepcid","Pepcid AC"],"DrugClass":"Histamine H2-receptor antagonist","MechanismOfAction":"Famotidine works by inhibiting the action of histamine at the H2 receptors of the gastric parietal cells, thereby reducing gastric acid secretion and concentration.","Pharmacodynamics":"By blocking H2 receptors in the stomach, famotidine decreases nighttime and meal-stimulated gastric acid secretion.","OnsetOfAction":"1 hour","DurationOfAction":"10 to 12 hours","PeakPlasmaConcentration":"1 to 3 hours after oral administration","Indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Prevention and treatment of heartburn associated with acid indigestion and sour stomach"],"RoutesOfAdministration":"Oral, intravenous","DosageForms":["Tablet","Oral suspension","Injection"],"StrengthsOfDosageForms":["Tablet: 10 mg, 20 mg, 40 mg","Oral suspension: 40 mg/5 mL","Injection: 10 mg/mL"],"Pharmacokinetics":{"Absorption":"Famotidine is incompletely absorbed (40-45%) after oral administration.","Distribution":"Widely distributed throughout the body; crosses placenta and enters breast milk.","Metabolism":"Metabolized minimally in the liver.","Excretion":"Excreted primarily in urine (25-30% unchanged)."},"SideEffects":["Headache","Dizziness","Constipation","Diarrhea","Fatigue"],"DrugInteractions":["Ketoconazole","Itraconazole","Atazanavir","Lopinavir","Ritonavir","Warfarin"],"Contraindications":"Hypersensitivity to famotidine or other H2-receptor antagonists.","ChemicalStructure":{"MolecularFormula":"C8H15N7O2S3","MolecularWeight":"337.45 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Famotidine should be used during pregnancy only if clearly needed.","PediatricUse":"Safety and effectiveness have been established in pediatric patients (1-16 years) for the treatment of GERD and peptic ulcer disease.","GeriatricUse":"No overall differences in safety or effectiveness have been observed between elderly and younger patients.","HepaticImpairment":"Famotidine should be used with caution in patients with hepatic impairment.","RenalImpairment":"Dose adjustment may be necessary in patients with moderate to severe renal impairment."},"StorageAndHandling":"Store famotidine at controlled room temperature, 20°C to 25°C (68°F to 77°F), protect from light and moisture."},{"GenericName":"Lansoprazole","BrandNames":["Prevacid","Prevacid SoluTab"],"DrugClass":"Proton Pump Inhibitor (PPI)","MechanismOfAction":"Lansoprazole blocks the proton pump of the gastric parietal cell, reducing gastric acid secretion by preventing the final step in acid production, which is the exchange of potassium ions with hydrogen ions in the stomach.","Pharmacodynamics":"Lansoprazole effectively increases gastric pH by decreasing gastric acid secretion. The suppression of gastric acid can last up to 24 hours with once-daily dosing, providing symptomatic relief for conditions like GERD.","OnsetOfAction":"Lansoprazole begins to have an effect within 1 to 3 hours after oral administration.","DurationOfAction":"The acid-reducing effects can last more than 24 hours, though plasma levels decline rapidly post-dosing.","PeakPlasmaConcentration":"Approximately 1.7 hours after oral administration.","Indications":["Gastroesophageal Reflux Disease (GERD)","Erosive esophagitis","Duodenal ulcers","Zollinger-Ellison syndrome","NSAID-induced gastric ulcer"],"RoutesOfAdministration":"Oral","DosageForms":["Capsules (delayed release)","Orally disintegrating tablets","Oral suspension"],"StrengthsOfDosageForms":["15 mg","30 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed with an absolute bioavailability of 80-90% after multiple doses.","Distribution":"Widely distributed; protein binding is about 97% primarily to albumin.","Metabolism":"Primarily metabolized in the liver by cytochrome P450 enzymes, mainly CYP2C19 and CYP3A4.","Excretion":"Excreted in urine (14-23%) and feces (55-65%), primarily as metabolites."},"SideEffects":["Headache","Diarrhea","Nausea","Abdominal pain","Constipation"],"DrugInteractions":["May interact with drugs that depend on gastric pH for absorption such as ketoconazole, itraconazole","May interfere with the elimination of drugs metabolized by CYP2C19, e.g., clopidogrel"],"Contraindications":"Known hypersensitivity to lansoprazole or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C16H14F3N3O2S","MolecularWeight":"369.36 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B. No adequate and well-controlled studies in pregnant women; use only if clearly needed.","PediatricUse":"Approved for use in children aged 1 year and older for certain indications such as GERD.","GeriatricUse":"No significant differences in safety or effectiveness observed between elderly and younger patients.","HepaticImpairment":"Use with caution; consider dosage reduction due to increased risk of adverse effects.","RenalImpairment":"No dosage adjustment is necessary."},"StorageAndHandling":"Store at 15°C to 30°C (59°F to 86°F). Protect from light and moisture."},{"GenericName":"Divalproex","BrandNames":["Depakote","Depakote ER","Depakote Sprinkles"],"DrugClass":"Anticonvulsant","MechanismOfAction":"Divalproex sodium dissociates to the valproate ion in the gastrointestinal tract. The valproate ion is believed to increase the levels of gamma-aminobutyric acid (GABA) in the brain, an inhibitory neurotransmitter, possibly by inhibiting the enzyme GABA transaminase or by inhibiting the reuptake of GABA into glial cells and nerve endings.","Pharmacodynamics":"Divalproex exerts its effects by increasing GABA levels in the brain, which may suppress seizures and stabilize mood in bipolar disorder. It also affects ion channels and neurotransmitter receptors, contributing to its anticonvulsant properties.","OnsetOfAction":"2-4 hours after oral administration.","DurationOfAction":"12-24 hours depending on the formulation and dosing regimen.","PeakPlasmaConcentration":"Achieved within 3-5 hours after oral administration.","Indications":["Seizure disorders (epilepsy)","Bipolar disorder","Migraine prophylaxis"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet, delayed-release","Tablet, extended-release","Capsule, delayed-release sprinkle"],"StrengthsOfDosageForms":["125 mg","250 mg","500 mg"],"Pharmacokinetics":{"Absorption":"Readily absorbed from the gastrointestinal tract with a bioavailability of approximately 81-89%.","Distribution":"Distributes into tissues; highly bound to plasma proteins (80-90%).","Metabolism":"Metabolized primarily by the liver through glucuronidation and mitochondrial beta-oxidation.","Excretion":"Excreted mainly in urine, with only a small percentage of the drug excreted unchanged."},"SideEffects":["Nausea","Vomiting","Drowsiness","Dizziness","Tremors","Weight gain","Hair loss"],"DrugInteractions":["Warfarin","Phenytoin","Lamotrigine","Carbamazepine","Topiramate"],"Contraindications":"Hepatic disease or significant hepatic dysfunction, urea cycle disorders, known mitochondrial disorders caused by mutations in the mitochondrial DNA polymerase gamma (POLG).","ChemicalStructure":{"MolecularFormula":"C16H31NaO4","MolecularWeight":"310.41 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Divalproex is associated with risks of birth defects and is typically not recommended during pregnancy unless clearly needed and the benefits outweigh the risks.","PediatricUse":"Safety and effectiveness for certain uses have not been established in children younger than 10 years.","GeriatricUse":"Use with caution; dose adjustment may be necessary due to altered pharmacokinetics in elderly patients.","HepaticImpairment":"Contraindicated in patients with severe hepatic impairment; use with caution in mild to moderate impairment.","RenalImpairment":"Use with caution and monitor clinical response as clearance may be reduced."},"StorageAndHandling":"Store at room temperature away from light and moisture. Keep container tightly closed."},{"GenericName":"Lamotrigine","BrandNames":["Lamictal","Lamictal XR","Subvenite","Lupin"],"DrugClass":"Anticonvulsant","MechanismOfAction":"Lamotrigine acts by stabilizing neuronal membranes and modulating presynaptic transmission of amino acids like aspartate and glutamate, which are excitatory neurotransmitters. The exact mechanism of action is unknown, but it is believed to inhibit voltage-sensitive sodium channels.","Pharmacodynamics":"Lamotrigine reduces seizure frequency and severity, improves mood stabilisation in bipolar disorder, and has a broad spectrum of anticonvulsant activity.","OnsetOfAction":"The onset is gradual over a span of days to weeks, depending on the titration speed.","DurationOfAction":"The half-life is approximately 25 hours in healthy adults, after which it's effectiveness reduces and re-dosing is required.","PeakPlasmaConcentration":"Peak plasma levels occur approximately 1.4 to 4.8 hours after dosing.","Indications":["Partial seizures","Generalized tonic-clonic seizures","Bipolar disorder","Lennox-Gastaut syndrome"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Chewable dispersible tablets","Oral tablets (extended-release)"],"StrengthsOfDosageForms":["25 mg","50 mg","100 mg","200 mg","300 mg (extended-release)","2 mg","5 mg (chewable)"],"Pharmacokinetics":{"Absorption":"Lamotrigine is rapidly and completely absorbed from the gastrointestinal tract with bioavailability ranging from 98%.","Distribution":"The volume of distribution is approximately 0.92-1.22 L/kg and is about 55% bound to plasma proteins.","Metabolism":"Lamotrigine is metabolized mainly by glucuronidation in the liver to form inactive 2-N-glucuronide.","Excretion":"About 70% is excreted in the urine primarily as glucuronide conjugates, and less than 10% is excreted unchanged. Approximately 20% is excreted in feces."},"SideEffects":["Dizziness","Headache","Ataxia","Nausea","Somnolence","Skin rash","Blurred vision","Tremor","Double vision"],"DrugInteractions":["Valproate (increases lamotrigine levels)","Carbamazepine (decreases lamotrigine levels)","Oral contraceptives (may decrease lamotrigine levels)","Phenytoin, phenobarbital, and primidone (increase clearance of lamotrigine)"],"Contraindications":"Known hypersensitivity to lamotrigine or any of the formulation constituents.","ChemicalStructure":{"MolecularFormula":"C9H7Cl2N5","MolecularWeight":"256.09 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C: Risk cannot be ruled out; use only if clearly needed.","PediatricUse":"Approved for use in children aged 2 years and older for seizure disorders and for children aged 16 years and older for bipolar disorder.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger adult patients.","HepaticImpairment":"Dose adjustment recommended due to decreased clearance.","RenalImpairment":"Use with caution and consider dose adjustment, as metabolites can accumulate."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F). Protect from moisture and light."},{"GenericName":"Estradiol","BrandNames":["Estrace","Climara","Vivelle-Dot","Femtrace","Alora"],"DrugClass":"Estrogens","MechanismOfAction":"Estradiol acts by binding to and activating specific nuclear estrogen receptors, leading to modulation of gene expression, and subsequent biological effects such as growth of specific tissues, retention of calcium in bones, and maintenance of secondary sexual characteristics.","Pharmacodynamics":"Estradiol helps alleviate menopausal symptoms such as hot flashes, vaginal atrophy, and prevents osteoporosis by replacing estrogen that is no longer naturally produced by the ovaries.","OnsetOfAction":"Depends on the form and route of administration; generally, some effects can be noticed within days to weeks.","DurationOfAction":"Varies by formulation: transdermal systems may last several days; oral formulations are usually dosed daily.","PeakPlasmaConcentration":"For oral estradiol, peak plasma concentration occurs approximately 6–8 hours after administration.","Indications":["Management of menopausal symptoms","Osteoporosis prevention in postmenopausal women","Hypoestrogenism due to hypogonadism","Primary ovarian failure","Female castration","Palliative treatment of breast cancer","Prostate cancer in men"],"RoutesOfAdministration":"Oral, transdermal, vaginal, intramuscular, topical","DosageForms":["Tablets","Transdermal patches","Vaginal rings","Creams","Gels"],"StrengthsOfDosageForms":["Tablet: 0.5 mg, 1 mg, 2 mg","Transdermal patch: 0.025 mg/day, 0.05 mg/day, 0.075 mg/day, 0.1 mg/day","Vaginal ring: 2 mg","Cream: 0.1 mg/g","Gel: 0.06%"],"Pharmacokinetics":{"Absorption":"Rapidly and extensively absorbed from the gastrointestinal tract.","Distribution":"Widely distributed in the body, about 95% bound to plasma proteins.","Metabolism":"Primarily metabolized in the liver to less potent or inactive metabolites.","Excretion":"Excreted in urine as sulfate and glucuronide conjugates."},"SideEffects":["Nausea","Headache","Breast tenderness","Irregular vaginal bleeding","Fluid retention","Weight change","Mood disturbances","Increased risk of thromboembolic events and stroke"],"DrugInteractions":["Warfarin","Other estrogen or hormone replacement products","Cimetidine","Carbamazepine","Ritonavir"],"Contraindications":"History of breast cancer, thromboembolic disorders, liver disease, known hypersensitivity, undiagnosed abnormal genital bleeding","ChemicalStructure":{"MolecularFormula":"C18H24O2","MolecularWeight":"272.38 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category X: Contraindicated in pregnancy due to potential adverse effects on the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"Use with caution; increased risk of adverse effects may be present in older populations.","HepaticImpairment":"Not recommended in patients with liver dysfunction due to increased risk of adverse effects.","RenalImpairment":"Use with caution; dosage adjustment may be required."},"StorageAndHandling":"Store at room temperature, away from light and moisture. Keep the medication in its original packaging until ready to be used."},{"GenericName":"Folic Acid","BrandNames":["Folacin","Folvite","FA-8"],"DrugClass":"Vitamin","MechanismOfAction":"Folic acid is a member of the vitamin B family that is necessary for the production and maintenance of new cells, for DNA and RNA synthesis, and for preventing changes to DNA that may lead to cancer. It is especially important during periods of rapid cell division and growth, such as infancy and pregnancy.","Pharmacodynamics":"Folic acid helps in the production of healthy red blood cells and prevents anemia. It aids in the conversion of homocysteine to methionine by functioning as a coenzyme, thus supporting normal cardiovascular function.","OnsetOfAction":"The onset of action is variable and depends on the condition being treated. In the case of megaloblastic anemia, improvement is usually noted within a few weeks.","DurationOfAction":"Folic acid is maintained in body tissues with a duration of effect that continues as long as regular dietary intake and storage are adequate.","PeakPlasmaConcentration":"Peak plasma concentration occurs within 1 hour of oral administration.","Indications":["Treatment and prevention of folate deficiency anemia","Supplementation during pregnancy to prevent neural tube defects","Megaloblastic anemia due to folate deficiency","Supplementation in certain conditions such as malabsorption syndromes"],"RoutesOfAdministration":"Oral, Intravenous, Intramuscular, Subcutaneous","DosageForms":["Tablets","Capsules","Injectable solution"],"StrengthsOfDosageForms":["0.4 mg","0.8 mg","1 mg (oral)","5 mg/mL (injectable)"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the small intestine after oral administration.","Distribution":"Distributed to all body tissues; stored in the liver.","Metabolism":"Metabolized in the liver to active tetrahydrofolate forms.","Excretion":"Excreted primarily in urine; excess amounts are also excreted in feces."},"SideEffects":["Allergic reactions (rash, itching)","Nausea","Bloating","Bitter taste","Sleep disturbances"],"DrugInteractions":["May decrease the effects of certain anticancer medicines (methotrexate)","Can interfere with the action of phenytoin and other anticonvulsants","May alter the effects of some medications metabolized by folate-dependent pathways"],"Contraindications":"Folic acid should not be used in individuals who have a known hypersensitivity to the formulation.","ChemicalStructure":{"MolecularFormula":"C19H19N7O6","MolecularWeight":"441.40 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Recommended in pregnancy to prevent neural tube defects; considered safe.","PediatricUse":"Safe and effective when used at recommended doses.","GeriatricUse":"Safe and effective when used at recommended doses.","HepaticImpairment":"No specific dose adjustment required, but caution advised.","RenalImpairment":"No specific dose adjustment required, but caution advised."},"StorageAndHandling":"Store at controlled room temperature away from moisture and heat. Protect from light."},{"GenericName":"Cholecalciferol (Vitamin D3) or Ergocalciferol (Vitamin D2)","BrandNames":["Drisdol","Vitamin D3"],"DrugClass":"Vitamin","MechanismOfAction":"Vitamin D promotes the absorption of calcium and phosphorus in the gut and maintains adequate serum calcium and phosphate concentrations to enable normal mineralization of bone.","Pharmacodynamics":"Vitamin D is essential for promoting calcium absorption in the gut, maintaining proper serum calcium and phosphate levels, and enabling bone mineralization.","OnsetOfAction":"Relatively slow; may take some weeks for full effects on calcium and bone to be realized.","DurationOfAction":"Depends on baseline vitamin D levels; effects on calcium homeostasis can last for weeks.","PeakPlasmaConcentration":"Varies considerably based on the formulation and individual metabolic differences.","Indications":["Prevention and treatment of vitamin D deficiency","Rickets treatment","Support in the management of osteoporosis"],"RoutesOfAdministration":"Oral, Intramuscular","DosageForms":["Tablet","Capsule","Liquid solution"],"StrengthsOfDosageForms":["400 IU","800 IU","1000 IU","2000 IU","5000 IU","50,000 IU"],"Pharmacokinetics":{"Absorption":"Well absorbed in the presence of bile.","Distribution":"Widely distributed; stored in fat and liver.","Metabolism":"Converted in the liver to calcifediol (25-hydroxyvitamin D) and in the kidneys to calcitriol (1,25-dihydroxyvitamin D).","Excretion":"Primarily via bile and feces."},"SideEffects":["Hypercalcemia","Hypercalciuria","Constipation","Nausea","Vomiting"],"DrugInteractions":["Thiazide diuretics","Digoxin","Aluminium-containing antacids","Bile acid sequestrants"],"Contraindications":"Hypercalcemia or vitamin D toxicity.","ChemicalStructure":{"MolecularFormula":"C27H44O","MolecularWeight":"384.65 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Generally considered safe at recommended doses.","PediatricUse":"Safe at recommended dietary allowances.","GeriatricUse":"May require dose adjustments based on renal function.","HepaticImpairment":"Use with caution; may affect metabolism.","RenalImpairment":"Dose adjustments may be necessary."},"StorageAndHandling":"Store in a cool, dry place away from sunlight. Keep out of reach of children."},{"GenericName":"Ezetimibe","BrandNames":["Zetia","Ezetrol"],"DrugClass":"Cholesterol absorption inhibitor","MechanismOfAction":"Ezetimibe lowers plasma cholesterol levels by selectively inhibiting the absorption of cholesterol at the brush border of the small intestine. It inhibits the sterol transporter Niemann-Pick C1-like 1 (NPC1L1) leading to a decrease in the amount of cholesterol delivered to the liver.","Pharmacodynamics":"Ezetimibe reduces total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG) while increasing high-density lipoprotein cholesterol (HDL-C).","OnsetOfAction":"Within 1-2 weeks of administration.","DurationOfAction":"24 hours, hence once daily dosing is sufficient.","PeakPlasmaConcentration":"1 to 2 hours after administration.","Indications":["Primary hyperlipidemia","Homozygous familial hypercholesterolemia","Homozygous sitosterolemia"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["10 mg"],"Pharmacokinetics":{"Absorption":"Ezetimibe is absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide).","Distribution":"Ezetimibe is highly bound to plasma proteins (>90%).","Metabolism":"Ezetimibe is glucuronidated in the intestine and liver to form the active ezetimibe-glucuronide.","Excretion":"Approximately 78% is excreted in feces and 11% in urine after oral administration."},"SideEffects":["Diarrhea","Upper respiratory tract infection","Pain in extremities","Arthralgia","Sinusitis","Fatigue"],"DrugInteractions":["Warfarin","Cyclosporine","Fibrates (especially gemfibrozil)","Cholestyramine"],"Contraindications":"Hypersensitivity to ezetimibe or any component of the product.","ChemicalStructure":{"MolecularFormula":"C24H21F2NO3","MolecularWeight":"409.43 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy have been established in children 10 years and older.","GeriatricUse":"No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.","HepaticImpairment":"Not recommended in patients with moderate or severe hepatic impairment.","RenalImpairment":"No dosage adjustment is necessary."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (between 59°F to 86°F)."},{"GenericName":"Donepezil","BrandNames":["Aricept"],"DrugClass":"Acetylcholinesterase inhibitor","MechanismOfAction":"Donepezil works by reversibly inhibiting cholinesterase, thereby increasing levels of acetylcholine in the brain, which is thought to play a role in memory and cognition.","Pharmacodynamics":"Donepezil increases cerebral acetylcholine, improving cholinergic function by inhibiting the breakdown of acetylcholine. This can result in an improvement in symptoms related to dementia.","OnsetOfAction":"Several weeks for noticeable effects","DurationOfAction":"About 70 hours","PeakPlasmaConcentration":"3 to 4 hours after oral administration","Indications":["Treatment of mild, moderate, and severe Alzheimer's disease"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Orally disintegrating tablets"],"StrengthsOfDosageForms":["5 mg","10 mg","23 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed with peak plasma levels achieved in 3 to 4 hours.","Distribution":"Widely distributed with a volume of distribution of about 12 L/kg","Metabolism":"Extensively metabolized in the liver primarily by CYP2D6 and CYP3A4","Excretion":"Primarily in the urine with a half-life of approximately 70 hours"},"SideEffects":["Nausea","Diarrhea","Insomnia","Muscle cramps","Fatigue","Anorexia"],"DrugInteractions":["Anticholinergic drugs may reduce effectiveness.","Other cholinesterase inhibitors","CYP3A4 inhibitors like ketoconazole increase levels.","CYP3A4 inducers like phenytoin decrease levels."],"Contraindications":"Hypersensitivity to donepezil hydrochloride or to piperidine derivatives","ChemicalStructure":{"MolecularFormula":"C24H29NO3","MolecularWeight":"379.5 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C - Risk cannot be ruled out.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No dosage adjustment is necessary in geriatric patients.","HepaticImpairment":"Use caution and adjust dose as per clinical response.","RenalImpairment":"No dosage adjustment is necessary."},"StorageAndHandling":"Store at room temperature away from moisture and heat. Keep tablets in their original container."},{"GenericName":"Enalapril","BrandNames":["Vasotec"],"DrugClass":"Angiotensin-Converting Enzyme (ACE) Inhibitor","MechanismOfAction":"Enalapril inhibits the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thus leading to vasodilation and blood pressure reduction.","Pharmacodynamics":"Lowers blood pressure and reduces the workload on the heart. Decreases peripheral resistance and reduces afterload.","OnsetOfAction":"1 hour","DurationOfAction":"12 - 24 hours","PeakPlasmaConcentration":"4 - 6 hours","Indications":["Hypertension","Heart failure","Asymptomatic left ventricular dysfunction"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Oral solution"],"StrengthsOfDosageForms":["2.5 mg","5 mg","10 mg","20 mg","Oral solution: 1 mg/mL"],"Pharmacokinetics":{"Absorption":"About 60% absorbed from gastrointestinal tract as enalaprilat.","Distribution":"Widely distributed; Volume of distribution: approximately 1.8 L/kg.","Metabolism":"Rapidly converted in the liver to enalaprilat, the active form.","Excretion":"Primarily excreted in urine as enalaprilat (40%) and unchanged drug (20%)."},"SideEffects":["Cough","Hypotension","Dizziness","Fatigue","Renal impairment","Hyperkalemia","Angioedema"],"DrugInteractions":["Diuretics (increase risk of hypotension)","Lithium (increased lithium levels)","NSAIDs (may reduce antihypertensive effect)"],"Contraindications":"Hypersensitivity to enalapril or any other ACE inhibitors. History of angioedema related to previous treatment with an ACE inhibitor.","ChemicalStructure":{"MolecularFormula":"C20H28N2O5","MolecularWeight":"376.45 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Not recommended due to risk of fetal toxicity, especially in the second and third trimesters.","PediatricUse":"Safety and effectiveness have been established for hypertension in children older than 1 month.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients.","HepaticImpairment":"Use with caution and monitor liver function.","RenalImpairment":"Dose adjustment may be necessary; monitor renal function."},"StorageAndHandling":"Store at room temperature between 15°C to 30°C (59°F to 86°F). Protect from light and moisture."},{"GenericName":"Azelastine","BrandNames":["Astelin","Astepro"],"DrugClass":"Antihistamine","MechanismOfAction":"Azelastine hydrochloride acts as a potent histamine H1-receptor antagonist, inhibiting the release of histamine and other mediators involved in the allergic response, thereby alleviating allergy symptoms.","Pharmacodynamics":"Azelastine exhibits antihistaminergic, mast-cell stabilizing, and anti-inflammatory activity. It reduces symptoms of allergic rhinitis, such as runny nose, sneezing, and nasal congestion.","OnsetOfAction":"15 minutes","DurationOfAction":"12 hours","PeakPlasmaConcentration":"0.5 to 2 hours (nasal spray)","Indications":["Seasonal allergic rhinitis","Perennial allergic rhinitis","Non-allergic rhinitis"],"RoutesOfAdministration":"Intranasal","DosageForms":["Nasal spray"],"StrengthsOfDosageForms":["0.1% solution","0.15% solution"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following intranasal administration. Bioavailability is about 40% with the nasal spray.","Distribution":"The volume of distribution is approximately 14.5 L/kg indicating extensive tissue distribution.","Metabolism":"Primarily metabolized via CYP450 enzymes, especially CYP3A4.","Excretion":"Excreted primarily in urine; 75% of the dose is excreted as unchanged drug and metabolites."},"SideEffects":["Bitter taste","Headache","Nasal irritation","Fatigue","Sneezing"],"DrugInteractions":["CNS depressants might increase drowsiness","Alcohol may enhance sedative effects"],"Contraindications":"Hypersensitivity to azelastine or any of its components.","ChemicalStructure":{"MolecularFormula":"C22H24ClN3O","MolecularWeight":"381.90 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies of azelastine in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients below the age of 5 have not been established.","GeriatricUse":"No overall differences in safety or effectiveness have been observed between elderly and younger patients.","HepaticImpairment":"Use with caution as azelastine is extensively metabolized by the liver.","RenalImpairment":"Use with caution as azelastine and its metabolites are excreted by the kidneys."},"StorageAndHandling":"Store at a controlled room temperature of 20°C to 25°C (68°F to 77°F), protected from light."},{"GenericName":"Chlorthalidone","BrandNames":["Hygroton","Thalitone"],"DrugClass":"Thiazide-like diuretic","MechanismOfAction":"Chlorthalidone inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron, leading to increased excretion of sodium and water, and, consequently, a reduction in plasma volume, which decreases blood pressure.","Pharmacodynamics":"Chlorthalidone acts to reduce blood pressure by decreasing systemic vascular resistance and intravascular volume. It increases the excretion of sodium and water, leading to a reduction in cardiac output and blood pressure.","OnsetOfAction":"2-3 hours (for diuretic effect)","DurationOfAction":"48-72 hours","PeakPlasmaConcentration":"2-6 hours","Indications":["Hypertension","Edema associated with heart failure","Edema associated with renal impairment","Prevention of calcium-containing kidney stones"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["25 mg","50 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Widely distributed; moderately bound to plasma proteins.","Metabolism":"Hepatically metabolized to inactive metabolites.","Excretion":"Excreted mainly in the urine."},"SideEffects":["Dizziness","Orthostatic hypotension","Hypokalemia","Hyperuricemia","Hyperglycemia","Rash","Photosensitivity"],"DrugInteractions":["NSAIDs can reduce the antihypertensive effects of chlorthalidone.","Concurrent use with lithium may increase the risk of lithium toxicity.","May enhance the effect of other antihypertensive drugs."],"Contraindications":"Anuria (complete absence of urine production) and hypersensitivity to chlorthalidone or other sulfonamide-derived drugs.","ChemicalStructure":{"MolecularFormula":"C14H11ClN2O4S","MolecularWeight":"338.76 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; potential for harm exists. Category B.","PediatricUse":"Safety and effectiveness have not been established.","GeriatricUse":"Use with caution due to potential for a higher risk of side effects.","HepaticImpairment":"Use with caution; may require dosage adjustment.","RenalImpairment":"Use with caution; may require dosage adjustment."},"StorageAndHandling":"Store at room temperature away from moisture, heat, and light."},{"GenericName":"Nebivolol","BrandNames":["Bystolic","Nebicard","Vasoxen"],"DrugClass":"Beta blocker","MechanismOfAction":"Nebivolol is a selective beta-1 adrenergic receptor blocker that works by blocking the action of certain natural substances on the heart and blood vessels, resulting in lower heart rate, blood pressure, and strain on the heart.","Pharmacodynamics":"Nebivolol's primary activity is the selective blockade of beta-1 adrenergic receptors in cardiac tissue, which leads to decreased heart rate and contractility, reducing cardiac output. It also has vasodilatory effects possibly related to the modulation of endothelial nitric oxide.","OnsetOfAction":"Approximately 1 to 2 hours post-dose.","DurationOfAction":"Lasts approximately 24 hours, supporting a once-daily dosing schedule.","PeakPlasmaConcentration":"Achieved within 1.5 to 4 hours after oral administration.","Indications":["Hypertension","Heart failure"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["2.5 mg","5 mg","10 mg","20 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract after oral administration.","Distribution":"Nebivolol is extensively distributed in the body. It is highly protein-bound, approximately 98%.","Metabolism":"Extensively metabolized in the liver mainly by CYP2D6 isoenzyme.","Excretion":"Primarily excreted via urine and feces. Half-life ranges from 12 to 19 hours in poor metabolizers."},"SideEffects":["Headache","Dizziness","Fatigue","Nausea","Bradycardia","Hypotension"],"DrugInteractions":["Drugs metabolized by CYP2D6 (e.g., certain antidepressants)","Other antihypertensive agents","Digitalis glycosides"],"Contraindications":"Nebivolol is contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, and severe hepatic impairment.","ChemicalStructure":{"MolecularFormula":"C22H25F2NO4","MolecularWeight":"405.44 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if potential benefit justifies the risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"Use with caution. Initial dose should be lower due to the increased sensitivity in this population.","HepaticImpairment":"Start with low doses or consider alternate treatment. It is contraindicated in severe hepatic impairment.","RenalImpairment":"Use with caution. No specific dosage adjustments provided, but monitor closely."},"StorageAndHandling":"Store at room temperature, between 20-25°C (68-77°F). Protect from moisture."},{"GenericName":"Hydralazine","BrandNames":["Apresoline","HydrALAZINE Hydrochloride"],"DrugClass":"Vasodilator","MechanismOfAction":"Hydralazine is a vasodilator that works by relaxing the smooth muscle in blood vessels, primarily the arterioles, leading to peripheral vasodilation. This action reduces peripheral resistance and allows blood to flow more easily.","Pharmacodynamics":"Hydralazine lowers blood pressure primarily by causing direct relaxation of vascular smooth muscle. Its effects on systemic vascular resistance, including the arterioles, contribute to its antihypertensive action.","OnsetOfAction":"30 minutes to 1 hour (oral), 10-20 minutes (intramuscular), 5-20 minutes (intravenous)","DurationOfAction":"2 to 6 hours","PeakPlasmaConcentration":"1 to 2 hours after oral administration","Indications":["Essential hypertension","Severe hypertension (emergency settings)","Congestive heart failure"],"RoutesOfAdministration":"Oral, Intramuscular, Intravenous","DosageForms":["Tablets","Injectable solution"],"StrengthsOfDosageForms":["10 mg (tablet)","25 mg (tablet)","50 mg (tablet)","100 mg (tablet)","20 mg/mL (injectable solution)"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract with variable bioavailability.","Distribution":"Widely distributed in body tissues, crosses the placenta and is present in breast milk.","Metabolism":"Extensively metabolized in the liver, involves acetylation which is subject to genetic polymorphism.","Excretion":"Primarily excreted in urine as metabolites; clearance may vary depending on acetylator status."},"SideEffects":["Headache","Nausea","Vomiting","Diarrhea","Palpitations","Tachycardia","Flushing","Dizziness"],"DrugInteractions":["Beta-blockers (increased hypotensive effect)","MAO inhibitors (enhanced hypotensive effects)","NSAIDs (reduced antihypertensive effect)"],"Contraindications":"Hypersensitivity to hydralazine or any component of the formulation; coronary artery disease; mitral valve rheumatic heart disease.","ChemicalStructure":{"MolecularFormula":"C8H8N4O","MolecularWeight":"160.17 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C - Risk cannot be ruled out. It may be used if clearly needed under medical supervision.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"Use with caution; start with lower doses due to potential for increased sensitivity to the drug.","HepaticImpairment":"Use with caution; dose adjustments may be necessary due to potential changes in metabolism.","RenalImpairment":"Use with caution; dose adjustments may be necessary due to renal excretion of metabolites."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F), protected from light and moisture. Keep tightly closed."},{"GenericName":"Olanzapine","BrandNames":["Zyprexa","Zydis","Zyprexa Relprevv"],"DrugClass":"Atypical antipsychotic","MechanismOfAction":"Olanzapine is believed to work by antagonizing multiple neurotransmitter receptors in the brain, including serotonin and dopamine receptors, which are thought to be linked to its antipsychotic and mood-stabilizing effects.","Pharmacodynamics":"Olanzapine improves symptoms of schizophrenia and bipolar disorder by modulating neurotransmitter activity, primarily serotonin and dopamine, to restore neurotransmitter balance.","OnsetOfAction":"Several hours, with noticeable effects seen within 1-2 weeks.","DurationOfAction":"Generally, effects last from 24 hours, but the half-life can be up to 30 hours indicating prolonged action.","PeakPlasmaConcentration":"Approximately 5 to 8 hours after oral administration.","Indications":["Schizophrenia","Bipolar disorder","Treatment-resistant depression (in combination with fluoxetine)"],"RoutesOfAdministration":"Oral, intramuscular","DosageForms":["Tablet","Dispersible tablet","Powder for injection"],"StrengthsOfDosageForms":["2.5 mg","5 mg","7.5 mg","10 mg","15 mg","20 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Widely distributed in the body with about 93% binding to plasma proteins.","Metabolism":"Hepatically metabolized predominantly via CYP1A2 and to a lesser extent by CYP2D6 to inactive metabolites.","Excretion":"Primarily excreted in urine (~57%) and feces (~30%) as metabolites."},"SideEffects":["Weight gain","Sedation","Increased appetite","Dizziness","Dry mouth","Dyslipidemia","Hyperglycemia"],"DrugInteractions":["CNS depressants","Levodopa","Anticholinergic drugs","CYP1A2 inhibitors (e.g., fluvoxamine)","CYP1A2 inducers (e.g., smoking)"],"Contraindications":"Known hypersensitivity to olanzapine or any of its components.","ChemicalStructure":{"MolecularFormula":"C17H20N4S","MolecularWeight":"312.44 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C; risks vs. benefits should be considered.","PediatricUse":"Safety and efficacy not established for children under 13 years.","GeriatricUse":"Increased risk of cerebrovascular adverse events; use with caution.","HepaticImpairment":"Use with caution and consider lower starting doses.","RenalImpairment":"No dose adjustment is necessary for mild to moderate impairment."},"StorageAndHandling":"Store below 30°C (86°F), protect from light and moisture. Use injection solution immediately after reconstitution."},{"GenericName":"Benzonatate","BrandNames":["Tessalon","Tessalon Perles"],"DrugClass":"Antitussive","MechanismOfAction":"Benzonatate works by numbing the stretch receptors located in the respiratory passages, lungs, and pleura. The drug acts peripherally, reducing the reflex at its source, reducing the urge to cough.","Pharmacodynamics":"Benzonatate helps to suppress cough by affecting the receptors in the lungs responsible for the cough reflex. It does not affect the central nervous system like other antitussives such as codeine.","OnsetOfAction":"15 to 20 minutes","DurationOfAction":"3 to 8 hours","PeakPlasmaConcentration":"1 to 2 hours after oral administration","Indications":["Cough"],"RoutesOfAdministration":"Oral","DosageForms":["Capsule, liquid-filled","softgel"],"StrengthsOfDosageForms":["100 mg","150 mg","200 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the GI tract.","Distribution":"Widely distributed in the tissues; however, specific data on distribution volumes are not available.","Metabolism":"Metabolized by hydrolysis to paraminobenzoic acid (PABA) and excreted as metabolites.","Excretion":"Primarily excreted through urine as metabolites."},"SideEffects":["Drowsiness","Dizziness","Headache","Nausea","Constipation","Stuffy nose","Hypersensitivity reactions"],"DrugInteractions":["Alcohol may enhance the CNS effects.","Opioids may increase respiratory depression."],"Contraindications":"Hypersensitivity to benzonatate or related compounds.","ChemicalStructure":{"MolecularFormula":"C30H53NO11","MolecularWeight":"603.75 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women. Benzonatate should be used during pregnancy only if clearly needed.","PediatricUse":"Safety and effectiveness in children under 10 years have not been established. There is a risk of accidental overdose in children.","GeriatricUse":"No specific dosage adjustment is generally necessary in elderly patients, but caution should be advised due to potential increased sensitivity.","HepaticImpairment":"Use with caution in patients with liver impairment.","RenalImpairment":"Use with caution in patients with renal impairment."},"StorageAndHandling":"Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). Keep out of reach of children."},{"GenericName":"Rivaroxaban","BrandNames":["Xarelto"],"DrugClass":"Direct Xa inhibitor","MechanismOfAction":"Rivaroxaban is a selective inhibitor of Factor Xa, interrupting the intrinsic and extrinsic pathway of the blood coagulation cascade and inhibiting thrombin formation and development of thrombi.","Pharmacodynamics":"Rivaroxaban reduces thrombin generation by selectively blocking the active site of factor Xa without the need of a cofactor or antithrombin.","OnsetOfAction":"2 to 4 hours","DurationOfAction":"24 hours","PeakPlasmaConcentration":"2 to 4 hours after administration","Indications":["Prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery","Treatment of deep vein thrombosis (DVT)","Treatment of pulmonary embolism (PE)","Reduction in the risk of recurrence of DVT and PE","Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["10 mg","15 mg","20 mg"],"Pharmacokinetics":{"Absorption":"Rivaroxaban is absorbed rapidly, with an absolute bioavailability of 80% to 100% for the 10 mg dose.","Distribution":"Volume of distribution is approximately 50 L.","Metabolism":"Metabolized by CYP3A4/5, CYP2J2 and by mechanisms independent of CYP enzymes.","Excretion":"Approximately 66% of the drug is excreted renally, and 28% via feces."},"SideEffects":["Bleeding","Anemia","Nausea","Vomiting","Elevated liver enzymes","Thrombocytopenia"],"DrugInteractions":["Strong inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, ritonavir)","Strong inducers of CYP3A4 and P-gp (e.g., rifampin, phenytoin)","Other anticoagulants"],"Contraindications":"Active pathological bleeding, severe hypersensitivity to rivaroxaban, and patients with significant hepatic disease associated with coagulopathy.","ChemicalStructure":{"MolecularFormula":"C19H18ClN3O5S","MolecularWeight":"435.88 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; insufficient data available, consult a healthcare provider.","PediatricUse":"Safety and efficacy in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness have been observed in elderly patients.","HepaticImpairment":"Avoid use in patients with moderate or severe hepatic impairment.","RenalImpairment":"Dosage adjustment may be necessary and caution is advised."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F). Keep in a dry place and protect from moisture."},{"GenericName":"Insulin Detemir","BrandNames":["Levemir"],"DrugClass":"Long-acting insulin analog","MechanismOfAction":"Insulin detemir binds to the insulin receptor on muscle and adipocytes, facilitating cellular uptake of glucose and inhibiting hepatic glucose output. It promotes storage of glycogen, triglycerides, and protein while inhibiting their breakdown.","Pharmacodynamics":"Insulin detemir lowers blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It has a prolonged duration of action due to its slow systemic absorption.","OnsetOfAction":"3 to 4 hours","DurationOfAction":"6 to 24 hours (dose-dependent)","PeakPlasmaConcentration":"6 to 8 hours (no pronounced peak)","Indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Solution for injection"],"StrengthsOfDosageForms":["100 units/mL"],"Pharmacokinetics":{"Absorption":"Prolonged absorption is achieved due to strong self-association of insulin molecules and albumin binding via the attached fatty acid molecule.","Distribution":"Insulin detemir distributes slightly higher than regular human insulin.","Metabolism":"Metabolized by the liver and kidneys through hydrolysis.","Excretion":"Excreted renally."},"SideEffects":["Hypoglycemia","Injection site reactions","Allergic reactions","Lipodystrophy"],"DrugInteractions":["Other antidiabetic agents (increased risk of hypoglycemia)","Beta-blockers (mask hypoglycemia symptoms)","Alcohol (affects glycemic control)"],"Contraindications":"Hypersensitivity to insulin detemir or any of its excipients","ChemicalStructure":{"MolecularFormula":"C267H402N64O76S6","MolecularWeight":".56.97 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B. Insulin detemir can be used during pregnancy. Blood glucose levels should be closely monitored.","PediatricUse":"Approved for use in children aged 2 years and older for the treatment of diabetes mellitus.","GeriatricUse":"Dose adjustments may be necessary based on clinical response and tolerability.","HepaticImpairment":"Monitor glucose levels closely in hepatic impairment; dose adjustments may be needed.","RenalImpairment":"Dose adjustment may be required for renal impairment due to reduced insulin clearance."},"StorageAndHandling":"Store unopened vials in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Once opened, vials can be stored at room temperature (below 30°C/86°F) or refrigerated and should be used within 42 days."},{"GenericName":"Apixaban","BrandNames":["Eliquis"],"DrugClass":"Anticoagulant, Factor Xa inhibitor","MechanismOfAction":"Apixaban selectively inhibits free and clot-bound factor Xa, resulting in decreased thrombin generation and thrombus development.","Pharmacodynamics":"Apixaban provides antithrombotic activity by inhibiting thrombin generation and indirectly reducing fibrin clot formation.","OnsetOfAction":"The onset of action of Apixaban is approximately 3 to 4 hours after oral administration.","DurationOfAction":"Approximately 24 hours with regular dosing.","PeakPlasmaConcentration":"3 to 4 hours after oral administration.","Indications":["Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation","Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)","Reduction in the risk of recurrent DVT and PE following initial therapy","Prophylaxis of DVT, which may lead to PE, in patients after hip or knee replacement surgery"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["2.5 mg","5 mg"],"Pharmacokinetics":{"Absorption":"Apixaban has an oral bioavailability of approximately 50%.","Distribution":"The volume of distribution is approximately 21 liters.","Metabolism":"Metabolized primarily by CYP3A4/5 and to a lesser extent by CYP1A2, 2C8, 2C9, 2C19, and 2J2.","Excretion":"Approximately 25% excreted as metabolites via urine and feces. The remaining is excreted as unchanged drug (primarily in feces)."},"SideEffects":["Bleeding","Nausea","Anemia","Skin rash"],"DrugInteractions":["Strong CYP3A4 inhibitors (e.g., ketoconazole) increase apixaban exposure and increase bleeding risk.","CYP3A4 inducers (e.g., rifampin) decrease apixaban effectiveness.","Antiplatelet agents increase bleeding risk."],"Contraindications":"Active pathological bleeding; severe hypersensitivity to apixaban.","ChemicalStructure":{"MolecularFormula":"C25H25N5O4","MolecularWeight":"459.5 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No dosage adjustment necessary solely on the basis of age.","HepaticImpairment":"Mild or moderate hepatic impairment does not require dose adjustments, but caution is advised.","RenalImpairment":"Patients with severe impairment should be monitored closely, dosage may need adjustment."},"StorageAndHandling":"Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)."},{"GenericName":"Glyburide","BrandNames":["Diabeta","Micronase","Glynase"],"DrugClass":"Sulfonylurea","MechanismOfAction":"Glyburide stimulates pancreatic beta cells to release insulin, by binding to sulfonylurea receptors on the beta cell surface, leading to closure of ATP-sensitive potassium channels.","Pharmacodynamics":"Glyburide lowers blood glucose by stimulating the secretion of insulin from the pancreas and increasing the insulin sensitivity of peripheral tissues.","OnsetOfAction":"2 to 4 hours","DurationOfAction":"12 to 24 hours","PeakPlasmaConcentration":"Approximately 4 hours","Indications":["Type 2 diabetes mellitus"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["1.25 mg","2.5 mg","5 mg"],"Pharmacokinetics":{"Absorption":"Well-absorbed (>90%) from the gastrointestinal tract.","Distribution":"Widely distributed in the body with high protein binding (~99%).","Metabolism":"Hepatic, primarily via CYP2C9 to active metabolites.","Excretion":"Excreted in urine (50%) and feces (50%)."},"SideEffects":["Hypoglycemia","Weight gain","Nausea","Heartburn","Rash"],"DrugInteractions":["Alcohol (potentiates hypoglycemic effect)","Beta-blockers (mask symptoms of hypoglycemia)","Diuretics (may reduce effectiveness)","Corticosteroids (may increase blood sugar)"],"Contraindications":"Hypersensitivity to glyburide or sulfonylureas, type 1 diabetes mellitus, diabetic ketoacidosis, prediabetes, type 2 diabetes without insulin, or renal/hepatic insufficiency.","ChemicalStructure":{"MolecularFormula":"C23H28ClN3O5S","MolecularWeight":"494.01 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C. Not recommended due to potential risk to the fetus.","PediatricUse":"Not recommended for children.","GeriatricUse":"Increased risk of hypoglycemia; dosing should be cautious.","HepaticImpairment":"Use with caution; dose adjustment may be needed.","RenalImpairment":"Contraindicated in severe renal impairment due to increased risk of hypoglycemia."},"StorageAndHandling":"Store at room temperature away from moisture and heat."},{"GenericName":"Insulin Lispro","BrandNames":["Humalog","Admelog"],"DrugClass":"Rapid-acting insulin analog","MechanismOfAction":"Insulin Lispro is a rapid-acting human insulin analog that enhances glucose uptake into cells and inhibits hepatic glucose output, thereby lowering blood glucose levels.","Pharmacodynamics":"It mimics the natural insulin response postprandially to reduce blood glucose effectively.","OnsetOfAction":"Within approximately 15 minutes of subcutaneous injection.","DurationOfAction":"The effects last 3 to 5 hours, allowing it to control blood glucose levels closely around meal times.","PeakPlasmaConcentration":"About 1 hour post-administration.","Indications":["Diabetes Mellitus Type 1","Diabetes Mellitus Type 2"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Injection","Vial","Cartridge","Prefilled pen"],"StrengthsOfDosageForms":["100 units/mL","200 units/mL"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following subcutaneous injection.","Distribution":"Distributed throughout the body similar to endogenous insulin.","Metabolism":"Metabolized in the liver, muscle, and kidney.","Excretion":"Primarily excreted by the kidneys."},"SideEffects":["Hypoglycemia","Injection site reactions","Allergic reactions","Lipodystrophy"],"DrugInteractions":["Beta-blockers","Thiazolidinediones","Alcohol","Monoamine oxidase inhibitors (MAOIs)"],"Contraindications":"Hypersensitivity to insulin lispro or any of its excipients.","ChemicalStructure":{"MolecularFormula":"C257H383N65O77S6","MolecularWeight":"5808 Da"},"UseInSpecialPopulations":{"Pregnancy":"Classified as Category B; generally considered safe but should be used with caution under medical supervision.","PediatricUse":"Safety and effectiveness have been established in children.","GeriatricUse":"Dose adjustments may be necessary due to potential decrease in renal function.","HepaticImpairment":"Use with caution; may require dose adjustment.","RenalImpairment":"May require dose adjustment based on frequent glucose monitoring."},"StorageAndHandling":"Store unopened vials in a refrigerator. Do not freeze. Once opened, vials can be kept at room temperature for up to 28 days."},{"GenericName":"Pioglitazone","BrandNames":["Actos"],"DrugClass":"Thiazolidinedione (TZD)","MechanismOfAction":"Pioglitazone works by reducing insulin resistance in the liver and peripheral tissues, leading to increased insulin-dependent glucose disposal and decreased hepatic glucose output. It acts as an agonist for the peroxisome proliferator-activated receptor-gamma (PPAR-γ).","Pharmacodynamics":"Pioglitazone improves the sensitivity of muscle, fat, and liver cells to insulin, which helps lower blood glucose levels. This effect reduces both fasting and postprandial hyperglycemia in patients with type 2 diabetes.","OnsetOfAction":"Several days to weeks, with maximal effects observed after several weeks.","DurationOfAction":"24 hours, due to its long half-life and continuous activity.","PeakPlasmaConcentration":"Approximately 2-4 hours after oral administration.","Indications":["Type 2 diabetes mellitus"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["15 mg","30 mg","45 mg"],"Pharmacokinetics":{"Absorption":"90% absorbed following oral administration.","Distribution":"Pioglitazone is extensively bound (>99%) to serum albumin.","Metabolism":"Primarily metabolized in the liver via CYP450 enzymes, mainly CYP2C8 and CYP3A4.","Excretion":"Excreted primarily in the feces (55%) and urine (15%)."},"SideEffects":["Weight gain","Edema","Heart failure","Hepatic dysfunction","Bone fractures","Bladder cancer (potential risk)"],"DrugInteractions":["Rifampin","Gemfibrozil","Oral contraceptives","Midazolam"],"Contraindications":"Patients with NYHA Class III or IV heart failure due to fluid retention risk.","ChemicalStructure":{"MolecularFormula":"C19H20N2O3S","MolecularWeight":"356.44 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; animal studies have shown an adverse effect, but there are no adequate human studies.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No dosage adjustment needed, but greater sensitivity of some elderly individuals cannot be ruled out.","HepaticImpairment":"Not recommended in patients with active liver disease or increased serum transaminase levels (greater than 2.5 times the upper limit of normal).","RenalImpairment":"No dosage adjustment is needed, but use with caution."},"StorageAndHandling":"Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). Protect from light and moisture."},{"GenericName":"Cefdinir","BrandNames":["Omnicef"],"DrugClass":"Third-generation cephalosporin antibiotic","MechanismOfAction":"Cefdinir inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins, thereby inhibiting the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, leading to cell lysis and death.","Pharmacodynamics":"Cefdinir is bactericidal against a wide range of Gram-positive and Gram-negative bacteria. It is effective in treating certain infections caused by susceptible strains, including respiratory tract infections, skin infections, and otitis media.","OnsetOfAction":"Onset of therapeutic effect typically occurs within 1 to 2 days of treatment, although symptomatic relief may take longer depending on the infection site and severity.","DurationOfAction":"Cefdinir is generally administered every 12 hours due to its half-life, leading to maintained therapeutic levels across the dosage interval.","PeakPlasmaConcentration":"The peak plasma concentration is approximately 2 to 4 hours after dosing.","Indications":["Acute exacerbations of chronic bronchitis","Community-acquired pneumonia","Pharyngitis/tonsillitis","Sinusitis","Skin and skin structure infections","Acute bacterial otitis media"],"RoutesOfAdministration":"Oral","DosageForms":["Capsule","Oral suspension"],"StrengthsOfDosageForms":["300 mg capsules","125 mg/5 mL oral suspension","250 mg/5 mL oral suspension"],"Pharmacokinetics":{"Absorption":"Cefdinir is absorbed from the gastrointestinal tract, with absorption reduced by food, although not significantly affecting its effectiveness.","Distribution":"Widely distributed; 60-70% bound to plasma proteins.","Metabolism":"Cefdinir is minimally metabolized. It is excreted predominantly as unchanged drug.","Excretion":"Cefdinir is primarily eliminated by the kidneys; the half-life is approximately 1.7 hours in patients with normal renal function."},"SideEffects":["Diarrhea","Nausea","Headache","Vaginal moniliasis","Abdominal pain"],"DrugInteractions":["Antacids containing aluminum or magnesium reduce the absorption of cefdinir","Iron supplements may interfere with cefdinir absorption","Probenecid increases cefdinir plasma levels by reducing renal excretion"],"Contraindications":"Contraindicated in patients with known allergy to cefdinir or other cephalosporin antibiotics.","ChemicalStructure":{"MolecularFormula":"C14H13N5O5S2","MolecularWeight":"395.42 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed. Categorized as Pregnancy Category B by the FDA.","PediatricUse":"Safe and effective use in pediatric patients is established; doses should be adjusted based on weight.","GeriatricUse":"No overall differences in effectiveness or safety between older and younger patients; caution should be used in dosing due to possible renal function decline.","HepaticImpairment":"No dosage adjustment necessary, as cefdinir is minimally metabolized by the liver.","RenalImpairment":"Dose adjustment is necessary for patients with renal impairment. Monitor renal function."},"StorageAndHandling":"Store at 20° to 25°C (68° to 77°F). Protect from light and moisture. Once reconstituted, the oral suspension can be stored at room temperature and should be used within 10 days."},{"GenericName":"Nitrofurantoin","BrandNames":["Macrobid","Macrodantin","Furadantin"],"DrugClass":"Nitrofuran antibacterial agent","MechanismOfAction":"Nitrofurantoin works by interfering with bacterial carbohydrate metabolism by inhibition of acetyl-CoA. It is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other macromolecules.","Pharmacodynamics":"Nitrofurantoin is bactericidal in urine at therapeutic doses. The drug is active against many gram-positive and gram-negative bacteria, including E. coli and some strains of Enterococcus.","OnsetOfAction":"Within 30 minutes","DurationOfAction":"Up to 12 hours depending on whether it's a macrocrystalline or monohydrate form used","PeakPlasmaConcentration":"Approximately 1-2 hours after administration","Indications":["Urinary tract infections (UTIs)","Cystitis"],"RoutesOfAdministration":"Oral","DosageForms":["Capsules","Oral suspension","Tablets"],"StrengthsOfDosageForms":["25 mg","50 mg","100 mg"],"Pharmacokinetics":{"Absorption":"Absorbed from the gastrointestinal tract; absorption is further enhanced by food intake.","Distribution":"Distributed into most body tissues; however, tissue levels are much lower than urinary levels.","Metabolism":"Liver","Excretion":"Primarily in the urine (approximately 30-40% excreted unchanged)"},"SideEffects":["Nausea","Vomiting","Diarrhea","Loss of appetite","Dizziness","Headache","Rash"],"DrugInteractions":["Antacids containing magnesium trisilicate","Norfloxacin","Probenecid"],"Contraindications":"Anuria, oliguria, significant renal impairment (creatinine clearance under 60 mL/min), and known hypersensitivity to nitrofurantoin or any formulation component.","ChemicalStructure":{"MolecularFormula":"C8H6N4O5","MolecularWeight":"238.16 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B; should be avoided at term (weeks 38-42) due to risk of hemolytic anemia in the newborn.","PediatricUse":"Contraindicated in infants younger than one month due to risk of hemolytic anemia.","GeriatricUse":"Use with caution, particularly in those with impaired renal function.","HepaticImpairment":"No specific adjustments provided, but caution is advised.","RenalImpairment":"Contraindicated in significant renal impairment."},"StorageAndHandling":"Store at room temperature away from moisture and heat. Keep in a tightly closed container."},{"GenericName":"Clindamycin","BrandNames":["Cleocin","Dalacin","ClindaMax"],"DrugClass":"Lincomycin antibiotic","MechanismOfAction":"Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and thus inhibiting the growth and replication of bacterial cells.","Pharmacodynamics":"Clindamycin shows bacteriostatic properties by targeting the 50S ribosomal subunit in bacteria, inhibiting bacterial protein synthesis. It has a broad spectrum, effective mainly against Gram-positive aerobes and anaerobes.","OnsetOfAction":"1-2 hours after oral administration","DurationOfAction":"Approximately 6 hours","PeakPlasmaConcentration":"2-3 hours after oral administration","Indications":["Treatment of serious infections due to susceptible anaerobic bacteria","Treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci","Bacterial vaginosis (as a topical application)","Skin and soft tissue infections"],"RoutesOfAdministration":"Oral, Intravenous, Intramuscular, Topical","DosageForms":["Capsule","Injection","Topical gel","Topical lotion","Suppository"],"StrengthsOfDosageForms":["150 mg capsule","300 mg capsule","75 mg/mL injection","2% topical gel","2% topical lotion","100 mg suppository"],"Pharmacokinetics":{"Absorption":"Approximately 90% absorbed after oral administration","Distribution":"Widely distributed in body tissues; does not penetrate well into the cerebrospinal fluid.","Metabolism":"Extensively metabolized in the liver.","Excretion":"Excreted primarily in the bile and urine."},"SideEffects":["Diarrhea","Nausea","Vomiting","Abdominal pain","Rash","Pseudomembranous colitis"],"DrugInteractions":["Erythromycin (antagonistic effect on clindamycin)","Neuromuscular blockers (enhanced neuromuscular blocking effect)","Warfarin (increased risk of bleeding)"],"Contraindications":"Known hypersensitivity to clindamycin, lincomycin, or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C18H33ClN2O5S","MolecularWeight":"424.98 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B. Should be used during pregnancy only if clearly needed.","PediatricUse":"Safety and effectiveness have been established for some forms, but caution is advised for immature liver function.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients, though greater sensitivity in some older individuals cannot be ruled out.","HepaticImpairment":"Use with caution. Dose adjustments may be necessary.","RenalImpairment":"Use with caution. Not significantly dialyzable."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) and protect from moisture."},{"GenericName":"Losartan/Hydrochlorothiazide","BrandNames":["Hyzaar"],"DrugClass":"Angiotensin II receptor blocker (ARB) and thiazide diuretic combination","MechanismOfAction":"Losartan is an angiotensin II receptor blocker that prevents vasoconstriction and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.","Pharmacodynamics":"The combination of losartan and hydrochlorothiazide results in additive antihypertensive effects, with losartan providing vasodilatation and reduction in blood pressure and hydrochlorothiazide inducing diuresis and reducing blood volume.","OnsetOfAction":"1 to 2 hours","DurationOfAction":"24 hours","PeakPlasmaConcentration":"1-2 hours for losartan and approximately 1-5 hours for hydrochlorothiazide","Indications":["Hypertension","Patients who benefit from the combination therapy of losartan and hydrochlorothiazide"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["50 mg/12.5 mg","100 mg/25 mg"],"Pharmacokinetics":{"Absorption":"Rapid absorption from the gastrointestinal tract.","Distribution":"Losartan is moderately bound to plasma proteins (approximately 99%). Hydrochlorothiazide is 40-68% protein bound.","Metabolism":"Losartan undergoes substantial first-pass metabolism by cytochrome P450 enzymes to form an active carboxylic acid metabolite.","Excretion":"Losartan: excreted in urine and bile. Hydrochlorothiazide: excreted primarily as unchanged drug in urine."},"SideEffects":["Dizziness","Fatigue","Hypotension","Hyperkalemia","Cough","Hyponatremia","Hyperuricemia","Hyperglycemia"],"DrugInteractions":["ACE inhibitors","Aliskiren","Potassium supplements","Corticosteroids","NSAIDs","Digoxin","Antidiabetic drugs"],"Contraindications":"Hypersensitivity to losartan, hydrochlorothiazide, or sulfonamide-derived drugs; anuria.","ChemicalStructure":{"MolecularFormula":"C22H23ClN6O and C7H8ClN3O4S2","MolecularWeight":"422.9 g/mol and 297.73 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated due to the risk of fetal harm, especially in the second and third trimesters.","PediatricUse":"Safety and efficacy have not been established in pediatric patients.","GeriatricUse":"Dosing should be cautious due to the potential for renal function decline.","HepaticImpairment":"Use caution; dosage reduction of losartan may be necessary.","RenalImpairment":"Caution advised; thiazides may be ineffective with severe renal impairment."},"StorageAndHandling":"Store at 20-25°C (68-77°F), protect from moisture, and keep in a tightly closed container."},{"GenericName":"Hydroxychloroquine","BrandNames":["Plaquenil"],"DrugClass":"Antimalarial and Disease-modifying antirheumatic drug (DMARD)","MechanismOfAction":"Hydroxychloroquine exhibits a variety of effects on many cellular pathways. It increases the pH of endosomal compartments in APCs, which interferes with antigen processing. It also inhibits toll-like receptor signaling and cytokine production, specifically interfering with TLR9 signaling. These actions help in dampening the immune response.","Pharmacodynamics":"Hydroxychloroquine modifies the underlying disease process and improves clinical symptoms in autoimmune diseases such as rheumatoid arthritis and lupus. It affects the function of the immune system, which helps reduce inflammation and pain in these conditions.","OnsetOfAction":"It typically takes several weeks to start seeing therapeutic effects for autoimmune diseases.","DurationOfAction":"The duration of action can be prolonged due to tissue accumulation. The plasma half-life is about 32 to 50 days.","PeakPlasmaConcentration":"Peak plasma concentrations are reached in 4 to 12 hours after oral administration.","Indications":["Rheumatoid arthritis","Systemic lupus erythematosus","Malaria prophylaxis and treatment","Discoid lupus erythematosus"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["200 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Widely distributed into body tissues; particularly high accumulation in liver, kidneys, and lungs.","Metabolism":"Metabolized in the liver to active metabolites.","Excretion":"Primarily through the kidneys as unchanged drug and metabolites."},"SideEffects":["Retinopathy","Nausea","Diarrhea","Rash","Dizziness","Headache"],"DrugInteractions":["Digoxin","Antidiabetic drugs","Cyclosporine","Cimetidine","Methotrexate"],"Contraindications":"Known hypersensitivity to hydroxychloroquine or related compounds like chloroquine, presence of retinal or visual field changes attributable to 4-aminoquinoline compounds, or presence of long-term therapy in children.","ChemicalStructure":{"MolecularFormula":"C18H26ClN3O","MolecularWeight":"335.87 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Generally considered safe in pregnancy for treating malaria and some autoimmune conditions, but use with caution.","PediatricUse":"Safety and efficacy for juvenile arthritis have not been established. Dosage should not exceed 6.5 mg/kg/day.","GeriatricUse":"Use with caution; elderly may be more sensitive to its effects, especially regarding renal function.","HepaticImpairment":"Use with caution in patients with liver disease due to potential for increased plasma levels.","RenalImpairment":"Dose adjustment may be needed; use with caution due to potential for increased plasma levels."},"StorageAndHandling":"Store at room temperature, away from light and moisture. Keep out of reach of children."},{"GenericName":"Carbamazepine","BrandNames":["Tegretol","Carbatrol","Epitol","Equetro"],"DrugClass":"Anticonvulsant","MechanismOfAction":"Carbamazepine works by inhibiting voltage-gated sodium channels in neuronal cell membranes, which decreases synaptic transmission in the central nervous system (CNS), thereby stabilizing hyper-excited nerve cells.","Pharmacodynamics":"Carbamazepine stabilizes hyper-excited nerve membranes, inhibits repetitive neuronal discharges, and reduces synaptic propagation of excitatory impulses. It is effective in the treatment of partial seizures and generalized tonic-clonic seizures.","OnsetOfAction":"1 to 4 hours after oral administration.","DurationOfAction":"Depends on the formulation; typically about 12 to 24 hours for extended-release formulations.","PeakPlasmaConcentration":"4 to 24 hours after administration, depending on the formulation.","Indications":["Epilepsy","Trigeminal neuralgia","Bipolar disorder (acute manic and mixed episodes)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Extended-release tablets","Chewable tablets","Suspension"],"StrengthsOfDosageForms":["100 mg","200 mg","300 mg","400 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed but bioavailability is variable (50-85%); food enhances absorption.","Distribution":"Distributed widely in bodily tissues; 70-80% protein bound.","Metabolism":"Primarily hepatic through CYP3A4 to active epoxide metabolite.","Excretion":"Eliminated primarily via urine as metabolites; 72% renal excretion, 28% fecal."},"SideEffects":["Dizziness","Drowsiness","Nausea","Vomiting","Loss of coordination (ataxia)","Blurred vision"],"DrugInteractions":["Inhibitors of CYP3A4 may increase carbamazepine levels.","Inducers of CYP3A4 may decrease its levels.","Concurrent use with MAO inhibitors may increase toxicity."],"Contraindications":"Patients with a history of bone marrow depression or hypersensitivity to carbamazepine or tricyclic compounds.","ChemicalStructure":{"MolecularFormula":"C15H12N2O","MolecularWeight":"236.27 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D: may cause harm to the fetus; benefits may warrant use despite risks.","PediatricUse":"Used for epilepsy with appropriate dose adjustments.","GeriatricUse":"Use with caution due to potential increased sensitivity.","HepaticImpairment":"Use with caution; monitor closely.","RenalImpairment":"Use with caution; monitor blood levels and adjust dose as needed."},"StorageAndHandling":"Store at controlled room temperature 20° to 25°C (68° to 77°F). Keep in a tight, light-resistant container."},{"GenericName":"Phenytoin","BrandNames":["Dilantin","Phenytek"],"DrugClass":"Anticonvulsant","MechanismOfAction":"Phenytoin acts by blocking voltage-sensitive sodium channels in neurons, thereby stabilizing the neuronal membrane and reducing repetitive neuronal firing.","Pharmacodynamics":"Phenytoin acts primarily on the motor cortex where it inhibits the spread of seizure activity. It affects ion channels and neurotransmitter release, thereby reducing the propagation of abnormal impulses in the brain.","OnsetOfAction":"1 to 3 hours after oral administration","DurationOfAction":"12 to 24 hours","PeakPlasmaConcentration":"3 to 12 hours after oral dose","Indications":["Seizure control in epilepsy","Status epilepticus","Prevention of seizures after neurosurgery"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Capsule","Tablet","Suspension","Injection"],"StrengthsOfDosageForms":["30 mg capsule","100 mg capsule","125 mg/5 mL oral suspension","50 mg/mL injection"],"Pharmacokinetics":{"Absorption":"Variable and dose-dependent; approximately 70-90% bioavailability orally.","Distribution":"Widely distributed in body tissues; crosses the blood-brain barrier; approximately 90-95% protein-bound.","Metabolism":"Primarily hepatic via the CYP2C9 and CYP2C19 isoenzymes.","Excretion":"Mainly in urine as inactive metabolites."},"SideEffects":["Nausea","Vomiting","Dizziness","Gingival hyperplasia","Nystagmus","Ataxia","Rash"],"DrugInteractions":["Warfarin","Oral contraceptives","Theophylline","Cyclosporine","Alcohol","Carbamazepine"],"Contraindications":"Hypersensitivity to phenytoin or its derivatives, sinus bradycardia, sinoatrial block, second and third degree AV block, or Stokes-Adams syndrome.","ChemicalStructure":{"MolecularFormula":"C15H12N2O2","MolecularWeight":"252.27 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D. Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Dosing should be guided by clinical response and carefully monitored.","GeriatricUse":"Dose selection should be cautious, usually starting at the lower end of the dosing range.","HepaticImpairment":"Use with caution; dose adjustment may be necessary.","RenalImpairment":"Use with caution; dose adjustment may be necessary depending on renal function."},"StorageAndHandling":"Store at 20° to 25°C (68° to 77°F) in a tightly closed container, protected from light and moisture."},{"GenericName":"Lithium","BrandNames":["Eskalith","Lithobid","Lithium Carbonate"],"DrugClass":"Mood Stabilizer","MechanismOfAction":"Although the exact mechanism is not fully understood, lithium is thought to work by moderating neurotransmission. It alters sodium transport in nerve and muscle cells and affects a shift toward intraneuronal catecholamine metabolism.","Pharmacodynamics":"Lithium stabilizes mood and reduces the severity and frequency of manic episodes in patients with bipolar disorder. It is also used in depression to augment other types of antidepressants.","OnsetOfAction":"1-3 weeks","DurationOfAction":"Variable; generally correlates with serum levels and typical dosing schedules.","PeakPlasmaConcentration":"0.5 - 1.5 mEq/L (therapeutic range)","Indications":["Bipolar disorder","Manic episodes","Depressive episodes in bipolar disorder","Augmentation in depression"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Capsule","Extended-release tablet"],"StrengthsOfDosageForms":["Lithium carbonate tablets: 150 mg, 300 mg, 600 mg","Lithium carbonate extended-release tablets: 300 mg, 450 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Volume of distribution is approximately 0.7-1 L/kg; not protein-bound.","Metabolism":"Not metabolized.","Excretion":"Primarily excreted in urine as unchanged drug."},"SideEffects":["Nausea","Tremor","Increased thirst","Increased urination","Diarrhea","Weight gain","Drowsiness"],"DrugInteractions":["Nonsteroidal anti-inflammatory drugs (NSAIDs)","Diuretics","ACE inhibitors","Antidepressants"],"Contraindications":"Known hypersensitivity to lithium or any excipients in the formulation. Severe renal impairment, cardiovascular disease, severe dehydration, sodium depletion.","ChemicalStructure":{"MolecularFormula":"Li","MolecularWeight":"6.94 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Lithium use during pregnancy can lead to a risk of cardiovascular defects in the developing fetus.","PediatricUse":"Safety and efficacy in pediatric patients have not been established.","GeriatricUse":"Use caution due to the increased risk of renal impairment.","HepaticImpairment":"Use with caution due to the risk of dehydration and electrolyte imbalance.","RenalImpairment":"Use with caution and monitor serum levels closely."},"StorageAndHandling":"Store lithium at room temperature, away from moisture and heat."},{"GenericName":"Digoxin","BrandNames":["Lanoxin","Digitek","Cardoxin","Lanoxicaps"],"DrugClass":"Cardiac glycoside","MechanismOfAction":"Digoxin works by inhibiting the sodium-potassium ATPase, which in turn increases intracellular sodium concentration. This leads to an increase in intracellular calcium concentrations which strengthens cardiac contraction (positive inotropic effect). It also affects the autonomic nervous system, increasing vagal tone and thereby reducing heart rate and conduction velocity through the AV node.","Pharmacodynamics":"Digoxin increases the force of myocardial contraction and is beneficial in heart failure management. It also slows down the ventricular rate in atrial fibrillation by increasing vagal tone.","OnsetOfAction":"30 minutes to 2 hours when taken orally; 5 to 30 minutes when given intravenously.","DurationOfAction":"The effects of digoxin can last 3 to 4 days after discontinuation.","PeakPlasmaConcentration":"1 to 3 hours after oral administration; 1 to 4 hours after IV administration.","Indications":["Heart failure","Atrial fibrillation","Atrial flutter"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablet","Injection","Oral solution"],"StrengthsOfDosageForms":["Tablets: 62.5 mcg, 125 mcg, 250 mcg","Oral solution: 0.05 mg/mL","Injection: 0.25 mg/mL"],"Pharmacokinetics":{"Absorption":"60% to 80% orally","Distribution":"Widely distributed in the body, binding to cardiac and skeletal muscles","Metabolism":"Minimal hepatic metabolism","Excretion":"Primarily excreted unchanged by the kidneys"},"SideEffects":["Nausea","Vomiting","Dizziness","Arrhythmias","Visual disturbances (e.g., blurred vision, yellowish vision)","Fatigue","Weakness"],"DrugInteractions":["Amiodarone","Verapamil","Quinidine","Spironolactone","Propafenone","Erythromycin"],"Contraindications":"Ventricular fibrillation, digoxin hypersensitivity, and known cases of digitalis toxicity.","ChemicalStructure":{"MolecularFormula":"C41H64O14","MolecularWeight":"780.95 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution. Classified as Category C.","PediatricUse":"Use with careful monitoring.","GeriatricUse":"Dose adjustment may be necessary due to renal function.","HepaticImpairment":"No dosage adjustment necessary, but caution is advised.","RenalImpairment":"Dose reduction recommended due to increased risk of toxicity."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) in a dry place away from light."},{"GenericName":"Sumatriptan","BrandNames":["Imitrex","Treximet (in combination with naproxen)"],"DrugClass":"Selective serotonin receptor agonists (Triptans)","MechanismOfAction":"Sumatriptan selectively binds with high affinity to the 5-HT1B and 5-HT1D receptors. This causes vasoconstriction of intracranial blood vessels and inhibition of pro-inflammatory neuropeptide release, thereby reducing migraine symptoms.","Pharmacodynamics":"Sumatriptan exerts its effects by agonist activity at specific 5-HT1 receptors in cranial arteries, leading to vasoconstriction which leads to relief of migraine.","OnsetOfAction":"30 minutes when administered subcutaneously, oral forms can take 1-2 hours.","DurationOfAction":"The duration is typically 2-6 hours.","PeakPlasmaConcentration":"Approximately 10-15 minutes post subcutaneous dose, and about 2 hours post oral administration.","Indications":["Acute treatment of migraine attacks with or without aura","Acute treatment of cluster headaches"],"RoutesOfAdministration":"Oral, subcutaneous, nasal","DosageForms":["Tablets","Injection","Nasal spray"],"StrengthsOfDosageForms":["Tablets: 25mg, 50mg, 100mg","Injection: 6mg/0.5ml autoinjector","Nasal spray: 5mg, 10mg, 20mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed after subcutaneous administration; oral bioavailability is about 15% due to first-pass metabolism.","Distribution":"Widely distributed throughout the body including the brain.","Metabolism":"Hepatically via monoamine oxidase A (MAO-A) pathway.","Excretion":"Renally and partially in feces."},"SideEffects":["Tingling","Warmth or cold sensations","Dizziness","Flushing","Fatigue or drowsiness","Nausea"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Selective serotonin reuptake inhibitors (SSRIs)","Serotonin norepinephrine reuptake inhibitors (SNRIs)","Ergotamine-containing drugs"],"Contraindications":"Sumatriptan is contraindicated in patients with ischemic heart disease, history of stroke or transient ischemic attack, and uncontrolled hypertension.","ChemicalStructure":{"MolecularFormula":"C14H21N3O2S","MolecularWeight":"295.4 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Caution should be exercised. Limited data on human pregnancies have been analyzed.","PediatricUse":"Safety and efficacy have not been established for children under 18 years of age.","GeriatricUse":"Use with caution due to potential cardiovascular effects.","HepaticImpairment":"Dosing adjustments may be required in patients with hepatic impairment.","RenalImpairment":"No specific data; use with caution due to renal excretion."},"StorageAndHandling":"Tablets should be stored at controlled room temperature, 20-25°C (68-77°F). Protect from light and moisture."},{"GenericName":"Epinephrine","BrandNames":["Adrenalin","EpiPen","Auvi-Q","Primatene Mist"],"DrugClass":"Adrenergic agonist","MechanismOfAction":"Epinephrine acts on both alpha and beta-adrenergic receptors, resulting in vasoconstriction, increased heart rate, bronchodilation, and other sympathetic nervous system responses.","Pharmacodynamics":"Epinephrine increases heart rate, myocardial contractility, and vasoconstriction, which leads to increased blood pressure. It also causes bronchodilation by relaxing the smooth muscles of the airways.","OnsetOfAction":"Within 5 minutes when injected intramuscularly or subcutaneously.","DurationOfAction":"1 to 4 hours, depending on route and dose.","PeakPlasmaConcentration":"3 to 5 minutes post-injection (intramuscular/subcutaneous).","Indications":["Anaphylaxis","Cardiac arrest","Asthma exacerbations","Severe hypotension"],"RoutesOfAdministration":"Intramuscular, Subcutaneous, Intravenous, Inhalation","DosageForms":["Injectable solution (vials, prefilled syringes, autoinjectors)","Aerosol for inhalation"],"StrengthsOfDosageForms":["1 mg/mL (1:1000)","0.1 mg/mL (1:10,000)","0.15 mg autoinjector","0.3 mg autoinjector"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following intramuscular or subcutaneous injection.","Distribution":"Widely distributed in the body, but does not cross the blood-brain barrier significantly.","Metabolism":"Metabolized in the liver and other tissues by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).","Excretion":"Excreted in the urine mainly as inactive metabolites."},"SideEffects":["Palpitations","Tachycardia","Hypertension","Anxiety","Headache","Dizziness"],"DrugInteractions":["Other sympathomimetics","Beta-blockers","MAO inhibitors","Tricyclic antidepressants"],"Contraindications":"There are no absolute contraindications to epinephrine in a life-threatening situation such as anaphylaxis. However, use with caution in patients with cardiovascular disease.","ChemicalStructure":{"MolecularFormula":"C9H13NO3","MolecularWeight":"183.204 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C. Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safe and effective when used in recommended dosages for emergencies such as anaphylaxis.","GeriatricUse":"May be more prone to adverse effects like increased blood pressure; use caution.","HepaticImpairment":"No specific dosage adjustment provided; use with caution as liver metabolizes epinephrine.","RenalImpairment":"No specific dosage adjustment provided; use with caution."},"StorageAndHandling":"Store at controlled room temperature and protect from light. Do not refrigerate or freeze."},{"GenericName":"Fluconazole","BrandNames":["Diflucan"],"DrugClass":"Antifungal","MechanismOfAction":"Fluconazole works by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase. This enzyme is necessary for converting lanosterol to ergosterol, an essential component of the fungal cell membrane. Inhibition of ergosterol synthesis leads to increased cellular permeability causing cell death.","Pharmacodynamics":"Fluconazole exhibits fungistatic activity by binding to the fungal cytochrome P-450 and inhibiting the conversion of lanosterol to ergosterol, thereby altering the cell membrane structure and function which leads to fungal cell death.","OnsetOfAction":"Varies depending on infection type; typically begins to work within 24 hours.","DurationOfAction":"Fluconazole has a half-life of approximately 30 hours, and its effects can be persistent from days to several days after a single dose, depending on the dose used.","PeakPlasmaConcentration":"Fluconazole reaches peak plasma concentration within 1-2 hours after oral administration.","Indications":["Candidiasis (esophageal, oropharyngeal, vaginal)","Cryptococcal meningitis","Prophylaxis of candidiasis in bone marrow transplant patients","Other systemic or topical fungal infections"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablets","Oral suspension","Injectable solution"],"StrengthsOfDosageForms":["50 mg tablets","100 mg tablets","150 mg tablets","200 mg tablets","Oral suspension 10 mg/mL","Oral suspension 40 mg/mL","200 mg/100 mL injection","400 mg/200 mL injection"],"Pharmacokinetics":{"Absorption":"Well absorbed from the GI tract, with a bioavailability over 90%.","Distribution":"Widely distributed; the volume of distribution approximates that of total body water. Crosses the blood-brain barrier.","Metabolism":"Minimal hepatic metabolism.","Excretion":"Primarily renal excretion (approximately 80% unchanged in urine)."},"SideEffects":["Headache","Nausea","Abdominal pain","Diarrhea","Dizziness","Taste perversion","Skin rash","Elevated liver enzymes"],"DrugInteractions":["Warfarin","Cyclosporine","Phenytoin","Rifampin","Tacrolimus","Oral hypoglycemic agents","Theophylline","Benzodiazepines"],"Contraindications":"Known hypersensitivity to fluconazole or other azole antifungal drugs.","ChemicalStructure":{"MolecularFormula":"C13H12F2N6O","MolecularWeight":"306.27 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D: Should be avoided during the first trimester unless the potential benefits outweigh the risks.","PediatricUse":"Data supports use, but dosing may differ from adults.","GeriatricUse":"No dose adjustment required unless renal function is impaired.","HepaticImpairment":"Use with caution; monitor liver function tests closely.","RenalImpairment":"Requires dosage adjustment based on renal function."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture."},{"GenericName":"Meclizine","BrandNames":["Antivert","Bonine","Dramamine Less Drowsy"],"DrugClass":"Antihistamine (H1 receptor antagonist)","MechanismOfAction":"Meclizine works by blocking the action of histamine at H1 receptors. It also has anticholinergic effects, which help to prevent nausea and vomiting associated with motion sickness and vertigo.","Pharmacodynamics":"Meclizine exhibits its antiemetic and antivertigo effects by altering neuronal signals in the brain and blocking the vestibular system's pathways.","OnsetOfAction":"1 hour","DurationOfAction":"12 to 24 hours","PeakPlasmaConcentration":"3 hours (after oral administration)","Indications":["Motion sickness","Vertigo (associated with vestibular diseases)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Chewable tablets"],"StrengthsOfDosageForms":["12.5 mg","25 mg","50 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Widely distributed in the body, crosses the blood-brain barrier.","Metabolism":"Extensively metabolized in the liver.","Excretion":"Primarily excreted in the urine as metabolites."},"SideEffects":["Drowsiness","Dry mouth","Blurry vision","Urinary retention","Constipation"],"DrugInteractions":["Alcohol","CNS depressants","Anticholinergics"],"Contraindications":"Hypersensitivity to meclizine or similar drugs.","ChemicalStructure":{"MolecularFormula":"C25H27ClN2","MolecularWeight":"390.95 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B - Generally considered safe, but should be used only if clearly needed.","PediatricUse":"Safety and effectiveness have not been established in children under 12 years of age.","GeriatricUse":"Dose adjustment may be necessary due to increased sensitivity in elderly patients.","HepaticImpairment":"Use with caution and monitoring.","RenalImpairment":"Use with caution and monitoring."},"StorageAndHandling":"Store at room temperature, protected from moisture and heat."},{"GenericName":"Oxybutynin","BrandNames":["Ditropan","Ditropan XL","Gelnique","Oxytrol"],"DrugClass":"Anticholinergic","MechanismOfAction":"Oxybutynin works by relaxing the bladder smooth muscle. It inhibits the action of acetylcholine on smooth muscle, thereby reducing bladder contractions and increasing bladder capacity.","Pharmacodynamics":"Oxybutynin decreases involuntary contractions of the bladder and increases the volume of the bladder before the urge to urinate begins, helping to control urinary incontinence.","OnsetOfAction":"Within 30 to 60 minutes","DurationOfAction":"6 to 10 hours","PeakPlasmaConcentration":"1 to 2 hours after oral administration","Indications":["Overactive bladder","Urge urinary incontinence","Frequent urination"],"RoutesOfAdministration":"Oral, transdermal","DosageForms":["Tablet","Extended-release tablet","Transdermal patch","Topical gel"],"StrengthsOfDosageForms":["5 mg tablet","10 mg extended-release tablet","3.9 mg/day patch","10% gel"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Widely distributed in body tissues, crosses the blood-brain barrier.","Metabolism":"Extensively metabolized in the liver by CYP3A4.","Excretion":"Primarily in urine as metabolites."},"SideEffects":["Dry mouth","Constipation","Blurred vision","Drowsiness","Dizziness","Nausea"],"DrugInteractions":["Other anticholinergics","CYP3A4 inhibitors like ketoconazole","CYP3A4 inducers like rifampin","Other drugs with anticholinergic properties"],"Contraindications":"Uncontrolled narrow-angle glaucoma, gastrointestinal obstruction, urinary retention.","ChemicalStructure":{"MolecularFormula":"C22H31NO3","MolecularWeight":"357.49 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed, as there are no adequate and well-controlled studies in pregnant women.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients younger than 5 years.","GeriatricUse":"May be more sensitive to the anticholinergic effects; monitor closely.","HepaticImpairment":"Use with caution; monitor closely.","RenalImpairment":"Use with caution; monitor closely."},"StorageAndHandling":"Store at room temperature away from moisture and heat."},{"GenericName":"Testosterone","BrandNames":["AndroGel","Depo-Testosterone","Axiron","Testim","Androderm"],"DrugClass":"Androgen","MechanismOfAction":"Testosterone acts by binding to the androgen receptor (AR), which then leads to gene transcription changes resulting in increased protein synthesis. This hormone is critical in the development of male reproductive tissues and secondary sexual characteristics.","Pharmacodynamics":"Testosterone promotes growth and development of male sex organs and maintains secondary sex characteristics. It has anabolic actions affecting body composition (increasing muscle mass and decreasing fat mass) and also affects mood and libido.","OnsetOfAction":"Varies depending on the route of administration, from hours (as with injections) to days (transdermal patches and gels).","DurationOfAction":"Depending on formulation, varies from hours (oral) to 1 to 2 weeks (intramuscular injection).","PeakPlasmaConcentration":"Achieved in approximately 24 to 72 hours, depending on the route of administration.","Indications":["Hypogonadism","Delayed puberty in males","Hormone therapy for transgender men"],"RoutesOfAdministration":"Intramuscular, transdermal, oral, subcutaneous","DosageForms":["Injection","Transdermal gel","Transdermal patch","Oral capsule"],"StrengthsOfDosageForms":["Intramuscular injection: 100 mg/mL, 200 mg/mL","Transdermal gel: 1%, 1.62%","Transdermal patch: 2 mg/24 hr, 4 mg/24 hr","Oral capsule: 30 mg"],"Pharmacokinetics":{"Absorption":"Varies by form; transdermal gels are absorbed through the skin, injections have direct intramuscular absorption.","Distribution":"Widely distributed throughout the body. Binds to sex hormone-binding globulin and albumin.","Metabolism":"Primarily hepatic via two different pathways; converted to dihydrotestosterone and estradiol.","Excretion":"Primarily in urine as conjugates of testosterone metabolites."},"SideEffects":["Acne","Gynecomastia","Increased hematocrit","Edema","Mood changes","Prostate enlargement"],"DrugInteractions":["Anticoagulants","Corticosteroids","Insulin and oral hypoglycemics"],"Contraindications":"Breast cancer in males, prostate cancer, pregnancy, and known hypersensitivity to testosterone products.","ChemicalStructure":{"MolecularFormula":"C19H28O2","MolecularWeight":"288.4 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated in pregnancy. Category X - can result in fetal harm.","PediatricUse":"Use in children should be limited to specific cases such as pubertal delay under specialist guidance.","GeriatricUse":"May require dose adjustments and monitoring of prostate health.","HepaticImpairment":"Use cautiously due to potential increased exposure.","RenalImpairment":"Use cautiously, monitor for side effects."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from light and do not freeze."},{"GenericName":"Cetirizine","BrandNames":["Zyrtec","Alleroff","Reactine"],"DrugClass":"Antihistamine (2nd generation)","MechanismOfAction":"Cetirizine is a selective antagonist of the peripheral H1 receptors. It works by blocking the action of histamine, which reduces allergy symptoms.","Pharmacodynamics":"Cetirizine is an H1-receptor antagonist which inhibits the effect of histamine, reducing symptoms such as hives, runny nose, and sneezing. It is less sedating than first-generation antihistamines because it penetrates poorly into the central nervous system.","OnsetOfAction":"Cetirizine typically begins to work within 20 to 60 minutes after oral administration.","DurationOfAction":"The effects of cetirizine last for approximately 24 hours.","PeakPlasmaConcentration":"The peak plasma concentration is achieved in about 1 hour after oral administration.","Indications":["Allergic rhinitis","Chronic urticaria (hives)","Allergic conjunctivitis"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Chewable tablet","Syrup"],"StrengthsOfDosageForms":["Tablets: 5 mg, 10 mg","Chewable tablets: 5 mg, 10 mg","Syrup: 5 mg/5 ml"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed after oral administration.","Distribution":"It is extensively distributed throughout the body and is about 93% bound to plasma proteins.","Metabolism":"Metabolized in the liver to a small extent, mostly via oxidative O-dealkylation to a metabolite with negligible antihistaminic activity.","Excretion":"Excreted in the urine, with approximately 70% eliminated unchanged."},"SideEffects":["Drowsiness","Fatigue","Dry mouth","Pharyngitis","Dizziness"],"DrugInteractions":["Alcohol may increase drowsiness.","Ritonavir can increase cetirizine levels.","CNS depressants can enhance drowsiness."],"Contraindications":"Hypersensitivity to cetirizine or hydroxyzine and lactating women where there is a concern for transfer through breast milk.","ChemicalStructure":{"MolecularFormula":"C21H25ClN2O3","MolecularWeight":"388.89 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B. Use should only be if clearly needed and potential benefits justify the potential risk.","PediatricUse":"Approved for use in children above 2 years of age.","GeriatricUse":"Dose adjustment may be necessary due to the potential for decreased renal function in the elderly.","HepaticImpairment":"Use with caution; dose adjustment may be required.","RenalImpairment":"Dose adjustment may be necessary depending on the severity of the impairment."},"StorageAndHandling":"Store at room temperature away from moisture and heat. Keep syrups and liquid formulations tightly closed."},{"GenericName":"Fexofenadine","BrandNames":["Allegra","Telfast"],"DrugClass":"Antihistamine","MechanismOfAction":"Fexofenadine is a selective peripheral H1 receptor antagonist. Blocking H1 receptors prevents the action of histamine, a substance in the body that causes allergic symptoms.","Pharmacodynamics":"Fexofenadine provides relief from allergic symptoms through its action as a non-sedating antihistamine, reducing symptoms like runny nose, sneezing, and itching.","OnsetOfAction":"1 hour","DurationOfAction":"24 hours","PeakPlasmaConcentration":"2-3 hours after administration","Indications":["Seasonal allergic rhinitis","Chronic idiopathic urticaria"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Oral suspension"],"StrengthsOfDosageForms":["Tablets: 30 mg, 60 mg, 180 mg","Oral suspension: 30 mg/5 ml"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract, with a bioavailability reduced by 30% when taken with a high-fat meal.","Distribution":"Protein binding is 60% to 70%, primarily bound to albumin and α1-acid glycoprotein.","Metabolism":"Minimal metabolism; approximately 5% is metabolized.","Excretion":"Primarily excreted in feces (80%) and urine (<11%)."},"SideEffects":["Headache","Drowsiness","Nausea","Dizziness"],"DrugInteractions":["Antacids containing magnesium or aluminum","Erythromycin","Ketoconazole"],"Contraindications":"Hypersensitivity to fexofenadine or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C32H39NO4","MolecularWeight":"501.67 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C. Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients below 6 months have not been established.","GeriatricUse":"No overall differences in safety or effectiveness observed between younger and older patients.","HepaticImpairment":"No specific dosage adjustment provided; use with caution.","RenalImpairment":"Use with caution; drug accumulation may occur with reduced renal function."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F), away from moisture and light."},{"GenericName":"Loratadine","BrandNames":["Claritin","Alavert","Claritin Reditabs"],"DrugClass":"Antihistamine (Second-generation)","MechanismOfAction":"Loratadine selectively antagonizes peripheral histamine H1-receptors, thereby inhibiting the action of histamine on these receptors and reducing allergy symptoms.","Pharmacodynamics":"Loratadine provides relief from allergic symptoms without causing significant drowsiness, as it does not readily cross the blood-brain barrier to a large extent.","OnsetOfAction":"1 to 3 hours","DurationOfAction":"24 hours","PeakPlasmaConcentration":"1 to 2 hours after administration","Indications":["Allergic rhinitis","Chronic idiopathic urticaria"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Orally disintegrating tablets","Syrup"],"StrengthsOfDosageForms":["Tablets: 10 mg","Orally disintegrating tablets: 10 mg","Syrup: 5 mg/5 mL"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract after oral administration.","Distribution":"Widely distributed throughout the body; minimally binds to plasma proteins.","Metabolism":"Extensively metabolized in the liver, primarily by CYP3A4 and CYP2D6, resulting in the active metabolite desloratadine.","Excretion":"Excreted in the urine and feces as metabolites."},"SideEffects":["Headache","Somnolence","Fatigue","Dry mouth"],"DrugInteractions":["Ketoconazole","Erythromycin","Cimetidine"],"Contraindications":"Hypersensitivity to loratadine or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C22H23ClN2O2","MolecularWeight":"382.89 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B; animal studies have not demonstrated a risk, but there are no adequate and well-controlled studies in pregnant women.","PediatricUse":"Safety and efficacy established for children 2 years and older.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger subjects.","HepaticImpairment":"Use with caution; dose adjustment may be needed due to decreased clearance.","RenalImpairment":"Use with caution; dose adjustment may be necessary."},"StorageAndHandling":"Store between 20° to 25°C (68° to 77°F) in a dry place away from direct sunlight."},{"GenericName":"Baclofen","BrandNames":["Lioresal","Gablofen","Kemstro"],"DrugClass":"Skeletal muscle relaxant","MechanismOfAction":"Baclofen acts as an agonist at beta-gamma aminobutyric acid (GABA-B) receptors, which inhibits both monosynaptic and polysynaptic reflexes at the spinal level and reduces the release of excitatory neurotransmitters, leading to diminished muscle spasticity.","Pharmacodynamics":"Baclofen reduces muscle tone and frequency of muscle spasms by depressing synaptic transmission through GABA-B receptors. It does not affect neuromuscular transmission.","OnsetOfAction":"The onset of action is within 1 hour of oral administration.","DurationOfAction":"The duration of action is about 4-8 hours after oral administration.","PeakPlasmaConcentration":"The peak plasma concentration is reached in 2-3 hours after oral administration.","Indications":["Treatment of spasticity due to multiple sclerosis","Spinal cord injuries or diseases","In certain cases of muscle spasticity from cerebral origins"],"RoutesOfAdministration":"Oral, Intrathecal","DosageForms":["Tablets","Oral solution","Intrathecal injection"],"StrengthsOfDosageForms":["10 mg tablets","20 mg tablets","Oral solution 5 mg/5 mL","Intrathecal injection (10 mg/20 mL, 20 mg/20 mL)"],"Pharmacokinetics":{"Absorption":"Rapid and complete following oral administration.","Distribution":"Widely distributed; approximately 30% of the dose is bound to plasma proteins.","Metabolism":"Partially metabolized in the liver.","Excretion":"Primarily excreted via urine, about 70-80% unchanged."},"SideEffects":["Drowsiness","Dizziness","Weakness","Fatigue","Headache","Insomnia","Nausea","Hypotension"],"DrugInteractions":["CNS depressants such as opioids, benzodiazepines, can increase the sedative effects.","May interact with antihypertensives, causing increased risk of hypotension."],"Contraindications":"Hypersensitivity to baclofen or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C10H12ClNO2","MolecularWeight":"213.66 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C: Risk cannot be ruled out; use only if clearly needed.","PediatricUse":"Safety and effectiveness have not been established in children under 12 years of age.","GeriatricUse":"Use with caution; monitor closely for side effects.","HepaticImpairment":"Use with caution; monitor closely as impairment may alter drug metabolism.","RenalImpairment":"Dose adjustment may be necessary; use with caution."},"StorageAndHandling":"Store in a tightly closed container at 20°C to 25°C (68°F to 77°F). Protect from moisture and light."},{"GenericName":"Tizanidine","BrandNames":["Zanaflex"],"DrugClass":"Skeletal muscle relaxant","MechanismOfAction":"Tizanidine is an alpha-2 adrenergic agonist. It decreases spasticity by increasing presynaptic inhibition of motor neurons.","Pharmacodynamics":"Tizanidine reduces the spasticity of muscles by inhibiting presynaptic motor neurons. It affects the central nervous system's ability to control muscle tone.","OnsetOfAction":"1 to 2 hours","DurationOfAction":"3 to 6 hours","PeakPlasmaConcentration":"Approximately 1.5 hours after oral administration","Indications":["Muscle spasticity associated with multiple sclerosis","Spinal cord injury","Other conditions causing spasticity"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Capsule"],"StrengthsOfDosageForms":["2 mg","4 mg","6 mg (capsules only)"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed, with a bioavailability of approximately 34% due to extensive first-pass metabolism.","Distribution":"Volume of distribution is 2.4 L/kg; 30% bound to plasma proteins.","Metabolism":"Metabolized in the liver primarily by cytochrome P450 1A2 (CYP1A2).","Excretion":"About 60% as metabolites in urine; 20% unchanged in urine."},"SideEffects":["Dry mouth","Drowsiness","Dizziness","Fatigue","Sedation","Hypotension","Bradycardia","Asthenia"],"DrugInteractions":["Ciprofloxacin","Fluvoxamine","Oral contraceptives","Antihypertensives","Other CYP1A2 inhibitors"],"Contraindications":"Hypersensitivity to tizanidine or any component of the formulation. Concomitant use with potent CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine).","ChemicalStructure":{"MolecularFormula":"C9H8ClN5S","MolecularWeight":"253.71 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C. Should only be used if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness not established in pediatric patients.","GeriatricUse":"Use caution when administering to the elderly due to increased risk of side effects.","HepaticImpairment":"Use with caution in patients with hepatic impairment. Monitor liver function tests before and during treatment.","RenalImpairment":"Use with caution; dose adjustment may be necessary as renal impairment increases systemic exposure."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) in a tight, light-resistant container."},{"GenericName":"Acyclovir","BrandNames":["Zovirax","Sitavig"],"DrugClass":"Antiviral","MechanismOfAction":"Acyclovir is a synthetic purine nucleoside analog that acts by inhibiting viral DNA synthesis. It does this by converting to acyclovir triphosphate within infected cells, where it competes with deoxyguanosine triphosphate to incorporate into viral DNA, resulting in chain termination.","Pharmacodynamics":"Acyclovir exhibits potent antiviral activity, particularly against various strains of herpes simplex virus (HSV) types 1 and 2, and varicella-zoster virus (VZV). Its efficacy involves a reduction in viral shedding, pain relief, and acceleration of lesion healing.","OnsetOfAction":"Within 24 to 48 hours for effects on lesion healing and pain reduction.","DurationOfAction":"The half-life of acyclovir is approximately 2.5 to 3 hours, but therapeutic effects may last throughout the duration of therapy depending on condition severity.","PeakPlasmaConcentration":"1.5 to 2 hours after oral administration.","Indications":["Herpes simplex infections (HSV-1 and HSV-2)","Varicella (chickenpox)","Herpes zoster (shingles)","Genital herpes (initial and recurrent)","Cold sores (herpes labialis)"],"RoutesOfAdministration":"Oral, topical, intravenous","DosageForms":["Tablet","Capsule","Suspension","Ointment","Cream","Injection (IV)"],"StrengthsOfDosageForms":["200 mg tablets","400 mg tablets","800 mg tablets","25 mg/mL suspension","30 mg/g ointment","50 mg/g cream","5 mg/mL IV solution"],"Pharmacokinetics":{"Absorption":"Bioavailability is approximately 10-20% after oral administration.","Distribution":"Widely distributed to body fluids and tissues, including the brain and cerebrospinal fluid. Protein binding is low, approximately 9-33%.","Metabolism":"Acyclovir is metabolized minimally by the liver to form 9-carboxymethoxymethylguanine.","Excretion":"Primarily excreted by the kidneys via glomerular filtration and tubular secretion. The clearance is decreased in patients with renal impairment."},"SideEffects":["Nausea","Diarrhea","Headache","Dizziness","Vomiting","Fatigue","Itching or rash","Nephrotoxicity (especially with IV use)"],"DrugInteractions":["Probenecid (can increase acyclovir levels)","Cimetidine (may increase acyclovir levels)","Other nephrotoxic drugs (increased risk of renal impairment)","Zidovudine (possible CNS side effects)"],"Contraindications":"Hypersensitivity to acyclovir or valacyclovir.","ChemicalStructure":{"MolecularFormula":"C8H11N5O3","MolecularWeight":"225.21 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B: Animal studies show no adverse effects; use only if clearly needed.","PediatricUse":"Safety and effectiveness have been established for certain indications; dosage may need adjustment based on weight.","GeriatricUse":"Dose adjustment may be required due to increased risk of renal impairment with age.","HepaticImpairment":"No significant dose adjustment needed, but caution advised in severe impairment.","RenalImpairment":"Dose adjustment required, especially with severe impairment or anuria."},"StorageAndHandling":"Store oral and topical forms at room temperature below 25°C (77°F). For IV form, follow manufacturer's instructions regarding dilution and storage of solutions."},{"GenericName":"Gabapentin","BrandNames":["Neurontin","Gralise","Horizant"],"DrugClass":"Anticonvulsant","MechanismOfAction":"Gabapentin works by altering the way nerves send messages to the brain. This helps to reduce seizure activity and neuropathic pain, though the exact mechanism is not fully understood. It is believed to interact with a specific binding site associated with voltage-sensitive calcium channels, inhibiting excitatory neurotransmitter release.","Pharmacodynamics":"Gabapentin has analgesic and anticonvulsant effects. It helps manage seizures and pain associated with neuropathic conditions by modulating the activity of calcium channels in the nervous system.","OnsetOfAction":"For pain relief, the onset is approximately 1-3 hours after oral administration.","DurationOfAction":"The duration of action is approximately 5 to 7 hours for a single dose.","PeakPlasmaConcentration":"Gabapentin reaches peak plasma concentrations within 2-3 hours after oral administration.","Indications":["Seizure disorders","Postherpetic neuralgia","Neuropathic pain","Restless legs syndrome (Horizant)"],"RoutesOfAdministration":"Oral","DosageForms":["Capsule","Tablet","Oral solution"],"StrengthsOfDosageForms":["Capsules: 100 mg, 300 mg, 400 mg","Tablets: 600 mg, 800 mg","Oral solution: 250 mg/5 ml"],"Pharmacokinetics":{"Absorption":"Absorption of gabapentin is nonlinear and dose-dependent, with bioavailability decreasing as the dose increases.","Distribution":"Gabapentin is not appreciably bound to plasma proteins and has a volume of distribution of approximately 58 liters after a 17 mg/kg dose.","Metabolism":"Gabapentin is not appreciably metabolized in humans.","Excretion":"Gabapentin is excreted renally largely as unchanged drug."},"SideEffects":["Dizziness","Fatigue","Drowsiness","Peripheral edema","Nausea and vomiting","Ataxia"],"DrugInteractions":["Antacids","Morphine"],"Contraindications":"Gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its components.","ChemicalStructure":{"MolecularFormula":"C9H17NO2","MolecularWeight":"171.24 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Classified as Pregnancy Category C.","PediatricUse":"Safety and effectiveness have been established in certain pediatric populations for the treatment of seizures.","GeriatricUse":"No overall differences in safety or efficacy observed between older and younger subjects, but increased sensitivity in some older individuals cannot be ruled out.","HepaticImpairment":"No dosage adjustment is necessary in patients with hepatic impairment.","RenalImpairment":"Dose adjustment is recommended in patients with renal impairment."},"StorageAndHandling":"Store gabapentin capsules, tablets, and oral solution at 20° to 25°C (68° to 77°F). Protect from moisture."},{"GenericName":"Terazosin","BrandNames":["Hytrin"],"DrugClass":"Alpha-1 adrenergic blocker","MechanismOfAction":"Terazosin works by blocking alpha-1 adrenergic receptors, leading to relaxation of smooth muscles in blood vessels and the prostate, resulting in vasodilation and decreased bladder outlet obstruction.","Pharmacodynamics":"Terazosin causes a decrease in blood pressure due to vasodilation and improves urine flow in patients with benign prostatic hyperplasia (BPH).","OnsetOfAction":"Approximately 15 minutes to 2 hours for effects on blood pressure.","DurationOfAction":"24 hours, which is why it is typically dosed once daily.","PeakPlasmaConcentration":"1-2 hours after oral administration.","Indications":["Hypertension","Benign prostatic hyperplasia (BPH)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["1 mg","2 mg","5 mg","10 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed with oral administration.","Distribution":"Widely distributed in the body; protein binding is about 90-94%.","Metabolism":"Metabolized in the liver.","Excretion":"Excreted primarily in the urine and feces."},"SideEffects":["Dizziness","Headache","Asthenia","Palpitations","Nausea","Nasal congestion"],"DrugInteractions":["Other antihypertensive drugs (may enhance hypotensive effect)","PDE5 inhibitors (e.g., sildenafil) can cause additive blood pressure lowering effects"],"Contraindications":"Hypersensitivity to terazosin or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C19H25N5O4","MolecularWeight":"395.43 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; classified as pregnancy category C.","PediatricUse":"Safety and efficacy not established in pediatric patients.","GeriatricUse":"No specific age-related precautions noted, though may have increased risk of side effects.","HepaticImpairment":"Use with caution, dosage adjustment may be necessary.","RenalImpairment":"Use with caution, dosage adjustment may be necessary."},"StorageAndHandling":"Store at room temperature, away from excess heat and moisture."},{"GenericName":"Doxazosin","BrandNames":["Cardura","Carduran"],"DrugClass":"Alpha-1 adrenergic blocker","MechanismOfAction":"Doxazosin works by selectively inhibiting alpha-1 adrenergic receptors on vascular smooth muscle, leading to vasodilation and a reduction in blood pressure. It also relaxes the smooth muscle in the bladder neck and prostate, improving urine flow in patients with benign prostatic hyperplasia (BPH).","Pharmacodynamics":"Doxazosin decreases peripheral vascular resistance and lowers blood pressure by causing relaxation of both resistance and capacitance vessels. It also alleviates symptoms of BPH by relaxing smooth muscles in the prostate and bladder neck, enhancing urine flow.","OnsetOfAction":"1-6 hours (for blood pressure lowering effect)","DurationOfAction":"Up to 24 hours","PeakPlasmaConcentration":"2-3 hours after oral administration","Indications":["Hypertension","Benign prostatic hyperplasia"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Extended-release tablet"],"StrengthsOfDosageForms":["Tablets: 1 mg, 2 mg, 4 mg, 8 mg","Extended-release tablets: 4 mg, 8 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed after oral administration.","Distribution":"Extensively bound to plasma proteins (~98%).","Metabolism":"Hepatic metabolism predominantly via O-demethylation and hydroxylation.","Excretion":"Excreted in the feces (~63%) and urine (~9%)."},"SideEffects":["Dizziness","Fatigue","Headache","Drowsiness","Edema","Nausea","Orthostatic hypotension"],"DrugInteractions":["Other antihypertensive drugs (additive hypotensive effects)","Phosphodiesterase-5 inhibitors (e.g., sildenafil)","Cimetidine (can increase doxazosin levels)"],"Contraindications":"Contraindicated in patients with a known hypersensitivity to doxazosin or any of its components.","ChemicalStructure":{"MolecularFormula":"C23H25N5O5","MolecularWeight":"451.48 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; no well-controlled studies in pregnant women. Category C.","PediatricUse":"Safety and effectiveness not established in pediatric patients.","GeriatricUse":"No special precautions required beyond those applicable to all adult patients.","HepaticImpairment":"Use with caution; metabolism occurs in the liver.","RenalImpairment":"No dosage adjustment necessary, as doxazosin is not primarily renally excreted."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light and moisture."},{"GenericName":"Minocycline","BrandNames":["Minocin","Dynacin","Solodyn"],"DrugClass":"Tetracycline antibiotic","MechanismOfAction":"Minocycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.","Pharmacodynamics":"Minocycline is effective against a broad range of Gram-positive and Gram-negative bacteria. It has anti-inflammatory properties as well, which can be beneficial in treating acne.","OnsetOfAction":"Within a few hours after administration.","DurationOfAction":"The effects typically last 12 to 24 hours depending on the dose and formulation.","PeakPlasmaConcentration":"1 to 4 hours after administration.","Indications":["Treatment of various bacterial infections","Acne vulgaris","Rocky Mountain spotted fever","Respiratory tract infections","Skin infections"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Capsules","Tablets","Powder for injection"],"StrengthsOfDosageForms":["50 mg capsules","100 mg capsules","80 mg tablets","100 mg tablets"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract, with a bioavailability of approximately 90% to 100%.","Distribution":"Widely distributed in body tissues and fluids. It is lipophilic, allowing it to penetrate well into tissues.","Metabolism":"Minocycline is partially metabolized in the liver.","Excretion":"Excreted in urine and feces as unchanged drug and metabolites."},"SideEffects":["Dizziness","Nausea","Diarrhea","Photosensitivity","Vestibular disturbances","Skin discoloration"],"DrugInteractions":["Antacids containing aluminum, calcium, or magnesium, and iron supplements can reduce absorption","Oral contraceptives may have reduced efficacy","May increase effects of anticoagulants"],"Contraindications":"Hypersensitivity to minocycline or any tetracyclines.","ChemicalStructure":{"MolecularFormula":"C23H27N3O7","MolecularWeight":"457.48 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use is generally avoided during pregnancy due to potential risk of fetal harm.","PediatricUse":"Not recommended for children under 8 years due to risk of permanent tooth discoloration.","GeriatricUse":"Use with caution, dose may need adjustment based on kidney function.","HepaticImpairment":"Use with caution in patients with hepatic impairment.","RenalImpairment":"Dose adjustment may be required in patients with renal impairment."},"StorageAndHandling":"Store at room temperature, away from light and moisture. Avoid freezing the medication."},{"GenericName":"Hydroxyzine","BrandNames":["Atarax","Vistaril"],"DrugClass":"First-generation antihistamine","MechanismOfAction":"Hydroxyzine works primarily as an antihistamine by inhibiting the H1 receptors, leading to reduced activity of the histamine pathways. It also suppresses the central nervous system, resulting in its sedative and anxiolytic effects.","Pharmacodynamics":"Hydroxyzine exhibits antihistaminic, anxiolytic, and sedative properties due to its antagonistic effects on H1 receptors and actions on the central nervous system.","OnsetOfAction":"15 to 30 minutes","DurationOfAction":"4 to 6 hours","PeakPlasmaConcentration":"2 hours","Indications":["Anxiety and tension","Preoperative sedation","Pruritus due to allergic conditions","Nausea and vomiting","Sedation"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Capsules","Oral suspension","Injectable solution"],"StrengthsOfDosageForms":["Tablets: 10 mg, 25 mg, 50 mg","Capsules: 25 mg, 50 mg, 100 mg","Oral suspension: 10 mg/5 mL","Injectable solution: 25 mg/mL, 50 mg/mL"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following oral administration.","Distribution":"Widely distributed across the body, crosses the blood-brain barrier.","Metabolism":"Metabolized in the liver into the active metabolite cetirizine.","Excretion":"Primarily excreted by the kidneys."},"SideEffects":["Drowsiness","Dizziness","Dry mouth","Blurred vision","Constipation","Headache"],"DrugInteractions":["Alcohol","CNS depressants","Monoamine oxidase inhibitors (MAOIs)","Tricyclic antidepressants"],"Contraindications":"Known hypersensitivity to hydroxyzine, cetirizine, or levocetirizine.","ChemicalStructure":{"MolecularFormula":"C21H27ClN2O2","MolecularWeight":"374.91 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Not recommended, especially in early pregnancy due to potential for fetal harm.","PediatricUse":"Use with caution, dosage adjustment may be required.","GeriatricUse":"Dose adjustment may be necessary due to increased sensitivity.","HepaticImpairment":"Use with caution, may require dose adjustment.","RenalImpairment":"Use with caution, dosage adjustment may be necessary."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and light."},{"GenericName":"Buspirone","BrandNames":["Buspar"],"DrugClass":"Anxiolytic","MechanismOfAction":"Buspirone primarily acts as a serotonin 5-HT1A receptor partial agonist. It also has some affinity to dopamine D2 receptors, though its exact mechanism in relieving anxiety is not entirely understood.","Pharmacodynamics":"Buspirone's anxiolytic effects are thought to be due to its action on serotonin and dopamine receptors, contributing to its effects on mood and anxiety.","OnsetOfAction":"1 to 2 weeks","DurationOfAction":"Approximately 24 hours","PeakPlasmaConcentration":"60 to 90 minutes after oral administration","Indications":["Generalized Anxiety Disorder (GAD)","Anxiety with depressive symptoms"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Film-coated tablets"],"StrengthsOfDosageForms":["5 mg","7.5 mg","10 mg","15 mg","30 mg"],"Pharmacokinetics":{"Absorption":"Buspirone is rapidly absorbed after oral administration.","Distribution":"Widely distributed throughout the body, approximately 86% bound to plasma proteins.","Metabolism":"Extensively metabolized by the liver, primarily via CYP3A4.","Excretion":"Excreted mainly in the urine and feces as metabolites."},"SideEffects":["Dizziness","Nausea","Headache","Nervousness","Lightheadedness","Excitement"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","CYP3A4 inhibitors","Alcohol","CNS depressants"],"Contraindications":"Hypersensitivity to buspirone or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C21H31N5O2","MolecularWeight":"385.51 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B. Should be used during pregnancy only if clearly needed.","PediatricUse":"Safety and efficacy in pediatric patients have not been established.","GeriatricUse":"Cautious use recommended; dose reduction may be necessary.","HepaticImpairment":"Use with caution; reduced doses may be necessary.","RenalImpairment":"Use with caution; reduced doses may be necessary."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) in a tightly closed container, away from moisture and heat."},{"GenericName":"Triamcinolone","BrandNames":["Nasacort","Kenalog","Aristocort","Azmacort"],"DrugClass":"Corticosteroid","MechanismOfAction":"Triamcinolone is a glucocorticoid receptor agonist. It acts by reducing inflammation by decreasing the release of inflammatory mediators and suppressing the recruitment of inflammatory cells.","Pharmacodynamics":"Triamcinolone exerts anti-inflammatory, antipruritic, and anti-allergic effects. It inhibits multiple inflammatory cytokines, leading to decreased proteolytic enzyme formation and reduced capillary permeation, which subsequently decreases inflammation and edema.","OnsetOfAction":"Several hours to days, depending on the route of administration and condition being treated.","DurationOfAction":"It varies; for injectable forms, the duration can be several weeks, while for topical or inhaled forms, the duration is linked to the period of usage.","PeakPlasmaConcentration":"Varies depending on the route of administration but generally within 1 to 2 hours for systemic use.","Indications":["Allergic reactions","Dermatologic diseases","Endocrine disorders","Gastrointestinal diseases","Hematologic disorders","Neoplastic diseases","Nervous system disorders","Renal diseases","Respiratory diseases","Rheumatic disorders"],"RoutesOfAdministration":"Oral, intramuscular, intra-articular, intradermal, inhalation, topical","DosageForms":["Cream","Ointment","Injectable suspension","Inhalation aerosol","Nasal spray"],"StrengthsOfDosageForms":["Cream: 0.025%","Ointment: 0.1%","Injectable suspension: 40 mg/mL","Nasal spray: 55 mcg/actuation"],"Pharmacokinetics":{"Absorption":"Variable depending on the route; oral forms are well absorbed, while topical or inhaled forms have minimal systemic absorption.","Distribution":"Widely distributed in the body, crosses the blood-brain barrier.","Metabolism":"Metabolized primarily in the liver.","Excretion":"Excreted in the urine, mainly as metabolites."},"SideEffects":["Cushing's syndrome","Glucose intolerance","Suppression of HPA axis","Hypertension","Osteoporosis","Weight gain","Increased risk of infections","Mood changes"],"DrugInteractions":["Nonsteroidal anti-inflammatory drugs (NSAIDs)","Anticoagulants","Vaccines","Diuretics","Insulin and oral hypoglycemics","Cyclosporine"],"Contraindications":"Systemic fungal infections, patients with hypersensitivity to the drug or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C21H27FO6","MolecularWeight":"394.44 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C. Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Long-term use can affect growth and development. Use the lowest possible dose for the shortest duration possible.","GeriatricUse":"May be more susceptible to the side effects, especially osteoporosis. Monitoring of bone density is recommended.","HepaticImpairment":"Use with caution due to reduced clearance of the drug.","RenalImpairment":"No specific dosage adjustments recommended, but use with caution."},"StorageAndHandling":"Store at room temperature away from light and moisture. Do not freeze liquid formulations."},{"GenericName":"Betamethasone","BrandNames":["Celestone","Diprolene","Luxiq","Valisone"],"DrugClass":"Corticosteroid","MechanismOfAction":"Betamethasone is a corticosteroid that works by mimicking the effects of endogenous corticosteroids, reducing inflammation by inhibiting the release of cytokines, prostaglandins, and other mediators of inflammation.","Pharmacodynamics":"Betamethasone has anti-inflammatory, immunosuppressive, and anti-proliferative properties. It decreases inflammation by inhibiting leukocyte infiltration at the site of inflammation, suppressing cytokine production, and reversing capillary permeability.","OnsetOfAction":"Hours (depending on the route and indication)","DurationOfAction":"Usually 1 to 4 days","PeakPlasmaConcentration":"Approximately 1 to 2 hours after oral administration","Indications":["Inflammatory and autoimmune conditions","Allergic disorders","Dermatologic diseases","Cerebral edema","Endocrine disorders (e.g., adrenocortical insufficiency)"],"RoutesOfAdministration":"Oral, intramuscular, topical, intra-articular, intravenous","DosageForms":["Tablets","Injection","Topical cream","Topical ointment","Topical lotion","Topical foam"],"StrengthsOfDosageForms":["0.6 mg (oral tablets)","0.1% (cream, ointment, lotion)","7 mg/mL (injectable)"],"Pharmacokinetics":{"Absorption":"Well absorbed via oral and injectable routes; varies topically depending on skin integrity","Distribution":"Widely distributed in the body and crosses the blood-brain barrier","Metabolism":"Primarily hepatic","Excretion":"Excreted in urine as metabolites"},"SideEffects":["Hyperglycemia","Fluid retention","Hypertension","Increased risk of infection","Osteoporosis","Mood changes","Muscle weakness"],"DrugInteractions":["NSAIDs - increased risk of gastrointestinal bleeding","Anticoagulants - altered effects","Diuretics - increased risk of hypokalemia","Vaccines - reduced efficacy"],"Contraindications":"Systemic fungal infections, hypersensitivity to betamethasone or any component of the formulation, caution in individuals with active infections.","ChemicalStructure":{"MolecularFormula":"C22H29FO5","MolecularWeight":"392.461 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed; may have potential adverse effects on fetal growth.","PediatricUse":"Use with caution; growth should be monitored during prolonged treatment.","GeriatricUse":"Use with caution; greater susceptibility to side effects such as osteoporosis.","HepaticImpairment":"Dosing adjustments may be required.","RenalImpairment":"No significant adjustment required but use with caution."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from freezing and extreme heat. Keep out of reach of children."},{"GenericName":"Fluorouracil","BrandNames":["Adrucil","Efudex","Carac","Fluoroplex"],"DrugClass":"Antineoplastic agent, Antimetabolite","MechanismOfAction":"Fluorouracil works as a pyrimidine analog. It inhibits DNA synthesis by blocking the methylation reaction of deoxyuridylic acid to thymidylic acid. It is also incorporated into RNA, interfering with RNA processing and function.","Pharmacodynamics":"Fluorouracil is primarily S-phase specific, although it may interfere with DNA synthesis to some extent during other cell cycle phases. It causes cell death by inducing unbalanced growth and apoptosis.","OnsetOfAction":"The onset of action is variable; effects may be observed within days to weeks depending on the condition being treated.","DurationOfAction":"The duration of effect varies; however, systemic effects can persist for days after administration.","PeakPlasmaConcentration":"Peak plasma concentrations are reached within 30 minutes when administered intravenously.","Indications":["Treatment of colorectal cancer","Breast cancer","Gastric cancer","Pancreatic cancer","Actinic keratoses","Superficial basal cell carcinoma"],"RoutesOfAdministration":"Intravenous (IV), Topical","DosageForms":["Injection","Topical cream","Topical solution"],"StrengthsOfDosageForms":["Injection: 50 mg/mL","Topical cream: 5%","Topical solution: 2% and 5%"],"Pharmacokinetics":{"Absorption":"Well absorbed with IV administration. Poorly absorbed via oral route.","Distribution":"Widely distributed throughout the tissues, including the CSF.","Metabolism":"Primarily metabolized by the liver to inactive metabolites.","Excretion":"Excreted in urine, mostly as metabolites."},"SideEffects":["Myelosuppression","Mucositis","Diarrhea","Nausea and vomiting","Alopecia","Dermatological reactions"],"DrugInteractions":["Leucovorin can enhance the toxicity of fluorouracil.","Cimetidine may increase the effects of fluorouracil by inhibiting its metabolism.","Warfarin may have an increased anticoagulant effect when taken with fluorouracil."],"Contraindications":"Patients with a known hypersensitivity to fluorouracil or any component of the formulation should not use it. It is also contraindicated in patients with severe bone marrow suppression due to treatment with other agents or from another cause.","ChemicalStructure":{"MolecularFormula":"C4H3FN2O2","MolecularWeight":"130.08 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated due to teratogenic effects observed in animal studies.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"Elderly patients may be at increased risk for severe toxicity, but it can be used with caution.","HepaticImpairment":"Use with caution; may require dose adjustment due to altered metabolism.","RenalImpairment":"Use with caution; may require dose adjustment due to altered excretion."},"StorageAndHandling":"Store at controlled room temperature. Protect from light. Solutions should not be mixed with other medications unless compatibility is known."},{"GenericName":"Ketoconazole","BrandNames":["Nizoral","Xolegel","Ketodan","Extina"],"DrugClass":"Antifungal","MechanismOfAction":"Ketoconazole works by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes, leading to increased membrane permeability and cell death.","Pharmacodynamics":"It exerts its antifungal action by interfering with the synthesis of ergosterol, impairing the cell membrane's ability to function properly, leading to cell death in susceptible fungi.","OnsetOfAction":"Ketoconazole shampoo typically shows improvement in symptoms within 1 to 2 weeks.","DurationOfAction":"The effect can last several days post application, depending on the formulation and site of application.","PeakPlasmaConcentration":"Peak plasma concentrations are reached within 1 to 2 hours after oral administration.","Indications":["Treatment of fungal infections","Seborrheic dermatitis","Tinea versicolor","Candidiasis","Cutaneous dermatophyte infections"],"RoutesOfAdministration":"Topical, Oral","DosageForms":["Shampoo","Cream","Tablet","Foam","Gel"],"StrengthsOfDosageForms":["Shampoo: 2%","Cream: 2%","Tablet: 200 mg","Foam: 2%","Gel: 2%"],"Pharmacokinetics":{"Absorption":"Oral absorption is variable and enhanced in acidic conditions; topical absorption is minimal.","Distribution":"Widely distributed in body tissues; approximately 84% bound to plasma proteins.","Metabolism":"Metabolized in the liver primarily through CYP3A4.","Excretion":"Primarily excreted in feces as metabolites; about 13% in urine."},"SideEffects":["Nausea","Vomiting","Abdominal pain","Dizziness","Itching","Menstrual irregularities","Rash"],"DrugInteractions":["Inhibitors of CYP3A4 can increase ketoconazole levels","Antacids can decrease absorption","Concomitant use with ergot derivatives is contraindicated"],"Contraindications":"Use with drugs that are metabolized by CYP3A4 and have a narrow therapeutic index, due to risk of increased levels and potential toxicity. Also contraindicated in liver disease when used systemically.","ChemicalStructure":{"MolecularFormula":"C26H28Cl2N4O4","MolecularWeight":"531.43 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in children are not well established.","GeriatricUse":"No specific guidance for elderly patients.","HepaticImpairment":"Caution should be used, as ketoconazole can cause hepatic toxicity.","RenalImpairment":"Use with caution; specific dosage adjustments are not provided, but systemic accumulation is possible."},"StorageAndHandling":"Store at room temperature, 20°C to 25°C (68°F to 77°F); do not freeze. Protect from light and moisture."},{"GenericName":"Methocarbamol","BrandNames":["Robaxin","Carbacot"],"DrugClass":"Muscle relaxant","MechanismOfAction":"Methocarbamol acts centrally to depress motor nerve transmission in the spinal cord. It does not directly relax tense skeletal muscles.","Pharmacodynamics":"Methocarbamol is centrally acting and is believed to cause relaxation of muscles by inhibiting central nerve transmission. It may have a sedative effect, which may contribute to its clinical advantages as a muscle relaxant.","OnsetOfAction":"30 minutes after oral administration","DurationOfAction":"1 to 2 hours","PeakPlasmaConcentration":"Approximately 1 to 2 hours after oral dose","Indications":["Muscle spasm associated with acute painful musculoskeletal conditions"],"RoutesOfAdministration":"Oral, Intravenous, Intramuscular","DosageForms":["Tablet","Injection"],"StrengthsOfDosageForms":["500 mg tablets","750 mg tablets","Injection, 100 mg/mL"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract following oral administration.","Distribution":"Methocarbamol is widely distributed throughout the body tissues.","Metabolism":"Primarily metabolized in the liver by dealkylation and hydroxylation.","Excretion":"Primarily excreted in urine as metabolites and unchanged drug."},"SideEffects":["Dizziness","Drowsiness","Nausea","Blurry vision","Headache"],"DrugInteractions":["Alcohol","CNS depressants (e.g., benzodiazepines, opioids)","Anticholinergic drugs"],"Contraindications":"Hypersensitivity to methocarbamol or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C11H15NO5","MolecularWeight":"241.24 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Safety has not been established. Use only if clearly needed.","PediatricUse":"Safety and effectiveness in pediatric patients below the age of 16 years have not been established.","GeriatricUse":"Caution is recommended due to potential for sedative and CNS effects.","HepaticImpairment":"Use with caution; potential for reduced metabolism.","RenalImpairment":"Use with caution; potential for reduced elimination."},"StorageAndHandling":"Store at 20° to 25°C (68° to 77°F), away from light and moisture."},{"GenericName":"Lidocaine","BrandNames":["Xylocaine","Lidoderm","Lignocaine"],"DrugClass":"Local anesthetic","MechanismOfAction":"Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby providing a local anesthetic effect.","Pharmacodynamics":"Lidocaine alters signal conduction in neurons by blocking the fast voltage-gated sodium (Na+) channels in the neuronal cell membrane responsible for signal propagation.","OnsetOfAction":"Rapid, generally within 1 to 5 minutes depending on the site of administration.","DurationOfAction":"Varies by route of administration (local: 30 to 60 minutes; intravenous: up to 2 hours).","PeakPlasmaConcentration":"Achieved rapidly after IV administration; depends on administration method and dosage.","Indications":["Local anesthesia","Ventricular arrhythmias","Pain management (patch)"],"RoutesOfAdministration":"Topical, intravenous, subcutaneous, epidural, transdermal patch","DosageForms":["Injection","Cream","Patch","Gel","Solution"],"StrengthsOfDosageForms":["Injection: 0.5%, 1%, 2%","Cream: 4%","Patch: 5%"],"Pharmacokinetics":{"Absorption":"Well absorbed following parenteral and topical administration.","Distribution":"Widely distributed; crosses blood-brain and placental barriers; protein binding approximately 60-80%.","Metabolism":"Metabolized primarily by the liver via CYP450, particularly CYP3A4 and CYP1A2.","Excretion":"Excreted primarily by the kidneys; approximately 90% as metabolites and 10% unchanged."},"SideEffects":["Dizziness","Nausea","Hypotension","Bradycardia","Seizures (in severe cases)"],"DrugInteractions":["Class I and III antiarrhythmics","Beta-blockers","Cimetidine","Phenytoin"],"Contraindications":"Known hypersensitivity to local anesthetics of the amide type, severe heart block, severe liver dysfunction.","ChemicalStructure":{"MolecularFormula":"C14H22N2O","MolecularWeight":"234.34 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B; should be used during pregnancy only if clearly needed.","PediatricUse":"The safety and effectiveness of lidocaine have been established in pediatric patients.","GeriatricUse":"Caution advised; may require dosage adjustment due to decreased renal and hepatic function.","HepaticImpairment":"Use with caution; increased risk of systemic toxicity.","RenalImpairment":"Use with caution; metabolites may accumulate."},"StorageAndHandling":"Store below 25°C (77°F); avoid freezing. Keep away from heat and light."},{"GenericName":"Diclofenac","BrandNames":["Voltaren Gel","Pennsaid"],"DrugClass":"Nonsteroidal Anti-inflammatory Drug (NSAID)","MechanismOfAction":"Diclofenac works by inhibiting the enzyme cyclooxygenase (COX), which results in a decrease in the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. This leads to its anti-inflammatory, analgesic, and antipyretic effects.","Pharmacodynamics":"The main effect of diclofenac is the reduction of inflammation and pain in conditions such as arthritis. By blocking COX enzymes, it helps prevent the synthesis of prostaglandins, which are mediators of inflammation.","OnsetOfAction":"Local relief of pain starts within a few hours of application on the skin. Full effect may take up to 7 days.","DurationOfAction":"Typically lasts for 12 hours.","PeakPlasmaConcentration":"There is minimal systemic absorption, and peak plasma concentrations are usually not clinically significant due to the topical administration route.","Indications":["Osteoarthritis pain in joints amenable to topical treatment, such as the knees or hands"],"RoutesOfAdministration":"Topical","DosageForms":["Topical gel","Topical solution"],"StrengthsOfDosageForms":["1% gel","2% topical solution"],"Pharmacokinetics":{"Absorption":"Absorbed through the skin, with approximately 6% of the applied dose reaching systemic circulation.","Distribution":"Topically administered diclofenac remains mostly at the site of application with minimal systemic distribution.","Metabolism":"Primarily metabolized in the liver.","Excretion":"Excreted mainly in the urine; some is excreted in the bile."},"SideEffects":["Application site redness and rash","Pruritus (itching)","Dry skin","Systemic side effects are rare due to minimal absorption but can include gastrointestinal issues similar to orally administered NSAIDs if absorbed systemically."],"DrugInteractions":["Oral NSAIDs","Anticoagulants","ACE inhibitors","Diuretics"],"Contraindications":"Patients with a known hypersensitivity to diclofenac or other NSAIDs. It should not be applied to open wounds, infections, or exfoliative dermatitis.","ChemicalStructure":{"MolecularFormula":"C14H11Cl2NO2","MolecularWeight":"296.15 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Not recommended due to potential risk to the developing fetus, especially in the third trimester.","PediatricUse":"Safety and efficacy have not been established in pediatric patients.","GeriatricUse":"Caution is advised in elderly patients considering the potential for systemic effects and risk of side effects.","HepaticImpairment":"Use with caution in patients with hepatic impairment as systemic exposure increases.","RenalImpairment":"Caution is advised; however, systemic exposure is limited with topical use."},"StorageAndHandling":"Store at room temperature away from moisture and heat. Keep the tube tightly closed when not in use."},{"GenericName":"Cortisone","BrandNames":["Cortone Acetate"],"DrugClass":"Corticosteroid","MechanismOfAction":"Cortisone is a corticosteroid that acts mainly by reducing inflammation and influencing the immune system. It mimics the action of cortisol by binding to glucocorticoid receptors, which then modify the expression of numerous genes, leading to its anti-inflammatory, immunosuppressive, and metabolic effects.","Pharmacodynamics":"Cortisone reduces inflammation by inhibiting the release of arachidonic acid through the phospholipase A2 lipocortins and inhibiting the expression of COX enzymes. It decreases the activity of the immune system by reducing the production of inflammatory mediators and immune cells.","OnsetOfAction":"Cortisone requires hepatic conversion to become active (cortisol), so its onset of action can vary but typically occurs within a few hours.","DurationOfAction":"24-48 hours","PeakPlasmaConcentration":"Around 1-2 hours after oral administration","Indications":["Adrenocortical insufficiency","Rheumatoid arthritis","Allergic conditions","Skin diseases","Endocrine disorders","Eye diseases","Respiratory diseases","Hemotologic disorders","Neoplastic diseases","GI diseases"],"RoutesOfAdministration":"Oral, intramuscular","DosageForms":["Tablet","Injection"],"StrengthsOfDosageForms":["25 mg tablet","100 mg/mL injection"],"Pharmacokinetics":{"Absorption":"Cortisone acetate is well absorbed from the gastrointestinal tract.","Distribution":"Widely distributed in the body; crosses the placenta and enters breast milk.","Metabolism":"Cortisone is converted in the liver to its active metabolite, cortisol.","Excretion":"Excreted primarily in urine as metabolites."},"SideEffects":["Increased appetite","Weight gain","Insomnia","Mood changes","Increased risk of infection","Hypertension","Hyperglycemia","Osteoporosis with long-term use"],"DrugInteractions":["Nonsteroidal anti-inflammatory drugs (NSAIDs)","Antidiabetic agents","Vaccines","Cyclosporine"],"Contraindications":"Systemic fungal infections, allergy to cortisone or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C21H28O5","MolecularWeight":"360.44 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Cortisone can be used in pregnancy if clearly needed but use should be cautiously justified with medical oversight.","PediatricUse":"Growth and development should be monitored in pediatric use, as prolonged use may affect growth.","GeriatricUse":"Use in elderly patients should be cautious due to potential for increased side effects.","HepaticImpairment":"Dose adjustment may be necessary based on hepatic function.","RenalImpairment":"No specific dosage adjustments are provided but care should be taken with excretion impacted patients."},"StorageAndHandling":"Store at controlled room temperature, away from moisture and heat. Dispose of in accordance with local regulations."},{"GenericName":"Insulin Degludec","BrandNames":["Tresiba"],"DrugClass":"Long-acting insulin analog","MechanismOfAction":"Insulin degludec lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to insulin receptors on muscle and fat cells, facilitating the uptake of glucose into these cells, and inhibits glucose output from the liver.","Pharmacodynamics":"Insulin degludec provides a prolonged and consistent insulin action lasting up to 42 hours, which contributes to steady glucose control with once-daily dosing. It reduces blood glucose levels by facilitating cellular uptake of glucose.","OnsetOfAction":"45 minutes to 1 hour","DurationOfAction":"As long as 42 hours","PeakPlasmaConcentration":"Steady state is reached after 3-4 days of daily dosing with minimal peak effect, providing a flat profile.","Indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Injection solution"],"StrengthsOfDosageForms":["100 units/mL (U-100)","200 units/mL (U-200)"],"Pharmacokinetics":{"Absorption":"Slow and prolonged absorption with a half-life of approximately 25 hours.","Distribution":"Vd is similar to the distribution of circulating insulin, typically limited distribution outside the blood volume.","Metabolism":"Metabolized by proteolytic enzymes to peptide fragments and amino acids.","Excretion":"Minor amounts excreted unchanged in urine."},"SideEffects":["Hypoglycemia","Injection site reactions","Allergic reactions","Lipodystrophy","Weight gain"],"DrugInteractions":["Beta-blockers","Clonidine","Alcohol","Monoamine Oxidase Inhibitors (MAOIs)","Thiazolidinediones"],"Contraindications":"Hypersensitivity to insulin degludec or any of its excipients. Not to be used during episodes of hypoglycemia.","ChemicalStructure":{"MolecularFormula":"C274H411N65O81S6","MolecularWeight":"6103.98 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use during pregnancy only if the potential benefit justifies the potential risk to the fetus; it is classified as FDA Pregnancy Category C.","PediatricUse":"Safety and effectiveness have been established in pediatric patients aged one year and older with type 1 and type 2 diabetes.","GeriatricUse":"Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.","HepaticImpairment":"No differences in safety and efficacy were observed. Monitor blood glucose levels closely.","RenalImpairment":"As with any insulin, dosage should be individualized based on patient needs and renal function. Close monitoring advised."},"StorageAndHandling":"Store in a refrigerator (36°F to 46°F or 2°C to 8°C). Do not freeze or expose to direct light or heat. Once in use, the FlexTouch pen can be kept at room temperature below 86°F (30°C) and used within 8 weeks."},{"GenericName":"Exenatide","BrandNames":["Byetta","Bydureon"],"DrugClass":"Glucagon-like peptide-1 receptor agonist (GLP-1 RA)","MechanismOfAction":"Exenatide works by mimicking the action of the incretin hormone GLP-1 which increases insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.","Pharmacodynamics":"Exenatide enhances glucose-dependent insulin secretion from the pancreas, suppresses inappropriate glucagon release, and slows gastric emptying to improve postprandial and fasting blood glucose levels.","OnsetOfAction":"Within 2 hours for immediate-release forms","DurationOfAction":"12-24 hours for immediate-release forms","PeakPlasmaConcentration":"2 hours for immediate-release forms","Indications":["Type 2 Diabetes Mellitus"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Immediate-release injection (pen)","Extended-release injection (pen)"],"StrengthsOfDosageForms":["5 mcg/dose (immediate-release)","10 mcg/dose (immediate-release)","2 mg (extended-release)"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following subcutaneous administration","Distribution":"Widely distributed with a volume of distribution of approximately 28.3 L","Metabolism":"Not extensively metabolized","Excretion":"Primarily excreted through the kidneys"},"SideEffects":["Nausea","Vomiting","Diarrhea","Hypoglycemia","Injection site reactions"],"DrugInteractions":["Increased risk of hypoglycemia with sulfonylureas or insulin","May delay the absorption of orally administered drugs"],"Contraindications":"Hypersensitivity to exenatide or any of its components, personal or family history of medullary thyroid carcinoma","ChemicalStructure":{"MolecularFormula":"C184H282N50O60S","MolecularWeight":"4186.60 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if potential benefit justifies the potential risk to the fetus","PediatricUse":"Safety and efficacy not established","GeriatricUse":"No notable differences in safety or efficacy; caution with renal function","HepaticImpairment":"No specific dosage adjustments, caution advised","RenalImpairment":"Not recommended in patients with severe renal impairment or end-stage renal disease"},"StorageAndHandling":"Stored refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze; discard if frozen."},{"GenericName":"Canagliflozin","BrandNames":["Invokana"],"DrugClass":"SGLT2 inhibitor (Sodium-glucose co-transporter-2 inhibitor)","MechanismOfAction":"Canagliflozin inhibits SGLT2, a transporter responsible for reabsorbing glucose from the proximal renal tubules. By inhibiting SGLT2, canagliflozin reduces renal glucose reabsorption, increases urinary glucose excretion, and lowers blood glucose levels.","Pharmacodynamics":"Canagliflozin lowers blood glucose levels by preventing glucose reabsorption in the kidneys, thereby increasing glucose excretion in the urine. It also leads to reductions in body weight and systolic blood pressure.","OnsetOfAction":"Within a few hours after dosing.","DurationOfAction":"Approximately 24 hours, allowing for once-daily dosing.","PeakPlasmaConcentration":"1 to 2 hours post-dose.","Indications":["Type 2 Diabetes Mellitus"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["100 mg","300 mg"],"Pharmacokinetics":{"Absorption":"Canagliflozin is rapidly absorbed with a bioavailability of approximately 65%.","Distribution":"The volume of distribution of canagliflozin is approximately 119 liters.","Metabolism":"Metabolized primarily by UGT1A9 and UGT2B4 to inactive O-glucuronide metabolites.","Excretion":"Excreted mainly via feces (41.5%) and urine (33%)."},"SideEffects":["Urinary tract infections","Genital mycotic infections","Increased urination","Hypotension","Hypoglycemia (when used with insulin or insulin secretagogues)","Electrolyte disturbances"],"DrugInteractions":["Diuretics: increased risk of volume depletion","Insulin and insulin secretagogues: increased risk of hypoglycemia","Rifampin: may decrease canagliflozin exposure","Digoxin","St. John's Wort"],"Contraindications":"Severe renal impairment (eGFR less than 30 mL/min/1.73 m2), end-stage renal disease, or patients on dialysis.","ChemicalStructure":{"MolecularFormula":"C24H25FO5S","MolecularWeight":"444.52 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women. Canagliflozin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No overall differences in effectiveness or safety were observed between older and younger patients.","HepaticImpairment":"Not recommended in patients with severe hepatic impairment.","RenalImpairment":"Dose adjustment is recommended based on renal function."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from moisture."},{"GenericName":"Empagliflozin","BrandNames":["Jardiance"],"DrugClass":"Sodium-glucose co-transporter 2 (SGLT2) inhibitor","MechanismOfAction":"Empagliflozin inhibits the sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, reducing reabsorption of filtered glucose from the tubular lumen and lowering the renal threshold for glucose, and thereby increases urinary glucose excretion.","Pharmacodynamics":"By increasing urinary glucose excretion, empagliflozin reduces plasma glucose concentrations. It also contributes to a mild diuretic effect due to natriuresis caused by the inhibition of sodium reabsorption in the proximal tubule.","OnsetOfAction":"Empagliflozin starts working within 1-2 hours after oral administration.","DurationOfAction":"The glucose-lowering effect lasts for approximately 24 hours with once-daily dosing.","PeakPlasmaConcentration":"Peak plasma concentrations are typically reached 1.5 hours after dosing.","Indications":["Type 2 diabetes mellitus","Cardiovascular risk reduction in adults with type 2 diabetes and known cardiovascular disease","Chronic heart failure with reduced ejection fraction"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["10 mg","25 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed with an estimated oral bioavailability of 78%.","Distribution":"The volume of distribution is approximately 73.8 L, and protein binding is 86%.","Metabolism":"Primarily metabolized by glucuronidation; minor contribution from CYP enzymes.","Excretion":"Almost exclusively eliminated by renal excretion, with approximately 54.4% excreted unchanged in urine."},"SideEffects":["Urinary tract infections","Female genital mycotic infections","Hypoglycemia (when used with insulin or insulin secretagogues)","Increased urination","Dehydration","Ketoacidosis","Acute kidney injury"],"DrugInteractions":["Diuretics","Insulin and insulin secretagogues","Rifampin","Barbiturates","Ritanovir"],"Contraindications":"Severe renal impairment, end-stage renal disease, or dialysis","ChemicalStructure":{"MolecularFormula":"C23H27ClO7","MolecularWeight":"450.91 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Not recommended due to potential risk to the fetus based on animal data.","PediatricUse":"Safety and efficacy have not been established in pediatric patients.","GeriatricUse":"No overall differences in effectiveness or safety compared to younger adults, but greater sensitivity of some older individuals cannot be ruled out.","HepaticImpairment":"Mild to moderate hepatic impairment does not affect exposure significantly; use with caution.","RenalImpairment":"Dose adjustment needed for moderate renal impairment; not recommended in severe renal impairment."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and light."},{"GenericName":"Linagliptin","BrandNames":["Tradjenta"],"DrugClass":"Dipeptidyl peptidase-4 (DPP-4) inhibitor","MechanismOfAction":"Linagliptin inhibits the enzyme DPP-4, which is responsible for breaking down incretin hormones. Incretins such as GLP-1 increase insulin synthesis and secretion from pancreatic beta cells in the presence of glucose and lower glucagon secretion from alpha cells, leading to lowered blood glucose levels.","Pharmacodynamics":"By inhibiting DPP-4, linagliptin increases the levels of active incretin hormones, thereby increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner, leading to a reduction of fasting and postprandial glucose levels.","OnsetOfAction":"Within 1 week","DurationOfAction":"Approximately 24 hours","PeakPlasmaConcentration":"1.5 hours after oral administration","Indications":["Type 2 diabetes mellitus (as an adjunct to diet and exercise to improve glycemic control)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["5 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed with a bioavailability of approximately 30%.","Distribution":"Extensively distributed to the tissues, with a volume of distribution of approximately 1110 liters.","Metabolism":"Minimal metabolism; primarily excreted unchanged.","Excretion":"Approximately 80% excreted unchanged via feces and urine."},"SideEffects":["Nasopharyngitis","Hyperlipidemia","Cough","Elevated liver enzymes","Hypersensitivity reactions"],"DrugInteractions":["Rifampin may decrease linagliptin exposure","Other hypoglycemic agents may enhance hypoglycemic effect"],"Contraindications":"Hypersensitivity to linagliptin","ChemicalStructure":{"MolecularFormula":"C25H28N8O2","MolecularWeight":"472.55 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects.","HepaticImpairment":"No dosage adjustment is required in patients with hepatic impairment.","RenalImpairment":"No dosage adjustment is required in patients with renal impairment."},"StorageAndHandling":"Store at room temperature between 15°C to 30°C (59°F to 86°F). Keep the bottle tightly closed when not in use."},{"GenericName":"Dapagliflozin","BrandNames":["Farxiga"],"DrugClass":"Sodium-glucose co-transporter 2 (SGLT2) inhibitor","MechanismOfAction":"Dapagliflozin inhibits SGLT2 in the proximal renal tubules, which reduces reabsorption of filtered glucose from the tubular lumen and lowers the renal threshold for glucose, resulting in increased urinary excretion of glucose.","Pharmacodynamics":"Dapagliflozin lowers plasma glucose levels by causing glucosuria. It also induces osmotic diuresis, leading to mild reductions in blood pressure.","OnsetOfAction":"Within 1-2 hours after dosing","DurationOfAction":"Approximately 24 hours","PeakPlasmaConcentration":"1-2 hours post-dose","Indications":["Type 2 diabetes mellitus","Heart failure","Chronic kidney disease"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["5 mg","10 mg"],"Pharmacokinetics":{"Absorption":"Dapagliflozin is rapidly absorbed from the gastrointestinal tract following oral administration.","Distribution":"Volume of distribution is approximately 118 liters.","Metabolism":"Metabolized primarily by UGT1A9 to dapagliflozin 3-O-glucuronide.","Excretion":"Excreted primarily in urine (75%) and to a lesser extent in feces (21%)."},"SideEffects":["Genital infections","Urinary tract infections","Polyuria","Dyslipidemia","Volume depletion"],"DrugInteractions":["Diuretics (enhanced diuretic effect)","Insulin and insulin secretagogues (increased risk of hypoglycemia)"],"Contraindications":"Severe renal impairment, end-stage renal disease, or patients on dialysis.","ChemicalStructure":{"MolecularFormula":"C21H25ClO6","MolecularWeight":"408.88 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","HepaticImpairment":"Mild or moderate hepatic impairment does not require dose adjustment, but caution is advised.","RenalImpairment":"Not recommended in patients with severe renal impairment."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F)."},{"GenericName":"Ertugliflozin","BrandNames":["Steglatro"],"DrugClass":"Sodium-glucose co-transporter 2 (SGLT2) inhibitor","MechanismOfAction":"Ertugliflozin inhibits SGLT2 in the proximal renal tubules, reducing reabsorption of filtered glucose from the tubular lumen and lowering the renal threshold for glucose, leading to increased urinary glucose excretion.","Pharmacodynamics":"Ertugliflozin leads to caloric loss through glucose excretion and osmotic diuresis, which can result in mild diuresis and potential reductions in blood pressure, in addition to its glucose-lowering effects.","OnsetOfAction":"Within 1 week of initiation of therapy","DurationOfAction":"Ertugliflozin exerts its effects continuously with daily dosing, and the duration of action is maintained with regular use.","PeakPlasmaConcentration":"Peak plasma concentrations are typically reached approximately 1 hour after oral administration.","Indications":["Type 2 diabetes mellitus"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["5 mg","15 mg"],"Pharmacokinetics":{"Absorption":"Ertugliflozin is rapidly absorbed with peak plasma concentrations reached approximately 1 hour post-dose.","Distribution":"The mean steady-state volume of distribution is 85.5 liters. High plasma protein binding of around 93.6%.","Metabolism":"Metabolized primarily via glucuronidation by UGT1A9 and UGT2B7 to inactive glucuronides.","Excretion":"Primarily excreted in feces (40.9%) and urine (50.2%) as unchanged drug; minor excretion as metabolites."},"SideEffects":["Hypoglycemia (when used with insulin or insulin secretagogues)","Genital mycotic infections","Urinary tract infections","Increased urination","Dizziness","Dehydration","Hypotension"],"DrugInteractions":["Diuretics (may enhance potential for dehydration and hypotension)","Insulin and insulin secretagogues (increased risk of hypoglycemia)","Rifampin (may decrease plasma levels of ertugliflozin)"],"Contraindications":"Severe renal impairment, end-stage renal disease, or dialysis","ChemicalStructure":{"MolecularFormula":"C22H25ClO7","MolecularWeight":"436.889 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness have been observed in elderly patients compared to younger patients, but greater sensitivity of some older individuals cannot be ruled out.","HepaticImpairment":"Use with caution, especially in severe hepatic impairment as clinical data is limited.","RenalImpairment":"Contraindicated in patients with severe renal impairment, end-stage renal disease, or on dialysis."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)."},{"GenericName":"Hydrocortisone","BrandNames":["Cortef","Solu-Cortef","Anucort-HC","Proctocort"],"DrugClass":"Corticosteroid","MechanismOfAction":"Hydrocortisone is a cortisol replacement that exerts its effect by binding to glucocorticoid receptors, influencing gene expression, and modulating the immune response as well as metabolic functions.","Pharmacodynamics":"Hydrocortisone is the active form of cortisol, which acts to reduce inflammation and modify the body's immune response.","OnsetOfAction":"Topical application: approximately 3 to 5 minutes; Oral administration: approximately 1 hour; Intravenous administration: immediate.","DurationOfAction":"Varies with route: Topical application: several hours; Oral and IV: 8-12 hours","PeakPlasmaConcentration":"Oral: Approximately 1.5 hours","Indications":["Adrenal insufficiency","Inflammatory and allergic conditions","Asthma","Arthritis","Dermatitis","Ulcerative colitis"],"RoutesOfAdministration":"Oral, topical, rectal, intravenous (IV), and intramuscular (IM)","DosageForms":["Tablets","Creams","Enemas","Injectable solutions","Suppositories"],"StrengthsOfDosageForms":["Tablets: 5 mg, 10 mg, 20 mg","Creams: 1%, 2.5%","Injectable solutions: 100 mg/vial","Suppositories: 25 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed via oral and rectal routes; limited absorption via topical route","Distribution":"Widely distributed throughout the body, crosses the placenta, and is excreted in breast milk","Metabolism":"Primarily hepatic","Excretion":"Urine, mainly as metabolites"},"SideEffects":["Increased appetite","Weight gain","Mood changes","Hypertension","Hyperglycemia","Osteoporosis","Increased risk of infection"],"DrugInteractions":["Warfarin","NSAIDs","Live vaccines","Rifampin","Phenytoin"],"Contraindications":"Systemic fungal infections, hypersensitivity to corticosteroids or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C21H30O5","MolecularWeight":"362.47 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; may cause fetal harm based on animal studies.","PediatricUse":"May affect growth; use lowest effective dose.","GeriatricUse":"Use with caution, especially in long-term therapy, due to increased risk of side effects.","HepaticImpairment":"Dose adjustment may be necessary.","RenalImpairment":"Generally no adjustment needed, but use with caution."},"StorageAndHandling":"Store at room temperature, protect from light and moisture. Do not freeze the injectable solution."},{"GenericName":"Chlorpheniramine","BrandNames":["Chlor-Trimeton","Aller-Chlor","Chlorphen-12"],"DrugClass":"Antihistamine","MechanismOfAction":"Chlorpheniramine works as a histamine H1 receptor antagonist by blocking the action of histamine, a substance in the body that causes allergic symptoms such as sneezing, itching, watery eyes, and runny nose.","Pharmacodynamics":"Chlorpheniramine alleviates allergy symptoms through its antihistaminic activity. It reduces the effects of the natural chemical histamine in the body.","OnsetOfAction":"Within 30 minutes to 1 hour.","DurationOfAction":"4 to 6 hours for immediate-release formulations.","PeakPlasmaConcentration":"Achieved within 2 to 6 hours after administration.","Indications":["Allergic rhinitis","Common cold","Urticaria","Allergic conjunctivitis"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Syrup","Extended-release tablets"],"StrengthsOfDosageForms":["4 mg tablet","12 mg extended-release tablet","2 mg/5 mL syrup"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Distributed widely throughout the body; approximately 70% bound to plasma proteins.","Metabolism":"Metabolized in the liver.","Excretion":"Primarily excreted in the urine."},"SideEffects":["Drowsiness","Dry mouth","Dizziness","Nausea","Constipation"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Central nervous system depressants","Alcohol","Other anticholinergic drugs"],"Contraindications":"Hypersensitivity to chlorpheniramine or other antihistamines.","ChemicalStructure":{"MolecularFormula":"C16H19ClN2","MolecularWeight":"274.788 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Chlorpheniramine is generally considered safe; however, it should be used only if clearly needed.","PediatricUse":"Use with caution in children; precise dosing is necessary.","GeriatricUse":"May require dose adjustments due to increased sensitivity.","HepaticImpairment":"Use with caution; adjustment may be needed.","RenalImpairment":"Use with caution; adjustment may be needed."},"StorageAndHandling":"Keep in a cool, dry place away from light and moisture. Keep out of reach of children."},{"GenericName":"Pseudoephedrine","BrandNames":["Sudafed","Genaphed","Advil Cold and Sinus","Nexafed"],"DrugClass":"Decongestant","MechanismOfAction":"Pseudoephedrine is a sympathomimetic amine that acts on alpha-adrenergic receptors to constrict blood vessels, leading to reduced nasal congestion by decreasing blood flow to the nasal mucosa.","Pharmacodynamics":"Pseudoephedrine reduces nasal congestion by vasoconstriction and causes an increase in nasal airflow, providing symptomatic relief from congestion associated with colds, allergies, or sinusitis.","OnsetOfAction":"30 minutes","DurationOfAction":"4 to 6 hours for immediate-release formulations","PeakPlasmaConcentration":"1 to 3 hours after administration (immediate-release)","Indications":["Nasal congestion","Sinus congestion","Eustachian tube congestion"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Controlled-release tablets","Syrup"],"StrengthsOfDosageForms":["30 mg","60 mg","120 mg (extended-release)","240 mg (extended-release)"],"Pharmacokinetics":{"Absorption":"Well absorbed from the gastrointestinal tract.","Distribution":"Widely distributed throughout the body.","Metabolism":"Minimal hepatic metabolism.","Excretion":"Excreted primarily in the urine, with about 43% to 96% unchanged; renal clearance rate varies with urinary pH."},"SideEffects":["Insomnia","Nervousness","Dizziness","Headache","Tachycardia","Nausea"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Antihypertensive medications","Other sympathomimetics"],"Contraindications":"Contraindicated in patients receiving MAO inhibitors or within 14 days of stopping such treatment.","ChemicalStructure":{"MolecularFormula":"C10H15NO","MolecularWeight":"165.23 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; limited data available, potential risks should be considered against potential benefits.","PediatricUse":"Suitable for children; dosages are based on age and weight.","GeriatricUse":"Use with caution; increased sensitivity in some older adults.","HepaticImpairment":"No specific dosage adjustment needed, but use with caution.","RenalImpairment":"Use with caution; dosage adjustment may be necessary."},"StorageAndHandling":"Store at room temperature away from moisture and heat. Keep out of reach of children."},{"GenericName":"Phentermine","BrandNames":["Adipex-P","Lomaira"],"DrugClass":"Sympathomimetic amine anorectic","MechanismOfAction":"Phentermine stimulates the release of norepinephrine and dopamine, thereby increasing synaptic concentrations in the central nervous system. This leads to reduced appetite, contributing to weight loss.","Pharmacodynamics":"Phentermine amplifies the effects of catecholamines, leading to appetite suppression, increased blood pressure, and occasionally increased heart rate.","OnsetOfAction":"3-4.4 hours","DurationOfAction":"4-14 hours","PeakPlasmaConcentration":"3-4.4 hours after oral administration","Indications":["Short-term weight management","Obesity","Weight loss"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Capsule","Dispersible tablet"],"StrengthsOfDosageForms":["37.5 mg (capsule/tablet)","15 mg (dispersible tablet)"],"Pharmacokinetics":{"Absorption":"Readily absorbed from the gastrointestinal tract.","Distribution":"Widely distributed throughout the body and crosses the blood-brain barrier.","Metabolism":"Primarily hepatic, involving hydroxylation and N-oxidation.","Excretion":"Excreted primarily in the urine. Half-life is approximately 19-24 hours."},"SideEffects":["Increased blood pressure","Palpitations","Insomnia","Dry mouth","Nervousness","Constipation"],"DrugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Other sympathomimetic agents","Corticosteroids","Amphetamines"],"Contraindications":"Contraindicated in individuals with cardiovascular disease, hyperthyroidism, glaucoma, and during or within 14 days following the taking of MAOIs.","ChemicalStructure":{"MolecularFormula":"C10H15N","MolecularWeight":"149.233 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category X. Use is contraindicated during pregnancy due to potential for fetal harm.","PediatricUse":"Safety and effectiveness have not been established in patients under 16 years of age.","GeriatricUse":"Use with caution, adjusting for potential increased sensitivity to CNS effects and impact on existing medical conditions.","HepaticImpairment":"Use with caution due to hepatic metabolism; clinical monitoring recommended.","RenalImpairment":"Use with caution; dose adjustment might be necessary due to renal excretion."},"StorageAndHandling":"Store at room temperature between 20° to 25°C (68° to 77°F). Protect from moisture and light."},{"GenericName":"Cyanocobalamin","BrandNames":["Nascobal","Calomist","B-12 Compliance","Cobal 1000"],"DrugClass":"Vitamin B12","MechanismOfAction":"Cyanocobalamin is a synthetic form of vitamin B12, which is required for the maintenance of normal erythropoiesis, the integrity of the nervous system, and a wide range of metabolic functions, including fat and carbohydrate metabolism and protein synthesis. It acts as a coenzyme in the synthesis of DNA and cell division and is essential for the formation of myelin sheath in the nervous system.","Pharmacodynamics":"Vitamin B12 is essential for the proper functioning and development of brain and nerve cells, and for the production of red blood cells. Cyanocobalamin supports energy production and helps decrease overall fatigue and weakness.","OnsetOfAction":"The onset of action can vary, but therapeutic effects in megaloblastic anemia are usually observed within a few days; clinical effects may take a few weeks.","DurationOfAction":"The duration of effect typically extends as long as adequate plasma levels are maintained.","PeakPlasmaConcentration":"Peak plasma concentrations are typically achieved within 1-2 hours of oral ingestion.","Indications":["Vitamin B12 deficiency","Pernicious anemia","Vitamin B12 malabsorption syndromes"],"RoutesOfAdministration":"Oral, Intramuscular, Intranasal","DosageForms":["Tablet","Injection","Nasal spray"],"StrengthsOfDosageForms":["Tablet: 1000 mcg","Injection: 1000 mcg/mL","Nasal spray: 500 mcg/0.1 mL"],"Pharmacokinetics":{"Absorption":"Approximately 10% of oral dose is absorbed by the terminal ileum when intrinsic factor is available.","Distribution":"Widely distributed to the liver, bone marrow, and other tissues.","Metabolism":"Undergoes metabolic conversion to active forms such as methylcobalamin and adenosylcobalamin.","Excretion":"Excreted mainly in urine, with approximately 50% of a dose being excreted within 24 hours."},"SideEffects":["Headache","Itching","Swelling","Diarrhea","Nausea","Vomiting"],"DrugInteractions":["Chloramphenicol","Proton pump inhibitors","Metformin"],"Contraindications":"Hypersensitivity to cobalt and/or vitamin B12.","ChemicalStructure":{"MolecularFormula":"C63H88CoN14O14P","MolecularWeight":"1355.37 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Generally considered safe to use during pregnancy as deficiency can cause harm.","PediatricUse":"Safe for children, especially those with dietary deficiencies or absorption issues.","GeriatricUse":"Use with caution as absorption may be reduced due to age-related changes.","HepaticImpairment":"No specific dosage adjustment is necessary.","RenalImpairment":"No specific dosage adjustment is necessary."},"StorageAndHandling":"Cyanocobalamin should be stored at room temperature, away from light and moisture. Do not freeze. Keep out of reach of children."},{"GenericName":"Niacin","BrandNames":["Niaspan","Niacor","Slo-Niacin"],"DrugClass":"Vitamin B3, Antihyperlipidemic Agent","MechanismOfAction":"Niacin is a water-soluble B vitamin which functions in the body as a component of coenzymes facilitating lipid and carbohydrate metabolism. At pharmacologic doses, niacin inhibits hepatic synthesis of VLDL and LDL. It also increases HDL levels.","Pharmacodynamics":"Niacin lowers LDL and triglyceride levels while raising HDL cholesterol in the blood. Its effects on lipid profiles can help reduce the risk of atherosclerosis.","OnsetOfAction":"Effects can be seen within hours, but full effects on lipid levels may take several weeks.","DurationOfAction":"24 hours with extended-release formulation; 2 to 4 hours with immediate-release forms.","PeakPlasmaConcentration":"1 to 4 hours for extended-release; 30 to 60 minutes for immediate-release","Indications":["Dyslipidemia","Hypertriglyceridemia","Pellagra (niacin deficiency)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Capsule"],"StrengthsOfDosageForms":["500 mg","750 mg","1000 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed, rate varies by formulation (immediate vs. extended-release)","Distribution":"Widely distributed in body tissues","Metabolism":"Primarily hepatic, with two main pathways: conjugative and nicotinamide metabolism","Excretion":"Excreted primarily in urine"},"SideEffects":["Flushing","Pruritus","Gastrointestinal upset","Hepatotoxicity","Hyperglycemia"],"DrugInteractions":["Statins","Antihypertensive agents","Aspirin","Bile acid sequestrants"],"Contraindications":"Liver disease, active peptic ulcer disease, arterial bleeding","ChemicalStructure":{"MolecularFormula":"C6H5NO2","MolecularWeight":"123.11 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C; use only if potential benefit justifies risk to fetus.","PediatricUse":"Safety and effectiveness not established in pediatric patients.","GeriatricUse":"Dose selection should be cautious due to higher risk of adverse effects.","HepaticImpairment":"Contraindicated in patients with significant or unexplained hepatic dysfunction.","RenalImpairment":"Use with caution; potential for increased adverse effects."},"StorageAndHandling":"Store at room temperature, protect from light and moisture."},{"GenericName":"Iron Supplements","BrandNames":["Feosol","Feraheme","Fer-In-Sol","Ferrlecit","Slow Fe"],"DrugClass":"Mineral Supplement","MechanismOfAction":"Iron supplements supply elemental iron to the body. Iron is a critical component of hemoglobin in red blood cells and myoglobin in muscle cells. It is essential for oxygen transport and utilization in the body. It also plays a role in various other cellular processes.","Pharmacodynamics":"Iron supplements increase the levels of iron in the body and replenish iron stores. This supports hemoglobin production and the treatment of anemia caused by iron deficiency.","OnsetOfAction":"Variable; may take several days to weeks to notice an improvement in symptoms of iron deficiency anemia.","DurationOfAction":"Variable; depends on the dosage form and individual patient.","PeakPlasmaConcentration":"Approximately 2 to 4 hours after oral administration, depending on the formulation and presence of food.","Indications":["Iron deficiency anemia","Prevention of iron deficiency in high-risk populations, such as pregnant women or individuals with chronic blood loss"],"RoutesOfAdministration":"Oral, Intravenous","DosageForms":["Tablets","Liquid solutions","Capsules","Injectable forms"],"StrengthsOfDosageForms":["Tablets: 65 mg elemental iron (as ferrous sulfate)","Capsules: 100 mg elemental iron","Liquid solutions: 44 mg elemental iron per 5 mL","Injectable forms: Varies"],"Pharmacokinetics":{"Absorption":"Iron absorption occurs primarily in the duodenum and proximal jejunum, and it is enhanced by acidic conditions.","Distribution":"Iron is distributed throughout the body, mostly bound to transferrin in the plasma.","Metabolism":"Iron itself is not metabolized. It is utilized in hemoglobin synthesis and stored in the liver, spleen, and bone marrow.","Excretion":"Iron is excreted in minimal amounts via feces, urine, and sweat."},"SideEffects":["Gastrointestinal upset","Constipation","Diarrhea","Nausea","Dark stools","Metallic taste"],"DrugInteractions":["Antacids can reduce iron absorption","Tetracyclines and quinolone antibiotics can have reduced efficacy if taken with iron supplements","Caffeine and calcium can reduce iron absorption","Vitamin C can increase the absorption of iron"],"Contraindications":"Known hypersensitivity to iron products; Hemochromatosis or hemosiderosis; Active infections not known to be associated with iron deficiency anemia.","ChemicalStructure":{"MolecularFormula":"Fe","MolecularWeight":"55.85 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Iron is generally considered safe and often necessary during pregnancy to prevent iron deficiency anemia.","PediatricUse":"Dosage should be adjusted based on age, weight, and severity of deficiency. Overdose in children can be harmful.","GeriatricUse":"Careful monitoring and dose adjustments may be necessary due to altered iron metabolism and absorption.","HepaticImpairment":"No specific adjustments, but caution is advised in patients with liver dysfunction.","RenalImpairment":"No specific adjustments, but patients should be monitored for iron overload."},"StorageAndHandling":"Keep in a cool, dry place away from light and moisture. Keep out of reach of children to prevent accidental overdose."},{"GenericName":"Lutein","BrandNames":["EyePromise Zeaxanthin + Lutein","Ocuvite","PreserVision Areds 2 Formula","Lutein Eye Complex","Nature's Way Lutein"],"DrugClass":"Carotenoid","MechanismOfAction":"Lutein acts as an antioxidant, filtering harmful high-energy blue wavelengths of light and helping to protect and maintain healthy cells in the eyes. It accumulates in the retina (macula and fovea), where it is believed to enhance visual performance and reduce the progression of age-related macular degeneration (AMD).","Pharmacodynamics":"Lutein is known to enhance the optical density of the macular pigment. By absorbing blue light, lutein helps in reducing photo-oxidative damage to the retina.","OnsetOfAction":"The onset of action is not immediately quantifiable as Lutein is used as a supplement for long-term health, particularly in eye health, rather than having an immediate pharmacologic effect.","DurationOfAction":"The duration of action is chronic; it requires sustained intake to maintain effects.","PeakPlasmaConcentration":"Not specifically determined, as lutein is used as a dietary supplement and not as a drug with acute action.","Indications":["Age-related macular degeneration (AMD)","General eye health","Cataract prevention"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Capsules","Soft gels"],"StrengthsOfDosageForms":["5 mg","10 mg","20 mg"],"Pharmacokinetics":{"Absorption":"Absorbed in the small intestine. Bioavailability can be improved when taken with dietary fats.","Distribution":"Distributed to various tissues, primarily accumulating in the retina of the eye.","Metabolism":"Metabolized in the liver.","Excretion":"Excreted predominantly via the feces."},"SideEffects":["Rare allergic reactions","Skin yellowing (with high intake)","Potential gastrointestinal discomfort"],"DrugInteractions":["Cholestyramine","Colestipol","Olestra can reduce absorption","Zetia (Ezetimibe) may inhibit absorption"],"Contraindications":"Known hypersensitivity to lutein or any components in the supplement form.","ChemicalStructure":{"MolecularFormula":"C40H56O2","MolecularWeight":"568.87 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Considered likely safe when taken in the amounts found in foods. Caution is advised when taken as supplements.","PediatricUse":"Considered safe when taken in typical dietary amounts.","GeriatricUse":"Generally safe, often used to support vision in older adults.","HepaticImpairment":"No specific guidelines, but generally considered safe.","RenalImpairment":"No specific guidelines, but generally considered safe."},"StorageAndHandling":"Store in a cool, dry place, away from sunlight and heat. Keep out of reach of children."},{"GenericName":"Zinc sulfate (common Zinc supplement form)","BrandNames":["Orazinc","Solvezink","Zinc 50"],"DrugClass":"Mineral Supplement","MechanismOfAction":"Zinc acts as a cofactor for numerous enzymatic reactions, is involved in DNA synthesis, cell division, and protein synthesis, and contributes to immune function and wound healing.","Pharmacodynamics":"Zinc is an essential trace element that plays a crucial role in various biological processes. It supports immune function, protein synthesis, wound healing, DNA synthesis, and cell division. Zinc is also necessary for proper sense of taste and smell.","OnsetOfAction":"Varies, typically days to see improvements in conditions like zinc deficiency.","DurationOfAction":"Depends on the duration of deficiency correction and maintenance needs.","PeakPlasmaConcentration":"1 to 4 hours post-ingestion, depending on the formulation and presence of food.","Indications":["Zinc deficiency","Dietary supplement","Acrodermatitis enteropathica","Wilson's disease adjunct"],"RoutesOfAdministration":"Oral, Topical (for some formulations)","DosageForms":["Tablets","Capsules","Liquid","Lozenges"],"StrengthsOfDosageForms":["10 mg","25 mg","50 mg"],"Pharmacokinetics":{"Absorption":"Zinc is absorbed primarily in the jejunum, but absorption can be decreased by dietary phytates and fiber.","Distribution":"Widely distributed throughout the body, with high concentrations in muscle and bone.","Metabolism":"Not metabolized, but regulated in part by intestinal uptake and loss through intestinal secretions.","Excretion":"Primarily in feces, with minor amounts in urine and sweat."},"SideEffects":["Nausea","Vomiting","Diarrhea","Stomach pain"],"DrugInteractions":["Copper supplements (compete for absorption)","Iron supplements (compete for absorption)","Tetracyclines (reduce absorption of both)","Fluoroquinolones (reduce absorption of both)"],"Contraindications":"Hypersensitivity to zinc containing products.","ChemicalStructure":{"MolecularFormula":"ZnSO4 · 7H2O (Zinc sulfate heptahydrate)","MolecularWeight":"287.54 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Considered likely safe when used in recommended doses; higher doses should be used with caution.","PediatricUse":"Safe when used in recommended doses for deficiency.","GeriatricUse":"No specific problems reported with normal doses, but deficiency should be corrected with care.","HepaticImpairment":"Use with caution; specific data not available but metabolism is not liver-dependent.","RenalImpairment":"Caution is advised; adjust dose as zinc is excreted by the kidneys."},"StorageAndHandling":"Store at room temperature away from light and moisture. Keep out of reach of children."},{"GenericName":"Omega-3 Fatty Acids","BrandNames":["Lovaza","Vascepa","Omtryg"],"DrugClass":"Nutritional supplement, lipid-modifying agent","MechanismOfAction":"Omega-3 fatty acids, including EPA and DHA, modulate lipoprotein metabolism by reducing triglyceride synthesis and increasing fatty acid oxidation. They decrease hepatic triglyceride production and cause a reduction in the total triglyceride pool.","Pharmacodynamics":"Omega-3 fatty acids lower triglyceride levels and have anti-inflammatory effects, which may contribute to their cardiovascular benefits.","OnsetOfAction":"Several hours to days for biochemical modifications with long-term effects on lipid levels","DurationOfAction":"Long-term lipid-lowering effect with continuous intake","PeakPlasmaConcentration":"3–8 hours post-dose (after a single dose)","Indications":["Hypertriglyceridemia","Cardiovascular disease prevention"],"RoutesOfAdministration":"Oral","DosageForms":["Capsule"],"StrengthsOfDosageForms":["1,000 mg per capsule","850 mg (often combined EPA/DHA) per capsule"],"Pharmacokinetics":{"Absorption":"Absorbed in the small intestine as part of chylomicrons","Distribution":"Widely distributed; incorporated into cell membranes","Metabolism":"Primarily hepatic; undergoes beta-oxidation in the liver","Excretion":"Primarily exhaled as CO2, minor renal excretion of byproducts"},"SideEffects":["Burping","Indigestion","Diarrhea","Abdominal pain","Bad aftertaste"],"DrugInteractions":["Anticoagulants (increased bleeding risk)","Antiplatelet agents","Other omega-3 fatty acid products (additive effects)"],"Contraindications":"Hypersensitivity to omega-3 fatty acids or any component of the formulation","ChemicalStructure":{"MolecularFormula":"Varies (e.g., C20H30O2 for EPA, C22H32O2 for DHA)","MolecularWeight":"e.g., 302.45 g/mol for EPA, 328.49 g/mol for DHA"},"UseInSpecialPopulations":{"Pregnancy":"Considered safe, with potential benefits for fetal development.","PediatricUse":"Generally considered safe, but dosing should be guided by a healthcare provider.","GeriatricUse":"Considered safe, attention needed for potential interactions and comorbidities.","HepaticImpairment":"Caution advised; increased monitoring may be needed.","RenalImpairment":"Generally safe, but dose adjustment may be needed in severe cases."},"StorageAndHandling":"Store in a cool, dry place away from direct sunlight. Keep capsules tightly closed in their original container."},{"GenericName":"Potassium Chloride","BrandNames":["Klor-Con","Micro-K","K-Dur"],"DrugClass":"Electrolyte replenisher","MechanismOfAction":"Potassium chloride dissociates into potassium and chloride ions in water. Potassium ion is the principal intracellular cation of most body tissues, participating in a number of physiological functions including maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function.","Pharmacodynamics":"Potassium chloride is used to replenish the body's potassium reserves in hypokalemia and to prevent potassium depletion in patients with normal renal functions and patients who are on diuretics or digitalis therapy.","OnsetOfAction":"Varies based on the route of administration; generally within 1-2 hours.","DurationOfAction":"Effect is sustained as long as potassium levels are maintained in the normal range.","PeakPlasmaConcentration":"Not typically applicable for potassium supplementation; plasma concentrations are maintained within therapeutic range rather than achieving a peak.","Indications":["Prevention and treatment of hypokalemia"],"RoutesOfAdministration":"Oral and intravenous","DosageForms":["Tablet","Capsule","Oral solution","Intravenous solution"],"StrengthsOfDosageForms":["8 mEq","10 mEq","20 mEq in various forms"],"Pharmacokinetics":{"Absorption":"Readily absorbed orally with gastrointestinal absorption varying based on dosage form.","Distribution":"Widely distributed in the body, predominantly intracellularly.","Metabolism":"Not metabolized.","Excretion":"Excreted primarily in urine."},"SideEffects":["Nausea","Vomiting","Diarrhea","Abdominal discomfort","Flatulence"],"DrugInteractions":["ACE inhibitors","Potassium-sparing diuretics","Non-steroidal anti-inflammatory drugs","Angiotensin receptor blockers"],"Contraindications":"Hyperkalemia and conditions associated with potassium retention","ChemicalStructure":{"MolecularFormula":"KCl","MolecularWeight":"74.55 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Considered safe; classified as Category C (should be used only if clearly needed).","PediatricUse":"Dosing should be adjusted; use with caution.","GeriatricUse":"Use caution due to potential for decreased renal function.","HepaticImpairment":"Caution recommended; monitoring of electrolytes advised.","RenalImpairment":"Use with caution; contraindicated in significant renal impairment."},"StorageAndHandling":"Store at room temperature, protect from moisture and heat."},{"GenericName":"Alendronate","BrandNames":["Fosamax","Binosto"],"DrugClass":"Bisphosphonate","MechanismOfAction":"Alendronate acts as a specific inhibitor of osteoclast-mediated bone resorption. It binds to hydroxyapatite found in bone, inhibiting osteoclast activity, which decreases bone resorption and turnover.","Pharmacodynamics":"Alendronate increases bone mineral density (BMD) by inhibiting osteoclast-mediated bone resorption. This results in a net gain in bone mass and strength, reducing the likelihood of fractures.","OnsetOfAction":"Effects on bone turnover can be seen within one month of starting treatment, but significant changes in bone density may take months.","DurationOfAction":"The effects of alendronate on bone metabolism can be sustained with continued use, but it can remain incorporated in bone for years due to its high affinity.","PeakPlasmaConcentration":"1 to 2 hours","Indications":["Treatment and prevention of osteoporosis in postmenopausal women","Treatment of osteoporosis in men","Treatment of glucocorticoid-induced osteoporosis","Paget's disease of bone"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Effervescent tablet"],"StrengthsOfDosageForms":["5 mg","10 mg","35 mg","40 mg","70 mg"],"Pharmacokinetics":{"Absorption":"Poor absorption; approximately 0.6% to 0.7% of an oral dose is absorbed in the fasted state","Distribution":"Binds to bone surfaces; not significantly distributed in other tissues","Metabolism":"Not metabolized","Excretion":"Primarily excreted unchanged in the urine"},"SideEffects":["Gastrointestinal upset","Musculoskeletal pain","Headache","Hypocalcemia","Esophageal irritation, ulcers, or erosion"],"DrugInteractions":["Calcium supplements","Antacids","Non-steroidal anti-inflammatory drugs (NSAIDs)","Aspirin","Proton pump inhibitors (PPIs)"],"Contraindications":"Esophageal abnormalities that delay esophageal emptying, inability to stand or sit upright for at least 30 minutes, hypocalcemia, hypersensitivity to any component of the product.","ChemicalStructure":{"MolecularFormula":"C4H13NO7P2","MolecularWeight":"249.12 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category C; should be used only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly subjects and younger patients, but greater sensitivity in some older individuals cannot be ruled out.","HepaticImpairment":"No dosage adjustment necessary.","RenalImpairment":"Not recommended for patients with creatinine clearance less than 35 mL/min."},"StorageAndHandling":"Store at room temperature between 68°F to 77°F (20°C to 25°C), protected from moisture and light. Keep in a tightly closed container."},{"GenericName":"Raloxifene","BrandNames":["Evista"],"DrugClass":"Selective Estrogen Receptor Modulator (SERM)","MechanismOfAction":"Raloxifene acts as an estrogen receptor agonist on bone and lipid metabolism and as an estrogen receptor antagonist on breast and uterine tissues, leading to decreased bone resorption and turnover without stimulating breast or endometrial tissues.","Pharmacodynamics":"Raloxifene reduces bone turnover, increases bone mass, and decreases LDL-c levels. It mimics the effects of estrogen on bone and lipid profiles while antagonizing estrogen effects in other tissues.","OnsetOfAction":"The effect on bone marker changes becomes significant within 3 months of treatment.","DurationOfAction":"The effects on bone mineral density continue as long as the drug is administered.","PeakPlasmaConcentration":"Approximately 6 hours after oral administration.","Indications":["Prevention and treatment of osteoporosis in postmenopausal women","Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis","Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["60 mg","RLC 60"],"Pharmacokinetics":{"Absorption":"Raloxifene is rapidly absorbed after oral administration, but its absolute bioavailability is low due to presystemic glucuronidation.","Distribution":"Volume of distribution is approximately 2,344 liters.","Metabolism":"Extensive first-pass glucuronidation in the liver and intestines.","Excretion":"Primarily excreted as glucuronides in feces; renal excretion is negligible."},"SideEffects":["Hot flashes","Leg cramps","Peripheral edema","Venous thromboembolism","Flu-like symptoms","Arthralgia"],"DrugInteractions":["Cholestyramine may reduce the absorption of raloxifene","Co-administration with warfarin may diminish the anticoagulant effect"],"Contraindications":"Raloxifene is contraindicated in women with active or history of venous thromboembolism, and in those with known hypersensitivity to Raloxifene.","ChemicalStructure":{"MolecularFormula":"C28H27NO4S","MolecularWeight":"473.58 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category X - Not for use in pregnancy.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No significant differences in safety or effectiveness were observed between elderly and younger populations.","HepaticImpairment":"Use with caution; monitor liver function.","RenalImpairment":"Use with caution; dosage adjustment may be necessary in severe impairment."},"StorageAndHandling":"Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Protect from light and moisture."},{"GenericName":"Calcitonin","BrandNames":["Miacalcin","Fortical"],"DrugClass":"Hormone","MechanismOfAction":"Calcitonin lowers blood calcium levels primarily by inhibiting osteoclast activity in bones, which decreases the release of calcium from bone stores. It also inhibits renal tubular reabsorption of calcium and phosphate, increasing their excretion in the urine.","Pharmacodynamics":"Calcitonin lowers the levels of calcium and phosphate in the blood, promoting their incorporation into bone. The action of calcitonin is rapid but relatively short-lived.","OnsetOfAction":"Immediate with parenteral administration, within 15 minutes.","DurationOfAction":"12 to 24 hours","PeakPlasmaConcentration":"1 hour after intramuscular injection","Indications":["Paget's disease of bone","Postmenopausal osteoporosis","Hypercalcemia"],"RoutesOfAdministration":"Subcutaneous, Intramuscular, Nasal","DosageForms":["Injection","Nasal spray"],"StrengthsOfDosageForms":["Injection: 200 units/mL","Nasal spray: 200 units/spray"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following subcutaneous or intramuscular administration.","Distribution":"Limited distribution beyond the bloodstream. Calcitonin is known to bind to specific receptors.","Metabolism":"Mainly metabolized in the kidneys.","Excretion":"Primarily excreted in urine."},"SideEffects":["Nausea","Flushing","Injection site reactions","Allergic reactions","Nasal symptoms for nasal spray (e.g., rhinitis, nosebleeds)"],"DrugInteractions":["Bisphosphonates may enhance the hypocalcemic effect","May interact with lithium affecting its plasma levels"],"Contraindications":"Hypersensitivity to calcitonin or any component of the formulation. Caution in patients with hypocalcemia.","ChemicalStructure":{"MolecularFormula":"C145-H240-N44-O48-S2","MolecularWeight":"3431.9 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; Category C. Risk versus benefit should be considered.","PediatricUse":"Safety and effectiveness not established.","GeriatricUse":"No specific precautions but use with caution considering decreased renal function in elderly.","HepaticImpairment":"Use with caution due to potential alteration in drug metabolism.","RenalImpairment":"Dose adjustment may be necessary; increased sensitivity is possible."},"StorageAndHandling":"Store in a refrigerator at 2-8°C (36-46°F). Protect from freezing. Nasal spray must be stored in an upright position, and opened bottles can be stored at room temperature for 30 days."},{"GenericName":"Denosumab","BrandNames":["Prolia","Xgeva"],"DrugClass":"Monoclonal Antibody","MechanismOfAction":"Denosumab is a monoclonal antibody that binds to RANKL (Receptor Activator for Nuclear Factor κ B Ligand), inhibiting its action. This inhibits osteoclast formation, function, and survival, leading to decreased bone resorption and increased bone mass and strength.","Pharmacodynamics":"Denosumab reduces bone turnover markers and increases bone mineral density (BMD). The suppression of osteoclasts results in less bone resorption and remodeling.","OnsetOfAction":"The onset of action is usually within 3 days, with a maximal effect on bone resorption markers observed between 1 to 3 months after administration.","DurationOfAction":"The effects, such as suppression of bone resorption, last for about 6 months after each dose.","PeakPlasmaConcentration":"Approximately 5 to 21 days after subcutaneous administration.","Indications":["Osteoporosis in postmenopausal women at high risk for fracture","Bone loss in men receiving androgen deprivation therapy for prostate cancer","Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer","Giant cell tumor of bone","Hypercalcemia of malignancy"],"RoutesOfAdministration":"Subcutaneous","DosageForms":["Injection"],"StrengthsOfDosageForms":["60 mg/mL (Prolia)","120 mg/1.7 mL (Xgeva)"],"Pharmacokinetics":{"Absorption":"Denosumab is absorbed slowly following subcutaneous injection, with an average bioavailability of 61%.","Distribution":"It is primarily distributed to the bone; the volume of distribution is approximately 0.1 L/kg.","Metabolism":"Denosumab is expected to be metabolized into small peptides and amino acids, like other proteins.","Excretion":"Denosumab does not appear to be eliminated via the liver or kidneys, suggesting it degrades via non-specific proteolytic pathways."},"SideEffects":["Hypocalcemia","Serious infections","Dermatologic reactions","Osteonecrosis of the jaw","Atypical femoral fractures","Back pain","Extremity pain","Hypercholesterolemia"],"DrugInteractions":["No known drug-drug interactions due to it being a monoclonal antibody, but caution is advised when used with other medications that can cause hypocalcemia."],"Contraindications":"Hypocalcemia; caution in patients with renal impairment or predisposition to hypocalcemia.","ChemicalStructure":{"MolecularFormula":"C6370H9912N1724O1998S50","MolecularWeight":"147 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Use is not recommended for pregnant women due to potential harm to the fetus. Category X.","PediatricUse":"Safety and efficacy have not been established in pediatric patients.","GeriatricUse":"No significant differences in safety and efficacy were observed in elderly versus younger patients.","HepaticImpairment":"No specific dose adjustment recommended; pharmacokinetics not significantly altered by hepatic impairment.","RenalImpairment":"Caution is advised because of increased risk of hypocalcemia in severe renal impairment and dialysis."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Do not shake. If necessary, the product may be at room temperature (up to 25°C) for a maximum single period of 14 days in original container."},{"GenericName":"Romosozumab","BrandNames":["Evenity"],"DrugClass":"Monoclonal antibody","MechanismOfAction":"Romosozumab works by binding to and inhibiting sclerostin, a regulatory factor in bone metabolism, which leads to an increase in bone formation and, to a lesser extent, a decrease in bone resorption.","Pharmacodynamics":"Romosozumab increases bone mineral density and bone strength through dual effects of increasing bone formation and decreasing bone resorption.","OnsetOfAction":"Increases in bone formation markers can be observed within a few weeks of administration.","DurationOfAction":"The effects on bone formation markers can be seen for several months after administration, although the exact duration can vary.","PeakPlasmaConcentration":"Occurs approximately 5 days after administration.","Indications":["Treatment of osteoporosis in postmenopausal women at high risk for fracture."],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Injection: prefilled syringe"],"StrengthsOfDosageForms":["210 mg/2.34 mL solution in a single-use prefilled syringe"],"Pharmacokinetics":{"Absorption":"Bioavailability is approximately 81% after subcutaneous injection.","Distribution":"The volume of distribution is approximately 2.94 L.","Metabolism":"As a monoclonal antibody, degradation to small peptides and amino acids occurs through catabolic pathways.","Excretion":"Elimination is primarily by non-specific pathways, similar to endogenous IgG."},"SideEffects":["Arthralgia","Headache","Injection site reactions","Hypocalcemia","Cardiovascular events"],"DrugInteractions":["Potential interaction with other medications affecting calcium levels, such as bisphosphonates.","No formal drug interaction studies have been conducted."],"Contraindications":"Hypocalcemia, known hypersensitivity to romosozumab or any of its excipients.","ChemicalStructure":{"MolecularFormula":"C6504H10006N1744O2038S46","MolecularWeight":"150 kDa (approximately)"},"UseInSpecialPopulations":{"Pregnancy":"Not recommended during pregnancy. There are no adequate data in pregnant women and animal studies are not sufficient to establish safety.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No differences in safety or efficacy were observed between elderly and younger patients.","HepaticImpairment":"No dose adjustment is necessary; however, studies are limited.","RenalImpairment":"No dose adjustment is necessary, but caution is advised in severe renal impairment due to increased risk of hypocalcemia."},"StorageAndHandling":"Store in the refrigerator (2°C to 8°C). Do not freeze or shake. Keep in the original carton to protect from light. Allow to reach room temperature for 30 minutes before administration."},{"GenericName":"Zoledronic Acid","BrandNames":["Reclast","Zometa"],"DrugClass":"Bisphosphonate","MechanismOfAction":"Zoledronic acid inhibits osteoclast-mediated bone resorption, which reduces the breakdown of bone. It achieves this by binding to hydroxyapatite found in bone, primarily affecting the osteoclasts to diminish their activity and survival.","Pharmacodynamics":"Zoledronic acid significantly inhibits osteoclast-mediated bone resorption. The drug leads to a reduction in bone turnover markers and achieves a sustained therapeutic effect due to its long half-life in the bone.","OnsetOfAction":"The onset of action is typically within 7 days for decreasing serum calcium levels in hypercalcemia of malignancy.","DurationOfAction":"The therapeutic effects can last up to a year, particularly in the context of osteoporosis treatment.","PeakPlasmaConcentration":"The peak plasma concentration occurs within 1 hour following intravenous administration.","Indications":["Treatment of hypercalcemia of malignancy","Treatment of multiple myeloma and bone metastases from solid tumors","Treatment of osteoporosis in postmenopausal women","Treatment to increase bone mass in men with osteoporosis","Treatment to increase bone mass in patients expected to be on glucocorticoid therapy"],"RoutesOfAdministration":"Intravenous","DosageForms":["Injection solution","Prefilled syringe"],"StrengthsOfDosageForms":["4 mg/5 mL","5 mg/100 mL"],"Pharmacokinetics":{"Absorption":"Zoledronic acid is administered intravenously, ensuring complete bioavailability.","Distribution":"The drug rapidly disappears from the systemic circulation and is taken up by bone with the volume of distribution being approximately 0.3 L/kg.","Metabolism":"Zoledronic acid is not metabolized.","Excretion":"Excreted unchanged by the kidneys. Approximately 39% of the administered dose is recovered in the urine within 24 hours."},"SideEffects":["Hypocalcemia","Acute phase reaction (fever, myalgia, flu-like symptoms)","Renal impairment","Osteonecrosis of the jaw","Atrial fibrillation"],"DrugInteractions":["Aminoglycosides (enhanced hypocalcemic effect)","Loop diuretics (increased risk of hypocalcemia)","Nephrotoxic drugs (increased risk of renal impairment)"],"Contraindications":"Hypocalcemia, hypersensitivity to zoledronic acid or other bisphosphonates, severe renal impairment (creatinine clearance < 35 mL/min).","ChemicalStructure":{"MolecularFormula":"C5H10N2O7P2","MolecularWeight":"272.10 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use in pregnancy is not recommended. Classified as Category D in some countries.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.","HepaticImpairment":"No specific dosage adjustment is necessary; not metabolized by the liver.","RenalImpairment":"Use with caution; contraindicated in patients with severe renal impairment (creatinine clearance < 35 mL/min)."},"StorageAndHandling":"Store at controlled room temperature 20°C to 25°C (68°F to 77°F). Do not freeze. Solutions should be used immediately once prepared and stored in a manner to prevent contact with metal ions."},{"GenericName":"Tamoxifen","BrandNames":["Nolvadex","Soltamox"],"DrugClass":"Selective Estrogen Receptor Modulator (SERM)","MechanismOfAction":"Tamoxifen binds to estrogen receptors (ER), competitively inhibiting estrogen-mediated transcription and cell growth in breast tissue. It acts as an estrogen antagonist in breast tissue and as a partial agonist in other tissues such as the uterus.","Pharmacodynamics":"Tamoxifen exhibits both estrogenic and anti-estrogenic properties depending on the target tissue. It primarily blocks estrogen receptors in breast cancer cells, which helps to slow the growth and proliferation of these cells.","OnsetOfAction":"4 to 10 weeks for the reduction of breast cancer recurrence risk","DurationOfAction":"Several weeks, depending on the sustained binding to estrogen receptors and prolonged biological effects","PeakPlasmaConcentration":"4 to 7 hours","Indications":["Treatment of estrogen receptor-positive breast cancer in pre- and post-menopausal women","Adjuvant therapy in early breast cancer","Prevention of breast cancer in high-risk patients"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Oral solution"],"StrengthsOfDosageForms":["10 mg tablets","20 mg tablets","10 mg/5 mL oral solution"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed from the gastrointestinal tract.","Distribution":"Widely distributed in body tissues. Highly protein-bound (~99%).","Metabolism":"Extensively metabolized in the liver by CYP3A4, CYP2C9, CYP2D6 into active metabolites such as endoxifen and 4-hydroxytamoxifen.","Excretion":"Primarily in feces (65-75%), less than 10% excreted in urine. Half-life is 5 to 7 days."},"SideEffects":["Hot flashes","Nausea","Fatigue","Mood swings","Increased risk of thromboembolic events","Endometrial changes/increased risk of uterine cancer","Cataracts"],"DrugInteractions":["Warfarin (may increase anticoagulant effect)","CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) may reduce the effectiveness of tamoxifen","Rifampin (may decrease the effectiveness of tamoxifen)"],"Contraindications":"Hypersensitivity to tamoxifen or any component of the formulation. Pregnancy and lactation are contraindicated due to potential harm to the fetus and infant.","ChemicalStructure":{"MolecularFormula":"C26H29NO","MolecularWeight":"371.51 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated. Tamoxifen can cause fetal harm when administered to a pregnant woman.","PediatricUse":"Safety and efficacy in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly and younger patients, but some older individuals may experience increased sensitivity.","HepaticImpairment":"Metabolized in the liver; use with caution in patients with hepatic impairment.","RenalImpairment":"Limited data in patients with renal impairment, but no dose adjustment is typically necessary."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture."},{"GenericName":"Letrozole","BrandNames":["Femara"],"DrugClass":"Aromatase inhibitor","MechanismOfAction":"Letrozole selectively inhibits the aromatase enzyme, which is involved in the conversion of androgens to estrogens. By inhibiting this enzyme, letrozole decreases estrogen production, which is beneficial in estrogen-receptor positive breast cancers that require estrogen for growth.","Pharmacodynamics":"Letrozole reduces plasma estrogen levels significantly, with a measurable effect on breast cancer tissue, leading to decreased tumor cell growth and proliferation in estrogen-sensitive tissues or tumors.","OnsetOfAction":"The onset of action is not precisely defined but it starts decreasing estrogen levels within hours, with clinical effects seen within weeks to months depending on the indication.","DurationOfAction":"Duration of action continues as long as the patient is taking the medication and therapy is not interrupted.","PeakPlasmaConcentration":"Approximately 2-6 hours after administration of a single dose.","Indications":["Adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women.","First-line treatment of postmenopausal women with hormone receptor-positive or receptor status unknown locally advanced or metastatic breast cancer.","Treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy."],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["2.5 mg tablet"],"Pharmacokinetics":{"Absorption":"Letrozole is rapidly and completely absorbed from the gastrointestinal tract.","Distribution":"Letrozole is largely distributed in the body with a volume of distribution. It is not highly protein-bound (~60%).","Metabolism":"Metabolized by the liver via CYP3A4 and CYP2A6 primarily to a pharmacologically inactive carbinol metabolite.","Excretion":"Primarily excreted via kidneys as metabolites, less than 5% is excreted unchanged in urine."},"SideEffects":["Hot flashes","Arthralgia","Fatigue","Nausea","Dizziness","Increased sweating","Edema"],"DrugInteractions":["Tamoxifen may reduce plasma concentrations of letrozole.","Strong CYP3A4 inhibitors could theoretically increase levels of letrozole, but no specific interactions noted."],"Contraindications":"Contraindicated in premenopausal women, pregnancy, and those with known hypersensitivity to letrozole or any of the components of the formulation.","ChemicalStructure":{"MolecularFormula":"C17H11N5","MolecularWeight":"285.31 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category X; not indicated for use in women who are or may become pregnant.","PediatricUse":"Safety and effectiveness not established in pediatric patients.","GeriatricUse":"No significant differences in safety or effectiveness observed between elderly (65 and older) and younger patients, but greater sensitivity in some older individuals cannot be ruled out.","HepaticImpairment":"No dosage adjustment is required for patients with mild to moderate hepatic impairment. Use cautiously in severe impairment.","RenalImpairment":"No dosage adjustment is required for renal impairment with creatinine clearance greater than 10 mL/min."},"StorageAndHandling":"Store at room temperature between 20-25°C (68-77°F) in a dry place, protected from light."},{"GenericName":"Anastrozole","BrandNames":["Arimidex"],"DrugClass":"Aromatase inhibitor","MechanismOfAction":"Anastrozole selectively inhibits the aromatase enzyme, which is responsible for the conversion of androgens to estrogens in peripheral tissues. This reduction in estrogen levels alleviates the growth stimulation of estrogen-dependent breast cancer cells.","Pharmacodynamics":"Anastrozole decreases serum estradiol concentrations. In postmenopausal women, it reduces the levels of circulating estrogens by inhibiting the peripheral conversion of androgens, which are produced by the adrenal glands, to estrogens.","OnsetOfAction":"The onset of action is typically within hours, but clinical effects may take several weeks to become evident.","DurationOfAction":"Reduction of estrogen levels persists for 6 days or more after a single dose of anastrozole.","PeakPlasmaConcentration":"Peak plasma concentrations are reached approximately 2 hours after dosing.","Indications":["Treatment of advanced breast cancer in postmenopausal women.","Adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women.","First-line treatment of hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer in postmenopausal women."],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["1 mg"],"Pharmacokinetics":{"Absorption":"Absorbed orally with 83-85% bioavailability.","Distribution":"Volume of distribution is approximately 347 L.","Metabolism":"Primarily metabolized in the liver by N-dealkylation, hydroxylation, and glucuronidation.","Excretion":"Excreted mainly in urine as inactive metabolites with a half-life of approximately 50 hours."},"SideEffects":["Hot flashes","Arthralgia","Weakness","Nausea","Headache","Hypertension","Depression","Osteoporosis"],"DrugInteractions":["Tamoxifen","Estrogen-containing therapies"],"Contraindications":"Contraindicated in premenopausal women, during pregnancy, and in women with known hypersensitivity to anastrozole.","ChemicalStructure":{"MolecularFormula":"C17H19N5","MolecularWeight":"293.37 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated during pregnancy (Pregnancy Category D).","PediatricUse":"Safety and efficacy have not been established in pediatric patients.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly and younger patients.","HepaticImpairment":"Use with caution; no modification of dosing is necessary but monitoring is advised.","RenalImpairment":"Use with caution in patients with severe renal impairment; no modification of dosing is necessary but monitoring is advised."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture."},{"GenericName":"Paclitaxel","BrandNames":["Taxol","Abraxane","Onxol","Bristaxol"],"DrugClass":"Antineoplastic agent, specifically a taxane","MechanismOfAction":"Paclitaxel is a mitotic inhibitor. It stabilizes microtubules, preventing their depolymerization which leads to inhibition of normal cell division, thus exerting its antitumor effects.","Pharmacodynamics":"Paclitaxel inhibits the disassembly of microtubules, which disrupts the normal processes of cell division, predominantly targeting the G2/M phase of the cell cycle.","OnsetOfAction":"Varies depending on the type of tumor being targeted and the specific regime of administration.","DurationOfAction":"Duration is variable and depends on the treatment regimen and the type of cancer.","PeakPlasmaConcentration":"Approximately 10 to 20 µmol/L (varies based on dose and patient factors)","Indications":["Ovarian cancer","Breast cancer","Non-small cell lung cancer","Kaposi's sarcoma","Bladder cancer","Prostate cancer"],"RoutesOfAdministration":"Intravenous","DosageForms":["Solution for Injection","Protein-bound suspension"],"StrengthsOfDosageForms":["Solution: 30 mg/5 mL, 100 mg/16.7 mL","Protein-bound suspension: 100 mg/vial"],"Pharmacokinetics":{"Absorption":"Not applicable (IV administration)","Distribution":"Widely distributed in body tissues, highly bound to plasma proteins","Metabolism":"Liver extensively metabolizes paclitaxel via CYP2C8 and CYP3A4 isoenzymes.","Excretion":"Primarily feces (via biliary excretion); 10% is excreted in urine."},"SideEffects":["Neutropenia","Thrombocytopenia","Alopecia","Peripheral neuropathy","Myalgia","Nausea","Vomiting","Hypersensitivity reactions"],"DrugInteractions":["CYP3A4 inducers/inhibitors","CYP2C8 substrates/inhibitors","Doxorubicin","Carboplatin"],"Contraindications":"Hypersensitivity to paclitaxel or any component of the formulation","ChemicalStructure":{"MolecularFormula":"C47H51NO14","MolecularWeight":"853.9 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D (there is evidence of human fetal risk, but potential benefits from the use of the drug in pregnant women may be acceptable despite the risk)","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness observed between older and younger patients, though increased sensitivity in some older individuals cannot be ruled out.","HepaticImpairment":"Patients with hepatic impairment may be at increased risk of toxicities; dose adjustments are necessary.","RenalImpairment":"No significant dose adjustment is typically necessary, although caution should be used."},"StorageAndHandling":"Store at controlled room temperature, protect from light. The reconstituted solution may require refrigeration depending on the formulation."},{"GenericName":"Doxorubicin","BrandNames":["Adriamycin","Doxil","Caelyx"],"DrugClass":"Anthracycline antibiotic","MechanismOfAction":"Doxorubicin intercalates into DNA, inhibiting the synthesis of DNA and RNA. It also generates free radicals that damage cellular components and inhibits topoisomerase II enzyme activity, preventing proper DNA replication and repair.","Pharmacodynamics":"Doxorubicin disrupts essential cellular processes, leading to apoptosis of rapidly dividing cells, which is particularly effective in targeting cancer cells.","OnsetOfAction":"Varies depending on the indication and administration, but typically within a few hours.","DurationOfAction":"Doxorubicin and its active metabolites may persist for 24-36 hours or longer in the body.","PeakPlasmaConcentration":"Occurs approximately within 30 minutes to 1 hour after intravenous administration.","Indications":["Breast cancer","Acute lymphoblastic leukemia","Acute myeloblastic leukemia","Soft tissue sarcoma","Ovarian cancer","Hodgkin's lymphoma","Non-Hodgkin's lymphoma"],"RoutesOfAdministration":"Intravenous","DosageForms":["Injection solution","Lyophilized powder for solution"],"StrengthsOfDosageForms":["10 mg vial","20 mg vial","50 mg vial"],"Pharmacokinetics":{"Absorption":"Not applicable; administered intravenously.","Distribution":"Widely distributed in the body with a volume of distribution of approximately 20 to 30 L/m².","Metabolism":"Hepatic; primarily metabolized by reduction and hydroxylation. Doxorubicinol is an active metabolite.","Excretion":"Excreted primarily in bile and feces; approximately 5%-12% excreted in urine."},"SideEffects":["Nausea","Vomiting","Myelosuppression","Alopecia","Cardiotoxicity","Mucositis","Diarrhea"],"DrugInteractions":["Trastuzumab (increased cardiotoxicity risk)","Cyclophosphamide (increased risk of myelosuppression)","Paclitaxel (increased doxorubicin levels)"],"Contraindications":"Doxorubicin is contraindicated in patients with severe myocardial insufficiency or recent myocardial infarction, those with severe persistent myelosuppression, or who have had previous treatment with high cumulative doses of doxorubicin, or other anthracyclines or anthracenediones.","ChemicalStructure":{"MolecularFormula":"C27H29NO11","MolecularWeight":"543.52 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D; can cause fetal harm when administered to a pregnant woman.","PediatricUse":"Safety and effectiveness have been established for pediatric patients, though long-term effects may include delayed cardiac toxicity.","GeriatricUse":"Elderly patients may be more susceptible to the cardiotoxic effects.","HepaticImpairment":"Dose reduction may be required as doxorubicin is primarily metabolized and excreted by the liver.","RenalImpairment":"Use with caution, although renal excretion is minimal."},"StorageAndHandling":"Store vials at 2°C to 8°C (36°F to 46°F). Protect from light. Unopened vials are stable until the expiration date indicated on the package."},{"GenericName":"Cisplatin","BrandNames":["Platinol","Platinol-AQ"],"DrugClass":"Platinum-based antineoplastic agents","MechanismOfAction":"Cisplatin interferes with the growth of cancer cells by forming cross-links between and within DNA strands, which inhibits DNA replication and transcription.","Pharmacodynamics":"Cisplatin forms platinum-DNA adducts, causing intra- and inter-strand DNA cross-links, leading to apoptosis. It is crucial in the treatment of various types of cancer due to its ability to disrupt DNA function.","OnsetOfAction":"Variable; antitumor effect observed as cells enter division","DurationOfAction":"The effects on cancer cells can persist for several days due to inherent cytotoxic activity; varies according to the cancer type and treatment regimen.","PeakPlasmaConcentration":"Occurs immediately after intravenous administration as it is given via a bolus infusion.","Indications":["Testicular cancer","Ovarian cancer","Bladder cancer","Head and neck cancer","Cervical cancer","Lung cancer"],"RoutesOfAdministration":"Intravenous","DosageForms":["Intravenous solution"],"StrengthsOfDosageForms":["1 mg/mL solution in 50 mL or 100 mL vials"],"Pharmacokinetics":{"Absorption":"N/A (given intravenously)","Distribution":"Widely distributed; crosses the blood-brain barrier and is found in all tissues, but especially in kidneys, liver, and spleen.","Metabolism":"Non-enzymatic transformation; reacts with water and plasma components to form active species.","Excretion":"Excreted primarily in urine, with 15-25% eliminated as unchanged drug in the first 24 hours."},"SideEffects":["Nephrotoxicity","Nausea and vomiting","Ototoxicity","Myelosuppression","Neurotoxicity","Hypersensitivity reactions"],"DrugInteractions":["Aminoglycosides (increased nephrotoxicity)","Loop diuretics (increased ototoxicity)","Other nephrotoxic drugs","Anticonvulsants (altered pharmacokinetics)"],"Contraindications":"Hypersensitivity to cisplatin or other platinum-containing compounds, pre-existing renal impairment, hearing impairment, myelosuppression.","ChemicalStructure":{"MolecularFormula":"Pt(NH3)2Cl2","MolecularWeight":"300.05 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D - Positive evidence of risk; should be used only if benefits justify the risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"Use with caution due to potential for increased renal clearance reduction in elderly.","HepaticImpairment":"No dose adjustment specified, but close monitoring is recommended.","RenalImpairment":"Use with caution due to potential for nephrotoxicity; dose adjustments may be necessary."},"StorageAndHandling":"Store intact vials at controlled room temperature (20°C to 25°C). Protect from light."},{"GenericName":"Etoposide","BrandNames":["Toposar","Etopophos","Vepesid"],"DrugClass":"Plant alkaloid, Topoisomerase inhibitor","MechanismOfAction":"Etoposide inhibits the enzyme topoisomerase II, which prevents DNA from unwinding and duplicating, leading to apoptosis of cancer cells.","Pharmacodynamics":"As an antineoplastic agent, etoposide causes DNA strand breaks, leading to apoptosis in rapidly dividing cells such as cancer cells.","OnsetOfAction":"Varies depending on administration route and patient condition, generally expected within hours to days of administration.","DurationOfAction":"Activity can last for several hours, but the therapeutic effects are generally assessed over the course of several treatment cycles.","PeakPlasmaConcentration":"Occurs approximately 1 to 2 hours after oral administration and immediately after intravenous infusion concludes.","Indications":["Small cell lung cancer","Testicular cancer","Hodgkin's lymphoma","Non-Hodgkin's lymphoma"],"RoutesOfAdministration":"Oral and intravenous (IV)","DosageForms":["Capsules","Injection solution"],"StrengthsOfDosageForms":["Capsules: 50 mg","Injection: 100 mg/5 mL"],"Pharmacokinetics":{"Absorption":"Etoposide displays variable oral bioavailability between 25% to 74% due to high interindividual variability.","Distribution":"Widely distributed in the body with a volume of distribution of 7-17 L/m2.","Metabolism":"Hepatically metabolized via CYP3A4 to both active and inactive metabolites.","Excretion":"Primarily excreted in the urine, with 44% reported as unchanged drug."},"SideEffects":["Myelosuppression","Nausea and vomiting","Alopecia","Fatigue","Hypotension"],"DrugInteractions":["CYP3A4 inhibitors and inducers","Anticoagulants like warfarin","Other myelosuppressive agents"],"Contraindications":"Hypersensitivity to etoposide or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C29H32O13","MolecularWeight":"588.56 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D - Positive evidence of risk; should be used only if clearly needed.","PediatricUse":"Safety and efficacy in pediatric patients have not been established, although it is used in pediatric oncology.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients, but caution should be exercised.","HepaticImpairment":"Dose adjustment may be necessary for patients with hepatic impairment.","RenalImpairment":"Use with caution and dose adjustments may be necessary."},"StorageAndHandling":"Store at controlled room temperature, 20° to 25°C (68° to 77°F). Protect from light and moisture."},{"GenericName":"Vincristine","BrandNames":["Oncovin","Vincasar PFS","Marqibo"],"DrugClass":"Vinca alkaloid","MechanismOfAction":"Vincristine inhibits microtubule formation in the mitotic spindle, blocking cell division in metaphase.","Pharmacodynamics":"Vincristine causes arrest of dividing cells in metaphase, leading to cell death, particularly in rapidly dividing cancer cells.","OnsetOfAction":"Onset of action is generally noted within hours of administration, affecting rapidly dividing cells shortly after treatment.","DurationOfAction":"The effects on blood cell counts and tumor suppression may last for several days to weeks after administration.","PeakPlasmaConcentration":"Achieved within 1-2 hours post-infusion.","Indications":["Acute lymphoblastic leukemia (ALL)","Hodgkin's lymphoma","Non-Hodgkin's lymphoma","Neuroblastoma","Wilms' tumor","Rhabdomyosarcoma"],"RoutesOfAdministration":"Intravenous infusion","DosageForms":["Solution for injection"],"StrengthsOfDosageForms":["1 mg/mL solution"],"Pharmacokinetics":{"Absorption":"Not applicable as it is administered intravenously.","Distribution":"Widely distributed in the body but has poor CNS penetration.","Metabolism":"Primarily hepatic metabolism via CYP3A4/5.","Excretion":"Biliary excretion is predominant with a minor fraction excreted in urine."},"SideEffects":["Peripheral neuropathy","Constipation","Hair loss","Bone marrow suppression","Nausea","Vomiting","Anemia"],"DrugInteractions":["CYP3A4 inhibitors","CYP3A4 inducers","Phenytoin","Itraconazole"],"Contraindications":"Patients with demyelinating form of Charcot-Marie-Tooth syndrome.","ChemicalStructure":{"MolecularFormula":"C46H56N4O10","MolecularWeight":"824.97 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have been established.","GeriatricUse":"May be used, however, patients should be monitored closely due to age-related decreases in hepatic, renal, or cardiac function.","HepaticImpairment":"May require dose adjustment due to hepatic metabolism.","RenalImpairment":"Use with caution; primarily eliminated via liver but some renal excretion occurs."},"StorageAndHandling":"Store under refrigeration at 2°C to 8°C (36°F to 46°F). Protect from light."},{"GenericName":"Ifosfamide","BrandNames":["Ifex"],"DrugClass":"Alkylating Agent","MechanismOfAction":"Ifosfamide is an alkylating agent that interferes with DNA replication and RNA transcription, ultimately cross-linking DNA strands, which leads to cell death.","Pharmacodynamics":"Ifosfamide exhibits cytotoxic effects by cross-linking DNA helices unspecifically, leading to an impairment of DNA replication, RNA, and protein synthesis. This action is effective in the treatment of cancer, resulting in the destruction of rapidly proliferating cells.","OnsetOfAction":"Varies with the protocol used and condition treated, typically within days.","DurationOfAction":"Approximate duration of therapeutic action ranges from a few hours to days, depending on the administration regimen.","PeakPlasmaConcentration":"Usually within 1-2 hours after administration.","Indications":["Testicular cancer","Sarcomas","Lymphomas","Certain carcinomas"],"RoutesOfAdministration":"Intravenous (IV)","DosageForms":["Injection","Infusion"],"StrengthsOfDosageForms":["1 gram","2 grams"],"Pharmacokinetics":{"Absorption":"Complete bioavailability via intravenous administration.","Distribution":"Widely distributed in the body, including cerebrospinal fluid.","Metabolism":"Primarily metabolized by the liver through cytochrome P450 enzymes to active and inactive metabolites.","Excretion":"Mainly excreted in urine, with approximately 15% as unchanged drug."},"SideEffects":["Myelosuppression","Nausea","Vomiting","Alopecia","Hemorrhagic cystitis","Neurotoxicity"],"DrugInteractions":["Concurrent use with other nephrotoxic agents can increase renal toxicity.","Interaction with anticoagulants may alter their effect.","Co-administration with CYP3A4 inhibitors or inducers can affect ifosfamide metabolism."],"Contraindications":"Known hypersensitivity to ifosfamide or any of its components, or any other components of the formulation.","ChemicalStructure":{"MolecularFormula":"C7H15Cl2N2O2P","MolecularWeight":"261.08 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated due to teratogenic effects.","PediatricUse":"Use with caution; safety and efficacy not fully established.","GeriatricUse":"Dose adjustment may be required due to altered pharmacokinetics.","HepaticImpairment":"Use with caution and monitor for toxicity; dose adjustment may be necessary.","RenalImpairment":"Dose adjustment and careful monitoring required due to increased risk of toxicity."},"StorageAndHandling":"Store at room temperature (20-25°C / 68-77°F). Protect from light and moisture."},{"GenericName":"Bleomycin","BrandNames":["Blenoxane"],"DrugClass":"Antineoplastic antibiotic","MechanismOfAction":"Bleomycin is a cytotoxic antibiotic that causes breaks in DNA strands by inducing free radical formation. This action interferes with DNA synthesis and can lead to cell death, which is effective against rapidly-dividing cancer cells.","Pharmacodynamics":"Bleomycin primarily affects DNA synthesis by incorporating its action at different stages of the cell cycle, leading to DNA breakage and eventual cell death, particularly in cancer cells.","OnsetOfAction":"The onset of action for therapeutic effects may take several weeks, depending on the condition being treated.","DurationOfAction":"The duration of action is not clearly defined but is generally considered to correlate with the half-life in the body, which is around 2-4 hours for elimination in patients with normal renal function.","PeakPlasmaConcentration":"Bleomycin reaches peak plasma concentrations approximately 30 minutes following intravenous administration.","Indications":["Testicular cancer","Hodgkin's lymphoma","Non-Hodgkin's lymphoma","Squamous cell carcinoma","Malignant pleural effusion"],"RoutesOfAdministration":"Intravenous, Intramuscular, Subcutaneous, Intrapleural","DosageForms":["Injection solution","Powder for reconstitution"],"StrengthsOfDosageForms":["15 units/vial (powder)"],"Pharmacokinetics":{"Absorption":"Not applicable (administered intravenously, intramuscularly, subcutaneously, or intrapleurally).","Distribution":"Widely distributed in body tissues, with higher concentrations in the skin, lungs, and lymphatic tissue.","Metabolism":"Not extensively metabolized.","Excretion":"Primarily renally excreted."},"SideEffects":["Pulmonary toxicity (e.g., pneumonitis, pulmonary fibrosis)","Mucositis","Alopecia","Nausea and vomiting","Fever","Chills","Skin reactions"],"DrugInteractions":["Other nephrotoxic agents","Other drugs causing pulmonary toxicity","Vaccines","Radiation therapy"],"Contraindications":"Hypersensitivity to bleomycin; patients with pulmonary fibrosis or severe pulmonary impairment.","ChemicalStructure":{"MolecularFormula":"C55H84N17O21S3","MolecularWeight":"1414.56 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category D: There is positive evidence of risk to the fetus, but benefits may warrant use in pregnant women despite potential risks.","PediatricUse":"Safety and effectiveness in pediatric patients have been established, but monitoring for side effects is essential.","GeriatricUse":"Dose selection should be cautious, usually starting at the low end of the dosing range due to potential decreases in hepatic, renal, or cardiac function.","HepaticImpairment":"Use with caution; dose adjustment may be necessary.","RenalImpairment":"Dose adjustment is required as bleomycin is primarily excreted renally."},"StorageAndHandling":"Store vials at 2-8°C (36-46°F). Protect from light. Reconstituted solutions should be used within specific timeframes depending on storage conditions."},{"GenericName":"Methotrexate","BrandNames":["Trexall","Rheumatrex","Otrexup","Xatmep","Rasuvo"],"DrugClass":"Antimetabolite, antifolate","MechanismOfAction":"Methotrexate inhibits dihydrofolate reductase, an enzyme involved in the synthesis of tetrahydrofolate, which is required for the synthesis of purine nucleotides and thymidylate, hence interfering with the synthesis of DNA and RNA.","Pharmacodynamics":"Methotrexate inhibits rapidly dividing cells, such as cancer cells, by blocking their ability to synthesize DNA. It also exerts immunosuppressive effects.","OnsetOfAction":"Rheumatoid arthritis: 3 to 6 weeks; Antineoplastic effects may take longer to observe.","DurationOfAction":"Variable based on indication and dosing regimen.","PeakPlasmaConcentration":"Occurs 1-2 hours after oral administration.","Indications":["Rheumatoid arthritis","Psoriasis","Acute lymphoblastic leukemia (ALL)","Non-Hodgkin's lymphoma","Other cancers"],"RoutesOfAdministration":"Oral, intramuscular, intravenous, subcutaneous, intrathecal","DosageForms":["Tablet","Solution for injection","Oral solution","Prefilled autoinjector"],"StrengthsOfDosageForms":["2.5 mg tablets","7.5 mg/ml injection","2.5 mg/ml oral solution","10 mg/ml injection"],"Pharmacokinetics":{"Absorption":"Variable; well absorbed orally at low doses","Distribution":"Widely distributed; stored in tissues, crosses the blood-brain barrier","Metabolism":"Hepatic and intracellular metabolism to active polyglutamate forms","Excretion":"Primarily renal (80-90% unchanged); also biliary excretion"},"SideEffects":["Nausea","Vomiting","Mucositis","Hepatotoxicity","Myelosuppression","Nephrotoxicity","Pulmonary toxicity"],"DrugInteractions":["Nonsteroidal anti-inflammatory drugs (NSAIDs)","Penicillins","Proton pump inhibitors","Trimethoprim/sulfamethoxazole"],"Contraindications":"Pregnancy, breastfeeding, alcoholism, liver diseases, immunodeficiency syndromes, pre-existing blood dyscrasias.","ChemicalStructure":{"MolecularFormula":"C20H22N8O5","MolecularWeight":"454.45 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated due to teratogenicity","PediatricUse":"Used with caution; dosing may vary","GeriatricUse":"May require dose adjustments","HepaticImpairment":"Contraindicated in patients with significant liver impairment","RenalImpairment":"Dose adjustments may be necessary"},"StorageAndHandling":"Store at room temperature, protect from light and moisture."},{"GenericName":"Rituximab","BrandNames":["Rituxan","MabThera","Truxima"],"DrugClass":"Monoclonal antibody","MechanismOfAction":"Rituximab targets the CD20 antigen on the surface of B-cells, leading to B-cell depletion. CD20 is a transmembrane protein present on pre-B and mature B lymphocytes but absent on stem cells, pro-B cells, normal plasma cells, or other normal tissues.","Pharmacodynamics":"Rituximab induces an immune response against CD20-positive B-cells. It effectively reduces B-cells in peripheral blood and tissues, which can attenuate the autoimmune and lymphoproliferative disease activity.","OnsetOfAction":"Initial biologic response usually occurs within 24 to 48 hours after infusion.","DurationOfAction":"B-cell depletion may last for up to 6 to 12 months post-treatment, depending on the disease and regimen.","PeakPlasmaConcentration":"Peak plasma concentrations are achieved at the end of the infusion depending upon the rate and duration of administration.","Indications":["Non-Hodgkin's lymphoma","Chronic lymphocytic leukemia","Rheumatoid arthritis","Granulomatosis with polyangiitis (Wegener's granulomatosis)","Microscopic polyangiitis","Pemphigus vulgaris"],"RoutesOfAdministration":"Intravenous","DosageForms":["Intravenous infusion"],"StrengthsOfDosageForms":["100 mg/10 mL","500 mg/50 mL"],"Pharmacokinetics":{"Absorption":"Not applicable since it is administered intravenously.","Distribution":"Widely distributed in lymphatic system and other tissues.","Metabolism":"Metabolism not fully defined, but it is presumed to be metabolized and eliminated via the reticuloendothelial system.","Excretion":"Not directly excreted, clearance is dependent on binding to the CD20 antigen and internalization and destruction of B-cells."},"SideEffects":["Infusion-related reactions","Fever","Chills","Infections","Cytopenias","Rash","Fatigue","Headache"],"DrugInteractions":["May interact with other immunosuppressants","Live vaccines","Other monoclonal antibodies"],"Contraindications":"Known hypersensitivity to rituximab or murine proteins, presence of active primary or secondary central nervous system (CNS) lymphoma.","ChemicalStructure":{"MolecularFormula":"C6416H9874N1688O1987S44","MolecularWeight":"145 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Category C; may harm fetus. Use only if potential benefits justify potential risks.","PediatricUse":"Safety and effectiveness in pediatric patients not established for non-Hodgkin's lymphoma. However, approval in some pediatric indications may vary by region.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly patients and younger adult patients.","HepaticImpairment":"Formal specific studies not conducted to evaluate effects of hepatic impairment.","RenalImpairment":"No adjustment necessary for renal impairment, but closely monitor patient response and presence of severe adverse effects."},"StorageAndHandling":"Store at 2-8°C (36-46°F). Do not freeze. Protect from light. Follow proper handling procedures for monoclonal antibodies."},{"GenericName":"Trastuzumab","BrandNames":["Herceptin"],"DrugClass":"Monoclonal antibody","MechanismOfAction":"Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) and inhibits the proliferation of tumor cells that overexpress HER2.","Pharmacodynamics":"Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) by binding to HER2 overexpressed on cancer cells. It inhibits the proliferation of cells that overexpress HER2.","OnsetOfAction":"Variable, generally within a few weeks of therapy initiation.","DurationOfAction":"The effects can persist during the course of therapy and as long as HER2 is expressed.","PeakPlasmaConcentration":"Concentration varies based on regimen; steady-state concentrations can be reached after approximately 7 weeks with a standard dosing regimen.","Indications":["Breast cancer","Gastric cancer","Gastroesophageal junction adenocarcinoma"],"RoutesOfAdministration":"Intravenous","DosageForms":["Injection solution"],"StrengthsOfDosageForms":["150 mg","420 mg"],"Pharmacokinetics":{"Absorption":"Not applicable (Intravenous administration).","Distribution":"Vd: Approximately 6 L.","Metabolism":"Not extensively metabolized. Clears from serum primarily through uptake by cellular reticuloendothelial system key cells such as monocytes/macrophages.","Excretion":"Not specifically characterized, not renally excreted."},"SideEffects":["Cardiotoxicity","Infusion reactions","Pulmonary toxicity","Fever","Nausea","Diarrhea","Rash"],"DrugInteractions":["Anthracyclines (increased cardiotoxicity)","Taxanes (potential for increased neutropenia and myelosuppression)"],"Contraindications":"Hypersensitivity to trastuzumab or its components, pregnancy (due to risk of fetal harm).","ChemicalStructure":{"MolecularFormula":"C6470H10012N1726O2013S42","MolecularWeight":"145531.5 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Contraindicated due to potential for fetal harm. Women of childbearing potential should use effective contraception during treatment and for 7 months after the last dose.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No overall differences in safety or effectiveness have been observed in geriatric patients compared to younger patients. However, caution should be used due to potential greater sensitivity.","HepaticImpairment":"No specific studies; no dose adjustment is currently recommended.","RenalImpairment":"No dose adjustment is usually required."},"StorageAndHandling":"Store vials at 2°C to 8°C (36°F to 46°F) before reconstitution. Protect from light. Do not freeze."},{"GenericName":"Pembrolizumab","BrandNames":["Keytruda"],"DrugClass":"Monoclonal Antibody, Immune Checkpoint Inhibitor","MechanismOfAction":"Pembrolizumab is a humanized monoclonal IgG4 kappa antibody that binds to the PD-1 (programmed cell death protein 1) receptor on T cells, blocking the interaction with its ligands PD-L1 and PD-L2. This inhibition enhances the immune system’s ability to detect and fight tumor cells.","Pharmacodynamics":"Pembrolizumab works by enhancing the ability of the immune system to fight cancer cells by preventing PD-1 pathway-mediated inhibition of immune surveillance.","OnsetOfAction":"Variable; therapeutic effects may be observed as early as a few weeks after initiation of therapy, but full response can take several months.","DurationOfAction":"The effects on the immune system can be long-lasting, even after treatment is stopped, due to immune cell memory.","PeakPlasmaConcentration":"Peak concentrations are not well defined as the therapeutic effectiveness is related to immune modulation rather than direct concentration effects.","Indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Classical Hodgkin lymphoma","Urothelial carcinoma","Head and neck squamous cell carcinoma","Renal cell carcinoma","Colorectal cancer","Gastric cancer"],"RoutesOfAdministration":"Intravenous","DosageForms":["Injection, solution"],"StrengthsOfDosageForms":["50 mg/vial","100 mg/4 mL (25 mg/mL)"],"Pharmacokinetics":{"Absorption":"Administered intravenously, no absorption phase.","Distribution":"Steady-state volume of distribution (Vd) is approximately 7.5 L.","Metabolism":"Catabolized to small peptides and amino acids via nonspecific pathways.","Excretion":"Elimination half-life is approximately 22 days."},"SideEffects":["Fatigue","Rash","Pruritus","Diarrhea","Nausea","Cough","Decreased appetite","Constipation","Arthralgia","Dyspnea"],"DrugInteractions":["Enhanced clearance of pembrolizumab may occur with concurrent use of corticosteroids or other immunosuppressants.","Close monitoring required when combined with other immune-modulating therapies."],"Contraindications":"Severe hypersensitivity to pembrolizumab or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C6534H10004N1716O2034S40","MolecularWeight":"146,248 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the patient. Pembrolizumab can cause fetal harm when administered to a pregnant woman.","PediatricUse":"Safety and effectiveness of pembrolizumab have been established in pediatric patients aged 12 years and older with certain cancer types.","GeriatricUse":"No overall differences in safety or efficacy were observed between elderly and younger patients; however, increased sensitivity cannot be ruled out.","HepaticImpairment":"The pharmacokinetics are not significantly influenced by hepatic impairment.","RenalImpairment":"The pharmacokinetics are not significantly influenced by renal impairment."},"StorageAndHandling":"Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze."},{"GenericName":"Nivolumab","BrandNames":["Opdivo"],"DrugClass":"Anti-PD-1 monoclonal antibody","MechanismOfAction":"Nivolumab blocks the interaction between PD-1 (programmed cell death protein 1) and its ligands PD-L1 and PD-L2, enhancing the immune system's ability to recognize and destroy cancer cells.","Pharmacodynamics":"Nivolumab enhances T-cell responses, including antitumor immune responses, by inhibiting the PD-1 pathways.","OnsetOfAction":"Variable, as it depends on the type and stage of the cancer being treated.","DurationOfAction":"The therapeutic effects may persist even after cessation of therapy, but the exact duration is variable.","PeakPlasmaConcentration":"The time to peak plasma concentration is approximately 1 to 4 hours after the end of the infusion.","Indications":["Melanoma","Non-small cell lung cancer (NSCLC)","Renal cell carcinoma","Hodgkin lymphoma","Squamous cell carcinoma of the head and neck","Urothelial carcinoma","Hepatocellular carcinoma","Colorectal cancer","Esophageal cancer"],"RoutesOfAdministration":"Intravenous infusion","DosageForms":["Solution for infusion"],"StrengthsOfDosageForms":["100 mg/10 mL (10 mg/mL)","240 mg/24 mL (10 mg/mL)"],"Pharmacokinetics":{"Absorption":"N/A (administered intravenously)","Distribution":"Nivolumab has a steady-state volume of distribution (Vss) of approximately 8L.","Metabolism":"Proteolytic degradation into small peptides and amino acids.","Excretion":"Clearance of nivolumab is primarily through the reticuloendothelial system, not excreted unchanged in urine."},"SideEffects":["Fatigue","Rash","Pruritus","Diarrhea","Nausea","Cough","Dyspnea","Decreased appetite","Constipation","Arthralgia"],"DrugInteractions":["No known significant drug interactions. However, immune suppression or stimulation therapies could potentially alter its efficacy."],"Contraindications":"Nivolumab is contraindicated in patients with severe hypersensitivity to the drug or its excipients.","ChemicalStructure":{"MolecularFormula":"C6364H9874N1710O1994S40","MolecularWeight":"146,288.37 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"The safety and effectiveness of nivolumab have been established in some pediatric patients (12 years and older) for specific conditions.","GeriatricUse":"No overall differences in safety or efficacy have been observed between elderly and younger patients.","HepaticImpairment":"Limited data available, use with caution.","RenalImpairment":"Limited data available, use with caution."},"StorageAndHandling":"Store nivolumab in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original package to protect from light. Do not freeze. Do not shake."},{"GenericName":"Atezolizumab","BrandNames":["Tecentriq"],"DrugClass":"PD-L1 inhibitor (Immunotherapy)","MechanismOfAction":"Atezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody. It binds to PD-L1, a protein expressed on tumor cells and tumor-infiltrating immune cells that enables them to evade detection and elimination by the immune system.","Pharmacodynamics":"Atezolizumab blocks the interaction between PD-L1 and its receptors PD-1 and B7.1, thereby enabling the activation of T-cells and restoration of anti-tumor immune response. This leads to potential reduction in tumor growth and proliferation.","OnsetOfAction":"The onset of action can vary depending on the individual and the condition being treated, but immune responses can typically be detected a few weeks after initial administration.","DurationOfAction":"The duration of action is variable but can last for a prolonged period after the last dose due to its mechanism of action of activating the immune system.","PeakPlasmaConcentration":"Peak plasma concentrations can be observed 1.5 to 3 days after intravenous administration.","Indications":["Metastatic urothelial carcinoma","Non-small cell lung cancer","Triple-negative breast cancer","Hepatocellular carcinoma","Small cell lung cancer"],"RoutesOfAdministration":"Intravenous","DosageForms":["Solution for injection"],"StrengthsOfDosageForms":["1,200 mg/20 mL in a single-dose vial"],"Pharmacokinetics":{"Absorption":"Not applicable as it is administered intravenously, leading to 100% bioavailability.","Distribution":"The volume of distribution is approximately 6.9 L, indicating distribution primarily in plasma and extracellular fluid.","Metabolism":"Metabolized by proteolytic enzymes into small peptides and amino acids.","Excretion":"Excretion primarily through degradation; clearance is approximately 0.2 L/day."},"SideEffects":["Fatigue","Decreased appetite","Nausea","Cough","Dyspnea","Diarrhea","Rash","Fever","Urinary tract infection"],"DrugInteractions":["Corticosteroids (may reduce efficacy)","Immunosuppressants"],"Contraindications":"Hypersensitivity to atezolizumab or any of its components.","ChemicalStructure":{"MolecularFormula":"C6452H10004N1716O2014S42","MolecularWeight":"145,000 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. May cause fetal harm.","PediatricUse":"Safety and efficacy in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects.","HepaticImpairment":"No specific dose adjustment recommended. Should be used with caution.","RenalImpairment":"No specific dose adjustment recommended. Should be used with caution."},"StorageAndHandling":"Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake."},{"GenericName":"Durvalumab","BrandNames":["Imfinzi"],"DrugClass":"Monoclonal antibody","MechanismOfAction":"Durvalumab is a fully human monoclonal antibody that binds to programmed death-ligand 1 (PD-L1) and blocks its interaction with PD-1 and CD80, thereby reversing T-cell suppression and promoting the immune response against tumor cells.","Pharmacodynamics":"Durvalumab induces T-cell activity, leading to enhanced immune response against cancer cells. It acts by inhibiting immune checkpoint pathways that tumor cells exploit to evade by immune surveillance.","OnsetOfAction":"The onset of action is not clearly defined and can vary depending on the malignancy being treated and individual patient response.","DurationOfAction":"The duration of action can vary, typically correlating with the half-life of the drug and clinical response, continuing as long as the drug is administered or disease progression.","PeakPlasmaConcentration":"Varies; specific peak plasma concentration details are not usually provided for monoclonal antibodies like durvalumab.","Indications":["Unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation","Advanced bladder cancer (urothelial carcinoma) after prior therapy"],"RoutesOfAdministration":"Intravenous infusion","DosageForms":["Solution for intravenous infusion"],"StrengthsOfDosageForms":["50 mg/mL"],"Pharmacokinetics":{"Absorption":"Administered intravenously, so bioavailability is 100%","Distribution":"Volume of distribution: approximately 5.6 L","Metabolism":"Proteolytic degradation into small peptides and amino acids","Excretion":"Mainly eliminated via proteolytic metabolism"},"SideEffects":["Fatigue","Cough","Rash","Decreased appetite","Muscle or joint pain","Nausea","Infections","Pneumonitis"],"DrugInteractions":["No formal studies have been conducted, but concurrent use with immunosuppressive medications should be approached with caution due to potential for reduced efficacy.","Immune-related adverse reactions may occur when used with other immune checkpoint inhibitors"],"Contraindications":"Severe hypersensitivity to durvalumab or any of its components","ChemicalStructure":{"MolecularFormula":"C6422H9912N1694O2014S46","MolecularWeight":"approximately 146 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Use with caution; benefits should outweigh risks. It falls under Pregnancy Category D for potential risks.","PediatricUse":"Safety and effectiveness not established in pediatric patients.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients, but caution should be exercised due to possible increased incidence of adverse effects.","HepaticImpairment":"Use with caution in moderate to severe hepatic impairment; monitor closely.","RenalImpairment":"No dosage adjustment needed, but data is limited for severe renal impairment."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original package to protect from light. Do not freeze. Do not shake."},{"GenericName":"Ipilimumab","BrandNames":["Yervoy"],"DrugClass":"Monoclonal Antibody","MechanismOfAction":"Ipilimumab works as a CTLA-4 inhibitor. CTLA-4 is a negative regulator of T-cell activation. By inhibiting CTLA-4, ipilimumab enhances T-cell response, leading to increased immune response against cancer cells.","Pharmacodynamics":"Ipilimumab enhances the immune response by increasing the proliferation and activity of T-cells, leading to an anti-tumor response.","OnsetOfAction":"The onset of action varies depending on the individual and specific indicators, but initial immune-related effects can be observed within weeks.","DurationOfAction":"The effects of ipilimumab can last several weeks to months as the immune system continues to be activated.","PeakPlasmaConcentration":"Cmax is typically achieved after the end of the infusion, which lasts approximately 90 minutes.","Indications":["Unresectable or metastatic melanoma","Renal cell carcinoma","Colorectal cancer (in combination with nivolumab)","Hepatocellular carcinoma (in combination with nivolumab)"],"RoutesOfAdministration":"Intravenous (IV) infusion","DosageForms":["Intravenous infusion solution"],"StrengthsOfDosageForms":["5 mg/mL"],"Pharmacokinetics":{"Absorption":"Not applicable due to intravenous administration.","Distribution":"The volume of distribution is approximately 7.77 L.","Metabolism":"Ipilimumab is degraded by normal catabolic pathways as a protein (monoclonal antibody) and is not metabolized by cytochrome P450 enzymes.","Excretion":"Ipilimumab is primarily eliminated through catabolism. The terminal half-life is about 14.7 days."},"SideEffects":["Diarrhea","Fatigue","Rash","Pruritus","Endocrine disorders","Colitis","Hepatitis"],"DrugInteractions":["No major drug-drug interactions have been identified, but concurrent use with immunosuppressive drugs may affect activity."],"Contraindications":"There are no specific contraindications listed, but treatment should be discontinued if severe immune-mediated adverse reactions occur.","ChemicalStructure":{"MolecularFormula":"C6764H11004N1712O2010S40","MolecularWeight":"148.0 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus (Pregnancy Category C).","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly subjects and younger adults.","HepaticImpairment":"Monitor patients with hepatic impairment closely for hepatotoxicity.","RenalImpairment":"No dose adjustment is necessary for patients with renal impairment."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light."},{"GenericName":"Bevacizumab","BrandNames":["Avastin"],"DrugClass":"Monoclonal Antibodies","MechanismOfAction":"Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), which plays a role in angiogenesis. By inhibiting VEGF-A, bevacizumab reduces the growth of blood vessels in tumors.","Pharmacodynamics":"Bevacizumab binds to VEGF and prevents the interaction of VEGF with its receptors on the surface of endothelial cells, leading to decreased neovascularization and tumor blood supply.","OnsetOfAction":"Variable, generally slow due to the requirement of accumulated effects on angiogenesis.","DurationOfAction":"Weeks to months, depending on the turnover rate of angiogenic endothelial cells.","PeakPlasmaConcentration":"Approximately 2 to 3 weeks after dosing in a multi-dose regimen.","Indications":["Metastatic colorectal cancer","Non-small cell lung cancer","Glioblastoma","Metastatic renal cell carcinoma","Cervical cancer","Ovarian cancer"],"RoutesOfAdministration":"Intravenous infusion","DosageForms":["Solution for injection"],"StrengthsOfDosageForms":["100 mg/4 mL","400 mg/16 mL"],"Pharmacokinetics":{"Absorption":"No oral bioavailability; administered intravenously.","Distribution":"Volume of distribution is approximately 3.2 L.","Metabolism":"Metabolized through proteolysis into peptides and amino acids.","Excretion":"Half-life is approximately 20 days; excreted primarily by the reticuloendothelial system."},"SideEffects":["Hypertension","Proteinuria","Bleeding","Gastrointestinal perforations","Impaired wound healing","Arterial thromboembolic events"],"DrugInteractions":["May increase the risk of bleeding with anticoagulants","Avoid use with sunitinib due to increased risk of microangiopathy","Concomitant use with anthracyclines may increase risk of cardiotoxicity"],"Contraindications":"Hypersensitivity to bevacizumab or its components, poor wound healing, recent surgery within 28 days.","ChemicalStructure":{"MolecularFormula":"C6638H10160N1720O2108S44","MolecularWeight":"149 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Category C; animal studies have shown adverse effects, and use should be avoided during pregnancy unless clearly needed.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No significant differences in safety and efficacy were observed between older and younger patients.","HepaticImpairment":"No dose adjustment is needed, but data is limited.","RenalImpairment":"No dose adjustment is needed, but data is limited."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze or shake."},{"GenericName":"Cetuximab","BrandNames":["Erbitux"],"DrugClass":"EGFR inhibitor","MechanismOfAction":"Cetuximab is a chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Binding of cetuximab to EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production.","Pharmacodynamics":"Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, resulting in inhibition of autocrine stimulation of EGFR-expressing tumor cells, leading to growth inhibition, angiogenesis inhibition, and apoptosis.","OnsetOfAction":"Varies depending on the condition being treated.","DurationOfAction":"Not specifically stated, but typically requires regular dosing due to half-life.","PeakPlasmaConcentration":"2.3 µg/mL (dose-dependent)","Indications":["Metastatic colorectal cancer","Head and neck cancer"],"RoutesOfAdministration":"Intravenous infusion","DosageForms":["Injection"],"StrengthsOfDosageForms":["100 mg/50 mL (2 mg/mL)","200 mg/100 mL (2 mg/mL)"],"Pharmacokinetics":{"Absorption":"Not applicable as it is administered intravenously.","Distribution":"Volume of distribution is approximately 2.9 L/m2.","Metabolism":"Not extensively metabolized; degraded by standard protein catabolism pathways.","Excretion":"Not well defined; primarily eliminated via slow metabolism."},"SideEffects":["Infusion reactions","Skin rash","Hypomagnesemia","Hypocalcemia","Hypokalemia","Fatigue","Diarrhea","Nausea"],"DrugInteractions":["Warfarin","Irinotecan","Other EGFR inhibitors"],"Contraindications":"Hypersensitivity to cetuximab or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C6488H10042N1732O2023S36","MolecularWeight":"145.78 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Category C - Risk cannot be ruled out.","PediatricUse":"The safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness observed in elderly in clinical trials.","HepaticImpairment":"No dose adjustment is required; however, use with caution.","RenalImpairment":"No dose adjustment is required; assess renal function prior to initiating therapy."},"StorageAndHandling":"Store vials in a refrigerator at 2° to 8°C (36° to 46°F). Do not freeze or shake. Protect from light."},{"GenericName":"Erlotinib","BrandNames":["Tarceva"],"DrugClass":"Tyrosine Kinase Inhibitor","MechanismOfAction":"Erlotinib inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), which is expressed on the cell surface of both normal and cancer cells. By blocking this receptor, erlotinib interferes with cell signaling pathways that promote cell growth and survival.","Pharmacodynamics":"Erlotinib acts by inhibiting the EGFR tyrosine kinase, leading to reduced cell proliferation and increased apoptosis in tumor cells that overexpress EGFR.","OnsetOfAction":"Varies depending on the individual patient and type of cancer; improvements in symptoms or tumor size may take several weeks to occur.","DurationOfAction":"The half-life is about 36 hours, but therapeutic effects may persist due to sustained receptor occupancy.","PeakPlasmaConcentration":"Achieved approximately 4 hours after oral administration under fasting conditions.","Indications":["Non-small cell lung cancer (NSCLC) with EGFR mutations","Pancreatic cancer (in combination with gemcitabine)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["25 mg","100 mg","150 mg"],"Pharmacokinetics":{"Absorption":"Oral bioavailability is approximately 60% in fasting conditions and increases to almost 100% when taken with food.","Distribution":"Extensively distributed throughout the body with a volume of distribution of approximately 232 liters.","Metabolism":"Primarily metabolized in the liver by cytochrome P450 enzymes, predominantly CYP3A4, and to a lesser extent by CYP1A2 and CYP1A1.","Excretion":"Approximately 83% is eliminated in feces and about 8% in urine, mainly as metabolites."},"SideEffects":["Rash","Diarrhea","Anorexia","Fatigue","Dyspnea","Cough","Nausea"],"DrugInteractions":["CYP3A4 inhibitors (e.g., ketoconazole) may increase exposure to erlotinib","CYP3A4 inducers (e.g., rifampicin) may decrease erlotinib levels","Proton pump inhibitors may reduce erlotinib absorption"],"Contraindications":"Hypersensitivity to erlotinib or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C22H23N3O4","MolecularWeight":"393.44 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus; classified as Category D for pregnancy.","PediatricUse":"Safety and efficacy have not been established in pediatric patients.","GeriatricUse":"No significant differences in safety and efficacy with respect to younger patients, but greater sensitivity in some older individuals cannot be ruled out.","HepaticImpairment":"Increased exposure may occur; close monitoring is recommended.","RenalImpairment":"No dose adjustment is needed for mild to moderate renal impairment, but caution is advised in severe cases."},"StorageAndHandling":"Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Protect from light and moisture."},{"GenericName":"Imatinib","BrandNames":["Gleevec","Glivec"],"DrugClass":"Tyrosine kinase inhibitor","MechanismOfAction":"Imatinib works by inhibiting the BCR-ABL tyrosine kinase, which is the result of a chromosomal translocation. This enzyme is constitutively active and leads to the uncontrolled growth of the cancer cells. By inhibiting this kinase, imatinib suppresses proliferation and induces apoptosis in BCR-ABL–expressing cells.","Pharmacodynamics":"Imatinib exerts its pharmacodynamic effect by selectively inhibiting the proliferation of BCR-ABL positive cells, leading to anti-tumor activity in conditions like chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).","OnsetOfAction":"The onset of action of imatinib can vary, with some hematological responses observed within weeks, but best response may take several months.","DurationOfAction":"The duration of action is linked to the continued presence of active drug in the system, which is typically maintained with regular daily dosing.","PeakPlasmaConcentration":"Peak plasma concentrations are achieved approximately 2-4 hours after oral administration of imatinib.","Indications":["Chronic myeloid leukemia (CML)","Acute lymphoblastic leukemia (ALL)","Gastrointestinal stromal tumors (GIST)","Chronic eosinophilic leukemia","Hypereosinophilic syndrome"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets","Capsules"],"StrengthsOfDosageForms":["100 mg tablets","400 mg tablets"],"Pharmacokinetics":{"Absorption":"Imatinib is well absorbed with high oral bioavailability.","Distribution":"Imatinib is extensively distributed throughout the body, with a volume of distribution of approximately 490 L.","Metabolism":"It is metabolized primarily by the liver, with CYP3A4 being the main enzyme responsible.","Excretion":"Approximately 68% is excreted in feces and 13% in urine, with parent drug and its metabolites contributing to the total excretion."},"SideEffects":["Nausea","Vomiting","Edema","Muscle cramps","Fatigue","Rash"],"DrugInteractions":["CYP3A4 inhibitors (like ketoconazole) can increase imatinib levels.","CYP3A4 inducers (like rifampin) can decrease imatinib levels.","Warfarin (increased risk of bleeding)"],"Contraindications":"Imatinib is contraindicated in patients with known hypersensitivity to the drug or any of its components.","ChemicalStructure":{"MolecularFormula":"C29H31N7O","MolecularWeight":"493.60 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Imatinib is categorized as pregnancy category D. It may cause fetal harm when administered to a pregnant woman.","PediatricUse":"Approved for use in children with CML and Ph+ ALL, but dosage adjustment is required based on body surface area.","GeriatricUse":"Older patients may require dose adjustments due to increased risk of adverse effects.","HepaticImpairment":"Dose adjustment may be necessary, and liver function should be monitored.","RenalImpairment":"Careful monitoring and possible dosage adjustment are recommended."},"StorageAndHandling":"Store imatinib at room temperature, between 15 - 30°C (59 - 86°F), away from light and moisture."},{"GenericName":"Dasatinib","BrandNames":["Sprycel"],"DrugClass":"Tyrosine kinase inhibitor","MechanismOfAction":"Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL, a fusion protein with constitutively active kinase activity found in most chronic myeloid leukemia (CML) cases. It also inhibits other kinases such as SRC, KIT, PDGFR.","Pharmacodynamics":"Dasatinib inhibits proliferation and induces apoptosis in leukemic cells with the Philadelphia chromosome positive (Ph+) including CML and acute lymphoblastic leukemia (ALL).","OnsetOfAction":"The onset of action varies depending on the indication and individual response.","DurationOfAction":"Dasatinib has a half-life of approximately 3-5 hours, but the duration of therapeutic action may be longer due to sustained kinase inhibition.","PeakPlasmaConcentration":"Achieved within 0.5 to 3 hours post-dose.","Indications":["Chronic Myeloid Leukemia (CML)","Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["20 mg","50 mg","70 mg","80 mg","100 mg","140 mg"],"Pharmacokinetics":{"Absorption":"Rapidly absorbed following oral administration.","Distribution":"Widely distributed with a volume of distribution roughly 2500 L.","Metabolism":"Primarily metabolized in the liver via CYP3A4 to active and inactive metabolites.","Excretion":"Excreted mainly in feces (approximately 85%); 4% is excreted in urine."},"SideEffects":["Myelosuppression","Bleeding events","Fluid retention","Diarrhea","Rash","Fatigue"],"DrugInteractions":["Strong CYP3A4 inhibitors (e.g., ketoconazole)","Strong CYP3A4 inducers (e.g., rifampin)","Grapefruit juice","Antacids","St. John's Wort"],"Contraindications":"Hypersensitivity to dasatinib or any excipients in the formulation.","ChemicalStructure":{"MolecularFormula":"C22H26ClN7O2S","MolecularWeight":"488.01 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use should be avoided unless absolutely necessary; potential fetal risk.","PediatricUse":"Safety and efficacy established in pediatric patients 1 year and older with Ph+ CML.","GeriatricUse":"No significant differences observed in safety relative to younger populations; caution advised due to potential decreased organ function.","HepaticImpairment":"Use caution; increased dasatinib exposure may occur.","RenalImpairment":"No dose adjustment required, but caution is advised."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)."},{"GenericName":"Nilotinib","BrandNames":["Tasigna"],"DrugClass":"Tyrosine kinase inhibitor","MechanismOfAction":"Nilotinib is a selective inhibitor of the BCR-ABL tyrosine kinase, an abnormal enzyme found in cells with Philadelphia chromosome positive chronic myeloid leukemia (CML). It blocks the proliferation of BCR-ABL positive cells by inhibiting their ability to transmit growth signals.","Pharmacodynamics":"Nilotinib binds to and inhibits the BCR-ABL tyrosine kinase, reducing cell proliferation and inducing apoptosis in BCR-ABL positive cells. It has shown effectiveness in patients with resistance or intolerance to prior therapies including imatinib.","OnsetOfAction":"The onset of action can vary, but clinical improvements may be observed within weeks of starting treatment.","DurationOfAction":"Nilotinib has a long half-life, allowing for twice-daily dosing, which suggests sustained activity with regular dosing.","PeakPlasmaConcentration":"The peak plasma concentration of nilotinib is typically observed 3 hours after oral administration.","Indications":["Chronic myeloid leukemia (CML) in chronic phase","CML in accelerated phase and blast crisis in adults who are resistant or intolerant to prior therapies"],"RoutesOfAdministration":"Oral","DosageForms":["Capsules"],"StrengthsOfDosageForms":["150 mg","200 mg"],"Pharmacokinetics":{"Absorption":"Nilotinib is absorbed primarily in the intestinal tract with an approximate bioavailability of 30%. Human plasma concentrations are dose proportional.","Distribution":"It is extensively distributed in tissues with a volume of distribution of approximately 4200 L.","Metabolism":"Nilotinib is hepatically metabolized primarily by CYP3A4.","Excretion":"Excretion is primarily through the feces with very little renal excretion."},"SideEffects":["Rash","Pruritus","Nausea","Fatigue","Headache","Vomiting","Diarrhea","QT prolongation","Myelosuppression"],"DrugInteractions":["Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole) may increase nilotinib concentrations","St. John's Wort may decrease nilotinib concentrations","Avoid grapefruit and grapefruit juice which can increase plasma concentrations of nilotinib"],"Contraindications":"Nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, and long QT syndrome. Patients with clinically significant, uncontrolled heart disease should not use nilotinib.","ChemicalStructure":{"MolecularFormula":"C28H22F3N7O","MolecularWeight":"529.52 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Should be avoided in pregnancy due to potential risk to the fetus. Effective contraception should be used.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No significant age-related differences in efficacy or safety profile, but caution should be applied due to greater sensitivity in some older individuals.","HepaticImpairment":"Mild, moderate, and severe hepatic impairment increases nilotinib exposure, requiring close monitoring and possible dose adjustment.","RenalImpairment":"Caution is advised as mild renal impairment does not significantly increase nilotinib exposure. Severe renal impairment or end-stage renal disease has not been studied."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F). Protect from moisture."},{"GenericName":"Ponatinib","BrandNames":["Iclusig"],"DrugClass":"Tyrosine kinase inhibitor","MechanismOfAction":"Ponatinib is a tyrosine kinase inhibitor that selectively targets BCR-ABL, an abnormal tyrosine kinase that drives chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It binds to the ATP-binding site of the BCR-ABL protein, blocking its activity.","Pharmacodynamics":"Ponatinib shows potent activity against various forms of the BCR-ABL protein, including those resistant to other tyrosine kinase inhibitors, such as T315I mutation. It reduces proliferation and induces apoptosis in cells expressing BCR-ABL.","OnsetOfAction":"Ponatinib can show reductions in leukemic cells within weeks.","DurationOfAction":"Ponatinib's effects can persist with daily administration; however, specific duration varies based on individual patient response and pharmacokinetic profile.","PeakPlasmaConcentration":"Approximately 4-6 hours after dosing.","Indications":["Chronic myeloid leukemia (CML) in chronic, accelerated, or blast phase","Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)","Treatment of patients who have failed other tyrosine kinase inhibitors or have the T315I mutation"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["15 mg","30 mg","45 mg"],"Pharmacokinetics":{"Absorption":"Ponatinib is well absorbed with an oral bioavailability of nearly 70%.","Distribution":"Widely distributed in body tissues with a volume of distribution of approximately 1223 L.","Metabolism":"Metabolized primarily in the liver by CYP3A4 enzyme.","Excretion":"Excreted in feces (87%) and urine (5%)."},"SideEffects":["Hypertension","Rash","Abdominal pain","Fatigue","Headache","Constipation","Nausea","Dry skin"],"DrugInteractions":["CYP3A4 inhibitors (e.g., ketoconazole) can increase ponatinib levels.","CYP3A4 inducers (e.g., rifampin) can decrease ponatinib levels."],"Contraindications":"Hypersensitivity to ponatinib or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C29H27F3N6O","MolecularWeight":"532.57 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Ponatinib can cause fetal harm when administered to a pregnant woman and should be used only if the potential benefit justifies the potential risk.","PediatricUse":"The safety and effectiveness of ponatinib in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness were observed between older and younger patients.","HepaticImpairment":"Use with caution; dose adjustments may be necessary.","RenalImpairment":"No dose adjustment is required for mild to moderate renal impairment, but caution should be exercised."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)."},{"GenericName":"Bosutinib","BrandNames":["Bosulif"],"DrugClass":"Tyrosine kinase inhibitor","MechanismOfAction":"Bosutinib inhibits the BCR-ABL kinase activity and reduces the proliferation of Philadelphia chromosome-positive cell lines.","Pharmacodynamics":"Bosutinib acts as a dual inhibitor of Src and Abl kinases, which leads to apoptosis and decreased cell proliferation in cancerous cells.","OnsetOfAction":"Not well characterized, but therapeutic effects are observed after regular use as per treatment schedule.","DurationOfAction":"Not well defined for the pharmacodynamic effect. The plasma half-life is approximately 22-34 hours.","PeakPlasmaConcentration":"Achieved 4-6 hours after oral administration.","Indications":["Chronic myelogenous leukemia (CML)"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["100 mg","400 mg","500 mg"],"Pharmacokinetics":{"Absorption":"Absorption is increased with food. Bioavailability is around 34% when administered with food.","Distribution":"Volume of distribution is approximately 6080 L.","Metabolism":"Metabolized primarily by CYP3A4 to inactive metabolites.","Excretion":"Eliminated via feces (91%) and urine (3.3%)."},"SideEffects":["Diarrhea","Nausea","Thrombocytopenia","Rash","Elevated liver enzymes","Abdominal pain"],"DrugInteractions":["Strong CYP3A4 inhibitors (e.g., ketoconazole)","Strong CYP3A4 inducers (e.g., rifampin)","Antacids and proton pump inhibitors"],"Contraindications":"Hypersensitivity to bosutinib or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C26H29Cl2N5O3","MolecularWeight":"530.45 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate data on the use of bosutinib in pregnant women. It can cause fetal harm.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No overall differences in safety or effectiveness were observed between geriatric and younger patients.","HepaticImpairment":"Use with caution in patients with hepatic impairment. Dose adjustments may be necessary.","RenalImpairment":"Dose adjustments are recommended for patients with renal impairment."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F). Protect from moisture."},{"GenericName":"Tofacitinib","BrandNames":["Xeljanz"],"DrugClass":"Janus kinase (JAK) inhibitors","MechanismOfAction":"Tofacitinib inhibits Janus kinase enzymes, which are intracellular enzymes that transmit cytokine-mediated signals via the JAK-STAT pathway. By blocking these enzymes, tofacitinib disrupts the production of pro-inflammatory cytokines.","Pharmacodynamics":"Tofacitinib modulates the immune response by reducing the levels of circulating cytokines. It leads to decreased inflammation and immune cell activity.","OnsetOfAction":"2 to 4 weeks for rheumatoid arthritis symptom relief","DurationOfAction":"12 hours for each dose","PeakPlasmaConcentration":"Approximately 0.5 to 1 hour after oral administration","Indications":["Rheumatoid arthritis","Psoriatic arthritis","Ulcerative colitis"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet"],"StrengthsOfDosageForms":["5 mg","11 mg (extended-release tablet)"],"Pharmacokinetics":{"Absorption":"Well absorbed orally with a bioavailability of approximately 74%.","Distribution":"Widely distributed with a volume of distribution of 87 L.","Metabolism":"Primarily metabolized in the liver by CYP3A4 and CYP2C19.","Excretion":"Excreted primarily in the urine (70%) and feces (30%) as metabolites."},"SideEffects":["Infections","Headache","Diarrhea","Hypertension","Anemia","Increased liver enzymes"],"DrugInteractions":["Potent CYP3A4 inhibitors (e.g., ketoconazole) increase tofacitinib levels.","CYP3A4 inducers (e.g., rifampin) decrease tofacitinib levels."],"Contraindications":"Known hypersensitivity to tofacitinib or any component of the product.","ChemicalStructure":{"MolecularFormula":"C16H20N6O","MolecularWeight":"312.37 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed and the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy not established in patients under 18 years of age.","GeriatricUse":"No overall differences in safety or effectiveness observed between older and younger patients, but caution is suggested.","HepaticImpairment":"Dose adjustment may be necessary; not recommended for severe hepatic impairment.","RenalImpairment":"Dose adjustment recommended for moderate to severe renal impairment."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F). Protect from moisture."},{"GenericName":"Baricitinib","BrandNames":["Olumiant"],"DrugClass":"Janus kinase (JAK) inhibitor","MechanismOfAction":"Baricitinib inhibits Janus kinase enzymes, which are part of the signaling pathway for various cytokines and growth factors that mediate signaling through transcription. By inhibiting these enzymes, baricitinib modulates the immune response.","Pharmacodynamics":"Baricitinib decreases inflammation and immune response by reversing the overactivation of the JAK-STAT pathway, which plays a role in immune system signaling.","OnsetOfAction":"1 to 2 weeks for initial response; may take up to 4 to 8 weeks for full response.","DurationOfAction":"12 to 24 hours after a single dose.","PeakPlasmaConcentration":"Approximately 1 hour post-dose.","Indications":["Rheumatoid Arthritis","COVID-19 (investigational usage for severe cases)","Alopecia Areata"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["1 mg","2 mg","4 mg"],"Pharmacokinetics":{"Absorption":"Following oral administration, baricitinib is rapidly absorbed with a mean oral bioavailability of approximately 79%.","Distribution":"The volume of distribution at steady-state is approximately 76 L.","Metabolism":"Minimal metabolism, primarily by CYP3A4.","Excretion":"Approximately 75% in urine and 20% in feces; excreted predominantly as unchanged drug."},"SideEffects":["Upper respiratory tract infections","Nausea","Headaches","Increased liver enzymes","Hypertension","Fatigue"],"DrugInteractions":["Rifampin (may decrease efficacy of baricitinib)","Biologic immunosuppressive drugs (increased risk of infection)","Live vaccines (avoid concurrent use)"],"Contraindications":"Known hypersensitivity to baricitinib or any component of the formulation.","ChemicalStructure":{"MolecularFormula":"C16H17N7O2S","MolecularWeight":"371.42 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate data on the developmental risk associated with the use of baricitinib in pregnant women.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects.","HepaticImpairment":"Use with caution in patients with moderate to severe hepatic impairment.","RenalImpairment":"Dose adjustment is required in patients with moderate to severe renal impairment."},"StorageAndHandling":"Store at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)."},{"GenericName":"Upadacitinib","BrandNames":["Rinvoq"],"DrugClass":"Janus kinase (JAK) inhibitor","MechanismOfAction":"Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor. JAK enzymes transmit intracellular signals via cytokine or growth factor receptor interactions with extracellular ligands. By inhibiting JAKs, upadacitinib modulates the pathway and reduces inflammation.","Pharmacodynamics":"Upadacitinib decreases inflammation and modulates the immune system by selectively inhibiting signaling pathways involving JAKs, crucial for the hematopoiesis and immune function.","OnsetOfAction":"May vary by condition, but effects can generally be seen within a few weeks.","DurationOfAction":"Half-life is approximately 6-16 hours, but the clinical effects might persist for longer after stopping the drug.","PeakPlasmaConcentration":"Peak plasma concentrations occur approximately 2-4 hours after administration.","Indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Atopic dermatitis","Ulcerative colitis"],"RoutesOfAdministration":"Oral","DosageForms":["Tablets"],"StrengthsOfDosageForms":["15 mg","30 mg"],"Pharmacokinetics":{"Absorption":"Well absorbed, with an absolute bioavailability of approximately 80%","Distribution":"Volume of distribution is approximately 450 L","Metabolism":"Primarily metabolized by CYP3A4, with minor contributions by CYP2D6","Excretion":"Eliminated via urine (24%) and feces (38%) as metabolites"},"SideEffects":["Infections","Nausea","Elevated liver enzymes","Hypertension","Headache"],"DrugInteractions":["CYP3A4 inhibitors","CYP3A4 inducers","Anticoagulants"],"Contraindications":"Known hypersensitivity to upadacitinib or any of its components","ChemicalStructure":{"MolecularFormula":"C17H19N7O2","MolecularWeight":"369.4 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Due to lack of data, use only if potential benefits justify potential risks to the fetus.","PediatricUse":"Safety and efficacy not established in children under 18.","GeriatricUse":"No overall differences in efficacy or safety were observed between older and younger patients.","HepaticImpairment":"Mild or moderate impairment does not require dose adjustment. Not recommended in severe impairment.","RenalImpairment":"No significant dosage adjustment needed for mild to moderate impairment."},"StorageAndHandling":"Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture and light."},{"GenericName":"Adalimumab","BrandNames":["Humira"],"DrugClass":"Tumor Necrosis Factor (TNF) Inhibitor","MechanismOfAction":"Adalimumab binds to tumor necrosis factor-alpha (TNF-α), blocking its interaction with the p55 and p75 cell surface TNF receptors. This action inhibits the inflammatory processes associated with autoimmune diseases.","Pharmacodynamics":"It reduces the inflammatory response associated with autoimmune diseases, resulting in decreased symptoms like pain and joint damage.","OnsetOfAction":"In rheumatoid arthritis, onset can be observed as early as 1 week, with significant clinical response typically occurring by 3 months.","DurationOfAction":"The effects may last for several weeks, typically requiring dosing every 1 to 2 weeks depending on the indication.","PeakPlasmaConcentration":"Occurs approximately 131 hours (5.5 days) following a 40 mg subcutaneous administration, though pharmacokinetics may vary in different populations.","Indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis","Plaque psoriasis","Juvenile idiopathic arthritis","Hidradenitis suppurativa","Uveitis"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Pre-filled syringe","Pen-injector"],"StrengthsOfDosageForms":["40 mg/0.8 mL","20 mg/0.4 mL (pediatric)"],"Pharmacokinetics":{"Absorption":"Following a subcutaneous dose, absorption is slow with peak concentrations attained within 5.5 days.","Distribution":"The apparent volume of distribution (Vd/F) is approximately 5-6 L.","Metabolism":"Not well understood, but involves catabolism into small peptides and amino acids.","Excretion":"Adalimumab is presumed to be excreted and degraded into small peptides and amino acids, as with other antibodies. The half-life is approximately 2 weeks."},"SideEffects":["Injection site reactions","Upper respiratory tract infections","Headache","Rash","Nausea","Serious infections (e.g., tuberculosis, fungal, viral)","Malignancies (e.g., lymphoma)"],"DrugInteractions":["Live vaccines","Anakinra","Abatacept"],"Contraindications":"Hypersensitivity to adalimumab or any of its components.","ChemicalStructure":{"MolecularFormula":"C6428H9912N1694O1987S46","MolecularWeight":"~148 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed and if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Approved for certain conditions in pediatric patients; safety and effectiveness for other indications in children have not been established.","GeriatricUse":"Care should be taken as elderly may have a higher incidence of infections.","HepaticImpairment":"No specific dosage adjustments are currently recommended but should be used with caution.","RenalImpairment":"No specific dosage adjustments are currently recommended but should be used with caution."},"StorageAndHandling":"Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. If needed, it can be stored at room temperature for up to 14 days, but must be discarded if not used within this period."},{"GenericName":"Etanercept","BrandNames":["Enbrel"],"DrugClass":"Tumor necrosis factor (TNF) inhibitor","MechanismOfAction":"Etanercept is a soluble receptor fusion protein that acts as a decoy receptor for TNF-alpha. It competitively inhibits the binding of TNF-alpha to its cell surface receptor, thereby interfering with endogenous TNF-alpha activity and mitigating its effects in inflammatory processes.","Pharmacodynamics":"Etanercept binds specifically to TNF and blocks its interaction with cell surface TNF receptors, reducing inflammation.","OnsetOfAction":"1 to 2 weeks","DurationOfAction":"Variable, depending on dosing frequency","PeakPlasmaConcentration":"48-60 hours post-dose","Indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Plaque psoriasis","Polyarticular juvenile idiopathic arthritis"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Single-use prefilled syringe","Single-use prefilled auto-injector","Lyophilized powder for reconstitution"],"StrengthsOfDosageForms":["25 mg (lyophilized powder)","50 mg/mL (prefilled syringe and auto-injector)"],"Pharmacokinetics":{"Absorption":"Approximately 58% bioavailability with subcutaneous administration.","Distribution":"Distributed mainly in extracellular fluid; volume of distribution approximately 7.6 L.","Metabolism":"Primarily degraded in reticuloendothelial system.","Excretion":"Not significantly excreted in urine, clearance primarily through the reticuloendothelial system."},"SideEffects":["Injection site reactions","Infections","Allergic reactions","Headache","Rash"],"DrugInteractions":["Live vaccines","Anakinra","Abatacept"],"Contraindications":"Hypersensitivity to etanercept or any of its components","ChemicalStructure":{"MolecularFormula":"C2224H3475N621O698S36","MolecularWeight":"51200 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B. Should be used only if clearly needed.","PediatricUse":"Approved for use in children aged 2 years and older for specific indications.","GeriatricUse":"No significant differences observed compared to younger patients, but consideration of comorbidities is recommended.","HepaticImpairment":"No specific dose adjustments recommended.","RenalImpairment":"No specific dose adjustments recommended."},"StorageAndHandling":"Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. May be stored at room temperature for a maximum of 14 days."},{"GenericName":"Infliximab","BrandNames":["Remicade","Inflectra","Renflexis","Ixifi","Avsola"],"DrugClass":"Monoclonal Antibody; Tumor Necrosis Factor (TNF) Inhibitor","MechanismOfAction":"Infliximab is a chimeric IgG1κ monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα), blocking its inflammatory effect in autoimmune diseases.","Pharmacodynamics":"By neutralizing TNFα, infliximab reduces inflammation and modifies the immune response in patients with autoimmune diseases, leading to a decrease in symptoms and progression of disease. It acts as an immunosuppressant.","OnsetOfAction":"3 to 7 days after administration","DurationOfAction":"Weeks to several months, depending on condition treated and patient response","PeakPlasmaConcentration":"3 to 6 days after infusion","Indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis"],"RoutesOfAdministration":"Intravenous infusion","DosageForms":["Injectable Solution"],"StrengthsOfDosageForms":["100 mg/vial"],"Pharmacokinetics":{"Absorption":"Not applicable (intravenous administration)","Distribution":"Volume of distribution is 3 to 6 liters","Metabolism":"Not extensively metabolized; primarily cleared via catabolism","Excretion":"Half-life is approximately 7.7 to 12 days; clearance involves reticuloendothelial system"},"SideEffects":["Infusion-related reactions","Infections (upper respiratory tract infections, pneumonia)","Headache","Abdominal pain","Nausea","Rash"],"DrugInteractions":["Anakinra","Abatacept","Live vaccines"],"Contraindications":"Patients with moderate to severe heart failure, patients with previous severe hypersensitivity to infliximab or other murine proteins","ChemicalStructure":{"MolecularFormula":"C6428H9912N1694O1987S46","MolecularWeight":"144190.3 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Category B; use only if clearly needed","PediatricUse":"Approved for use in Crohn's disease and ulcerative colitis in children older than 6 years","GeriatricUse":"Use with caution due to increased risk of infections","HepaticImpairment":"No specific dosing recommendations; monitor for adverse effects","RenalImpairment":"No specific dosing recommendations; monitor for adverse effects"},"StorageAndHandling":"Store vials at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze or shake."},{"GenericName":"Certolizumab Pegol","BrandNames":["Cimzia"],"DrugClass":"Tumor Necrosis Factor (TNF) Inhibitor","MechanismOfAction":"Certolizumab pegol is a humanized antibody fragment that binds with high affinity to soluble and membrane TNF-alpha, inhibiting its action. By doing so, it neutralizes the pro-inflammatory effects of TNF-alpha, reducing inflammation and other systemic responses associated with autoimmune conditions.","Pharmacodynamics":"Certolizumab reduces the effects of TNF-alpha, a key mediator in inflammatory processes, which results in decreased inflammation and symptomatic relief in conditions like rheumatoid arthritis and Crohn's disease.","OnsetOfAction":"The onset of action can be as early as one to two weeks after initial administration, although clinical improvements may be observed within a few days for some patients.","DurationOfAction":"The therapeutic effects typically last for two to four weeks per dose, correlating with its dosing schedule of every two or four weeks depending on the condition being treated.","PeakPlasmaConcentration":"The maximum plasma concentration is reached approximately 54 to 171 hours after dosing.","Indications":["Rheumatoid Arthritis","Ankylosing Spondylitis","Psoriatic Arthritis","Crohn's Disease","Non-radiographic Axial Spondyloarthritis"],"RoutesOfAdministration":"Subcutaneous","DosageForms":["Injectable solution"],"StrengthsOfDosageForms":["200 mg/ml"],"Pharmacokinetics":{"Absorption":"Following subcutaneous administration, maximum concentration is reached within 54 to 171 hours.","Distribution":"It has a volume of distribution of approximately 4 to 6 liters, suggesting limited distribution outside the vascular compartment.","Metabolism":"Certolizumab is broken down into smaller peptides and amino acids.","Excretion":"Excreted as small peptides and amino acids, with clearance half-life typically around 14 days."},"SideEffects":["Upper respiratory tract infections","Rash","Urinary tract infection","Headache","Hypertension","Nausea"],"DrugInteractions":["Biologic DMARDs including abatacept and anakinra","Live vaccines","CYP450 substrates may be affected due to modulation by pro-inflammatory cytokines"],"Contraindications":"Patients with known hypersensitivity to certolizumab or any of its components.","ChemicalStructure":{"MolecularFormula":"C65H92N18O17S2","MolecularWeight":"1446.6 g/mol (peptide moiety only, not including PEG)"},"UseInSpecialPopulations":{"Pregnancy":"Category B; animal studies do not show harm to the fetus but there are no adequate studies in pregnant women. It is recommended to use only if clearly needed.","PediatricUse":"Safety and effectiveness in pediatric patients has not been established.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","HepaticImpairment":"No specific studies have been conducted, but no dosage adjustment is typically required.","RenalImpairment":"No specific studies have been conducted, and no dosage adjustment is typically required."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and store in the original carton until time of administration."},{"GenericName":"Golimumab","BrandNames":["Simponi","Simponi Aria"],"DrugClass":"Tumor necrosis factor (TNF) blocker","MechanismOfAction":"Golimumab is a human monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine. By binding to TNFα, golimumab inhibits its interaction with TNF receptors, thereby reducing inflammation and other symptoms associated with autoimmune diseases.","Pharmacodynamics":"Golimumab exerts its therapeutic effects by reducing the activity of TNF-alpha, thus leading to decreased inflammation and modified immune response in diseases like rheumatoid arthritis, ankylosing spondylitis, and ulcerative colitis.","OnsetOfAction":"The onset of action can vary but is generally observed within a few weeks after starting treatment.","DurationOfAction":"The duration of action is typically related to dosing interval, with monthly administration maintaining efficacy.","PeakPlasmaConcentration":"Peak plasma concentrations are reached approximately 2-6 days following subcutaneous administration.","Indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Ankylosing Spondylitis","Ulcerative Colitis"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Prefilled syringe","Autoinjector","Intravenous infusion"],"StrengthsOfDosageForms":["50 mg/0.5 mL for subcutaneous use","100 mg/1 mL for subcutaneous use","Intravenous infusion 50 mg/4 mL vial"],"Pharmacokinetics":{"Absorption":"After subcutaneous administration, golimumab is absorbed with peak concentrations occurring approximately 2-6 days after dosing.","Distribution":"The volume of distribution is approximately 58-126 mL/kg.","Metabolism":"Golimumab is expected to be degraded into small peptides and amino acids via catabolism.","Excretion":"The exact route of excretion is not well characterized but is presumed to be through plasma clearance after degradation."},"SideEffects":["Infections (upper respiratory, urinary tract)","Injection site reactions","Headache","Nausea","Hypertension"],"DrugInteractions":["Concomitant use with live vaccines","Other TNF blockers","Certain biologics"],"Contraindications":"Sepsis","ChemicalStructure":{"MolecularFormula":"C6534H10066N1712O2032S42","MolecularWeight":"150 kDa (approximately)"},"UseInSpecialPopulations":{"Pregnancy":"Insufficient data; use only if clearly needed.","PediatricUse":"Approved for certain conditions in children over 2 years.","GeriatricUse":"No specific dosage adjustments are recommended, yet caution due to higher susceptibility to infections.","HepaticImpairment":"No specific studies, use with caution.","RenalImpairment":"No specific studies, use with caution."},"StorageAndHandling":"Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Keep in original packaging until use."},{"GenericName":"Tocilizumab","BrandNames":["Actemra"],"DrugClass":"Interleukin-6 receptor antagonist","MechanismOfAction":"Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), inhibiting IL-6-mediated signaling through these receptors. This blockade results in inhibition of IL-6 receptor signaling, which otherwise would activate a number of cellular systems leading to inflammation and other immune responses.","Pharmacodynamics":"Through its action of blocking IL-6 receptors, tocilizumab reduces inflammation and immune response, which are elevated in conditions like rheumatoid arthritis and cytokine release syndrome.","OnsetOfAction":"Variable depending on condition treated; symptomatic improvement can be observed within weeks for conditions like rheumatoid arthritis.","DurationOfAction":"Varies with condition and dosing regimen, effects can last for weeks to months depending on the individual and the indication.","PeakPlasmaConcentration":"Peak plasma concentrations usually occur between 1 and 2 hours post-infusion.","Indications":["Rheumatoid arthritis","Systemic juvenile idiopathic arthritis","Giant cell arteritis","Cytokine release syndrome","Polyarticular juvenile idiopathic arthritis"],"RoutesOfAdministration":"Intravenous and subcutaneous","DosageForms":["Injection solution"],"StrengthsOfDosageForms":["20 mg/mL"],"Pharmacokinetics":{"Absorption":"Subcutaneous absorption is slow, with peak concentrations reached in about 2-8 days post-administration.","Distribution":"Apparent volume of distribution is approximately 6-7 L.","Metabolism":"Metabolized via standard protein catabolism pathways.","Excretion":"Elimination half-life ranges between 8 and 14 days, depending on dose and condition."},"SideEffects":["Infections","Gastrointestinal perforation","Neutropenia","Hepatotoxicity","Infusion reactions or hypersensitivity reactions","Hyperlipidemia","Increased liver enzymes"],"DrugInteractions":["May interact with drugs metabolized by CYP450 enzymes due to modulation of these enzymes by IL-6 blockade","Increased risk of infection with concomitant use of immunosuppressive drugs"],"Contraindications":"Known hypersensitivity to tocilizumab or any component of the product","ChemicalStructure":{"MolecularFormula":"C6428H9976N1720O2018S42","MolecularWeight":"148000 g/mol (approximate)"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefits justify the potential risks; limited data available.","PediatricUse":"Approved for use in children with systemic juvenile idiopathic arthritis (ages 2 years and older).","GeriatricUse":"Clinical studies have not identified differences in responses between the elderly and younger patients.","HepaticImpairment":"Use with caution; monitor liver function tests closely.","RenalImpairment":"No specific dose adjustment recommended, but use with caution."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze and protect from light."},{"GenericName":"Anakinra","BrandNames":["Kineret"],"DrugClass":"Interleukin-1 receptor antagonist","MechanismOfAction":"Anakinra blocks the biologic activity of interleukin-1 (IL-1) by competitively inhibiting the binding of IL-1 to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs.","Pharmacodynamics":"Anakinra reduces inflammation by mimicking the naturally occurring IL-1 receptor antagonist, thus blocking the activity of IL-1, a cytokine involved in inflammatory pathways.","OnsetOfAction":"Response may be seen within 1 to 2 weeks.","DurationOfAction":"The biological effects can last up to 3 to 4 days after the last dose.","PeakPlasmaConcentration":"3 to 7 hours after subcutaneous administration.","Indications":["Rheumatoid arthritis","Neonatal-onset multisystem inflammatory disease (NOMID)","COVID-19 (off-label use)"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Injection solution"],"StrengthsOfDosageForms":["100 mg/0.67 mL in prefilled syringes"],"Pharmacokinetics":{"Absorption":"Approximately 95% absorption following subcutaneous administration.","Distribution":"Volume of distribution: ~0.17 L/kg.","Metabolism":"Metabolized by the liver.","Excretion":"Eliminated via the kidneys with a half-life of 4 to 6 hours."},"SideEffects":["Injection site reactions","Increased risk of infections","Headache","Nausea","Diarrhea","Neutropenia"],"DrugInteractions":["TNF-blockers (increased risk of infections)","Live vaccines"],"Contraindications":"Hypersensitivity to anakinra or any of its components.","ChemicalStructure":{"MolecularFormula":"C759H1186N208O232S10","MolecularWeight":"17.3 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Use only if clearly needed as there is limited data on use during pregnancy.","PediatricUse":"Safety and efficacy established for certain conditions like NOMID.","GeriatricUse":"No specific differences in safety or efficacy, but caution due to potential decreased renal function.","HepaticImpairment":"No dosage adjustment is needed.","RenalImpairment":"Dose adjustment recommended in severe renal impairment."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. May be stored at room temperature up to a maximum of 25°C (77°F) for a maximum of 12 hours before use."},{"GenericName":"Secukinumab","BrandNames":["Cosentyx"],"DrugClass":"Biologic agent; IL-17A inhibitor","MechanismOfAction":"Secukinumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a pro-inflammatory cytokine.","Pharmacodynamics":"Secukinumab modulates the inflammatory process by inhibiting IL-17A, thereby reducing the inflammatory and immune responses associated with autoimmune disorders.","OnsetOfAction":"The onset of action varies depending on the condition being treated, typically 3-4 weeks for psoriasis.","DurationOfAction":"The effects of secukinumab last for approximately 4 weeks after the last injection.","PeakPlasmaConcentration":"The peak plasma concentration is typically reached 2-5 days after subcutaneous administration.","Indications":["Plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Prefilled syringe","Autoinjector"],"StrengthsOfDosageForms":["150 mg/ml","300 mg/ml"],"Pharmacokinetics":{"Absorption":"Secukinumab is absorbed subcutaneously with an average bioavailability of 73%.","Distribution":"The steady-state volume of distribution is approximately 7.1 liters.","Metabolism":"Secukinumab is degraded to small peptides and amino acids via catabolic pathways, similar to endogenous IgG.","Excretion":"The elimination half-life of secukinumab is approximately 27 days."},"SideEffects":["Upper respiratory tract infections","Nasopharyngitis","Diarrhea","Headache","Hypertension","Back pain"],"DrugInteractions":["Live vaccines","Immunosuppressants may impact infection risk"],"Contraindications":"Hypersensitivity to secukinumab or any of its excipients","ChemicalStructure":{"MolecularFormula":"C6584H10136N1752O2042S46","MolecularWeight":"147,935 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"There is limited data on the use of secukinumab in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"The safety and effectiveness of secukinumab in pediatric patients below 6 years of age have not been established.","GeriatricUse":"No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.","HepaticImpairment":"No dose adjustment is required for patients with hepatic impairment.","RenalImpairment":"No dose adjustment is required for patients with renal impairment."},"StorageAndHandling":"Store secukinumab in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and do not shake."},{"GenericName":"Ixekizumab","BrandNames":["Taltz"],"DrugClass":"Monoclonal antibody (IL-17A inhibitor)","MechanismOfAction":"Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds to interleukin 17A (IL-17A), a pro-inflammatory cytokine. By inhibiting IL-17A, ixekizumab disrupts the inflammatory pathways that contribute to inflammatory diseases like psoriasis.","Pharmacodynamics":"Ixekizumab helps to reduce inflammation and symptoms such as scaling, pain, and skin thickening associated with psoriasis.","OnsetOfAction":"Initial improvement may be seen within 1 week.","DurationOfAction":"The duration of action is maintained with periodic dosing after initial treatment.","PeakPlasmaConcentration":"Approximately 4 to 7 days post-dose for the initial subcutaneous dose.","Indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Prefilled syringe","Autoinjector"],"StrengthsOfDosageForms":["80 mg/mL"],"Pharmacokinetics":{"Absorption":"Bioavailability is approximately 54% following subcutaneous administration.","Distribution":"The apparent volume of distribution is approximately 7.11 L.","Metabolism":"Ixekizumab is expected to be degraded into small peptides and amino acids via catabolic pathways.","Excretion":"Primarily eliminated by cellular catabolism with a half-life of approximately 13 days."},"SideEffects":["Injection site reactions","Upper respiratory tract infections","Nausea","Fungal infections"],"DrugInteractions":["No notable drug-drug interactions, but concurrent live vaccines are not recommended."],"Contraindications":"Known hypersensitivity to ixekizumab or any of its excipients","ChemicalStructure":{"MolecularFormula":"C6534H10008N1732O2042S46","MolecularWeight":"Approximately 146 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Limited data available, use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness have been established in pediatric patients 6 years and older with moderate-to-severe plaque psoriasis.","GeriatricUse":"No significant differences in response rates between elderly and younger subjects were observed.","HepaticImpairment":"No formal studies have been conducted.","RenalImpairment":"No formal studies have been conducted."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze."},{"GenericName":"Brodalumab","BrandNames":["Siliq"],"DrugClass":"Monoclonal antibody","MechanismOfAction":"Brodalumab is a human monoclonal antibody that targets the interleukin-17 receptor (IL-17RA) and inhibits the action of inflammatory cytokines involved in the pathogenesis of psoriasis.","Pharmacodynamics":"Brodalumab inhibits cytokines responsible for inflammation in psoriasis, leading to improved skin lesions and reduced symptoms.","OnsetOfAction":"Clinical improvement in skin lesions may be observed within one week, with further improvements over a period of 12 weeks.","DurationOfAction":"The effects of brodalumab may last several months post-treatment, but continuous treatment is required to maintain efficacy.","PeakPlasmaConcentration":"Peak plasma concentrations are typically reached within 2 to 4 days following subcutaneous administration.","Indications":["Moderate to severe plaque psoriasis"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Injection, solution"],"StrengthsOfDosageForms":["210 mg/1.5 mL solution in a single-dose prefilled syringe"],"Pharmacokinetics":{"Absorption":"Brodalumab is absorbed slowly into the systemic circulation.","Distribution":"The volume of distribution is approximately 7.7 L.","Metabolism":"Brodalumab is metabolized into small peptides and amino acids.","Excretion":"Elimination occurs via degradation to small peptides and amino acids."},"SideEffects":["Arthralgia","Headache","Fatigue","Diarrhea","Nausea","Oropharyngeal pain","Injection site reactions"],"DrugInteractions":["Live vaccines should be avoided","Interaction with CYP450 substrates could potentially occur due to cytokine alteration"],"Contraindications":"Hypersensitivity to brodalumab or any component of the formulation, and patients with Crohn's disease.","ChemicalStructure":{"MolecularFormula":"C6474H10004N1732O2016S46","MolecularWeight":"143.9 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness have not been established in pediatric patients.","GeriatricUse":"No overall differences in safety or effectiveness have been observed between elderly and younger subjects.","HepaticImpairment":"No specific guidelines; use with caution.","RenalImpairment":"No specific guidelines; use with caution."},"StorageAndHandling":"Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze or shake."},{"GenericName":"Ustekinumab","BrandNames":["Stelara"],"DrugClass":"Monoclonal antibody","MechanismOfAction":"Ustekinumab is a human IgG1κ monoclonal antibody that binds to the p40 protein subunit used by the interleukin (IL)-12 and IL-23 cytokines, preventing these cytokines from binding to their IL-12Rβ1 receptor, which subsequently leads to a decrease in inflammation and immune response.","Pharmacodynamics":"Ustekinumab works by reducing inflammation and altering immune responses by inhibiting the inflammatory pathways mediated by interleukin-12 and interleukin-23.","OnsetOfAction":"4 to 8 weeks for significant response (may vary based on condition being treated).","DurationOfAction":"Variable; long half-life supports infrequent dosing schedule.","PeakPlasmaConcentration":"Approximately 8-15 days post subcutaneous administration.","Indications":["Plaque psoriasis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"RoutesOfAdministration":"Subcutaneous and intravenous","DosageForms":["Subcutaneous injection","Intravenous infusion"],"StrengthsOfDosageForms":["45 mg/0.5 mL prefilled syringe","90 mg/mL prefilled syringe","130 mg/26 mL vial for infusion"],"Pharmacokinetics":{"Absorption":"Subcutaneous administration results in peak concentration within 8-15 days.","Distribution":"Volume of distribution is approximately 8.7 L.","Metabolism":"Likely degraded by proteolytic enzymes into small peptides and amino acids.","Excretion":"Elimination through usual protein catabolism pathways; not specifically excreted renally or hepatically."},"SideEffects":["Nasopharyngitis","Headache","Fatigue","Upper respiratory tract infection","Back pain"],"DrugInteractions":["Live vaccines (vaccination with live or live-attenuated vaccines should be avoided in patients receiving ustekinumab)","CYP450 enzymes (indirect effects due to inflammation modulation)"],"Contraindications":"Hypersensitivity to ustekinumab or any of its components.","ChemicalStructure":{"MolecularFormula":"C6480H10004N1732O2016S42","MolecularWeight":"148,600 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Pregnancy Category B. Limited human data suggest low risk, but data is not sufficient to exclude risk.","PediatricUse":"Approved for use in pediatric patients aged 6 years and older with plaque psoriasis.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","HepaticImpairment":"No specific guidelines available, use with caution.","RenalImpairment":"No specific guidelines available, use with caution."},"StorageAndHandling":"Store refrigerated at 2°C to 8°C (36°F to 46°F); do not freeze or shake. Protect from light and keep in the original carton until ready for use."},{"GenericName":"Guselkumab","BrandNames":["Tremfya"],"DrugClass":"Interleukin Inhibitor","MechanismOfAction":"Guselkumab is a monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), thereby inhibiting its interaction with the IL-23 receptor, which leads to a reduction in inflammation and autoimmune responses.","Pharmacodynamics":"Guselkumab reduces IL-23-mediated release of proinflammatory cytokines and chemokines, decreasing psoriatic lesions and systemic inflammation associated with psoriasis and other autoimmune conditions.","OnsetOfAction":"Reduction in psoriatic lesion symptoms usually begins within 2 to 4 weeks of starting treatment.","DurationOfAction":"Typically, the effects of the medication last for about 8 weeks after administration, which aligns with its dosing schedule.","PeakPlasmaConcentration":"Approximately 5.5 days after dosing.","Indications":["Plaque psoriasis","Psoriatic arthritis"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Solution for injection in a pre-filled syringe","Solution for injection in an auto-injector"],"StrengthsOfDosageForms":["100 mg/mL"],"Pharmacokinetics":{"Absorption":"Following subcutaneous administration, guselkumab is absorbed with peak serum concentrations reached in approximately 5.5 days.","Distribution":"Volume of distribution is approximately 13.5 L.","Metabolism":"Expected to be degraded into small peptides and amino acids via catabolic pathways.","Excretion":"Elimination half-life is about 15 to 18 days, primarily cleared through hepatic pathways and reticuloendothelial systems."},"SideEffects":["Upper respiratory tract infections","Headache","Injection site reactions","Arthralgia","Diarrhea","Gastroenteritis"],"DrugInteractions":["Live vaccines: Should be avoided during treatment","Interactions with other immunosuppressants need careful monitoring"],"Contraindications":"Known hypersensitivity to guselkumab or any excipients in the formulation.","ChemicalStructure":{"MolecularFormula":"C6498H9996N1720O2016S46","MolecularWeight":"approx. 149 kDa"},"UseInSpecialPopulations":{"Pregnancy":"No adequate data on the developmental risk associated with the use during pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy have not been established in pediatric patients.","GeriatricUse":"No overall differences in safety or efficacy observed between older and younger patients.","HepaticImpairment":"No specific dosage adjustments are recommended, though use with caution.","RenalImpairment":"No specific dosage adjustments are recommended, though use with caution."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake."},{"GenericName":"Tildrakizumab","BrandNames":["Ilumya","Ilumetri"],"DrugClass":"Anti-interleukin-23 monoclonal antibody","MechanismOfAction":"Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23). This inhibits the interaction of IL-23 with its receptor, leading to reduced release of pro-inflammatory cytokines and chemokines involved in inflammatory processes.","Pharmacodynamics":"Tildrakizumab reduces the levels of markers associated with inflammation and activities of psoriasis, which helps in the reduction of plaque formation and skin symptoms in patients. The efficacy is generally observed after several weeks of treatment.","OnsetOfAction":"4 weeks","DurationOfAction":"Approximately 12 weeks (in terms of injection frequency for maintenance)","PeakPlasmaConcentration":"Tildrakizumab reaches peak plasma concentration approximately within 6 days after subcutaneous administration.","Indications":["Moderate-to-severe plaque psoriasis"],"RoutesOfAdministration":"Subcutaneous","DosageForms":["Solution for injection"],"StrengthsOfDosageForms":["100 mg/mL in a pre-filled syringe"],"Pharmacokinetics":{"Absorption":"Subcutaneous administration reaches peak plasma concentrations in approximately 6 days.","Distribution":"Volume of distribution is approximately 10.8 L.","Metabolism":"Degraded into small peptides and amino acids via catabolic pathways similar to endogenous IgG.","Excretion":"The exact excretion pathway is not well defined, but it is primarily eliminated through typical protein degradation pathways."},"SideEffects":["Upper respiratory infections","Injection site reactions","Diarrhea","Headache"],"DrugInteractions":["Live vaccines (increased risk of infection)","Immunosuppressive drugs (potential additive effects)"],"Contraindications":"Known hypersensitivity to tildrakizumab or any of its excipients.","ChemicalStructure":{"MolecularFormula":"C6470H9986N1726O2016S46","MolecularWeight":"145.3 kDa"},"UseInSpecialPopulations":{"Pregnancy":"There is limited information available; use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No differences in efficacy or safety were observed between older and younger patients, but caution is advised due to potential comorbidities.","HepaticImpairment":"No specific studies have been conducted; use with caution.","RenalImpairment":"No specific studies have been conducted; use with caution."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep in original carton to protect from light."},{"GenericName":"Risankizumab","BrandNames":["Skyrizi"],"DrugClass":"Monoclonal antibody","MechanismOfAction":"Risankizumab selectively binds to the p19 subunit of interleukin 23 (IL-23), inhibiting its interaction with the IL-23 receptor. This leads to inhibition of the inflammatory cascade involved in psoriasis.","Pharmacodynamics":"Risankizumab modulates the pro-inflammatory cytokine pathway, reducing inflammation and symptoms related to moderate to severe plaque psoriasis.","OnsetOfAction":"Approximately 4 weeks for symptom improvement.","DurationOfAction":"Long; dosing every 12 weeks after initial loading doses.","PeakPlasmaConcentration":"Achieved within 3-14 days, depending on the dosing regimen.","Indications":["Plaque psoriasis"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Solution for injection"],"StrengthsOfDosageForms":["75 mg/0.83 mL","150 mg/mL"],"Pharmacokinetics":{"Absorption":"Subcutaneous absorption with maximum concentrations reached between 3-14 days.","Distribution":"Volume of distribution is 11.2 L.","Metabolism":"Expected to be metabolized into small peptides and amino acids via catabolic pathways, similar to other proteins.","Excretion":"Very limited renal excretion, catabolism similar to endogenous IgG."},"SideEffects":["Upper respiratory infections","Headache","Fatigue","Injection site reactions","Tinea infections"],"DrugInteractions":["No significant drug interactions have been identified."],"Contraindications":"Known hypersensitivity to risankizumab or any of its components.","ChemicalStructure":{"MolecularFormula":"C6428H9896N1690O2020S46","MolecularWeight":"149.2 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Limited data available; use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No significant differences have been observed in older patients compared to younger ones.","HepaticImpairment":"No specific studies have been conducted, but hepatic impairment is not expected to affect risankizumab pharmacokinetics significantly.","RenalImpairment":"No specific studies have been conducted, but renal impairment is not expected to affect risankizumab pharmacokinetics significantly."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake."},{"GenericName":"Omalizumab","BrandNames":["Xolair"],"DrugClass":"Monoclonal Antibody","MechanismOfAction":"Omalizumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that selectively binds to human immunoglobulin E (IgE). This binding inhibits the IgE from attaching to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils. The reduced IgE binding limits the release of mediators involved in the allergic response.","Pharmacodynamics":"Omalizumab decreases IgE levels and their receptors on surface cells, reducing allergen-induced responses. This results in fewer allergic symptoms and incidents in predisposed individuals.","OnsetOfAction":"60 to 90 minutes following administration.","DurationOfAction":"Up to 2 to 4 weeks, allowing for extended intervals between doses.","PeakPlasmaConcentration":"The peak plasma concentrations are reached approximately 7–8 days following administration.","Indications":["Moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen who are inadequately controlled with inhaled corticosteroids","Chronic idiopathic urticaria in adults and adolescents (12 years of age and above) who remain symptomatic despite H1 antihistamine treatment"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Injection"],"StrengthsOfDosageForms":["75 mg/0.5 mL single-use prefilled syringe","150 mg/1 mL single-use prefilled syringe"],"Pharmacokinetics":{"Absorption":"Subcutaneous bioavailability ranges from 62% to 78%.","Distribution":"The apparent volume of distribution after subcutaneous administration is approximately 78 ± 32 mL/kg.","Metabolism":"Omalizumab is expected to be metabolized within the reticuloendothelial system.","Excretion":"Primarily eliminated by protein catabolism mechanisms."},"SideEffects":["Injection site reactions (e.g., pain, redness, swelling)","Headache","Dizziness","Fatigue","Upper respiratory tract infections","Arthralgia"],"DrugInteractions":["No formal drug interaction studies have been performed.","Omalizumab does not appear to interact significantly with co-administered medications."],"Contraindications":"Hypersensitivity to omalizumab or any of its inactive ingredients.","ChemicalStructure":{"MolecularFormula":"C6458H9918N1694O2018S42","MolecularWeight":"149 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Data are limited; use only if clearly needed and the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy established in patients 6 years of age and older for asthma indications.","GeriatricUse":"No overall differences observed in safety or effectiveness between elderly and younger adult patients.","HepaticImpairment":"Has not been studied extensively; use with caution.","RenalImpairment":"Has not been studied extensively; use with caution."},"StorageAndHandling":"Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Do not use beyond the expiration date on the container."},{"GenericName":"Dupilumab","BrandNames":["Dupixent"],"DrugClass":"Monoclonal antibody","MechanismOfAction":"Dupilumab is an interleukin-4 receptor alpha antagonist that inhibits signaling of both IL-4 and IL-13, which are cytokines involved in chronic inflammation associated with atopic dermatitis, asthma, and other allergic conditions.","Pharmacodynamics":"Dupilumab decreases markers of inflammation associated with atopic dermatitis and other allergic conditions. It significantly lowers levels of certain inflammatory markers while improving clinical symptoms.","OnsetOfAction":"Improvement in symptoms can often be seen within 2 weeks of starting treatment.","DurationOfAction":"Each administered dose generally has a duration of approximately 2 to 4 weeks.","PeakPlasmaConcentration":"2 to 7 days after administration, depending on the regimen (e.g., initial loading dose or maintenance doses).","Indications":["Moderate to severe atopic dermatitis in adult and pediatric patients","Moderate to severe asthma in patients aged 12 and older","Chronic rhinosinusitis with nasal polyposis in adults"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Prefilled syringe","Pre-filled pen"],"StrengthsOfDosageForms":["200 mg/1.14 mL","300 mg/2 mL"],"Pharmacokinetics":{"Absorption":"High bioavailability when administered subcutaneously with peak concentrations reached approximately 3-7 days post-injection.","Distribution":"Steady-state volume of distribution is 4.8 ± 1.3 L, indicating that Dupilumab is primarily distributed in the interstitial space.","Metabolism":"Dupilumab is degraded into small peptides and individual amino acids via proteolytic enzymes.","Excretion":"Clearance is primarily through catabolism; the exact pathways are not fully elucidated."},"SideEffects":["Injection site reactions","Conjunctivitis","Blepharitis","Oral herpes","Keratitis","Influenza","Oropharyngeal pain","Hypersensitivity reactions"],"DrugInteractions":["Avoid live vaccines in patients receiving Dupilumab","Potential interaction with other cytokine-modulating therapies"],"Contraindications":"Known hypersensitivity to Dupilumab or any of its excipients.","ChemicalStructure":{"MolecularFormula":"C6528H10002N1726O2030S42","MolecularWeight":"147.896 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Limited data; should only be used if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy have been established in patients aged 6 years and older with atopic dermatitis. In asthma, safety and efficacy have been established for patients aged 12 years and older.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients.","HepaticImpairment":"No dosage adjustment is required for patients with mild or moderate hepatic impairment.","RenalImpairment":"No dosage adjustment is required for patients with mild to moderate renal impairment."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light by storing in the original carton until time of administration. May be stored at room temperature up to 30°C (86°F) for a maximum of 14 days."},{"GenericName":"Mepolizumab","BrandNames":["Nucala"],"DrugClass":"Monoclonal Antibody","MechanismOfAction":"Mepolizumab is an IL-5 antagonist monoclonal antibody (IgG1 kappa) that reduces eosinophil levels and the associated inflammatory response by preventing interleukin-5 (IL-5) from binding to its receptor on the surface of eosinophils.","Pharmacodynamics":"It leads to reduced eosinophil levels in blood and tissues, which assists in decreasing the frequency and severity of asthma exacerbations in individuals with eosinophilic phenotype.","OnsetOfAction":"The onset of action is generally observed after several weeks of treatment, where a significant reduction in blood eosinophil levels can be detected.","DurationOfAction":"The duration of action corresponds with the approximately one-month dosing schedule, although effects on eosinophils can persist for several weeks beyond this.","PeakPlasmaConcentration":"Peak plasma concentrations are typically reached in about 4 to 8 days after subcutaneous administration.","Indications":["Severe eosinophilic asthma","Eosinophilic granulomatosis with polyangiitis","Hypereosinophilic syndrome"],"RoutesOfAdministration":"Subcutaneous","DosageForms":["Solution for injection"],"StrengthsOfDosageForms":["100 mg/mL in single-dose vial"],"Pharmacokinetics":{"Absorption":"Following subcutaneous administration, the absolute bioavailability of mepolizumab was estimated to be approximately 80%.","Distribution":"The volume of distribution is approximately 3.6 L.","Metabolism":"As a monoclonal antibody, mepolizumab is expected to be broken down into small peptides and amino acids via catabolism.","Excretion":"Elimination is primarily via catabolism, with a half-life of approximately 20 days."},"SideEffects":["Headache","Injection site reactions","Back pain","Fatigue"],"DrugInteractions":["There are no known major drug interactions, but use with other immunosuppressive therapies should be monitored."],"Contraindications":"Hypersensitivity to mepolizumab or any of its excipients.","ChemicalStructure":{"MolecularFormula":"C6470H10004N1732O2036S46","MolecularWeight":"149 kDa"},"UseInSpecialPopulations":{"Pregnancy":"There are no adequate data on the use of mepolizumab in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Approved for use in children 6 years and older with severe eosinophilic asthma.","GeriatricUse":"No overall differences in safety or efficacy have been observed between older and younger patients.","HepaticImpairment":"No specific studies have been conducted, but adjustments are not expected due to monoclonal antibody catabolism.","RenalImpairment":"No specific studies have been conducted, but adjustments are not required."},"StorageAndHandling":"Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Store in the original carton to protect from light."},{"GenericName":"Reslizumab","BrandNames":["Cinqair"],"DrugClass":"Monoclonal antibody (anti-IL-5)","MechanismOfAction":"Reslizumab is a monoclonal antibody that targets interleukin-5 (IL-5) and inhibits its biological activity. IL-5 is a cytokine crucial for the growth, differentiation, recruitment, activation, and survival of eosinophils. By blocking IL-5, reslizumab reduces eosinophil activity and numbers, which helps control asthma symptoms in patients with elevated eosinophils.","Pharmacodynamics":"Reslizumab decreases blood eosinophil levels and improves lung function and other asthma-related outcomes in patients with eosinophilic asthma.","OnsetOfAction":"Effects can be observed after the first few doses; however, peak clinical effects may take several weeks.","DurationOfAction":"The half-life of reslizumab is approximately 24 days, indicating a prolonged action after administration.","PeakPlasmaConcentration":"Approximately reached within 8 days after intravenous infusion.","Indications":["Maintenance treatment of severe eosinophilic asthma in adults"],"RoutesOfAdministration":"Intravenous","DosageForms":["Solution for infusion"],"StrengthsOfDosageForms":["100 mg/10 mL (10 mg/mL)"],"Pharmacokinetics":{"Absorption":"Administered intravenously; therefore, absorption is immediate and complete.","Distribution":"Volume of distribution is 5 liters, indicating limited distribution outside the vascular compartment.","Metabolism":"As an immunoglobulin, reslizumab is expected to be metabolized into small peptides and amino acids via catabolic pathways.","Excretion":"The exact elimination pathway is not well characterized, but monoclonal antibodies are usually not eliminated in urine."},"SideEffects":["Oropharyngeal pain","Increased blood creatine phosphokinase","Myalgia","Anaphylactic reactions"],"DrugInteractions":["No known significant drug interactions"],"Contraindications":"Known hypersensitivity to reslizumab or any of its excipients.","ChemicalStructure":{"MolecularFormula":"C6492H10064N1732O2036S46","MolecularWeight":"146 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus as there are no adequate and well-controlled studies in pregnant women.","PediatricUse":"Safety and effectiveness have not been established in patients younger than 18 years.","GeriatricUse":"No overall differences in safety or efficacy were observed between elderly patients and younger patients.","HepaticImpairment":"Unknown; use with caution.","RenalImpairment":"Unknown; use with caution."},"StorageAndHandling":"Store unused vials in a refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze."},{"GenericName":"Benralizumab","BrandNames":["Fasenra"],"DrugClass":"Monoclonal antibody","MechanismOfAction":"Benralizumab is an anti-IL-5 receptor alpha-directed cytolytic monoclonal antibody. It binds to the interleukin-5 receptor alpha subunit on eosinophils and basophils, leading to recruitment of natural killer cells that induce apoptosis of these cells.","Pharmacodynamics":"Benralizumab reduces eosinophil counts in the blood, thereby decreasing airway inflammation and improving asthma control.","OnsetOfAction":"Reductions in blood eosinophil counts can be observed within 24 hours of administration.","DurationOfAction":"Eosinophil depletion is sustained for an extended period following discontinuation of treatment.","PeakPlasmaConcentration":"Peak concentration is typically reached within a few days after administration, depending on the route of administration.","Indications":["Severe eosinophilic asthma"],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Prefilled syringe","Autoinjector"],"StrengthsOfDosageForms":["30 mg/mL"],"Pharmacokinetics":{"Absorption":"Well-absorbed following subcutaneous administration with a bioavailability of approximately 60%–70%.","Distribution":"The steady-state volume of distribution is approximately 5 liters.","Metabolism":"Catabolized through the reticuloendothelial system.","Excretion":"Elimination route largely depends on modulation within the immune system rather than renal or hepatic pathways."},"SideEffects":["Headache","Pharyngitis","Hypersensitivity reactions","Injection site reactions"],"DrugInteractions":["No major documented interactions"],"Contraindications":"Hypersensitivity to Benralizumab or any of its excipients.","ChemicalStructure":{"MolecularFormula":"C6404H9918N1702O1996S46","MolecularWeight":"146 kDa"},"UseInSpecialPopulations":{"Pregnancy":"Limited data; should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and efficacy have not been established in children under 12 years of age.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients.","HepaticImpairment":"No dosage adjustment is required.","RenalImpairment":"No dosage adjustment is required."},"StorageAndHandling":"Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Avoid exposure to heat."},{"GenericName":"Romiplostim","BrandNames":["Nplate"],"DrugClass":"Thrombopoietin receptor agonist","MechanismOfAction":"Romiplostim is a peptibody that binds to and activates the human thrombopoietin receptor, leading to increased platelet production.","Pharmacodynamics":"Romiplostim promotes the production of platelets by stimulating megakaryocyte proliferation and differentiation in a dose-dependent manner.","OnsetOfAction":"Platelet count increases can be observed within 1 to 2 weeks of administration.","DurationOfAction":"The effects on platelet counts can last for several weeks, but decrease after discontinuation of treatment.","PeakPlasmaConcentration":"Variable depending on dosage; pharmacokinetics are not fully linearly correlated with dose.","Indications":["Treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy."],"RoutesOfAdministration":"Subcutaneous injection","DosageForms":["Lyophilized powder for solution for injection"],"StrengthsOfDosageForms":["125 mcg per vial","250 mcg per vial","500 mcg per vial"],"Pharmacokinetics":{"Absorption":"Romiplostim is administered subcutaneously and absorption is variable.","Distribution":"The volume of distribution is approximately 122 to 126 mL/kg.","Metabolism":"The metabolism of romiplostim is not well characterized but may involve peptide catabolism pathways.","Excretion":"Specific excretion pathways are not well documented. Clearance is thought to be primarily by reticuloendothelial system phagocytes."},"SideEffects":["Headache","Fatigue","Dizziness","Nausea","Arthralgia","Thrombotic complications"],"DrugInteractions":["No significant drug-drug interactions have been noted; nonetheless, caution should be used when administered with anticoagulant therapies."],"Contraindications":"None specific, but caution advised in patients with a history of thromboembolism or myelodysplasia.","ChemicalStructure":{"MolecularFormula":"C15H12N2O4S2","MolecularWeight":"368.4 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus.","PediatricUse":"Safety and effectiveness in pediatric patients have not been established.","GeriatricUse":"No overall differences in safety or effectiveness observed between elderly and younger patients.","HepaticImpairment":"Caution is recommended, as dosing adjustments may be necessary.","RenalImpairment":"Use with caution, and monitor platelet counts frequently."},"StorageAndHandling":"Store lyophilized powder at 2°C to 8°C (36°F to 46°F) and protect from light. Do not freeze. Reconstituted solution should be used within 24 hours."},{"GenericName":"Eltrombopag","BrandNames":["Promacta","Revolade"],"DrugClass":"Thrombopoietin receptor agonist","MechanismOfAction":"Eltrombopag is an orally bioavailable, small molecule agonist of the thrombopoietin receptor, which increases platelet production through binding and activation of the thrombopoietin receptor found on megakaryocyte precursors in the bone marrow.","Pharmacodynamics":"Eltrombopag stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets.","OnsetOfAction":"Platelet responses after administration can be observed within 1 to 2 weeks.","DurationOfAction":"The platelet count tends to increase over the first few weeks of therapy and return to baseline within 2 weeks after discontinuation.","PeakPlasmaConcentration":"Typically achieved within 2 to 6 hours after oral administration.","Indications":["Chronic immune thrombocytopenia (ITP)","Severe aplastic anemia","Thrombocytopenia in patients with chronic hepatitis C to initiate and maintain interferon-based therapy"],"RoutesOfAdministration":"Oral","DosageForms":["Tablet","Oral suspension"],"StrengthsOfDosageForms":["Tablet: 12.5 mg, 25 mg, 50 mg, 75 mg","Oral suspension: 12.5 mg per packet"],"Pharmacokinetics":{"Absorption":"Eltrombopag shows dose-dependent absorption with a peak plasma concentration at about 2 to 6 hours post-dose.","Distribution":"Eltrombopag is approximately 99.4% bound to plasma proteins.","Metabolism":"Metabolized predominantly by UGT1A1 and CYP2C8, with minor contributions from CYP1A2, CYP2C9, and CYP2D6.","Excretion":"About 59% of a dose is excreted in the feces primarily as unchanged drug, and about 31% is excreted in the urine mainly as metabolites."},"SideEffects":["Hepatotoxicity","Thrombosis","Cataracts","Nausea","Diarrhea","Myalgia","Dermatitis"],"DrugInteractions":["Polyvalent cations (e.g., in antacids) may reduce the absorption of eltrombopag.","CYP1A2 inducers or inhibitors may affect eltrombopag metabolism.","Increased risk of bleeding when used with anticoagulants."],"Contraindications":"Eltrombopag is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.","ChemicalStructure":{"MolecularFormula":"C25H22N4O4S","MolecularWeight":"442.54 g/mol"},"UseInSpecialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk to the fetus. Category C.","PediatricUse":"Safety and efficacy in patients younger than 1 year have not been established.","GeriatricUse":"No overall differences in safety or effectiveness were observed between elderly and younger adult patients.","HepaticImpairment":"Dose adjustments are recommended for patients with hepatic impairment to reduce the risk of hepatotoxicity.","RenalImpairment":"No specific dose adjustment is required in mild to moderate renal impairment."},"StorageAndHandling":"Store at room temperature, 20°C to 25°C (68°F to 77°F), away from light and moisture."}]